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ABSTRACT 
Men who have sex with men (MSM) are at increased risk of human papillomavirus (HPV) 
infection and related disease. There are two licensed HPV vaccines against the high-risk HPV 
types, HPV16/18, one of which, the quadrivalent vaccine, additionally targets low-risk HPV 
types (HPV6/11). MSM will not benefit from the UK’s school-based HPV vaccine programme 
targeting girls. Sexual Health clinics (SHC) are the most feasible setting for vaccinating MSM. 
This thesis aimed to inform the policy decision on whether to vaccinate MSM attending 
SHCs in the UK by estimating underlying epidemiological parameters: HPV exposure in the 
MSM population attending SHCs, expected vaccine coverage and the effect of HPV16 
vaccination on anal cancer incidence. 
A cross-sectional survey of 522 MSM was conducted at a SHC. Specimens (anal and external 
genital swabs, urine, oral rinse and serum) were tested for HPV and demographic, 
behavioural and clinical information was collected (HPV-MSM-MMC study). A static 
deterministic cohort model was developed of HPV16 infection and anal cancer in SHC-
attending MSM. 
A substantial burden of HPV infection in MSM could be prevented at SHCs: a third of HPV-
MSM-MMC participants were infected with ≥1 quadrivalent-vaccine HPV types yet none 
with all four. Therefore all had potential to benefit, at least partially, from vaccination. An 
additional third had evidence of prior exposure (seropositive or history of anogenital warts) 
to quadrivalent-vaccine types and a final third had no evidence of exposure.  
A targeted HPV vaccine programme at SHCs would result in ≥50% coverage of the UK’s MSM 
population.  Vaccination at SHCs would efficiently interrupt HPV transmission because SHC-
attenders represent MSM at high risk of HPV infection. Vaccination against HPV16 was 
predicted to substantially reduce anal cancer incidence, even without the effect of herd 
immunity. This thesis provides strong evidence for HPV vaccine effectiveness using a 
programme targeting MSM attending SHCs. 
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1. INTRODUCTION 
1.1 BACKGROUND AND RATIONALE 
Human papillomaviruses (HPV) are known to cause cancers at several sites as well as warts. 
The most common HPV-related cancer, and cause of the greatest loss of life and health, is 
that of the cervix. Other HPV-related cancers, most notably anal cancers and head and neck 
cancers are less common but of increasing concern1–4. Whilst the burden of HPV-related 
disease in all men is lower than in all women, men who have sex with men (MSM) are at 
known high risk for HPV-related disease. For example, the odds of anal cancer in MSM is 33 
times greater than in men with no history of receptive anal sex5 and the odds of head and 
neck cancer are 8.9 times higher in MSM compared to heterosexual men in the US6. In 
addition, in the UK, the incidence of genital warts, the most commonly diagnosed viral 
sexually transmitted disease, was 163 per 100,000 men in 2008, of which 6% were in MSM7, 
yet MSM only represent 2.8% of the UK population and are therefore disproportionately 
burdened by this disease8.  
Two vaccines against HPV16/18 infection (the most common high-risk HPV types; HR-HPV) 
are now widely used. The bivalent vaccine (Cervarix®) protects against HPV16/18. The 
quadrivalent vaccine (Gardasil®) protects against HPV16/18, and the low-risk types HPV6/11 
which are responsible for the majority of genital warts9. A 9-valent vaccine targeting five 
additional HR-HPV types10,11, 31/33/45/52/58, responsible for a further 20% of cervical 
cancers12,13, was approved by the US food and drug administration in December 2014 and is 
expected to be licensed for use in Europe14–17.  
In 2008, the UK introduced an HPV immunisation programme for adolescent girls, primarily 
as prevention of cervical cancer18,19, following recommendation from the Joint Committee 
on Vaccination and Immunisation (JCVI). The JCVI acknowledged a lack of evidence to assess 
the value of an HPV vaccine programme targeted at MSM (Box 1). Based on findings of a 
mathematical model, boys were not included in the vaccination programme19. 
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Mathematical modelling studies have shown that if boys are vaccinated, as well as girls, the 
population prevalence of HPV diminishes more quickly but that improving the coverage in 
girls is more cost-effective than extending vaccination to boys19,20.  
With the current immunisation policy, heterosexual men will gain indirect protection from 
HPV because their female sexual partners will, as a result of immunisation, be less likely to 
be infected. The benefit to MSM is expected to be far less and appear more slowly, as their 
male sexual partners will not have been protected from infection by immunisation. There is 
some overlap between MSM and heterosexual populations, but it is unclear to what extent 
indirect protection will, in time, effect any reduction in HPV-related disease amongst MSM.  
It is likely that MSM will continue to experience high levels of HPV infection and disease 
while these are declining in the heterosexual population. 
BOX 1. EXCERPT FROM THE 2008 JCVI STATEMENT ON HPV VACCINES TO PROTECT AGAINST 
CERVICAL CANCER   
“At the time of recommendation, JCVI considered that there was insufficient 
evidence on the protective effects of the vaccine against cancers affecting 
males such as anal, and head and neck cancers. When more data becomes 
available, high-risk groups such as men who have sex with men would be 
considered.” 
JCVI 2008 
Given the difficulty of identifying MSM at an early stage in their lifetime, for example in a 
school setting before their sexual debut, the earliest opportunity for a health intervention in 
this population is likely to be in a sexual health clinic (SHC). Whether this is a suitable service 
in which to deliver a prophylactic HPV vaccine programme will depend on: 
• The proportion of MSM accessing SHCs 
• The proportion of MSM at SHCs currently infected with HPV 
• The proportion of MSM at SHCs who have prior exposure to HPV and have immunity 
• The proportion of MSM at SHCs at risk of HPV exposure 
• The proportion of MSM at SHCs who would complete a vaccine course 
• The administrative and logistical factors affecting programme delivery 
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This thesis examines the potential effectiveness of an HPV vaccination programme targeted 
at MSM attending SHCs by estimating key characteristics of HPV epidemiology and 
estimates of vaccine coverage in this population. Figure 1 represents the conceptual 
framework for this thesis and uses colour for concepts that will be estimated as part of this 
work, for example estimating risk of HPV exposure (current, prior and future), and grey for 
concepts that will be derived from the literature when synthesising the findings of this 
thesis.  
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FIGURE 1. SCHEMATIC REPRESENTATION OF THE CONCEPTUAL FRAMEWORK OF THE THESIS  
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1.2 RESEARCH QUESTION 
Would a targeted HPV vaccine programme for MSM in the UK, delivered in sexual health 
clinics (SHCs), be likely to be effective? 
1.3 AIMS AND OBJECTIVES 
The aim of this thesis is to inform the policy decision on whether to vaccinate MSM 
attending SHCs in the UK 
OBJECTIVES 
The broad objectives are: 
1. To describe the population of MSM attending the Mortimer Market Centre (SHC) in 
terms of demographics, behaviours and sexually transmitted infections 
2. To estimate HPV prevalence and risk factors in MSM who attend SHCs in the UK 
using different specimen types (anal, external genital, urine and oral) 
3. To compare HPV prevalence and risk factors across specimen types 
4. To estimate HPV16/18 seroprevalence in MSM who attend SHCs in the UK 
5. To estimate anogenital wart (AGW) prevalence in MSM who attend SHCs in the UK 
6. To estimate potential vaccine coverage of MSM attending SHCs in the UK 
7. To systematically review, appraise and summarise the literature on oral HPV 
infection in MSM 
8. To estimate the effect of a hypothetical targeted HPV vaccine programme for MSM, 
delivered at SHCs, on HPV16 prevalence and related anal cancer incidence 
Specific objectives are listed at the beginning of each results chapter. 
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FIGURE 2. TIMELINE OF PHD AND HPV IN MSM AT MORTIMER MARKET CENTRE STUDY  
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1.4 STRUCTURE OF THE THESIS 
This thesis is based on an empirical study carried out at the MMC, a sexual health service in 
central London, among MSM (HPV-MSM-MMC study), and a mathematical modelling study 
of anal HPV16 infection and anal cancer in SHC-attending MSM. The timeline of the HPV-
MSM-MMC study alongside the PhD timeline, including interruptions, is shown in Figure 2.  
Chapter 2 summarises the literature on aspects of HPV relevant to this thesis, including the 
estimates of HPV exposure in MSM available in 2009, at the start of this PhD.  
Chapter 3 is a systematic review and meta-analysis of oral HPV infection in MSM up to 
2014.  
Chapter 4 details the methods used in the HPV-MSM-MMC study, includes descriptive 
results relating to participant characteristics and behaviour, and addresses the external 
validity of the study’s findings.  
Chapter 5 presents the estimates of HPV prevalence and risk factors for HPV DNA 
detection. The relationship between DNA detection across anatomical sites (anal, external 
genital, urine and oral) is also explored and risk factors for HPV type-specific concordance 
at anogenital sites are identified. Findings are put into context with random effects meta-
analyses of studies of HPV prevalence in MSM up to mid-2015.  
In chapters 6 and 7, prior exposure to HPV infection is estimated, first by measuring 
seroprevalence of HPV16/18 (chapter 6) and then by measuring the prevalence of AGW 
(chapter 7). 
Chapter 8 explores health service use, HPV knowledge, vaccine attitudes and likelihood of 
accepting the vaccine, and provides estimates of vaccine uptake in SHC-attending MSM.   
Chapter 9 describes a preliminary mathematical modelling study used to inform estimates 
of vaccine effectiveness against HPV16 and HPV16-related anal cancer in HIV-negative and 
HIV-positive MSM attending SHCs.  
Each chapter’s findings are put into context by comparing to estimates from the literature 
up to 2014.  
Chapter 10 extends the context surrounding the research question and discusses the main 
findings of the PhD and addresses the research question. 
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1.5 ROLE OF THE CANDIDATE 
I received funding for this PhD from the Medical Research Council (MRC DTA). My PhD 
advisory panel consisted of my primary supervisor, Dr Pam Sonnenberg, my secondary 
supervisor, Dr Richard Gilson, supervisors of the mathematical modelling study (Professor 
John Edmunds and Dr Mark Jit) and advisors from Public Health England (PHE; Dr Simon 
Beddows and Dr Kate Soldan).  
HPV-MSM-MMC STUDY 
I was involved in the HPV-MSM-MMC study from its conception and was responsible for 
survey design and development, instrument testing/validation, project management, 
applications to funders, ethics committee and regulatory bodies, data management, 
cleaning and analyses and writing the first drafts of publications. I was supported in the 
study conception by Professor Graham Hart, Dr Pam Sonnenberg and Dr Richard Gilson 
(RG), and in developing the study protocol and materials by the advisory panel. RG, 
consultant in genitourinary medicine (GUM), was the principal investigator and he met with 
the study team regularly to monitor the progress of the study and to discuss problems and 
solutions, where necessary. He was also involved in the administration and ethics 
application for the study. While I was on maternity leave, RG was responsible for quality 
assurance at MMC. The study nurse, Carmel Young, recruited all men to the study, 
processed blood and oral samples before storing them and shipped all laboratory 
specimens to PHE. Dr Simon Beddows was responsible for all HPV DNA testing at the Virus 
Reference Department, PHE, Colindale and Dr Kate Soldan (PHE) organised for Dr Ezra 
Linley to conduct HPV serology testing at the vaccine evaluation unit, PHE, Manchester. I 
undertook all the data analyses relating to the HPV-MSM-MMC study in this thesis with 
statistical support from Dr Andrew Copas and Philip Prah. 
ANAL CANCER MODEL 
I undertook all the mathematical model development and analyses in this thesis. Dr Richard 
White and Professor John Edmunds advised on the model set-up at the outset of this PhD.  I 
was supported in decision-making, methodology and interpretation of results in the 
modelling study by Professor John Edmunds and Dr Mark Jit.  
ORAL HPV IN MSM SYSTEMATIC REVIEW AND META-ANALYSIS 
I designed and undertook all of the methods in the systematic review and meta-analysis. I 
was assisted in the interpretation of the random-effects analyses by Dr Andrew Copas, a 
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senior statistician. Dr Soonita Oomeer, a GUM & HIV speciality trainee registrar, replicated 
the search strategy, risk of bias assessment and data extraction (in a subset of articles), to 
validate the findings.   
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1.6 PUBLICATIONS AND CONFERENCE PRESENTATIONS RESULTING FROM THIS PHD 
PUBLICATIONS (APPENDIX VI, PAGE 320) 
1. King EM, Gilson R, Beddows S, Soldan K, Panwar K, Young C, Prah P, Jit M Edmunds WJ, 
Sonnenberg P. Human papillomavirus DNA in men who have sex with men: type-specific 
prevalence, risk factors and implications for vaccination strategies. Br J Cancer 2015;112: 
1585–1593. doi:10.1038/bjc.2015.90. 
2. King EM, Gilson R, Beddows S, Soldan K, Panwar K, Young C, Prah P, Jit M Edmunds WJ, 
Sonnenberg P.  Oral human papillomavirus (HPV) infection in men who have sex with men: 
prevalence and lack of anogenital concordance. Sex Transm Infect 2015;91:284–286. doi: 
10.1136/sextrans-2014-051955.  
REPORTS 
3. King EM, Gilson R, Beddows S, Soldan K, Panwar K, Young C, Prah P, Jit M Edmunds WJ, 
Sonnenberg P. Human papillomavirus DNA in men who have sex with men: type-specific 
prevalence, risk factors and implications for vaccination strategies. Submission to the Joint 
Committee on Vaccination and Immunisation (JCVI), 22 September 2014. 
4. Ong KJ, Lin A, Hobbelen P, King EM, Mesher D, Edmunds WJ, Sonnenberg P, Gilson R, Bains I, 
Soldan K,  Jit M. The impact and cost-effectiveness of selective HPV vaccination of men who 
have sex with men via sexual health clinics: a rapid assessment. Submission to the Joint 
Committee on Vaccination and Immunisation (JCVI), 22 September 2014. 
ARTICLES SUBMITTED TO PEER-REVIEWED JOURNALS 
5. King EM, Oomeer S, Gilson R, Copas AJ, Beddows S, Soldan K, Jit M, Edmunds WJ, Sonnenberg 
P. Oral human papillomavirus infection in men who have sex with men: a systematic review 
and meta-analysis. Cancer Epidemiol Biomarkers Prev 
CONFERENCE PROCEEDINGS  
1. King EM, Sonnenberg P, Panwar K, Beddows S, Prah P, Jit M, Soldan K, Edmunds WJ, Gilson R. 
Prevalence of, and risk factors for, detectable HPV DNA in anogenital swabs and urine of MSM 
attending a sexual health clinic in London, UK. Poster PH.PP02.41. Poster presentation at the 
29th Annual International Papillomavirus Conference, 21–25 August 2014, Seattle, Washington. 
2. King EM, Sonnenberg P, Panwar K, Beddows S, Prah P, Jit M, Soldan K, Edmunds WJ, Gilson R. 
Prevalence of, and risk factors for, detectable HPV DNA in anogenital swabs and urine of MSM 
attending a sexual health clinic in London, UK: evidence to inform HPV vaccination policy. Poster 
presentation at the Public Health England Annual Conference 2014, 16–17 September 2014, 
Warwick University, UK; Poster 202. 
3. King EM, Oomeer S, Gilson R, Copas AJ, Beddows S, Soldan K, Jit M, Edmunds WJ, Sonnenberg P. 
Oral human papillomavirus infection in men who have sex with men: a systematic review and 
meta-analysis. Abstract: HPV15-0355. Poster presentation at the 30th Annual International 
Papillomavirus Conference, 17-21 September 2015, Lisbon, Portugal. 
4. King EM, Sonnenberg P, Panwar K, Beddows S, Prah P, Jit M, Soldan K, Edmunds WJ, Gilson R. 
HPV DNA detection in urine, external genital and anal specimens in MSM: concordance between 
sites, and risk factor comparison. Abstract: HPV15-0352. Poster presentation at the 30th Annual 
International Papillomavirus Conference, 17-21 September 2015, Lisbon, Portugal. 
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2. LITERATURE REVIEW 
In this chapter, I establish the context of the thesis, combining background information with 
literature reviews of the epidemiological parameters estimated in this thesis. I adopted this 
approach in order to reflect the conceptual framework of the thesis (Figure 1, page 20) and 
the discussion narrative (chapter 10). I have restricted the review to the literature available 
when developing the research question, up to 2009, and, due to the rapidly accumulating 
evidence-base during this PhD, have updated these to mid-2015, in the “findings in context” 
section of each results chapter, and in the discussion.  
It starts with a summary of HPV classification and then considers studies that quantify the 
burden of potentially vaccine-preventable HPV-related disease in MSM. The explanation of 
HPV natural history, in terms of replication cycle and pathogenesis, links HPV infection to 
disease. I then review the epidemiology of current HPV infection (DNA detection) in MSM, 
including age-specific prevalence and risk factors, followed by prior HPV infection, in terms 
of anti-HPV antibodies and history of AGW. Then I describe the relevance of future risk of 
infection, estimated from age-specific HPV prevalence and transmission behaviour.   
After discussion of HPV infection, I turn to vaccination. First I describe the theory behind 
interrupting sexually transmitted infections (STIs) through vaccination. I then describe the 
HPV vaccines and review vaccine efficacy studies. There were no estimates of vaccine 
efficacy in men at the outset of this PhD, and these important data are reviewed in detail in 
the thesis discussion, so in this chapter I review efficacy estimates in women, available in 
2009. I then describe issues relating to MSM and age at vaccination. Finally, I discuss 
potential vaccine coverage in the target MSM population and summarise findings from cost-
effectiveness analyses available in 2009. 
2.1 CLASSIFICATION OF HUMAN PAPILLOMAVIRUSES  
Human papillomaviruses belong to the Papovaviridae family which is characterised by virus 
structure and genome organisation. The structure consists of a non-enveloped icosahedral 
capsid composed of two proteins (the major coat protein, L1; and the minor protein, L2) 
containing circular double-stranded DNA associated with cellular histones. Of the eight 
open reading frames (ORF) within the genome, the L1 is the most conserved and is used for 
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taxonomy. Genera share less than 60% nucleotide sequence identity in the L1 ORF and 
species share 60-70%. Within species, types share 71-89%, subtypes 90-97% and variants 
98%21. So far, over 100 types of HPV that infect humans have been identified22, some of 
which are displayed in Figure 3. 
FIGURE 3. A CLADOGRAM TO SHOW THE EVOLUTIONARY RELATIONSHIP AND CLASSIFICATION OF 
PAPILLOMAVIRUSES.  
 
Based on the complete L1 ORF of 96 HPV types and 22 animal papillomavirus types. Source: de Villiers et al21. 
HPV types are differentially equipped to infect cells, evade immune responses, replicate 
within, and transmit from, specific host tissue sites. For example, HPV16 is sexually 
transmitted, infects mucosal surfaces such as the mouth, oesophagus and cervix and can 
lead to cancer. This work focuses on sexually transmitted HPV types, within the genus 
alpha-papillomaviruses, that are tropic to mucosal surfaces of the genital and upper 
digestive tracts of men. Of alpha-papillomaviruses, those that cause warts or respiratory 
papillomatosis, HPV6 and HPV11, are referred to as low-risk (LR-HPV), those that are 
associated with malignancies, notably HPV16/18/31/33/35/39/45/51/52/56/58/59/68, are 
referred to as high risk (HR-HPV) and those possibly associated with malignancies, 
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HPV26/53/66/70/73/82, are referred to as possible HR-HPV10,11. Possible HR-HPV suggests 
that these types might not be oncogenic, however, given their phylogenetic proximity to 
other HR-HPV types, it is expected that they would be re-classified as HR-HPV once 
sufficient data have accumulated to detect this association. 
2.2 SEXUALLY TRANSMITTED HPV 
HPV transmission depends on skin-to-skin contact and there is strong evidence for sexual 
transmission, weaker evidence for mouth-to-mouth transmission and inconclusive evidence 
for fomite or auto-inoculation. Different sex practices involve different anatomical sites 
with distinct local epithelial environments. For example, the cervix and the anal canal have 
transformation zones, which are particularly sensitive to HPV infection compared to the 
keratinised skin of the penis. These differences are reflected in the epidemiology of HPV 
infection and disease at different anatomical sites.  
2.3 HPV-RELATED DISEASE IN MEN AND MSM 
HPV-related disease in men includes LR-HPV-related AGW and recurrent respiratory 
papillomatosis and HR-HPV-related oropharyngeal, penile and anal cancers. Human 
immunodeficiency virus (HIV) infection is a risk factor for HPV infection, as described on 
page 42, and MSM are at increased risk of HIV infection, as well as numerous other STIs, 
compared to men who have sex exclusively with women (MSEW)23. Therefore, where 
possible, the estimates of HPV-related disease outcomes are stratified by HIV status in this 
review. Furthermore, there appears to be an HIV-independent risk of HPV-related disease 
in MSM because HIV-negative MSM are at greater risk compared to HIV-negative MSEW. 
MSM IN BRITAIN 
The National Surveys of Sexual Attitudes and Lifestyles (Natsal) collect population-level data 
about sexual behaviour in Britain.  In 2009, two of these stratified probability sample 
surveys of the general population had been completed, the first in 1990-1991 (Natsal-1)  
and the second (Natsal-2) between 1999 and 200124. Table 1 shows the proportion of the 
British male population reporting same-sex behaviour. In 1990, the proportion of men, 
aged 16-44, reporting having genital contact with another man in the last five years was 
1.5% and in 2000 it was 2.8%8.  
30  
 
TABLE 1. PROPORTION OF THE BRITISH MALE POPULATION, AGED 16-44, REPORTING SAME-SEX 
BEHAVIOUR 
 Natsal-1 
(1990) 
% (95% CI) 
Natsal-2 
(2000)  
% (95% CI) 
Homosexual experience ever: any experiences with men-did not 
necessarily lead to genital contact 
6.0 (5.4–6.7)  8.4 (7.6–9.3) 
 
Oral or anal sex, or any other genital contact, with a man ever 3.6 (3.1–4.2) 5.4 (4.8–6.1) 
Genital contact with another man in the last 5 years 1.5 (1.2–1.9) 2.8 (2.3–3.3) 
Abbreviations: CI= confidence interval, Natsal= National Surveys of Sexual Attitudes and Lifestyles 
ANOGENITAL WARTS 
Overall in men in England in 2009 the incidence of diagnosed episodes of AGW was 163 per 
100,000 person years. In 2009, the number of episodes in MSM attending SHC clinics in 
England was 2,592, representing 6% of all male AGW episodes recorded in SHCs, of which 
1,010 (39%) were in MSM residing in London. Incidence was not calculated in MSM due to 
the uncertainty in the size of the denominator25. In women, over 90% of genital warts were 
associated with HPV types 6 and 1126.  
ANAL CANCER 
Anal cancer is rare in men in the UK, with a cancer registry estimate in 2008 of 1.5 per 
100,000 person years27, but is increasing (Figure 4), perhaps due to changes in sexual 
behaviour27–29.  
FIGURE 4. DIRECTLY AGE-STANDARDISED RATESa OF NEWLY DIAGNOSED CASES OF ANAL CANCER PER 
100,000 MEN IN ENGLAND 1995-2012b 
 
aStandardised to the new European Standard Population 2013.  bCancers registered before February 2014. 
Cancer registries do not collect data on sexual identity or behaviour so determining the risk 
associated with same-sex sexual behaviour in men compared to exclusively heterosexual 
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sex is complex. The age-specific rates of anal cancer in men in England (Figure 5) show that 
cancer is diagnosed in later life, probably resulting from slow disease progression rates. 
FIGURE 5. AGE-SPECIFIC RATES OF NEWLY DIAGNOSED CASES OF ANAL CANCER PER 100,000 MEN IN 
ENGLAND IN 2012a 
 
aCancers registered before February 2014. Due to fewer than 20 reported cases in the younger age groups, there is low 
reliability in the younger estimates. 
At Chelsea and Westminster hospital, London, in 40,126 patients-years of follow-up of their 
HIV cohort, there were 26 cases of anal cancer and 25 of these were in MSM. The incidence 
before the introduction of antiretroviral therapy (ART) in 1996 was 35 per 100,000 patient-
years (1984-1995; 95% CI: 15-72) compared to 92 per 100,000 patient-years (95% CI: 52-
149) in the post-ART era (1996-2003). Having compared these estimates to those expected 
in a gender- and age-matched population in England in the same time-frame, these 
estimates were 67 and 176 times higher in the pre- and post-ART eras, respectively, 
compared with the general population30.  
Figure 6 shows international studies that have estimated anal cancer incidence in MSM 
populations. The majority of estimates are from the US. Men in registered homosexual 
partnerships in Denmark between 1989 and 1997 had 31 times the risk of diagnosed anal 
cancer compared to the expected incidence from the overall male population31. It has been 
estimated that 77-88% of anal cancer is related to HPV32,33. Evidence that the risk of anal 
cancer is greater in MSM31 suggests that they are also more susceptible, because of risk 
behaviour, to other HPV-related outcomes. 
See page 42, for 
an explanation of 
different estimates 
in MSM by HIV 
treatment status. 
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FIGURE 6. ANAL CANCER INCIDENCE ESTIMATES, WITH 95% CONFIDENCE INTERVALS, IN 
INTERNATIONAL MSM POPULATIONSa, ACCORDING TO HIV STATUS AND COMBINED ANTIRETROVIRAL 
THERAPY ERA. 
Abbreviations: HIV=human immunodeficiency virus, post-ART= post combined anti-retroviral therapy era (1996-2009), pre-
ART=pre-combined ART era (before 1996), US=United States of America. ain studies conducted before 2009 in Australia,  
Denmark, France, Italy and the US. Koblin (1996)34, D’Souza(2008)35, Van Leeuwen (2009)36, Piketty (2008)37, Frisch (2003)31, 
Dal Maso (2009)38, Chaturvedi (2009)39, Silverberg (2009)40. 
PENILE CANCER 
Like anal cancer, cancer of the penis is rare in the UK, with a similar incidence for men of 
2.0 per 100,000 person years in 200827, but the proportion estimated to be HPV-related is 
lower at 50%41. The overall preventable disease burden in men is therefore less than for 
anal cancer. 
OROPHARYNGEAL CANCER 
HPV is associated with oropharyngeal cancers10. The tonsils and base of tongue (anatomical 
sites within the oropharynx) have HPV-susceptible reticulated epithelium at the base of 
crypts within the stratified squamous epithelium of lymphatic tissue. In men in the UK in 
2008, the incidence of cancers of the lip, oral cavity and pharynx was 16.8 per 100,000 
person years. Incidence of male tonsillar cancer was 2.7 per 100,000 person years and of 
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male base-of-tongue cancer was 1.5 per 100,000 person years27. The proportion of 
oropharyngeal cancers attributed to HPV varied by region and by time period, rising (in 
Europe) from 35% in cohorts recruited before 2000 to 59% in cohorts recruited between 
2000 and 2004 and 73% between 2005 and 200942. While it is known that  approximately 
25% of head and neck cancers and 45-90% of oropharyngeal cancers are associated with 
HPV infection43,44, it is uncertain what the rate of disease progression is in those with HPV 
infection, or what co-factors may be involved.  
2.4  HUMAN PAPILLOMAVIRUS REPLICATION AND NATURAL HISTORY 
HPV-related disease epidemiology does not correspond directly to the underlying pattern 
of HPV infection because the majority of HPV infections are not pathogenic and are 
transient, and, in those with persistent infections, the development of cancer takes many 
years.  
The course of HPV infection depends on both the host immune response and viral factors, 
especially HPV immune evasion capabilities, including the replication cycle, and 
pathogenesis. Viral pathogenesis and replication are controlled by the eight genes of the 
viral genome which are grouped into early (E1-E2; E4-E7), late (L1 and L2; capsid proteins) 
and the LCR. E1 and E2 genes encode the viral replication proteins and E6 and E7 are the 
viral oncogenes.  
Current understanding of the natural history of anal HR-HPV infection is assumed to be 
similar to that of the cervix, which has been studied in detail. Sexually transmitted HR-HPV 
is thought to infect keratinocytes at the basal layer of the stratified epithelium at sites of 
micro-abrasion as shown in Figure 7. Once infected (Figure 8. ), either silent infections 
develop, where viral replication is inhibited and not associated with pathogenicity, or new 
viral particles are synthesised and released from the upper epithelial layers. Viral synthesis 
occurs in both productive infections and cervical intra-epithelial neoplasia grade 1 (CIN1). 
Viral synthesis is associated with ordered viral gene expression and completion of viral 
replication. Progression to high-grade CIN (CIN2/3) develops with de-regulated gene 
expression, and progression to cancer is associated with persistence of high-grade CIN (HG-
CIN), viral genome integration and deregulated oncogene expression. Regression as well as 
progression between disease states occurs. Nonetheless, the majority of infections resolve 
naturally, either completely or resulting in viral latency45. Anal lesions are defined similarly 
to the cervix and termed as anal intra-epithelial neoplasia (AIN). 
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FIGURE 7. HR-HPV ENTRY INTO BASAL LAYER OF STRATIFIED MUCOSAL EPITHELIUM 
 
Source: Kahn (2009)46 
 
The viral replication cycle is linked to the differentiation of the keratinocyte. During cell 
division, minimal replication occurs with approximately 50-100 viral copies per cell and 
then, during cell differentiation, ordered gene expression is triggered, resulting in 
thousands of viral copies per cell. For a variety of reasons, including the absence of 
cytolysis, HPV replication does not result in inflammation. Therefore the innate immune 
response is not triggered and the adaptive immune response is ineffectively primed, 
permitting HPV infections to persist47.  
Intra-epithelial neoplasia is diagnosed using histology and is graded according to the depth 
of lesion invasion into the epithelium and the severity of the dysplasia. Using cytology, the 
Bethesda system classifies squamous cell abnormalities into four categories: atypical 
squamous cells (ASC), squamous cells of undetermined significance (ASCUS), low-grade 
squamous intraepithelial lesions (LSIL) and high-grade squamous intra-epithelial lesion 
(HSIL). HSIL is the equivalent of AIN2 or AIN3, and LSIL of AIN148.  
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FIGURE 8. CERVICAL HR-HPV INFECTION  
 
 
Cells in cycle are indicated by the presence of red nuclei. Cells expressing E4 are shown in green, while those expressing L1 are shown in yellow. The brown shading identifies all the cells (differentiated and un-
differentiated) that contain viral genomes. Source: Doorbar et al45.  
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2.5 PREVALENCE OF HPV INFECTION IN MSM 
HPV DNA detection by polymerase chain reaction (PCR) is indicative of HPV infection but 
detection of mRNA would indicate ongoing viral replication, suggestive of active infections 
that may persist and progress to disease and are probably more clinically relevant49–51. All 
studies estimating the prevalence of HPV infection in MSM have used HPV DNA detection by 
hybrid capture or PCR and in this thesis, as in the wider literature, HPV DNA detection is 
used interchangeably with HPV infection.  
HIV infection is a risk factor for HPV infection, as described on page 42, so HPV prevalence 
estimates in this review are stratified by HIV status. 
PREVALENCE OF ANAL HPV INFECTION  
Studies estimating the crude prevalence of anal HPV infection in MSM up to 2009 are 
displayed for HR-HPV in Figure 9, for HPV16 in Figure 10, for LR-HPV in Figure 11 and for 
HPV6 infection in Figure 12. Estimates were not age-standardised.  As shown in Figure 9, all 
five studies measuring the prevalence of at least one HR-HPV type in HIV-negative MSM 
were performed in the US and only one of these recruited participants in a clinic setting (the 
acquired immunodeficiency disease syndrome (AIDS) Prevention Project of the Seattle-King 
County Department of Public Health)52. There was variability in the classification of HR-HPV 
types, especially before 2009, which would have contributed to the differences in estimates 
between studies10,53.  A quarter to a third of HIV-negative MSM (range: 26-38%) had at least 
one detectable HR-HPV type in the anal canal. Chin-Hong et al. conducted the largest study 
in 1218 HIV-negative MSM, the EXPLORE study, and estimated HR-HPV prevalence at 25%54.  
The prevalence of HR-HPV in the anus was generally higher in HIV-positive MSM populations 
ranging from 40 to 86 percent.  
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 FIGURE 9. STUDIES MEASURING THE ANAL CANAL PREVALENCE OF HR-HPV IN HIV-NEGATIVE AND 
HIV-POSITIVE MSM POPULATIONS BEFORE 2009. 
 
Abbreviations: N= sample size. Chin-Hong (2008)55, Chin-Hong (2004)54, Critchlow (1998)52,  Friedman (1998)56, Palefsky 
(1998)57, Anderson (2008),   Piketty (2004)58, Lacey (1999)59, Sayers (1998)60, Palefsky (1990)61. 
 
Figure 10 shows that there were two studies measuring anal HPV16 prevalence in HIV-
negative MSM in SHC settings, both in Europe, in 105 MSM in Edinburgh (prevalence=11%) 
and 241 in Rotterdam (prevalence=9%). 
There were more studies of anal HPV16 prevalence in HIV-positive MSM populations. Of the 
five studies in European clinics, two were in the UK: Edinburgh (n=11)60 and Manchester 
(n=54)59. Heterogeneity between studies is introduced not only from underlying differences 
in the population, such as socio-cultural influences on sexual behaviour, or sexual network 
properties, but also from measurement differences such as sampling method, storage 
conditions or laboratory assays.  
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FIGURE 10. STUDIES MEASURING THE ANAL CANAL PREVALENCE OF HPV16 IN MSM POPULATIONS, 
BY HIV STATUS, BEFORE 2009 
Chin-Hong (2004)54, Van der Snoek (2003)62, Friedman (1998)56, Palefsky (1998)57, Sayers (1998)60, Sirera (2006)63, Piketty 
(2004)58 Lacey (1999)59,  Palefsky (1997)64. 
Figure 11 shows the four studies measuring anal LR-HPV prevalence in MSM. Varied 
classification of LR-HPV types limits the comparison of estimates between studies so Figure 
12 displays the estimates from the six studies measuring HPV6 prevalence, of which four 
recruited from clinic settings. Having stratified estimates by HIV status, four estimates were 
in HIV-negative (range 4-13%) and six in HIV-positive populations (range 7-36%). Compared 
to estimates for HPV16 and HR-HPV prevalence, for LR-HPV and HPV6, prevalence did not 
appear to differ, to the same extent, by HIV status. This pattern was repeated for estimates 
of HPV11 prevalence, ranging from 3-13% for HIV-negative and 5-27% for HIV-positive MSM. 
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FIGURE 11. STUDIES MEASURING THE ANAL CANAL PREVALENCE OF LR-HPV IN POPULATIONS OF 
MSM BEFORE 2009  
 
Abbreviations: N= sample size. LR-HPV definitions: Chin-Hong (2004)54 =HPV6/11/53/54/55/66/pap155/pap291,  Van der 
Snoek (2003)62=HPV6/11, Friedman (1998)56=HPV6/11/40/53/54/55/66/pap155/pap291, Lacey (1999)59=HPV6/11.  
FIGURE 12. STUDIES MEASURING ANAL HPV6 PREVALENCE IN POPULATIONS OF MSM BEFORE 2009 
 
Abbreviations: N= sample size. Van der Snoek (2003)62, Friedman (1998)56, Palefsky (1998)57, Sayers (1998)60, Sirera (2006)63,  
Palefsky (1997)64
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PREVALENCE AT OTHER ANATOMICAL SITES 
The three studies measuring the prevalence of HPV infection at other anatomical sites in 
MSM populations, before 2009, are presented in Table 2. There were no studies in MSM 
attending SHCs in the UK. Other studies have compared HPV prevalence at different 
anatomical sites in non-MSM populations63,65–67.  Van der Snoek et al, conducted a study 
in Rotterdam, and found that in HIV-positive men, HPV16 was the most frequently 
detected type (2/17) in penile specimens and in HIV-negative men HPV6 was the most 
frequently detected type (12/241). Penile HR-HPV prevalence was 3/17 and 19/241 in 
HIV-positive and HIV-negative MSM, respectively62. 
TABLE 2. STUDIES ESTIMATING HPV PREVALENCE AT EXTRA-ANAL ANATOMICAL SITES IN MSM 
POPULATIONS 
Author 
(year) Population 
Sample size by HIV 
status 
Penile 
prevalence 
% (95% CI) 
Oral prevalence 
% (95% CI) 
Van der 
Snoek 
(2003)62 
STI clinic and gay bars/saunas, Rotterdam, 
The Netherlands 
17 HIV+ve 
241 HIV-ve 
23 (7-50) 
16 (11-21)  
Sirera 
(2006)63 
 HIV clinic, Barcelona, Spain 
52 HIV+ve 
 
38 (25–53) 
  33 (20–47) 
Coutlée 
(1997)68 STI/Gasteroenterology clinic, Canada 177 unknown HIV  15 (10-21) 
AGREEMENT IN HPV DETECTION BETWEEN ANATOMICAL SITES 
Characterising the relationship between HPV infection at different anatomical sites is 
helpful to understand HPV natural history, to estimate transmission efficiency of specific 
sexual acts and to explain HPV and related cancer epidemiology. 
Few studies had examined the relative detection of type-specific HPV between sites. In 
Spain, penile HPV infection was related to oral HPV infection (OR, 2.7; 95% CI, 1.0–7.7)63. 
However, in 30 men with anogenital HPV-associated lesions, in São Paulo, Brazil, of 
whom three were homosexual, none had HPV detected at oral mucosa69. 
As a marker for the sensitivity of DNA detection at each anatomical site, the quantity of 
viral DNA can be measured using real-time PCR and compared across sites. In men in the 
US, real-time PCR detected the most HPV16 genomes per cell in the penile shaft 
specimen followed by the anal, peri-anal, coronal sulcus/glans penis, scrotum, semen 
and urethral specimens70.  
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AGE-SPECIFIC PREVALENCE OF HPV INFECTION 
Aggregate HPV prevalence is useful for predicting population-level risk but age-specific 
prevalence provides additional information that is necessary to decide when to 
vaccinate. The cervical prevalence of HPV rapidly rises in mid-adolescence, 
corresponding to sexual debut, peaks in late adolescence and declines thereafter (Figure 
13)71. 
FIGURE 13. AGE RELATIONSHIP OF HPV-RELATED CERVICAL DISEASE 
 
Source: Garland et al71. 
The age-specific anal canal prevalence of HPV was examined in the EXPLORE study of 
1218 HIV-negative MSM in the US (Figure 14)54. There was no statistically significant age 
relationship with anal HPV infection (overall, HR-HPV or LR-HPV) or with anal lesions 
(overall, high grade or low grade). Unlike at the cervix71, there was no peak in prevalence 
in the study age range (18-70 years) nor was there a decline in prevalence by age. The 
majority of men in the EXPLORE study were older than 40 so identifying any age-
association in younger men, where prevention is likely to be most beneficial, was limited 
by sample size. 
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FIGURE 14. ANAL HPV INFECTION, BY AGE GROUP, IN HIV-NEGATIVE MSM PARTICIPATING IN 
THE EXPLORE STUDY. 
 
Adapted from Chin-Hong et al (2008) to include confidence intervals that were determined using the binomial exact 
method. HR-HPV types were defined as HPV16/18/31/33/35/39/45/51/52/56/58/59/68/73 and LR-HPV types were 
defined as HPV6/11/53/54/55/66/Pap 155/Pap 29154. NB. The EXPLORE study definition of HR-HPV differs from that used 
in this thesis (Box 5, page 92) 
RISK FACTORS FOR HPV INFECTION AND DISEASE  
Factors that have been identified as risk factors for HPV infection in MSM are displayed 
in Table 3. HIV infection is associated with widespread disruption of the innate and 
adaptive immune responses, including depletion of CD4+ T cells which are required for 
effective cell-mediated immunity (CMI)72. This impairment to the CMI response might 
contribute to HIV-associated increased susceptibility to HPV infection, reactivation from 
latency or duration of infection. Immunosuppression, in combination with increased STI 
transmission behaviours, would explain the higher HPV prevalence estimates in HIV-
positive MSM (Figure 9, page 37) and increased likelihood of HPV disease progression. 
For example, Palefsky et al found that a larger proportion of HIV-positive MSM, who 
were free of baseline anal HPV-related disease, were found to develop AIN, compared 
with HIV-negative MSM73. 
A marker for severity of HIV-associated immunosuppression is the CD4 T cell count; the 
number of T cells expressing the cell surface glycoprotein CD4 per cubic millimetre of 
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blood. A marker for HIV replication is the number of HIV RNA copies per millilitre of 
blood. ART has evolved in efficacy over the last 25 years to restore CD4 cell counts and 
reduce viral replication so that viral load can become undetectable. HPV infection is 
more likely at reduced CD4 counts yet, following population-level immune 
reconstitution (ART era), anal cancer rates are still increasing (Figure 6). This is because 
HIV-positive populations on therapy have increased life expectancy and therefore 
increased time at risk of HPV-related cancer development, in later life, when the 
majority of HPV-related cancers are diagnosed (Figure 5). Furthermore, whilst CD4 T cell 
numbers are restored with ART, the complex balance of functionally different T cells and 
the associated cytokine cocktail is not regained so there remains immune function 
impairment in treated HIV-positive populations. 
Other factors that increase susceptibility to HPV-related disease include 
immunosuppressive therapy in transplant recipients74,75, oestrogen levels76; smoking77; 
injected drug use; age; coinfection with Chlamydia trachomatis78 or herpes simplex  
virus (HSV)79; anal receptive intercourse in men; and constant irritation or chronic 
inflammation of the anus80–83. Factors that have been identified in MSM are displayed in 
Table 3. 
TABLE 3. RISK FACTORS FOR HPV INFECTION IN MSM IDENTIFIED IN STUDIES PUBLISHED UP TO 
2009 
Risk factor HIV statusa Association (95% CI) Ref. 
Behaviours 
   
Medium/high Lifetime level (frequency and time period) of 
receptive anal sex compared to no receptive anal sex 
- RR=1.5 (1.1-2.1) 57 
> 500 lifetime partners compared to <50 - OR=2.22 (1.01-4.87) 84 
> 30 partners in the last 6 months compared to <6 - aOR=2.3 (1.5-3.6) 54 
Receptive anal intercourse in the last 6 months - aOR=2.0 (1.5-2.8) 54 
Versatile compared to insertive preference during anal sex  - OR=2.09(1.09-2.01) 84 
Lifetime rectal drug use in HIV-negative MSM - RR=1.4 (1.1-1.7) 57 
Sexually Transmitted Infections 
   
HIV-positive N/A RR=1.5 (1.4-1.7) 57 
Chlamydia infection of the anus in last 12 months - OR 3.06 (0.83-11.35) 84 
Seropositivity for HSV-2 - OR 1.86 (1.01-3.45) 84 
Clinical  
   
Anal bleeding in the last 12 months  + OR=8.36 (1.05-66) 84 
Lifetime history of genital warts  - OR 3.26 (1.45-7.33) 
aOR 3.00 (1.30-6.81) 
84 
Lifetime history of rectal discharge  - RR=1.3 (1.0-1.7) 57 
aHIV status of the population in which the association was found. Abbreviations: ref.=reference number, -=HIV-negative, 
+=HIV-positive, -/+=Both HIV-negative and HIV-positive.  HSV=herpes simplex virus, RR=relative risk, OR=Odds ratio, 
aOR=adjusted OR, HR=Hazard Ratio,  95% CI= 95% confidence interval, N/A=Not Applicable 
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2.6 CUMULATIVE EXPOSURE TO HPV 
Prevalence is a measure of the proportion of infected individuals at one point in time. It 
does not convey information about the dynamics of the infection that are important for 
estimating cumulative risk of HPV exposure. Prevalence is a function of incidence, the 
rate of occurrence of new infections, and duration of infection (prevalence=incidence x 
duration). Age-specific HPV type-specific incidence and clearance rates could be 
estimated in longitudinal studies but in 2009 these studies had not been conducted in 
MSM.  
The utility of age-specific HPV prevalence for estimating periods of high incidence was 
demonstrated in women, where maximum incidence occurs in late adolescence (Figure 
13). In MSM, where no age-relationship has been defined, other measures of cumulative 
risk, such as age-specific seroprevalence and history of AGWs, precancerous lesions or 
cancer, are useful. Each measure has its own limitations so combining these 
measurements provides the best estimate of age-specific likelihood of prior exposure to 
HPV. 
2.7 HPV SEROPREVALENCE  
Seropositivity is a specific but insensitive marker of prior exposure because 
seroconversion does not always follow natural infection and duration of antibody 
persistence is variable. In a population of young heterosexual male students in Seattle 
less than 36 percent seroconverted within two years of HPV infection and 
seroconversion was associated with genital site of infection and smoking85. Questions 
remain as to the clinical relevance of seropositivity: are infection-induced antibodies 
effective against re-infection and are they involved in clearance? Seroconversion is not 
necessary for viral clearance and antibody concentrations are several times lower than 
those induced by vaccination86,87. Furthermore the distribution of duration of infection-
induced serum antibodies is not well characterised which limits the use of seropositivity 
as a direct marker of cumulative exposure. 
Laboratory tests of seropositivity involve binding of antibodies to virus-like particles 
(VLPs) detected in a variety of ways such as traditional enzyme-linked immunosorbent 
assay (ELISA) or competitive Luminex assays. Each assay has its own sensitivity for 
antibody detection and calibration for antibody quantification.   
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Seroprevalence had been estimated in one population of MSM, recruited between 1989 
and 1995 to an AIDS prevention study from a clinic in Seattle88. Less than half of HIV-
negative MSM were seropositive for HPV16 (48%; 95% CI 37-58) or HPV6 (41%; 95% CI 
31-51) with similar estimates in HIV-positive MSM (HPV16=42%; HPV6=32%). The 
presence of AGW, a history of gonococcal urethritis and detectable anal HPV6 DNA were 
associated with HPV6 antibody detection. In contrast, HPV16 seropositivity was 
associated with being older than 35 years, reporting more than 50 lifetime partners and 
intravenous drug use. Notably, HIV status, anal HPV16 DNA detection and anal 
squamous intraepithelial lesions (low or high grade) were not associated with 
seropositivity88. 
AGE-SPECIFIC SEROPREVALENCE 
Men in the National Health and Nutrition Examination Survey (NHANES), between 2003–
2004, representing the US population, had a lower seroprevalence, of any quadrivalent-
vaccine type, than women (Figure 15) and far lower than MSM in Seattle (as above) with 
overall estimates of 6% for HPV6, 2% for HPV11, 5% for HPV16, and 2% for HPV18. 
Seroprevalence was significantly associated with age with men aged 50-59 having a 13-
fold risk of seropositivity for any quadrivalent type compared to men aged 14-19 years89. 
FIGURE 15. SEROPREVALENCE OF ANY QUADRIVALENT HPV TYPE, AMONG MALES AND FEMALES, 
BY AGE GROUP, IN THE NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY 2003–2004. 
 
Source: Markowitz et al (2009)89. Quadrivalent vaccine types=HPV6/11/16/18. National Health and Nutrition Examination 
Survey (NHANES) is a population-based survey in the US. 
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2.8 AGE-SPECIFIC AGW PREVALENCE 
A diagnosis of AGW is a useful marker for exposure to LR-HPV types because AGW 
development is more likely following HPV infection and occurs sooner than HPV-related 
cancer development. In England, the genitourinary medicine clinic activity dataset 
(GUMCAD) routinely collects data on AGWs episodes diagnosed at SHCs, including MSM 
status, age, and clinic90. Of the 2,592 AGW episodes diagnosed in MSM attending SHCs 
in England in 2009, 8% were in 15-19 year olds, 25% in 20-24 year olds, 33% in 25-34 
year olds and 34% in MSM older than 34 years25. At a population-level, there is potential 
for selection bias if not all AGWs episodes are diagnosed or recorded by health services. 
2.9 FUTURE RISK OF INFECTION 
Although age-specific HPV DNA prevalence, seroprevalence and AGW history can inform 
estimates of future risk of HPV infection, prevalence at older ages might also be due to 
increased duration of HPV infection or antibodies resulting from changes in host 
immunity over time. Age-specific estimates of STI transmission behaviour, such as 
condomless anal sex, offer an alternative, as proxy measures for risk of infection, in the 
absence of any studies directly measuring HPV incidence in MSM in 2009.  
It is possible that in MSM, like in women, STI transmission declines with age. For 
example, in the GMSHS, conducted in community venues and SHCs in London in 1996, 
66/356 (19%) of MSM younger than 25 years, 220/1149 (19%) of MSM aged 25-34 and 
84/612 (14%) of men older than 34 years reported condomless sex with a partner of 
unknown or discordant HIV status in the last year91.   
2.10 EPIDEMIC THEORY AND VACCINATION 
The basic reproduction number, R0, is defined as the expected number of secondary 
cases produced by a single, typical, infection in a susceptible population. For STIs, R0 can 
be calculated by multiplying the average transmission probability per partnership (𝛽𝛽) by 
the number of partnerships per unit of time (c) by the duration of infectiousness (D)92.  
The basic reproduction number is not applicable to the HPV epidemic in MSM, where a 
proportion of the population are infectious, a proportion immune (assuming that there 
is effective natural immunity) and a proportion susceptible. In such a mature epidemic, 
the number of new cases arising from an infectious person is represented by the 
effective reproduction number (Rn) which is calculated by multiplying R0 by the 
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proportion of the population that is susceptible. Vaccination reduces the proportion of 
the population that is susceptible, by “removing” them if they develop effective vaccine-
induced immunity, and therefore further reduces Rn. 
Rn is a useful epidemic parameter for predicting the course of an epidemic because 
when this is above one an epidemic will occur, when below one an epidemic cannot be 
sustained and at unity it will persist so becoming endemic. This threshold property can 
be manipulated to determine the critical proportion of the population that must be 
immune to eliminate transmission, the herd immunity threshold, which is calculated as 
one minus the reciprocal of R0. Vaccine coverage above the herd immunity threshold will 
result in elimination of transmission and below the threshold will result in the reduction 
of Rn but not elimination. 
This theory is based on population average estimates of 𝛽𝛽, c and D. In reality, however, 
MSM populations are heterogeneous in terms of 𝛽𝛽 because different sexual acts are 
associated with different transmission risks and both partnership duration and 
frequency of sexual acts within partnerships are variable. Furthermore, there is a highly 
skewed and wide distribution of partner change rates with some individuals reporting 
monogamy and others numerous overlapping partnerships, and rates are not constant 
for the same individual over time. In HPV infection, there is also heterogeneity in D: 
estimates of clearance rates are type-specific and persistent infections, with a unique D, 
represent a distinct infection type from transient infections93.  
Heterogeneity results in a different Rn in each sub-population contributing differentially 
to the overall Rn. Targeting constrained intervention resources at sub-populations with a 
high Rn, such as MSM attending SHCs, compared to sub-populations with low STI 
transmission behaviours (low Rn), or spreading resources throughout the entire 
population, will maximise the reduction of average Rn. This explains the concept of a 
“core group”, one which disproportionately influences the spread of disease by virtue of 
its higher Rn, often attributed to higher rates of partner change (c)92. 
SEXUAL NETWORKS 
Calculations of R0 and Rn rely on the assumption that individuals acquire sexual partners 
at random (mass action principle) which does not reflect reality where a set of complex 
factors play a role in sexual selection. Social network theory can estimate an individual’s 
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importance in a network which is proportional to the extent the network would be 
interrupted if they were removed. Graph theory can quantify numerous network 
properties such as clustering and connectedness, and percolation theory allows 
estimation of the spread of infection through a network and so can dynamically predict 
the size of an epidemic. This is relevant to vaccination because an individual’s network 
position puts them at risk of acquiring and transmitting an infection which may not be 
discernible from their individual risk behaviour. Immunising individuals at important 
network positions will be the most efficient way of disrupting the spread of infection 
and reducing both individual and population-level risk of HPV infection94.  
2.11 HPV VACCINES 
In 2009, there were two licensed vaccines in the UK: the bivalent vaccine (Cervarix®) 
protecting against HPV16/18 and the quadrivalent vaccine (Gardasil®) protecting against 
HPV16/18, and the low-risk types HPV6/11. Gardasil® was indicated for use in women 
aged 9-26 and Cervarix® in women aged 10-25. Neither had yet been evaluated for use 
in men.  
MODE OF ACTION, TARGETED TYPES 
Vaccines contain VLPs that are made up of genetically engineered L1 proteins conferring 
type-specific humoral immunity when injected intramuscularly. Vaccine-induced HPV 
type-specific neutralising antibodies are thought to prevent the virus from entering 
human cells but not from attaching to the cell surface. The bivalent vaccine induces 
antibodies specific to HPV16 and 18 and the quadrivalent induces antibodies to HPV6, 
11, 16 and 18.  
RANDOMISED CONTROLLED VACCINE TRIALS IN WOMEN 
Vaccine efficacy is estimated in randomised double-blinded controlled trials. For HR-
HPV, it is not feasible to estimate the efficacy against cancer, because of slow 
progression rates, so efficacy was estimated against HPV infection and cancer 
precursors. At the outset of this PhD, vaccine efficacy estimates were only available in 
populations of young women with no detectable history of HPV infection. The phase III 
trials for the bivalent and quadrivalent vaccines showed continued efficacy above 90% 
See discussion, 
page 238, for 
review of vaccine 
efficacy literature 
2009-present 
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against CIN2/3 in the per protocol arm for 6.4 years (Cervarix®) and 5 years (Gardasil®)95 
with no safety concerns96.  
2.12 TIMING OF HPV VACCINATION 
As shown in Figure 13, in order to prevent HPV infection in women it is critical to 
vaccinate prior to the increase in HPV incidence. Previous exposure to HPV might reduce 
the vaccine benefit if effective natural immunity is generated so that there would be no 
additional benefit from vaccination or if previous exposure or increasing age reduces 
immunogenicity of the vaccine. Furthermore, women already infected when vaccinated 
do not clear these infections more readily and may still develop disease so intervening 
before infection is the optimal strategy for prevention97,98.  
Early vaccination of MSM has feasibility issues. Targeting adolescent boys by sexual 
identity, perhaps in schools or university societies, would be difficult and inefficient for a 
variety of socio-cultural reasons. MSM attending SHCs are engaged with healthcare but, 
by definition, having engaged in sex with men, may have been exposed to HPV already.  
There is also likely to be heterogeneity of sexual behaviour and HPV prevalence between 
MSM sub-populations, especially across cultural settings (including place) and between 
those accessing sexual health services and those who do not.  
There is no evidence that vaccines have any therapeutic effect on current HPV 
infections, in that they do not increase the rate of viral clearance or lesion 
regression97,99–101. A determinant of vaccine effectiveness of MSM at SHCs is what 
proportion are infected, or have already experienced HPV, by the time (age at which) 
they attend a SHC. 
In 2008, a school-based HPV vaccination programme, targeting girls aged 12-13 years, 
using the bivalent vaccine, was introduced. Gender-neutral vaccination was considered 
to be too expensive given the expected indirect benefits for boys/men resulting from 
female vaccination: men would be having sex with vaccinated women, who would not 
be infected, so would not be at risk19. MSM, on the other hand, would not benefit, to 
the same extent, from this herd immunity despite being disproportionately affected by 
HPV-related disease. 
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2.13 POTENTIAL VACCINE COVERAGE 
Interrupting HPV transmission in MSM in the UK by vaccinating MSM who attend SHCs 
will be optimised if all MSM attend SHCs, opt to receive the vaccine, and complete the 
vaccine course.  
MSM AND SEXUAL HEALTH SERVICE USE 
There is inconsistency in the definition of MSM throughout the UK’s sexual health 
clinics. British Association for Sexual Health and HIV (BASSH) guidelines recommend 
asking about sexual behaviour in the last three months which may offer more 
standardisation of this population102. In 2007, 63,181 episodes of care at SHCs were 
recorded for MSM and 45,748 HIV tests were offered. In 2008, 70,146 episodes of care 
at SHCs were recorded for MSM7 and a proportion of these represent repeat 
attendances.  In the Natsal-2 (2000) survey, 27% of men who reported having sex with 
another man in the last year had attended a SHC in the last five years 8. 
The results of the Gay Men’s Sexual Health Survey (GMSHS) carried out annually in 
London suggest that men selected from pubs, clubs and bars in 2000 were more likely to 
attend a SHC than those in the general population103. In addition, men in the GMSHS 
who attended a SHC were more likely to have had ten or more sexual partners, had an 
HIV test or an STI diagnosis than those who had not attended a SHC. In Natsal-2, MSM 
attending a SHC were more likely to be unemployed, of black ethnicity, and to have ten 
or more sexual partners than those in the general population104. 
VACCINE UPTAKE 
Predictors of vaccine uptake 
MSM who perceive themselves to be at risk of HPV infection, believe in the efficacy of 
the vaccine (outcome expectancies) and in their ability to receive the vaccine and 
complete the course (perceived self-efficacy) are more likely to intend to receive the 
vaccine. Behavioural intention is the first stage in the process of health behaviour 
change105. 
Hepatitis B virus vaccine in sexual health clinics 
In 2001 in the UK, the National Strategy for Sexual Health and HIV (Department of 
Health) recommended that all MSM should be offered hepatitis B virus (HBV) 
vaccination at their first attendance at a SHC106. The HPV vaccines have similar dosing 
schedules to the HBV vaccine with either a course with injections at 0, 1 and 6 months 
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or 0, 2, and 6 months. Uptake data from the HBV programme are likely to reflect the 
anticipated uptake of any vaccination programme with the HPV vaccine. 
The effectiveness of this policy has been monitored by the UK’s Health Protection 
Agency (HPA; from 2013 part of Public Health England; PHE) using the HepB3 survey. In 
2006, 92% of eligible MSM accepted the 1st dose of the vaccine course but only 38% of 
eligible MSM received the 3rd dose107.  
2.14 HPV VACCINE COST-EFFECTIVENESS STUDIES IN MEN IN THE UK 
In the UK, two dynamic cost-effectiveness modelling studies had been performed of HPV 
vaccination of girls by 2009, and both showed this strategy was likely to be cost-
effective19,108. One model also assessed the impact of vaccinating 12 year-old boys on 
AGWs and cervical cancer and found that extending vaccination to boys slightly reduced 
the incidence of cervical cancer and AGWs, particularly when vaccine protection was 
short-lived, but was unlikely to be cost-effective because there were few additional 
benefits given the high expected effectiveness that would be achieved with high vaccine 
coverage of girls (80%)19. 
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BOX 2. SUMMARY OF RELEVANT KNOWLEDGE BASE AT THE OUTSET OF THIS PHD 
HPV-related disease burden in MSM: 
 • HPV-related disease in MSM includes anogenital warts, anogenital cancers and 
head and neck cancers 
• Anal cancer incidence in HIV-negative MSM is higher than in HIV-negative 
MSEW and increasing 
• Anal cancer incidence is higher in HIV-positive MSM compared to HIV-negative 
MSM, especially in the ART era 
HPV-epidemiology in MSM:  
 • Few studies on HPV infection in SHC populations of MSM 
• Few studies on HPV infection in MSM in Europe 
• Little known on anatomical site-specific prevalence 
• Few studies estimating age-specific prevalence of HPV infection in MSM 
• No longitudinal studies of HPV infection in MSM  
• Only one study estimating seroprevalence in MSM 
• No studies estimating age-specific seroprevalence in MSM 
HPV vaccine efficacy:  
 • Had not been demonstrated in men 
• Had only been demonstrated against HPV infection and cervical disease 
endpoints 
• Uncertainty whether vaccine prevents re-infection or confers cross-protection 
• No studies in previously-exposed or immune-impaired (e.g. HIV-positive) 
populations 
HPV vaccine estimates of cost-effectiveness in UK: 
 •  Mathematical modelling studies suggest that gender-neutral HPV vaccine 
programmes in schools would not be cost-effective while coverage in girls is 
high 
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3. ORAL HUMAN PAPILLOMAVIRUS INFECTION IN MEN WHO HAVE 
SEX WITH MEN: A SYSTEMATIC REVIEW AND META-ANALYSIS 
In this chapter I describe the objectives, methods and results of a systematic review of oral 
HPV DNA detection in MSM. Analyses include a meta-analysis and meta-regression of oral 
HPV prevalence and a meta-analysis of the association of same-sex sexual behaviour in men 
and oral HPV infection. I also summarise risk factors for oral HPV infection in men and MSM, 
review oral incidence and clearance rates and summarise findings on oral-anogenital 
concordance.  
3.1 OBJECTIVES 
1. To conduct a meta-analysis of the prevalence of oral HPV infection in MSM (HPV16, 
quadrivalent-vaccine type HPV, HR-HPV and any HPV). 
2. To explore heterogeneity of oral HPV prevalence using meta-regression. 
3. To conduct a meta-analysis of the association of HPV infection in MSM compared to 
MSEW.  
4. To review incidence and clearance rates for oral HPV infection. 
5. To review risk factors for oral HPV prevalence, incidence and persistence. 
6. To review the relationship of oral and anogenital infection. 
3.2 METHODS 
A systematic review was performed of studies measuring HPV DNA prevalence, incidence 
and/or persistence in the oral cavity of MSM. Studies were included in HIV-negative and 
HIV-positive populations, published in English, where an MSM-specific estimate was 
available in at least five MSM. Case-control studies and studies in clinical case series (e.g. 
transplant recipients, oral lesions), which might have introduced additional heterogeneity to 
prevalence estimates, were excluded. 
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For oral HPV prevalence estimates, conference abstracts that were superseded by journal 
articles were excluded and baseline estimates were selected from multiple estimates in 
longitudinal studies.  
Databases were searched on 20th October 2014 using the search terms mouth/oral 
/oropharangeal, HPV/ papillomavirus /papillomaviridae and man/ men /boy$/ adult /male$ 
/MSM/ "men who have sex with men"/ gay$ /homosexual$ /bisexual$. Medline was 
searched via PubMed and Medline, Embase and psycINFO using the Ovid platform (Version: 
OvidSP_UI03.13.01.101, SourceID 63482) using the search strategy in Box 3. Reference lists 
of included articles were also reviewed to validate the search strategy. 
BOX 3. SEARCH TERMS AND STRATEGY FOR MEDLINE/EMBASE/PSYCHINFO VIA THE OVID PLATFORM 
AND PUBMED 
  
STUDY SELECTION 
All screening and study selection methods were performed independently by Eleanor King 
(EK) and Soonita Oomeer (SO) and discrepancies were resolved by consensus. Publications 
were screened via the title, then, if not enough detail was available, via the abstract, and 
then the full text. Where data were not stratified by sex and sexual orientation, and both 
variables were reported in the publication (not conference abstract), the corresponding 
Ovid platform 
search strategy 
1. ((mouth or oral or oropharangeal) and (HPV or papillomavirus or papillomaviridae) and (man or men 
or boy$ or adult or male$ or MSM or "men who have sex with men" or gay$ or homosexual$ or 
bisexual$)).mp. [mp=title, abstract, original title, name of substance word, subject heading word, 
keyword heading word, protocol supplementary concept word, rare disease supplementary concept 
word, unique identifier] 
2. limit 1 to english language 
3. remove duplicates from 2 
Pubmed user 
query 
((("mouth"[MeSH Terms] OR "mouth"[All Fields]) OR ("mouth"[MeSH Terms] OR "mouth"[All Fields] OR 
"oral"[All Fields]) OR oropharangeal[All Fields]) AND (HPV[All Fields] OR ("papillomaviridae"[MeSH 
Terms] OR "papillomaviridae"[All Fields] OR "papillomavirus"[All Fields]) OR ("papillomaviridae"[MeSH 
Terms] OR "papillomaviridae"[All Fields]))) AND (("men"[MeSH Terms] OR "men"[All Fields] OR "man"[All 
Fields]) OR ("men"[MeSH Terms] OR "men"[All Fields]) OR boy$[All Fields] OR ("adult"[MeSH Terms] OR 
"adult"[All Fields]) OR ("male"[MeSH Terms] OR "male"[All Fields]) or MSM or “men who have sex with 
men” or “gay$” or “homosexual$” or “bisexual$”) AND English[lang] 
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author was contacted, via emails (initial and three week follow-up), for additional data. If 
there was no response the publication was excluded.  Additional stratified data were 
obtained from four of the six authors contacted for this purpose.  
DATA EXTRACTION 
All data extraction was performed by EK using a data extraction form. An independent 
reviewer (SO) checked and validated a random 50% of articles. Independent data extraction 
is based on good practice, as outlined in the PRISMA guidelines, although the proportion of 
papers extracted that needs validation is not specified109. Discrepancies would have been 
agreed by consensus but none were identified. Data extracted, where available, are detailed 
in Box 4.  
BOX 4. DATA EXTRACTED FROM STUDIES, OVERALL AND FOR EACH ANALYSIS 
All studies: 
 Author name, year of publication, median age and range (years), study location, source of 
recruitment, HIV status, specimen collection method and HPV DNA detection/genotyping 
assay(s)  
Studies included in the summary HPV prevalence estimation:  
 Number of MSM in the sample and those with any HPV DNA detected, any high risk HPV 
types, and low risk HPV types and, individually, the number with HPV16, HPV18, HPV6, 
and HPV11. 
Studies examining risk factors for oral HPV DNA:  
 Statistically significant (p<0.05) risk factors in univariate analyses, factors included in 
multivariate models, and factors that were statistically significant in multivariate models 
Studies included in meta-analysis of oral HPV prevalence in MSM compared to MSEW: 
 The number of MSM and the number of MSEW with and without HPV 
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Little variation was found in the authors’ definition for HR-HPV and LR-HPV and this was 
used in the meta-analysis. Substantial variation was found in HPV detection/genotyping 
assays (Table 4). Definitions of MSM varied according to what was available in each 
publication and were based on either reported behaviours (any sex with men) or sexual 
orientation. Median age was used to reduce the impact of skewness on the summary 
statistic for the age distribution. Where median age (for MSM strata, by HIV status) was not 
available, authors were contacted. If there was no response the mean age was used. 
Median age estimates were obtained from nine of the 11 authors contacted.  
ASSESSMENT OF RISK OF BIAS 
For studies included in the HPV prevalence estimation and risk factors for current HPV DNA 
detection the STROBE checklist (which examines selection and information bias) was used, 
for items to be included in reports of observational studies110. A count of checklist items was 
used as a marker for risk of bias in each study. Low risk of bias was assigned if at least 20 
items were identified, medium if 15 to 19, and high if fewer than 15. Strobe count was 
explored as a potential source of heterogeneity using meta-regression. 
STATISTICAL ANALYSIS 
HPV DNA prevalence in MSM was determined as the percentage with detectable DNA in the 
total number of samples that were tested and adequate for PCR. For consistency, Clopper-
Pearson 95% confidence intervals (CI) were calculated for each study, superseding the 
published intervals. The true population prevalence was not expected to be equal in all 
studies due to heterogeneity in study populations, specimen collection, and testing, so 
random effects meta-analysis was used to calculate a pooled estimate with a 95% 
confidence interval. Heterogeneity was quantified using the I2 statistic.  
 
A random effects meta-regression was performed to examine the effect of HIV status, 
recruitment source (sexual health clinic [SHC], HIV clinic, community), oral specimen 
collection method (rinse/gargle alone or combination, other without rinse/gargle), STROBE 
count, and median age of participants on prevalence of HPV DNA and HR-HPV DNA. Age and 
HIV were included a priori in a multivariate meta-regression model and other variables 
significant in univariate analyses.  P values were obtained by comparing the multiparameter 
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Wald test statistic to the appropriate F distribution with Knapp-Hartung modification to 
standard errors.  
 
Odds ratios (OR) were calculated to represent the effect of male same-sex activity on oral 
HPV prevalence within each study, and random-effects meta-analysis was used to calculate 
a pooled OR and 95% CI. Small study bias was considered by examining a funnel plot of the 
inverse of the standard error and the OR.  
 
Estimates of incidence and clearance rates were standardised to the same unit (per 1000 
person-months), and these rates were approximately calculated if they were not presented 
but sufficient information was reported. For example if median duration of infection was 
given, in months, an exponential rate was assumed and the rate of clearance was calculated 
as the inverse of median duration of infection multiplied by 1000. 95% CIs were calculated 
for these rates using the Poisson exact method. Given the heterogeneity introduced by 
different approximate methods of estimation, a meta-analysis was not performed on these 
data. 
 
All meta-analyses were conducted using either the metareg, metaprop111 or metan 
functions downloadable from the Boston College Statistical Software Components (SSC) 
archive and used with Stata 13.1. 
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TABLE 4. CHARACTERISTICS OF THE STUDIES, AND THEIR PARTICIPANTS, DESCRIBING ORAL HPV PREVALENCE, INCIDENCE, CLEARANCE RATE, RISK FACTORS AND 
ANOGENITAL CONCORDANCE IN MSM. CONTINUED. 
     
Laboratory assays 
    
Number of MSM 
Study/ 
publication Ana.a 
risk of 
bias b 
Study 
location 
Oral 
spec.c DNA extraction PCR amplification Genotyping 
HR-
HPV 
def. d 
Med. 
Age 
(year
s) Recruit. HIVe MSM 
Any HPV 
det. 
HR-HPV 
det. 
Human papillomavirus in men (HIM) 
rin/g 
Robotic MDx Media kit 
(Qiagen) 
 HPV Linear Array Genotyping 
test (Roche) 
  
com/ clin 
    Kreimer (2011)112 r 
 
Mexico, 
Brazil, USA  
n/a
 
U 130 4
 Kreimer (2013)113 p, i/c low 
 
n/a 32 U 147 7 2
               HIV & HPV in MSM (H2M) 
rin/g MagNA Pure LC Total Nucleic Acid Isolation Kit (Roche) 
DNA Enzyme Immuno 
Assay (HPV DEIA, Labo 
Bio-medical Products) 
HPV LiPA25 (Labo Bio-
medical products) 
  
com/ clin 
    Mooij (2013)114 p,r low Amsterdam A 
37.6 - 453 125 40 
    
45.6 + 314 178 78 
   
 
      Mooij (2014)115 i/c 
 
A 38 - 413
  
    
47 + 276 
                Van Rijn (2014)116; relationship to seropositivity 
   
D 46 - 441
  
         
38 + 306 
                 Multicenter AIDS Cohort Study (MACS) 
rin/g   
PGMY09/11 & reverse blot 
hybridisation 
C
 
com
    Beachler (2012)117 p,r low Baltimore, 
Chicago, 
Pittsburgh 
magnetic bead automated platform 
(QIAsymphonySP, Qiagen) 
   
- 173 48 29
       
+ 192 86 44 
               Can Ruti HIV-positive Men cohort (CARH-MEN) 
cytob/g Qiamp Viral DNA kit (Qiagen)  IVD-CE F-HPV typing (Molgentix) 
B
 
HIV clin
    Videla (2013)118 p, i/c low Spain 
  
40
 
+ 458 71
             Darwich (2014)119 i/c 
                       Melbourne SHC cohort study 
 
tampon- 
& rin/g 
&swab 
MagNA Pure LC Total Nucleic 
Acid Isolation Kit (Roche) 
PGMY09/11 &PCR-
ELISA detection 
protocol 
HPV Linear Array Genotyping 
test (Roche) 
B
 
STI clin
    Read (2012)120 p,r low Australia 
 
33
 
- 251 18 5
     
37 
 
+ 249 47 20 
               Ong (2014)121  i/c 
 
Australia rin/g 
   
mean=52
 
+ 173
                 Human papillomavirus infection in adolescent men who have sex with men (HYPER)  
         
Zou (2014)122 p low Australia rin/g 
VERSANT kPCR Molecular 
System SP (Siemens) or 
MagNA Pure 96 (Roche) 
PGMY09/11 &PCR-
ELISA detection 
protocol 
HPV Linear Array Genotyping 
test (Roche) n/a 19 com - 200 4 
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TABLE 4. CHARACTERISTICS OF THE STUDIES, AND THEIR PARTICIPANTS, DESCRIBING ORAL HPV PREVALENCE, INCIDENCE, CLEARANCE RATE, RISK FACTORS AND 
ANOGENITAL CONCORDANCE IN MSM. CONTINUED. 
     
Laboratory assays 
    
Number of MSM 
Study/ 
publication Ana.a 
risk of 
bias b 
Study 
location 
Oral 
spec.c DNA extraction PCR amplification Genotyping 
HR-
HPV 
def. d 
Med. 
Age 
(year
s) Recruit. HIVe MSM 
Any HPV 
det. 
HR-HPV 
det. 
Other 
    
   
       
Beachler (2013)123 i/c 
 
Baltimore, 
US rin/g 
Puregene DNA purification 
kit (Gentra systems) PGMY09/11 & reverse blot hybridisation C 46 
 
+ 69 
  
Parisi (2011)124 p medium Italy swab 
QIAamp DNA mini kit 
(Qiagen) & ExoSAP-IT (USB 
corp.) 
MY09/MY11 primers 
followed by 
GP5+/GP6+ if negative 
sequencing and analysis in 
NCBI BLAST C 42 HIV clin + 134 27 2 
Sirera (2006)63  p,r high Spain cytob 
F-HPV Typing Kit (Molgentix, 
BCN, Spain)  
 
multiplex F-HPV PCR 
with a set of 15 
fluorescently labeled 
primers 
Capillary electrophoresis on 
ABI 3,130 XL genetic analyzer 
and GeneMapper 4.0 
Software (Applied 
Biosystems, CA). B 
mean
=42 HIV clin + 52 17 
 
Del Mistro 
(2012)125 p,r high Italy saliva 
proteinase 
K/phenol/chloroform 
MY09/MY11 primers 
followed by nested 
biotinylated 
GP5+/GP6+ if negative 
direct sequencing or reverse 
line Blot using Consensus 
High Risk HPV genotyping kit 
(Qiagen) A 40.3 HIV clin + 38 16 7 
Colon-López 
(2014)126  p,r low 
Puerto 
Rico rin/g 
DNA purification from buccal 
cell protocol from Gentra 
PureGene kit (Qiagen) 
INNO-LiPA HPV 
Genotyping Extra Amp 
INNO-LiPA HPV genotyping 
Extra assay (Innogenetics) n/a 
mean
=38.
5 STI clin U 57 11 
 
Gaester (2014)127 p,r high Sao Paulo rin 
Illustra Tissue and Cells 
GenomicPrep Mini Spin Kit 
(Easton Turnpike) 
MY09/MY11 primers 
&g gel electrophoresis 
Papillomastrip, based on 
reverse blot 
technique(Operon Immune & 
molecular diagnostics) n/a 43 HIV clin + 127 10 
 
Ong (2014)121 p high Australia 
rin/g & 
rin/g 
after 
brushing 
& toothb 
MagNA Pure 96 isolation and 
purification systmen (Roche) 
PGMY09/11 &PCR-
ELISA detection 
protocol 
HPV Linear Array Genotyping 
test (Roche) or SPF10-LiPA 25 
assay version B 52 STI clin + 173 45 26 
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TABLE 4. CHARACTERISTICS OF THE STUDIES, AND THEIR PARTICIPANTS, DESCRIBING ORAL HPV PREVALENCE, INCIDENCE, CLEARANCE RATE, RISK FACTORS AND 
ANOGENITAL CONCORDANCE IN MSM. CONTINUED. 
     
Laboratory assays 
    
Number of MSM 
Study/ 
publication Ana.a 
risk of 
bias b 
Study 
location 
Oral 
spec.c DNA extraction PCR amplification Genotyping 
HR-
HPV 
def. d 
Med. 
Age 
(year
s) Recruit. HIVe MSM 
Any HPV 
det. 
HR-HPV 
det. 
Coutlée (1997)68 p,r low Canada cytob 
Lysed with Tween 20 and 
NP-40 
MY09/MY11 primers, 
spotting onto nylon 
membranes, HPV 
generic probe labelled 
with 32P-
deoxynucleotides 
type-specific oligonucleotide 
probes end-labelled with 32P-
ATP n/a 40 
STI / 
gastro-
enterocli
n  U 177 26 
 
D'Souza (2014)128 p,r low 
Baltimore, 
US rin/g 
magnetic bead-based 
automated QIASymphony SP 
(Qiagen) 
PGM09/11 followed by 
reverse line blot 
hybridisation 
HPV Linear Array Genotyping 
test (Roche)  C 22 STI clin U 21 1 0 
Antonsson 
(2014)129 p,r medium 
Brisbane, 
Australia rin/g 
QIAamp DNA mini kit 
(Qiagen) QIAGEN 
supplementary protocol for 
isolation of DNA 
GP5+/GP6+ agarose 
gel; Agencourt AMPure 
PCR purification kit 
Sequencing followed by 
BLAST database n/a 22 uni U 15 1 
 
Cameron (2005)130 
  
Louisiana, 
US saliva 
Qiagen DNA extraction kit 
(extracted for saliva cellular 
pellets) PGMY09/11 
   
HIV clin + 
   Abbreviations: SHC=sexual health clinic, HYPER= human papillomavirus infection in adolescent men who have sex with men,  aAna=analysis: publications included in prevalence study meta-analysis 
(p), risk factor analysis (r), incidence/clearance rates (ic).Oral specc=oral specimen type:rin=rinse, g=gargle, cytob=cytobrush, toothb=toothbrush dHR-HPV def=definition: 
HPV16/18/31/33/35/39/45/51/52/56/58/59= A; with additional/68=B; with additional /68/73=C. HPV16/18/31/33/45/52/58=D. Med age=median age. Recruit=recruitment strategy, com=community, 
clin=clinic, uni=university, gasteroentero=gasteroenterology e HIV status: +=HIV-positive; -=HIV-negative; U=unknown. Det.=detection. 
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3.3 RESULTS 
2175 articles were identified and 1978 excluded based on information in the title. A further 
80 were excluded based on information in the abstract and a further 96 having retrieved the 
full text (Figure 16). 20 articles were included and one letter representing 17 different 
studies. Details of the studies, including methods, risk of bias, number of MSM recruited and 
number with HPV detected are shown in Table 4. 
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FIGURE 16. FLOW DIAGRAM OF SCREENING AND SELECTION PROCESS 
 
Potentially relevant publications identified and screened for retrieval (n=2175) 
Excluded via title (n=1978) 
Publications retrieved for more detailed evaluation (n=197) 
Potentially appropriate publications (n=117) 
Publications included (n=21) 
• Letters (n=1) 
• Articles (n=20) 
Excluded via abstract (n=80) 
Excluded via full text (n=96): 
• Case-control (n=18) 
• Age <15 years (n=4) 
• Prevalence estimate in men but not MSM (n=47) 
• No prevalence estimate for men (n=12) 
• Other (n=12) 
• Conference abstracts, superseded by articles (n=3) 
Risk factors for any HPV DNA prevalence (n=11) 
Risk factors for HR-HPV DNA prevalence (n=1) 
Incidence/clearance estimates 
Articles (n=6), studies (n=5) 
Risk factors for any HPV DNA incidence/clearance (n=4)  
Included prevalence estimates (n=15) 
• Letters (n=1) 
• Articles (=14) 
Records identified through database searching (n=3620) 
Duplicates removed (n=1445) 
Estimate of effect of MSM compared to 
heterosexual men on oral HPV prevalence (n=9) 
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ORAL HPV DNA PREVALENCE 
For oral HPV DNA prevalence, 16 studies were included. Estimates of HPV16 prevalence, 
were available from ten studies, for any quadrivalent-vaccine type from four studies 
113,114,120,127, for HR-HPV from 11 studies68,113,126,128,129 and for any HPV DNA prevalence 
estimates were available from five studies that included 1228 HIV-negative 
MSM114,117,120,122,131, nine studies that included 1737 HIV-positive 
MSM63,114,117,118,120,121,124,125,127, and five studies that included 417 MSM with unknown HIV 
status.  
Figure 17 shows that the random-effects pooled prevalence of HPV16 was 3.6% (95% CI -
2.4-9.6) in HIV-negative and 3.9% (95% CI 1.4-6.4) in HIV-positive MSM. High heterogeneity 
was seen across studies in both HIV groups (I2= 80% and 82%, respectively).  
FIGURE 17. RANDOM-EFFECTS ANALYSES OF STUDIES ESTIMATING ORAL HPV16 PREVALENCE IN 
MSM.  
Weights are from random effects analyses. Abbreviations: HPV= Human papillomavirus, MSM=Men who have sex with men, 
HIV=Human immunodeficiency virus. Beachler (2012)117,  Read (2012)120, Parisi (2011)124, Sirera (2006)63, Gaester (2014)127, Ong 
(2014)121 and Kreimer (2013)113. 
HIV negative
Beachler (2012)
Read (2012)
Subtotal  (I² = 89.3%, p = 0.00)
HIV positive
Beachler (2012)
Read (2012)
Parisi (2011)
Sirera (2006)
Gaester (2014)
Ong (2014)
Subtotal  (I² = 82.3%, p = 0.00)
Unknown HIV prevalence
Kreimer (2013)
Subtotal  (I² = .%, p = .)
Study
173
251
192
249
134
52
127
173
147
(n)
size
Sample
6.9 (3.6, 11.8)
0.8 (0.1, 2.8)
3.6 (-2.4, 9.6)
6.8 (3.7, 11.3)
4.4 (2.2, 7.8)
0.7 (0.0, 4.1)
19.2 (9.6, 32.5)
0.8 (0.0, 4.3)
4.6 (2.0, 8.9)
3.9 (1.4, 6.4)
0.7 (0.0, 3.7)
0.7 (-0.6, 2.0)
Prevalence (95% CI)
  0 10 20 30
Prevalence (%)
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Only three studies measured HPV18, HPV11 and HPV6 prevalence, all in HIV-positive 
MSM63,124,127. Only one of these detected HPV18 in 2/52 MSM (3.8% 95% CI 0.5-13.2)63 and 
two studies detected HPV11 DNA (2/52 and 1/134)63,124.  All three studies detected HPV6 
(2/52, 1/134, 1/127), with a pooled estimate of 1.1% (95% CI -0.0-2.3%) and low 
heterogeneity between these three estimates (I2= 0%, p=0.48). Figure 18 shows the four 
studies measuring the prevalence of any quadrivalent-vaccine type HPV detection. The 
pooled prevalence was 2.8% (95% CI 1.3-4.3%) in HIV-negative MSM and 5.9% (95% CI 0.8-
11.0%) in HIV-positive MSM. 
FIGURE 18. RANDOM-EFFECTS ANALYSES OF STUDIES ESTIMATING ORAL QUADRIVALENT-VACCINE TYPE 
HPV PREVALENCE IN MSM.  
 
Weights are from random effects analyses. Abbreviations: HPV= Human papillomavirus, MSM=Men who have sex with men, 
HIV=Human immunodeficiency virus. Mooij (2013)114, Read (2012)120, Gaester (2014)127 and Kreimer (2013)113. 
Figure 19 shows that the random-effects pooled prevalence of HR-HPV was 8.0% (95% CI 
2.7-13.3%) in HIV-negative MSM and 14.8% (95% CI 6.2-23.4%) in HIV-positive MSM (I2= 
92% and 96%, respectively).  
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FIGURE 19. RANDOM-EFFECTS ANALYSES OF STUDIES ESTIMATING ORAL HR-HPV PREVALENCE IN 
MSM.  
 
Weights are from random effects analyses. Abbreviations: HPV= Human papillomavirus, MSM=Men who have sex with men, 
HIV=Human immunodeficiency virus. Mooij (2013)114, Beachler (2012)117,  Read (2012)120, Parisi (2011)124, Del Mistro (2012)125, 
Ong (2014)121 and Kreimer (2013)113. 
Figure 20 shows that the pooled prevalence of any HPV was 15.9% (95% CI 3.4-28.4%) in 
HIV-negative and 29.1% (95% CI 18.0-40.1%) in HIV-positive MSM (I2= 98% and 97%, 
respectively). 
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FIGURE 20. RANDOM-EFFECTS ANALYSES OF STUDIES ESTIMATING ORAL HPV (ANY TYPE) PREVALENCE 
IN MSM.  
Weights are from random effects analyses. Abbreviations: HPV= Human papillomavirus, MSM=Men who have sex with men, 
HIV=Human immunodeficiency virus. Mooij (2013)114, Beachler (2012)117,  Read (2012)120, Zou (2014)122, Videla (2013)118,  Parisi 
(2011)124, Sirera(2006)63,  Del Mistro (2012)125, Gaester (2014)127, Ong (2014)121, Colon-López (2014) 126, Kreimer (2013)113, 
D’Souza (2014)128, Coutlée (1997)68 and Antonsson (2014)129.  
The number of included studies was too low (<10 per stratum) to perform meta-regression 
stratified by HIV status. As single covariates, HIV status (adjusted R2=21%, p=0.07), source of 
recruitment (adjusted R2=-5%, p=0.56), mode of sample collection (adjusted R2=-3%, 
p=0.44), and STROBE count (adjusted R2=-6%, p=0.85) were not significant contributors to 
the heterogeneity of any HPV prevalence estimates (Table 5). Heterogeneity in any HPV and 
HR-HPV prevalence estimates was, in part (45% and 54%, respectively), explained by median 
age of study participants (p<0.01 and p=0.01, respectively) (Figure 21) but this effect was 
not significant for HPV16. After adjusting for HIV status, the effect of age remained a 
significant source of heterogeneity in any HPV prevalence estimates.  
  
HIV negative
Mooij (2013)
Beachler (2012)
Read (2012)
Zou (2014)
Subtotal  (I² = 98.1%, p = 0.00)
HIV positive
Mooij (2013)
Beachler (2012)
Videla (2013)
Read (2012)
Parisi (2011)
Sirera (2006)
Del Mistro (2012)
Gaester (2014)
Ong (2014)
Subtotal  (I² = 96.8%, p = 0.00)
Unknown HIV prevalence
Colon-López (2014)
Kreimer (2013)
D'Souza (2014)
Coutlee (1997)
Antonsson (2014)
Subtotal  (I² = 73.1%, p = 0.00)
Study
453
173
251
200
314
192
458
249
134
52
38
127
173
57
147
21
177
15
(n)
size
Sample
27.6 (23.5, 32.0)
27.7 (21.2, 35.1)
7.2 (4.3, 11.1)
2.0 (0.5, 5.0)
15.9 (3.4, 28.4)
56.7 (51.0, 62.2)
44.8 (37.6, 52.1)
15.5 (12.3, 19.1)
18.9 (14.2, 24.3)
20.1 (13.7, 27.9)
32.7 (20.3, 47.1)
42.1 (26.3, 59.2)
7.9 (3.8, 14.0)
26.0 (19.6, 33.2)
29.1 (18.0, 40.1)
19.3 (10.0, 31.9)
4.8 (1.9, 9.6)
4.8 (0.1, 23.8)
14.7 (9.8, 20.8)
6.7 (0.2, 31.9)
9.8 (3.8, 15.9)
Prevalence (95% CI)
  0 10 20 30 40 50 60
Prevalence (%)
 
67  
 
TABLE 5. META-REGRESSION OF ORAL HPV PREVALENCE IN MSM AND STUDY-RELATED FACTORS 
  
UNIVARIATE MULTIVARIATE 
  
Coeff Τ2 Residual I
2 
(%) 
Adjusted 
R2 (%) 
p 
value Coeff Τ
2 Residual  I2 (%) 
Adjusted 
 R2 (%) 
p 
value 
HPV16 
 Multivariate 
model 
     
 9 81 -12 0.68 
HIV infection 
 
13 84 -61 0.76     0.99 
No ref
    
ref     
Yes 0.80 
   
0.84 0.09     
Unknown -2.84 
   
0.62 -0.49     
Median Age of 
study (years) 0.23 3 75 57 0.12 0.23    0.36 
Recruitment 
source  13 85 -67 0.94 
     HIV clinic ref     
     STI clinic -0.16     
     Community 1.18     
     Oral specimen 
collection      
     Not rinse/gargle ref 12 83 -50 0.69 
     Rinse/gargle -1.69     
     STROBE count -0.07 11 83 -40 0.81 
     
HR-
HPV 
 Multivariate 
model       47 93 37 0.15 
HIV infection  72 96 3 0.35     0.83 
No ref     ref     
Yes 5.73     2.94     
unknown -7.60     -0.97     
Median Age of 
study (years) 0.82 34 92 54 0.01 0.73    0.09 
Recruitment 
source  81 96 -9 0.58      
HIV clinic ref          
STI clinic -0.16          
community 6.30          
Oral specimen 
collection  79 95 -7 0.63      
Not rinse/gargle ref          
rinse/gargle 3.87          
STROBE count -0.10 84 96 -13 0.89      
              
Any 
HPV 
Multivariate 
model       132 94 41 0.02 
HIV infection  177 96 21 0.07     0.57 
No ref     ref     
Yes 12.98     6.04     
unknown -5.92     -2.26     
Median Age of 
study (years) 1.06 122 94 45 <0.01 0.84    0.03 
Recruitment 
source  236 98 -5 0.56      
HIV clinic ref          
STI clinic -7.51          
community 1.78          
Oral specimen 
collection  231 97 -3 0.44      
Not rinse/gargle ref          
rinse/gargle -7.19          
STROBE count 0.16 237 97 -6 0.85      
Abbreviations: Coeff=coefficient, Τ2=tau-squared (between study variance), Not rinse/gargle= oral specimen collection method 
did not involve a rinse/garge; STROBE= STrengthening the Reporting of OBservational studies in Epidemiology. 
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FIGURE 21. META-REGRESSION OF MEDIAN AGE OF STUDY POPULATION ON STUDY ESTIMATE FOR 
ORAL HPV DNA PREVALENCE  
 
Bubbles are weighted in size by inverse of within-study variance. References: a=Mooij (2013)114, b=Beachler (2012)117, c=Read 
(2012)120, d=Zou (2014)122, e=Videla (2013)118, f=Parisi (2011)124, g=Sirera (2006)63, h=Del Mistro (2012)125, i=Gaester (2014)127, 
j=Ong (2014)121, k=Colon-López (2014)126, l=Kreimer (2013)113, m=D’Souza (2014)128, n=Coutlée (1997)68, o=Antonsson (2014).
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RISK FACTORS FOR ORAL HPV DNA DETECTION 
Twelve studies that examined risk factors for oral HPV DNA detection, and stated the 
number of MSM in the population, were analysed (Figure 16). With the exception of Mooij 
et al who examined factors associated with HR-HPV114, all studies explored factors 
associated with any HPV.  Table 6 shows that the two studies within MSM populations114,120 
identified HIV infection, age (only HIV-negative MSM in Mooij et al) , smoking (only HIV-
positive MSM in Mooij et al), and number of sex partners (only HIV-negative MSM in Mooij 
et al) as risk factors. These were similar to the risk factors identified in studies that had, in 
addition to MSM, MSEW participants63,112,118,123,125–127 and/or female participants117,123,125.  
The meta-analysis showed no evidence that MSM were at higher risk of oral HPV DNA 
detection compared to MSEW (Figure 22). All nine studies measuring oral HPV in both MSM 
and MSEW were included. With MSEW as the reference group, meta-analysis resulted in a 
pooled OR of 1.07 (95% CI 0.65-1.74; p=0.80), I2=51.7%, heterogeneity p=0.04. There was 
little difference in effect size in the four studies in HIV-positive populations compared to the 
five with unknown HIV status. No studies in HIV-negative populations presented appropriate 
data to examine this effect. Excluding estimates from studies with a high risk of bias reduced 
the heterogeneity (I2) to 38.4% (heterogeneity p=0.15) and gave a pooled OR of 1.05 (95% CI 
0.65-1.68; p=0.85). There were too few studies to formally test for small study bias.  
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TABLE 6. STUDIES EXAMINING RISK FACTORS FOR ORAL HPV DNA DETECTION IN POPULATIONS THAT INCLUDE MSM 
             DEMOGRAPHIC LIFESTYLE SEXUAL BEHAVIOUR STIs HIV 
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bias 
HI
V  Population 
Pl
ac
e 
Se
x 
Ag
e 
Ed
uc
at
io
n 
le
ve
l 
Se
xu
al
ity
 o
r s
am
e-
se
x 
be
ha
vi
ou
r 
Te
et
h 
br
us
hi
ng
 
Sm
ok
in
g 
Us
e 
of
 p
op
pe
rs
 
Ca
nn
ab
is 
Al
co
ho
l 
Cu
rr
en
t p
ar
tn
er
 
Nu
m
be
r o
f p
ar
tn
er
s 
Ej
ac
ul
at
io
n 
du
rin
g 
or
al
 
se
x 
Co
nd
om
 u
se
 
Or
al
 se
x 
on
 w
om
an
 
Or
al
 se
x 
Ri
m
m
in
g 
Re
ce
pt
iv
e 
an
al
 se
x 
W
ar
ts
 
Hi
st
or
y 
of
 S
TI
 
Pe
ni
le
 H
PV
 in
fe
ct
io
n 
Hu
m
an
 h
er
pe
s v
iru
s 8
 
sh
ed
di
ng
 
HI
V 
st
at
us
 
Ti
m
e 
sin
ce
 H
IV
 d
ia
gn
os
is 
CD
4 
na
di
r 
Cu
rr
en
t C
D4
 
HI
V 
lo
ad
 
HA
AR
T 
us
e 
Read (2012)120 Low U MSM 
 
                            
Mooij (2013)114, * Low 
+/- 
MSM 
                            
-                             
+                             
Videla (2013)118 Low + ♂                             
Kreimer (2011)112 Medium U ♂                             
Colon-López 
(2014)126 Medium U ♂   
                          
Sirera (2006)63  High + ♂                             
Gaester (2014)127 High + ♂                             
Del Mistro 
(2012)125 High + ♀ and ♂                             
Coutlée (1997)68 Low U ♀ and ♂                             
D'Souza (2014)128 Low U ♀ and ♂                             
Antonsson 
(2014)129 Medium U ♀ and ♂                             
Beachler (2012)117 Low 
+/- 
♀ and ♂ 
                            
-                             
+                             
*All studies examined risk factors for any HPV except for Mooij (2013) which examined risk factors for HR-HPV. 
          Key: 
                                : Significant (p<0·05) in univariate analyses 
 
U  : Unknown HIV status 
          : Significant in multivariate analyses -  : HIV negative 
            : Covariate in multivariate analyses  +  : HIV positive 
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FIGURE 22. STUDIES EXAMINING THE EFFECT OF HAVING SEX WITH MEN (AND WOMEN) COMPARED TO 
HAVING SEX EXCLUSIVELY WITH WOMEN ON THE PREVALENCE OF ORAL HPV 
 
Weights are from random effects meta-analysis. Videla (2013)118 , Sirera(2006)63, Gaester (2014)127, Del Mistro (2012)125, 
Kreimer (2013)113, Colon-López (2014)126, Antonsson (2014)129, Coutlée (1997)68 and D’Souza (2014)128. 
ORAL HPV DNA INCIDENCE AND CLEARANCE RATES 
HPV DNA incidence and clearance rates were examined in five longitudinal studies (Table 7). 
There was inconsistency in the reporting of rates, due to variability in study design, 
particularly visit schedule and follow-up period. Incidence of oral HPV in MSM ranged from 
four to 38 per 1000-person months.  Men who also had sex with women had higher oral 
HPV incidence than men who exclusively had sex with men in the two studies where 
comparison was possible113,123 but there was no difference in the probability of persistent 
infections123. In the study where direct comparison of HIV-positive and HIV-negative MSM 
was possible, incidence was more than three times higher in HIV-positive MSM115.  
Definitions of cleared HPV infection differed by study (single undetectable following a 
detectable or two consecutive undetectable following a detectable). In some studies only 
incident infections were ‘at risk’ for clearance, and clearance rate was reported in various 
.
.
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%
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ways, eg median duration of infection, percentage with persistent infection at six months, 
and number of incident infections clearing in 1000 person-months. However, clearance rate 
(range: 12-900/1000 person-months) was generally higher than acquisition rate, and in one 
study, stratified by HIV infection, clearance rate was lower in HIV-positive MSM115.  
Risk factors for oral HPV acquisition and persistence are described, but were not formally 
examined, due to the low number of longitudinal studies. In MSM, Mooij et al found HIV 
infection increased the risk of oral HPV acquisition115 but no other risk factors were 
identified in MSM populations.  In populations that included both MSM and non-MSM (and 
women123),  living in Mexico compared to USA113, smoking113, divorced/separated/widowed 
marital status113, increasing education level113, history of rimming123, bisexuality113, and 
female gender123 were identified as risk factors for increased oral HPV incidence. Oral HPV 
persistence was associated with increased time since HIV diagnosis118,132 and with prevalent 
compared to incident HPV infections123.  
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TABLE 7. INCIDENCE AND CLEARANCE ESTIMATES OF ORAL HPV DNA IN MSM 
      
 
Per 1000 person-months (95% CI) 
Study 
Oral 
sampling 
interval 
(monthly) 
Length of 
follow-up 
(months) 
HIV 
status Population 
Sample 
size 
INCIDENCE 
 
CLEARANCE 
Any HPV  HR-HPV   HPV16  Any HPV HR-HPV HPV16 
Mooij 
(2014)115 3-6 6 
- MSM 413  7 (4-11) 
 
  115 (76-168) 54 (11-162) 
+ MSM 276  24 (17-32) 
 
  86 (59-120)  107 (49-203)  
Videla 
(2013)118/ 
Darwich 
(2014)119 
12 median=24 IQR=12-36 + MSM 333  5 (4-7)  1 (0-2)  16 (11-23)  19 (9-34) 
Ong (2014)132 36 36 + MSM 249  4 (3-6) 3 (2-4) 
 
 12 (7-20) 15 (7-27) 15 (4-32) 
Beachler 
(2013)123 6 
median=18.2  
IQR=6.2-24.0 
max=31.6 
+ 
MSM 69 31 (NE-NE)  
 
 750 (733-767);  
900 (866-935)* 
  
MSEW 168 38 (NE-NE)  
 
   
Kreimer 
(2013)113 6 
median=12.7 
IQR=12.1-
14.7 
range=0.3-
37.2 
U 
MSEM 54 4 (1-12) 3 (0-10) 
 
 
175 (NE-NE)*+ 175 (NE-NE)*+ 
 
MSMW 93 14 (8-23) 5 (2-11) 
 
 
129 (NE-153)*+ 153 (NE-192)*+ 
 
MSEW 1392 5 (4-6) 2 (2-3) 
 
 154 (102-161)*+ 159 (NE-167)*+ 137 (NE-159)*+ 
HIV status: +=HIV-positive; -=HIV-negative; U=unknown *Clearance from incident infections only +Calculated from median duration of infection. Abbreviations: MSM=Men who have sex with men, 
MSEW=Men who have sex exclusively with women, MSEM=Men who have sex exclusively with men, MSMW=Men who have sex with both men and women NE= Not possible to estimate
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CONCORDANCE BETWEEN ORAL AND ANOGENITAL HPV INFECTION 
Four studies116,120,124,131 presented data on HPV type-specific concordance at oral and 
anogenital sites, but only two in MSM where samples were taken at the same time: 
concordance was not found in 151 HIV-negative oral-anogenital pairs across 21 tested 
types131 nor in 166 HIV-positive MSM across 25 tested types124. In MSEW HIV-positive men, 
Videla et al. found that 2/191 (1%) had HPV16 detected in the anal brushing, penile swab, 
and oral brushing118.  
Concurrent HPV detection, without details of HPV type, at oral and anogenital sites in MSM 
was presented in two studies63,118. Videla et al. found that 65/458 (14%) MSM had 
concurrent oral and anal HPV infection and 30/457 (7%) had concurrent oral and penile118. 
Sirera et al. showed that penile HPV infection was related to oral HPV infection (OR 2·7; 95% 
CI 1·0-7·7) and that two or three site (penile, anal, oral) concordance of any HPV was 48%63. 
A further three studies were identified in which oral and anogenital samples had been 
tested for HPV but concordance estimates were not presented113,122,123.  
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3.4 KEY FINDINGS 
The pooled estimate from this meta-analysis for HIV-negative MSM (any HPV=16%; 
HPV16=2%) was half that for HIV-positive MSM (any HPV=29%; HPV16=4%), although the 
contribution of HIV status to heterogeneity in oral HPV prevalence across studies was of 
borderline statistical significance (p=0.07). Furthermore, HIV status was consistently found 
to be a risk factor for oral HPV infection in cross-sectional studies114,117,120,126 and oral HPV 
incidence was three-fold higher in HIV-positive MSM than HIV-negative MSM in the only 
study where comparison was possible115.  
A positive correlation between median age of study participants and oral prevalence was 
shown, which partly explained heterogeneity between study estimates, and may be 
modified by HIV status. No within-study associations between age and oral HPV were found 
in studies of HIV-positive MSM, but four studies including HIV-negative MSM did find a 
statistically significant association with age114,117,120,126 (only one in multivariate)114 and 
another found a non-significant trend112. This may suggest that oral HPV infection is 
independent of age in HIV-positive MSM but increases with age in HIV-negative MSM. 
However the HIV-positive MSM populations studied were generally older than HIV-negative 
populations so there was potential to conceal an age-association in younger HIV-positive 
MSM.  
Although it appears that participants with unknown HIV status have lower prevalence than 
either the HIV-positive or HIV-negative groups (Figures 17-20), this is likely to be an artefact 
of the one study that contributed data to the unknown HIV prevalence estimates. Kreimer 
et al. (2013) reported low oral HPV prevalence for all types among HIM study participants 
compared to studies in both HIV-negative MSM and HIV-positive MSM (Figures 17-20)113. 
The HIM study samples from populations in three countries (Mexico, Brazil, US) using a 
variety of methods that differ across countries, including military recruits, universities and 
advertisements. Men were compensated if included. Among the inclusion criteria for the 
HIM study were no reported history of HIV/AIDS (HIV tests were not performed) and no 
history of AGW diagnosis133. The generalisability of estimates from the HIM study is 
therefore complex and the low estimates of oral HPV prevalence may reflect the effects of 
participant selection into the study. 
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There was no evidence from this analysis that MSM are more at risk of oral HPV infection 
than MSEW (although varying definition of MSM between studies and lack of data in HIV-
negative MSM limits this conclusion).  
Women may play a role in oral HPV transmission in MSM: in one study113 compared to 
MSEW, oral HPV acquisition was higher in men who have sex with men and women, but not 
men having sex exclusively with men; in another study MSEW, but not MSM, were more at 
risk compared to women113,123. Perhaps the transmission probability from female genital 
mucosa to oral is higher than the probability from penile to oral. 
Clearance rates were greater than incidence in all five longitudinal studies. The clearance 
rate applies only to MSM infected with HPV (10-30% of the MSM population) and incidence 
to the susceptible portion (70-90% of MSM, assuming no natural immunity) so that, all other 
things equal, in the total population the number of new infections will eventually equal the 
number of cleared infections and the prevalence will stabilise.  
3.5 FINDINGS IN CONTEXT 
A global systematic review of oral HPV infection in healthy men and women was performed 
in 2010 which estimated the prevalence of oral HPV as 4.6% and 4.4% for men and women, 
respectively134. Oral HPV prevalence estimates in MSM from this meta-analysis were three 
to six times higher.  
There has been no meta-analysis of the incidence and clearance rates of oral HPV infection, 
nor for risk factors for oral HPV acquisition.  
Using pooled data collected by the international head and neck cancer epidemiology 
consortium, a history of same-sex sexual contact in men was shown to be strongly 
associated with cancers at the base of the tongue but not with other oral cancers6.  
3.6 STRENGTHS AND LIMITATIONS 
The strengths of this study include the high inter-rater agreement in study selection and 
data extraction and the exploration of reasons for heterogeneity in prevalence estimates 
including risk of bias. Yet there remain several limitations. The extreme heterogeneity 
between prevalence estimates was not explained so pooled estimates should be used with 
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caution. Approximation methods were used to estimate incidence and clearance rates and 
standardise them across studies; this, undoubtedly, introduced uncertainty into the 
estimates and so precluded meta-analysis. Although not designed for measuring risk of bias 
in meta-analyses, the STROBE checklist was used, which was not ideal for assessing the 
quality of study designs. It was not possible to include data from four potentially eligible 
studies135–138.   
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4. HPV-MSM-MMC STUDY: OVERVIEW OF METHODS AND 
DESCRIPTION OF STUDY PARTICIPANTS 
In this chapter, I describe the cross-sectional study of HPV in MSM attending a sexual health 
clinic in London. The methods in this chapter are referred to in subsequent chapters, each 
addressing specific objectives and presenting results. Here, I first summarise the study and 
its aims, then describe the data collection, data management, specimen 
collection/storage/transportation/testing, statistical methods and challenges to study 
implementation. Finally, I describe participant demographic and behavioural characteristics 
and consider potential participation bias and external validity. 
4.1 AIMS OF THE HPV-MSM-MMC STUDY 
1. Estimate the size of sub-populations composing the overall SHC-attending MSM 
population that are likely to have differential response to or benefit from  the HPV 
vaccine  
2. Estimate risk of future infection with HPV in SHC-attending MSM 
3. Estimate potential vaccine coverage, via  SHCs, in MSM in the UK 
4.2 OBJECTIVES ADDRESSED IN CHAPTER 4 
• To describe study design, data management, laboratory and statistical methods 
• To describe non-participation and missing data 
• To describe key characteristics of study participants, including HIV prevalence, and 
the age-association of STI transmission risk behaviours 
• To compare study participants to other MSM populations 
• To discuss potential participation bias and external validity introduced as a result of 
study design 
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4.3 METHODS 
SUMMARY 
522 MSM attending the Mortimer Market Centre (MMC) between October 2010 and July 
2012, aged 16 to 40 years inclusive, were consented to participate in this cross-sectional 
study. Participants completed a computer-assisted self-interview (CASI) questionnaire 
covering demographics, sexual behaviour, history of STIs (including AGWs and HIV), 
knowledge of HPV, attitudes to HPV vaccination and health service use. Biological specimens 
(anal, external genital, urine and oral) were collected and tested for HPV DNA. Blood was 
also collected and serum was tested for the presence of antibodies specific to HPV16 and 
HPV18. STI diagnoses and HIV test history were extracted from the clinic database using 
Sexual Health and HIV Activity Property Type (SHAAPT) codes139. 
STUDY SETTING 
The study was conducted at MMC, Camden, London, one of the largest outpatient clinics for 
general sexual health problems in Europe, with approximately 80,000 patient attendances 
per year. Of the men attending the clinic, approximately half are MSM. At MMC, there is a 
separate clinic for HIV-positive patients, but it is common for HIV-positive patients, both 
registered at MMC or elsewhere, to use the sexual health clinic for other STI-related 
services.  
Patients attend MMC for a variety of STI-related reasons, including asymptomatic screens 
and HIV tests. While we do not have data on reasons MSM attend this particular clinic, 
these are likely to be similar to those reported in the Maximising STI control in local 
populations survey, which was conducted in 2009140. In 109 MSM attending the three 
London clinics 42.3% attended because they reported symptoms; 9.6% because their 
partners had symptoms; 37.5% for an asymptomatic screen and 34.6% because they wanted 
an HIV test. Participants could report multiple reasons for attending.  
For HIV-positive MSM attending the sexual health clinic at MMC, HIV-related clinical data, 
including immunological and viral markers and prescription history, were not available. 
However, in the UK in 2010/11, MSM were less likely than heterosexual men to receive a 
late HIV diagnosis (<350 CD4 cell per μl). MSM were likely to be linked to HIV care (over 90% 
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had received a CD4 count within three months of diagnosis) and to have received ART 
within a year of their diagnosis141. The majority of HIV-positive MSM attending SHCs in the 
UK are therefore likely to have suppressed HIV infection. 
STUDY POPULATION 
Men were eligible for this study, and were approached consecutively, if they attended MMC 
during the recruitment period; were aged between 16 and 40 years inclusive; reported anal 
or oral sex with another man in the last 5 years; were able to understand the consent 
process and questionnaire in English; and had not participated in the study already.  
These eligibility criteria were devised so it was possible to compare this study to other UK 
studies; to capture the population most likely to be targeted for HPV vaccination; to address 
the effect of age on HPV infection and for practical reasons.  
Using the same definition as that used in Natsal, this study defined an MSM risk population 
(anal or oral sex with another man in the last five years) that moderated between men who 
are at very low risk of acquiring STIs, for example having had one same-sex experience in 
their lifetime, and those MSM at higher risk who had had sex with another man in the last 
three months8. Adhering to the Natsal definition facilitated comparison of MSM attending 
SHCs to MSM in the general population. 
It was hypothesised that younger men, with less lifetime exposure to HPV, would be more 
likely to be HPV-naïve and would gain more benefit from the prophylactic vaccine so young 
MSM were targeted by the age eligibility criterion. Due to ethical considerations the lower 
age limit was 16 years. A distribution of age was required, in order to examine the 
association of age and HPV prevalence and risk of HPV acquisition, but the upper age limit 
was 40 years to avoid oversampling older men.  
Men who were not able to understand the CASI questionnaire in English were not eligible 
for the study. This was assessed by the researcher. This exclusion was necessary for the 
following reasons: 
• It was not feasible (within time and finance constraints) to translate and validate all the 
study materials into all of the possible languages encountered at MMC. 
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• It was hypothesised that only a small proportion (estimated to be 10%) of the MSM 
attending the clinic would be excluded because of language and/or literacy. 
• Reporting bias: if some respondents were to answer the questionnaire via translator 
and the rest of the participants to answer via CASI, there was a risk of distortion of data 
due to social desirability bias. 
SAMPLE SIZE CALCULATIONS 
In 2009, the expected MSM population prevalence (?̂?𝑝) of anal HR-HPV ranged from 26-96% 
(Figure 9) and of HPV16 ranged from 9-52% (Figure 10). The single required accuracy 
formula (Equation 1) was used to calculate that more than 384 MSM were required to 
measure prevalence in the sample within 5% (𝑎𝑎 =0.05) of 52%.  
Assuming that the majority of MSM attending MMC are HIV-negative, 17% was considered a 
reasonable estimate for HPV16 prevalence. With an estimate for HPV16 prevalence of 17%, 
a sample size of 532 men would provide 80% power (μ=0.84) to detect a difference between 
two equally sized subgroups (e.g. age groups) at the 5% significance level if the true 
prevalence in the subgroups is 12% (π1) and 21% (π2), i.e. a relative risk of 1.75 (Equation 2).  
For HR-HPV, a sample of 532 men would provide more than 90% power to detect a relative 
risk of 1.75 between two equally sized subgroups if the true prevalence in those subgroups 
was 42% and 24%, at the 5% significance level, and the overall prevalence was 33%.  
EQUATION 1. SINGLE REQUIRED ACCURACY FORMULA 
𝑛𝑛 ≥ �
1.96
𝑎𝑎
�
2 × ?̂?𝑝(1 − ?̂?𝑝) 
  
EQUATION 2. COMPARISON OF TWO PROPORTIONS 
 
𝑛𝑛 ≥
𝜇𝜇�(1 − 𝜋𝜋1) +  𝜋𝜋2(1 − 𝜋𝜋2) + 1.96�2𝜋𝜋� (1 − 𝜋𝜋�)(𝜋𝜋1 − 𝜋𝜋2)2  
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Where 𝜋𝜋1 = prevalence in sub-group 1, 𝜋𝜋2 = prevalence in sub-group 2, 𝜋𝜋� = 𝜋𝜋1+ 𝜋𝜋22  = mean prevalence and 𝜇𝜇 = the value 
obtained from standard normal distribution at the percentile corresponding to the chosen level of power 
DATA COLLECTION  
Patient identification and recruitment 
The method of recruitment was designed so as to ensure patient confidentiality. Patient 
consent and questionnaire completion took place in a clinic room designated for study use. 
Clinic staff identified eligible potential participants and referred them to the study nurse 
based in the clinic. The study nurse discussed the study with the patient, checked eligibility 
for the study, gave them the patient information sheet to read and, if appropriate, 
witnessed them consenting to the study.  
Study procedures 
The study nurse performed both the routine National Health Service (NHS) and the study 
procedures in one visit as this was more time efficient for the participant. After consenting, 
the participant completed a CASI questionnaire and then study specimens were taken at the 
same time as the routine clinic tests. Five specimens were obtained from each participant: 
urine, one external genital swab, one intra-anal swab, one oral rinse/gargle and 6ml of 
blood.  
Questionnaire development and validation 
Key principles informing the development of the questionnaire 
In order to maximise the quality, completeness and validity of the survey data, it was 
necessary to consider which variables to measure, how to phrase questions, how to order 
questions, how many questions to include, the respondent’s understanding of how to 
respond to questions and how to facilitate the recollection of the fact relating to the 
question142,143.  
Measurement objectives 
In addition to risk factors that were identified in previous studies (Table 3, page 43), other 
basic demographic information, sexual behaviour, history of STIs (including AGWs) and 
markers for intention to accept the HPV vaccine were measured.. 
Research variables 
Both Natsal and the GMSHS have been validated through extensive development, cognitive 
interviewing, piloting and/or use in the field. Where possible, questions in the HPV-MSM-
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MMC survey were phrased in the same way as in other surveys, such as Natsal and GMSHS, 
in order to confer validity of tested questions to this survey, and to ensure external validity 
of the work.  
Use of alcohol was measured using the abbreviated alcohol use and disorders identification 
test (AUDIT-C) that has been validated for screening for high-risk drinking in primary 
care144,145.  
Based on the importance of use of health services, perceived risk, outcome expectancies 
and perceived self-efficacy as predictors of vaccine uptake105, data were captured relating to 
perceived risk of HPV acquisition and the likelihood of both being offered (use of health 
services) and accepting (perceived self-efficacy) the HPV vaccination if a targeted 
programme existed. There were nine true or false items designed to assess existing 
knowledge about HPV. Questions were devised to address risk perception, outcome 
expectancies/belief in efficacy and perceived self-efficacy. It was considered that the patient 
information sheet contained sufficient detail to answer these questions correctly.  
There were 62 questions in the survey some of which were made up of multiple items. 
There were a total of 101 items in the survey. The questionnaire is included in this thesis as 
Appendix I.  
Interview method 
CASI was used in this study for several reasons. Firstly, the questionnaire format and 
questions were identical for each respondent. This consistency helped to diminish 
measurement error that might have resulted in reporting bias if, for example, in a face-to-
face interview different men were asked questions with a different tone or by different 
clinicians. For example, it is known that people (especially women) tend to report more 
information to female interviewers146.  
Secondly, respondents were not concerned with the reaction of the interviewer to their 
responses. This anonymity helped to diminish social desirability bias where responses are 
amended in order to appear more favourable to others. For example, respondents may 
have felt that health care professionals would not have approved of high frequency of 
partner change and accordingly reduced their estimate of number of partners in the last 
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month. With CASI, social desirability bias can be significantly reduced, especially if there are 
no personal identifiers (e.g. name, place of work etc) on the questionnaire, which results in 
CASI measuring higher risk sexual behaviour (e.g. more sexual partners, more unprotected 
intercourse) than clinician interview146.  
Additionally, a well-designed questionnaire can use skipping and auto-completion of items 
to reduce the completion time and response error compared to a pen-and-paper 
questionnaire. These features, as well as the question consistency and reduction in social 
desirability bias, result in more complete data than face-to-face interviews. This is important 
because item non-response can introduce bias to survey data if those who do not answer a 
particular question are systematically more or less likely to report that behaviour than those 
who do answer the question147. For this reason and to maximise the statistical power in the 
analyses, it is important to minimise non-response. CASI is also generally acceptable to 
respondents when measuring sexual behaviour and requires no data entry therefore 
reducing transcription errors148. 
Description of survey instrument  
Any potential ambiguity in the meaning of questions or terms was minimised by 
questionnaire testing and use of previously validated questions. Mapping the response to 
the questionnaire was simplified by using mutually-exclusive and collectively-exhaustive 
multiple choice or open-ended fields with the units specified (e.g. years). For open-ended 
questions, the field type (i.e. numeric or string) was assigned during questionnaire 
development so that potential completion errors were mitigated. The survey was designed 
and delivered in SNAP 10 survey software. 
The questionnaire was designed to take approximately ten minutes to complete with 
variability due to routing. Ten minutes was deemed a suitable length of time to ask 
participants to spend on the questionnaire without interfering with their routine NHS visit. It 
was not considered so long that patients would be put off participating nor would it affect 
item completion due to fatigue. It did provide enough time to answer the 101-item 
questionnaire. The range of questionnaire items was 44-99 due to routing.  
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Questions relating to a similar topic were grouped into sections. To facilitate fact recall, 
logical groupings were made, such as a set of behaviours within the same time-frame. 
Sections and questions were ordered to begin with less sensitive items, to ease the 
participant into the questionnaire format, which then gained focus. To maximise 
consistency and continued relevance, some items were ordered to allow for routing.  
The questionnaire tone mirrored that which would be used in the clinic for taking a sexual 
history. Thus, for example, the phrase ‘insertive anal sex’ was used rather than the 
colloquial term ‘fucking’ that has been used in other sexual behaviour surveys of gay men in 
the UK. Young people in focus groups in 1998 in the UK generally preferred health 
professionals to use formal rather than vernacular terms149. Signposting and guidance were 
included to aid understanding and patience. For example, the series of questions relating to 
the three most recent partners was preceded with comments explaining which partners 
were eligible to be included and stating that “it will be helpful for you to think of them 
now”.  
Questionnaire testing 
The survey was pre-tested and piloted to assess its acceptability and validity. First it was 
reviewed by experienced researchers in the field of sexual behaviour surveys (Dr Catherine 
Mercer & PS) and their comments were incorporated. Then it was tested on a sexual health 
clinician (RG) and colleagues in the centre for sexual health & HIV research, particularly 
those who had designed their own behaviour surveys. 
The survey, the patient information sheet and the informed consent form were piloted on 
ten MSM who met the study’s eligibility criteria at MMC. Half of these men completed the 
survey without interruption so that the completion time could be monitored followed by a 
discussion of any ambiguities. The rest “thought aloud” and asked questions as they went 
along. The questionnaire was edited between each interview and piloting continued until no 
new issues were revealed.  A summary of the findings from the pilot survey are in Appendix 
II. 
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SEXUALLY TRANSMITTED INFECTIONS, INCLUDING HIV 
All SHAAPT codes reported within 30 days of the study visit were retrieved and assumed to 
represent a diagnosis made at study visit. HIV test history was recorded from beginning of 
clinical records up to 30 days after the visit. Gonorrhoea, chlamydia, herpes simplex virus 
(HSV) and syphilis infections were reported individually. All remaining STIs (hepatitis A, HBV, 
hepatitis C, chancroid, lymphogranuloma venereum, Donovanosis, trichomoniasis, scabies, 
pediculosis pubis, molluscum contagiosum, epididymitis, balanitis, candidosis and other 
conditions requiring treatment) were collapsed into the ‘other’ category.  
The electronic patient records, of participants who attended the clinic because they thought 
they had an episode of AGW but did not receive a related SHAAPT code, were accessed to 
explore this discrepancy.  
DATA MANAGEMENT 
Anonymisation, data-linking 
Enrolment Log 
MMC uses stickers in patient notes that are attached to forms and laboratory specimens. 
The stickers are printed with the clinic’s patient identification (ID) number, the date of birth 
and the patient’s name. Participants in the study were assigned a study ID number ranging 
from 4000 to 4531. Bar-coded labels were used in the study as shown in Figure 23. The 
study ID number was encoded (bar code 39) so that the samples arriving at the laboratory 
could be identified using a scanner. The clinic sticker and the study ID number were both 
listed on the study’s enrolment log which was also maintained as an excel spreadsheet.  
FIGURE 23. STUDY-SPECIFIC BARCODE LABELS 
 
Informed consent form 
The other written linking of study participant to the patient was the study’s consent form. 
This listed both the participant’s study ID number and the patient’s name. The participant 
signed three copies of the consent form. One was placed in the medical notes, one was kept 
in the study’s site file and the other was given to the participant.   
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Merging datasets 
Figure 24 displays the process of merging datasets. Study ID numbers were used to identify 
participants’ questionnaire responses and study laboratory samples. STI diagnoses were 
retrieved from the NHS records for all patients in the clinic during the study period. These 
were identifiable by name and clinic ID. The questionnaire responses were merged with the 
HPV test results using the study ID. The STI diagnoses were merged with the electronic 
enrolment log using clinic ID and date of visit. The clinic ID was deleted from the resulting 
dataset. The STI diagnoses were then merged with the questionnaire responses and HPV 
results using the study ID. 
QUALITY ASSURANCE & CONTROL   
Instructions were written and tested for all study procedures: the laboratory protocol and 
the specimen collection and processing manual. The enrolment log and survey data were 
regularly checked for anomalies and there were frequent meetings with the study nurse to 
discuss study processes. The PHE laboratory checked samples for leakage and appearance 
when they received them. Any problems were reported back to the research nurse and 
study co-ordinator. Recruitment rate was monitored regularly by updating an electronic 
participant tracker. This tracker gave estimated date of end of recruitment and also allowed 
for the monitoring of the age profile of the sample. Data checks were performed for 
eligibility, consistency between answers and consistency between answers and STI 
diagnoses. 
ETHICAL CONSIDERATIONS 
The questionnaire collected personal sensitive information such as income, smoking, 
drinking and sexual behaviour. Confidentiality of the participant was addressed so that 
social desirability bias was minimised and privacy was respected. The participant completed 
the questionnaire in a closed clinic room while the study nurse labelled the biological 
specimen tubes. The study nurse was not in a position to see the computer screen but was 
available to answer any questions about the survey. All of the questions were optional as it 
was decided that having the participant feel that they could opt out and were volunteering 
information outweighed the negative impact of item non-completion. 
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Routine clinic visit tests, diagnoses and reporting were unaffected by participation in the 
study. Participants were not informed of the results of their HPV tests. Not only is the HPV 
assay not validated for clinical use, but also, there is currently no clinical intervention for a 
participant who receives a positive HPV test. All laboratory tests were performed together, 
at the end of the study. HPV infection is often transient, lasting approximately one year150. 
Men who participated at the beginning of the enrolment period might have cleared their 
infections spontaneously by the time their samples were tested so the results would no 
longer be relevant.  
ETHICAL APPROVAL 
We gained ethical approval for the study from the Camden and Islington Research Ethics 
Committee on 6th October 2009 (REC reference number: 09/H0722/71) and received 
research and development approval from the North Central London Research Consortium 
on 7th October 2010 (R&D ref: CSP 30296). The ethics committee and R&D office were 
informed of the closure of the study on 8th August 2012. 
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FIGURE 24. MERGING DATASETS 
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BIOLOGICAL SPECIMENS 
Collection and transportation 
A first-void urine sample was collected and refrigerated at 4○C until transportation. The anal 
and the external genital specimens were obtained using a sterile plastic shaft flocked swab 
that was pre-soaked in sterile saline (one each). The anal swab was inserted 3cm into the 
anal canal and rotated 360○ applying gentle pressure to the walls of the canal. The external 
genital specimen was obtained by rubbing the following areas with the swab: 
1. Glans penis/coronal sulcus 
2. Penile shaft including the prepuce (if present) 
3. Scrotum 
4. Perianal area 
Both swabs were inserted into their own Copan Universal Transport Medium (UTM-RT) ™ 
collection vial and stored at 4○C until they were transported.  
Delays, due to the additional logistical requirements for on-site oral sample processing, 
resulted in oral specimens only being collected in the latter five months of the recruitment 
period (7th March 2012 onwards). The oral specimen involved a 30-second gargle/rinse with 
15ml of Scope® mouthwash according to a published protocol112. Oral samples were 
refrigerated immediately and processed the same day. To process, the rinse was centrifuged 
at 3200 RPM for 15 min at 4°C and, after the supernatant was discarded, the pellet was 
resuspended in 20 ml of cold PBS (4○C). The centrifugation/resuspension was repeated twice 
and the final pellet was resuspended in 1.2 ml of PBS with repeat pipetting and vortexing to 
ensure a homogeneous sample.  
Urine and swabs were transported with a cold pack within 48 hours of collection and oral 
specimens were transported on dry ice at the end of the study (22nd October 2012) to the 
virus reference department, PHE, Colindale. 
A blood sample was collected using gold-topped BD vacutainer SST II Advance tubes. The BD 
instructions were followed to separate the plasma from the serum. Two aliquots of serum 
were stored at -20○C. These samples were shipped on dry ice to the VEU, Public Health 
Laboratory, Manchester.  
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LABORATORY METHODS 
HPV DNA extraction, amplification, detection, genotyping 
On arrival at the Colindale laboratory, urine specimens (1ml) were centrifuged (13 000 rpm 
for 20 min) and the pellet resuspended in 300μl sterile phosphate buffered saline prior to 
storage at -80°C.  Swab specimens were vortexed to agitate the material from the swab into 
the buffer and aliquots of 300μl were stored at -80○C. At the end of the study (timeline, 
page 22), specimens were removed for batch processing wherein all available specimens 
from each individual were processed for DNA extraction and HPV testing in the same run. 
Thawed aliquots were lysed with 40μl Qiagen Protease and 265μl Qiagen buffer then nucleic 
acid was extracted on a BioRobot Universal platform using QIAamp®DNA Blood BioRobot® 
MDx kit (Qiagen Limited, Crawley, West Sussex, UK). Ten microlitres of the 100μl elution 
were used for PCR amplification using the in-house single-round multiplex PCR, with 
modified GP5+ and GP6+ primers, targeting the L1 gene, and type-specific infections were 
resolved using a genotyping assay based on the Bio-Plex® (Luminex xMAP®, Bio-Rad 
Laboratories, Hemel Hempstead, Hertfordshire, UK) platform151. Specimen integrity was 
established by incorporating a control PCR targeting the human pyruvate dehydrogenase 
gene.  
Real-time PCR on anal and external genital samples 
In order to quantify cellular and HPV DNA, real-time PCR was performed on anal and 
external sample pairs in which both samples had detectable HPV16 in the genotyping assay. 
PCR primers and probes targeting HPV E6 and glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) were optimized for the ABI 7500 Fast PCR machine (Applied Biosystems) using 
Platinum UDG Supermix (Life Technologies). The original aliquot (300uL) was eluted from 
extraction into 100uL and 10% (10uL) was used for typing. Therefore the viral copies per 
reaction can be converted to copies per ml by multiplying by 33.333. Viral load (VL) was 
calculated as HPV copies per cell (c/c) as determined by dividing the number of viral copies 
per reaction by the half the number of GAPDH copies per reaction. A positive control of 
pooled HPV16, HPV18, HPV31 and HPV45 DNA from a mixture of samples demonstrated 
good reproducibility152. Samples positive for HPV16 by genotyping assay but negative via 
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real-time PCR, were assumed to result from differences in assay sensitivity, and were 
censored at five copies per reaction for calculation purposes.  
LCR sequencing of HPV16 in anal and external samples 
To explore whether same genotype concordance was reliably the same variant and the 
proportion of mixed variant infections, sequencing of the variable LCR was performed in 
external and anal samples with detectable HPV16: an 1187 base-pair (bp) fragment 
encompassing the entire LCR and a portion of the E6 ORF was sequenced to identify intra-
type variants. HPV16 samples were amplified in a single 1329 bp fragment with primers 16-
F101 and 16-R20. Template amplification was performed in a 25μL reaction mix containing 
Kapa HiFi HotStart ReadyMix (Kapa Biosystems), 5pmol of each primer and 5μL of template 
DNA sample under the indicated cycling conditions on a PTC-200 thermal cycler (MS 
research). The resulting PCR product was evaluated for its molecular weight using a DNA 
mass ladder (Invitrogen) and GelAnalyzer software (www.gelanalyzer.com) and sequenced 
using 5pmol of each indicated sequencing primer153.  
Classification of HPV genotypes 
Box 5 shows the oncogenic risk classification of HPV genotypes as used in all analyses from 
the HPV-MSM-MMC study. 
BOX 5. ONCOGENIC RISK AND VACCINE-PREVENTABLE CLASSIFICATION OF HPV GENOTYPES 
Bivalent vaccine types 16/18 
Quadrivalent vaccine types 6/11/16/18 
9-valent vaccine types 6/11/16/18/31/33/45/52/58 
HR-HPV types 16/18/31/33/35/39/45/51/52/56/58/59/68 
LR-HPV types 6/11 
Possible HR-HPV types 26/53/66/70/73/82 
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HPV antibody detection 
Serum was tested for Immunoglobulin G (IgG) to HPV types 16 and 18 using a type-specific 
ELISA that has been validated against a pseudovirion-based neutralization assay in post-
vaccination samples from women154.  Briefly, VLP16 and VLP18, purified from recombinant 
baculovirus were pre-coated onto separate 96-well microtitre plates for between 60 and 
120 hours at 4oC.  Following blocking to prevent non-specific binding, test, positive control 
and standard serum were added to VLP16 and VLP18 plates, double diluted and incubated 
for 60 minutes at room temperature. The microtitre plates were then washed. Specific 
bound antibody was detected using horseradish peroxidise mouse anti-human conjugate 
and developed with a specific chromogenic substrate.  Optical density was determined at 
450nm with a 620nm reference.  Quantitative results were calculated from the standard 
and expressed in arbitrary ELISA units per millilitre (EU/mL).  The lower limit of the assay at 
the VEU was 19 and 18 EU/mL for HPV16 and HPV18, respectively, with values below this 
classed as seronegative.   
STATISTICAL METHODS 
Data cleaning and categorising  
Eligibility, range and consistency checks were performed on the survey dataset. Categorical 
variables were cross-tabulated to identify inconsistencies between answers which were 
corrected or recoded as missing, as appropriate. Distributions of continuous variables were 
explored for consideration as predictors in regression models and checked for outliers using 
histograms. If approximately normally distributed, or potentially transformed into a normal 
distribution, we used all data for continuous variables in regression models. Continuous 
variables that were highly skewed, and could not be transformed, were collapsed by 
recoding as categorical variables with meaningful cut-offs whilst maintaining sufficient 
numbers within each group for analyses.  
Statistical standards in HPV in MSM study 
All statistical analyses were conducted using STATA v13.1 and, unless otherwise specified, a 
p value of <0.05 was considered statistically significant. CIs around estimates of proportions 
(prevalence estimates) were determined at 95% using the Clopper-Pearson (exact) method. 
During multivariate model analyses, the Wald test (instead of the likelihood ratio test) was 
performed to assess the statistical significance of individual predictor variables on the 
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outcome. A non-parametric test for trend, based on the Wilcoxon rank-sum test, was used 
to assess the existence of a trend across ordered categories for variables with at least three 
categories.  Not all tables display missing data for each variable but this can be calculated 
from totals. Missing data were not imputed and complete case analyses were performed. 
Odds ratios (OR) are reported for univariate analyses, and adjusted ORs for multivariate 
logistic regression models.  
Participant characteristics and missing data  
The frequency of collected and tested biological samples and completed questionnaire 
items was summarised. A comparison was made between MSM who declined to participate 
and participants. The mean age was compared between the two groups using a t test. The 
difference in the proportion of those that were new patients between the two groups was 
tested using the χ2 test. The difference in mean age and proportion of new patients across 
the reasons for not participating were tested using one-way ANOVA and χ2 tests. The 
proportion of missing data for each questionnaire item was determined as the number of 
men who were asked the question who did not provide a response.  
In participants, demographic and behavioural variables were categorised and frequency was 
summarised. For continuous variables the median and inter-quartile range (IQR) was 
reported. Age at first sex was compared between HIV-negative and HIV-positive populations 
using the t test. To explore the potential for future HPV acquisition at any age, the effect of 
age on sexual behaviour was examined. Firstly, the association of number of sexual partners 
and age was explored both by logistic regression (≤ 30 compared to >30 lifetime partners) 
and linear regression (number of partners in the last year). Then, a categorical age variable 
(18-30 compared to 31-40 years) was used in logistic regression with other categorical 
behavioural variables.  
External validation 
External comparisons of the study population were made with the MSM aged 16-40 
attending MMC and other STI clinics in England in 2011 (Genitourinary Medicine Clinic 
Activity Dataset; GUMCADv2139), MSM in the general population 2010-2012 who reported 
attending an STI clinic in the last 5 years (Natsal-3155), and MSM who participated in the 
GMSHS in London’s pubs and clubs in 2011156. Variables explored, where available, were 
Results on pages 
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age, ethnicity, lifetime partners and anal partners (in total and without a condom) in the last 
year.  
HPV PREVALENCE AND RISK FACTORS  
HPV prevalence 
HPV DNA prevalence was estimated by HPV type, HIV status, specimen type and age. 
Estimates were made of the number of men with detectable HPV DNA out of the number of 
men with an adequate sample for HPV testing. Anogenital HPV DNA prevalence was defined 
as the proportion of participants with detectable HPV DNA in ≥1 of the three anogenital 
specimen types (anal swab, external genital swab or urine) in participants with ≥1 specimen 
type that was adequate for HPV testing. HIV status was determined from both 
questionnaire data (self-reported) and clinical records at MMC. 
Risk factors for HPV  
Univariate logistic regression was used to explore the age-relationship with HPV infection 
detected at ≥1 anogenital site (any type, HPV16/18, any of the quadrivalent-vaccine types, 
any 9-valent vaccine types, any HR-HPV, and HPV6/11) with age as a continuous predictor 
variable.  
The effect of demographic and behavioural risk factors was examined on the detection of 
HR-HPV DNA at each anatomical site. Age-adjusted logistic regression models were fitted to 
all the data allowing multiple outcomes from individuals by HPV type (rather than collapsing 
the HR-HPV variable) using the generalised equation estimation (GEE) method assuming an 
exchangeable working correlation (i.e the same correlation between pairs of HPV types; an 
unstructured correlation matrix failed to converge)157. Variables were considered significant 
if p<0.05 using the Wald test.   
Demographic and behavioural risk factors for quadrivalent-vaccine types were also assessed 
using age-adjusted logistic regression having collapsed the quadrivalent-vaccine type 
variable so that each participant contributed a single outcome. 
Results in chapter 
5, page 117 
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ANALYSES OF SPECIMEN AGREEMENT ON HPV DNA DETECTION  
The occurrence of joint detection of HPV at two or more anatomical sites was quantified by 
estimating prevalence of each 9-valent vaccine type by sample combination and using 
agreement, concordance and kappa estimates and the McNemar test, as described in Box 6. 
Agreement was used to describe the proportion of MSM that are either negative or positive 
at both sites for HPV detection ((𝑎𝑎 + 𝑑𝑑)/𝑁𝑁). Concordance was used for the proportion of 
MSM who have the same HPV DNA detected at both sites in MSM (𝑎𝑎/𝑁𝑁). Expected 
concordance, due to chance, was estimated as the type-specific prevalence at anatomical 
site A multiplied by that prevalence at site B. Confidence intervals around the kappa 
estimates were determined using an analytical method. Kappas were summarised across 
multiple HPV types by calculating the weighted average of the kappas, where for each 
kappa the weight is proportional to 1 minus the expected agreement, and 95% CIs were 
generated using bootstrapping (1000 replications)158. For all joint detection measures, 
within the compared sites, MSM were included if each specimen type was adequate for HPV 
testing.  
BOX 6. CALCULATIONS OF AGREEMENT, CONCORDANCE, KAPPA AND THE MCNEMAR TEST STATISTIC 
FOR MEASURING THE RELATIONSHIP BETWEEN DETECTING HPV AT ONE SITE COMPARED TO ANOTHER 
           
  Site B  
𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝑛𝑛𝐴𝐴 =  (𝑎𝑎 + 𝑑𝑑)
𝑁𝑁
 
 
Site A  
+ve -ve Total  𝑅𝑅𝑎𝑎𝑛𝑛𝑑𝑑𝑅𝑅𝐴𝐴 𝑎𝑎𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝑛𝑛𝐴𝐴 = (𝑎𝑎 + 𝑏𝑏)(𝑎𝑎 + 𝑐𝑐) + (𝑐𝑐 + 𝑑𝑑)(𝑏𝑏 + 𝑑𝑑)
𝑁𝑁
 
 +ve 𝑎𝑎 𝑏𝑏 𝑎𝑎 + 𝑏𝑏  𝐶𝐶𝑅𝑅𝑛𝑛𝑐𝑐𝑅𝑅𝐴𝐴𝑑𝑑𝑎𝑎𝑛𝑛𝑐𝑐𝐴𝐴 = 𝑎𝑎𝑁𝑁 
 -ve 𝑐𝑐 𝑑𝑑 𝑐𝑐 + 𝑑𝑑  𝐶𝐶𝑅𝑅𝑛𝑛𝑐𝑐𝑅𝑅𝐴𝐴𝑑𝑑𝑎𝑎𝑛𝑛𝑐𝑐𝐴𝐴 𝑑𝑑𝑑𝑑𝐴𝐴 𝐴𝐴𝑅𝑅 𝑐𝑐ℎ𝑎𝑎𝑛𝑛𝑐𝑐𝐴𝐴 = (𝑎𝑎 + 𝑏𝑏)𝑁𝑁 × (𝑎𝑎 + 𝑐𝑐)𝑁𝑁  
     𝑁𝑁  𝐾𝐾𝑎𝑎𝑝𝑝𝑝𝑝𝑎𝑎 = 𝑎𝑎𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝑛𝑛𝐴𝐴 − 𝐴𝐴𝑎𝑎𝑛𝑛𝑑𝑑𝑅𝑅𝐴𝐴 𝑎𝑎𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝑛𝑛𝐴𝐴1 − 𝐴𝐴𝑎𝑎𝑛𝑛𝑑𝑑𝑅𝑅𝐴𝐴 𝑎𝑎𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝑛𝑛𝐴𝐴  
       𝑀𝑀𝑐𝑐𝑁𝑁𝐴𝐴𝐴𝐴𝑎𝑎𝐴𝐴′𝑠𝑠 𝐴𝐴𝐴𝐴𝑠𝑠𝐴𝐴 𝑠𝑠𝐴𝐴𝑎𝑎𝐴𝐴𝑠𝑠𝑠𝑠𝐴𝐴𝑠𝑠𝑐𝑐 = 𝜒𝜒2 = (𝑏𝑏 − 𝑐𝑐)2
𝑏𝑏 + 𝑐𝑐  
        
 
Results in chapter 
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The distributions of number of cells per reaction, number of HPV16 copies per reaction and 
number of HPV16 copies per cell (VL) were compared between anal and external swabs 
using kernel density plots, medians and IQRs and differences were formally tested using the 
matched-pairs signed-ranks test. 
The effect of demographic and behavioural risk factors on the odds of detectable HR-HPV at 
two or more anogenital sites (concordance) was compared to no infection and to anogenital 
single infection.  Age-adjusted logistic regression models were fitted using the generalised 
equation estimation method as on page 95.  
Serology analyses 
The association of age and HPV-IgG detection was explored by HIV status using logistic 
regression with age first as a continuous and then as a categorical independent variable. In 
MSM with detectable IgG for HPV16 and/or HPV18, an analysis of the relationship between 
IgG titre and age was performed using linear regression. 
Risk factors for detectable HPV16-IgG were explored first using univariate logistic 
regression, or Fisher’s exact test if any cell of the contingency table contained fewer than 
five MSM,  and then using multivariate logistic regression having adjusted for age and 
number of lifetime partners a priori and stratified by HIV status. This was repeated for 
HPV18-IgG.   
HPV6/11, AGWS AND STI ANALYSES 
History of AGW was derived from two data items: reporting ever having had an AGW 
diagnosis and receiving a SHAAPT code for AGW within 30 days of the visit (hereafter, 
diagnosis at visit). Sensitivity and specificity of a suspected AGW episode was estimated 
using a diagnosis of AGW at visit as the gold standard. Demographic, behavioural and 
biological variables (anogenital HPV6/11 and HPV16/18 DNA, anti-HPV16 /18 and STIs) were 
examined for association with AGWs using logistic regression or the Fisher’s exact test 
(where cells had an expected frequency of five or fewer). Unadjusted ORs and aORs, 
adjusting for age and number of lifetime partners, are presented. Correlation was examined 
between age and age of most recent partner using Pearson’s r: r=0 indicates no correlation, 
Results on page 
136 
Results on page 
138 and appendix 
IV, Appendix table 
6, page 309  
Results in chapter 
6, page 153 
Results on pages 
156-169 
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r=1 indicates a perfect positive linear relationship and r=-1 indicates a perfect negative 
linear relationship. 
HEALTH-SEEKING BEHAVIOUR, VACCINE ATTITUDES AND HPV KNOWLEDGE 
The association of anogenital HPV DNA (6/11 and 16/18), HPV16/18 antibodies and AGWs 
with the mean age at first attending a SHC in the UK were explored using t tests. The 
prevalence of anogenital HPV, HPV serum antibodies and AGWs were estimated in the sub-
group of MSM attending a SHC for the first time. 
The history of health service use in SHC-attending MSM was described and factors that 
affect MSM’s intentions to receive vaccines were assessed. Health service use, HPV 
knowledge and STI risk perception, by quadrivalent HPV type status, were explored to 
identify potential opportunities and barriers for delivery of vaccination.  
To explore the open-ended reasons for or against perceived likelihood of accepting the HPV 
vaccine, answers were grouped. Each answer was assessed and, if it did not fit into existing 
groups, either a new group was created, or the definition of an existing group was amended 
so it became inclusive.  
Random-effects meta-analyses 
In chapters 5 and 6, random-effects meta-analyses were performed on chapter estimates 
and other HPV prevalence estimates from studies published up to mid-2015 using methods 
described  in chapter 3, page 56. Studies for these ‘findings in context’ sections were not 
identified systematically. 
Strengths and limitations of the HPV-MSM-MMC study 
Recruitment 
It was beneficial to run the study at MMC because the large patient population enhanced 
recruitment and the entire research team were in the same building. This facilitated 
trouble-shooting and motivating the clinic researchers. However, the recruitment rate was 
slower than predicted and was hindered by only having one study nurse working on the 
study, who was not able to be present during all of the clinic opening hours.  
In the clinic, it was difficult to identify the broader risk group of MSM that had had sex with 
another man in the last five years and men were usually recruited using the operational 
Results in chapter 
8, pages 196-199 
Results on page 
199 
Results on page 
201 
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definition at MMC: anal or oral sex with another man in the last three months. The study 
population was therefore a higher risk subset of the targeted population.  
Data 
Eleven surveys that were completed in October 2011 and four surveys completed in 
February 2012 were lost during the transfer from the study’s CASI tablet computer to the 
main UCL server and on three occasions the CASI survey failed to save the data.  
There was a period in which the study’s screening log was not completed. The log was 
completed from the start of recruitment (25th October 2010) until 31st October 2011 and 
then restarted on 14th February 2012 until the end of recruitment (18th July 2012). There 
was therefore missing data on the participation rate between 1st November 2011 and 13th 
February 2012, three and a half months of the 20-month recruitment period. 
4.4 RESULTS 
PARTICIPATION RATE 
A total of 522 men participated in the study. Of 413 eligible men who were approached 
when the screening log was active 341 (82.6%) consented to participate in the study. Men 
who participated were slightly older (mean = 29.7 years; 95% CI 29.1-30.3) than men who 
did not agree to participate (mean = 28.2; 95% CI 26.8-29.6; p=0.05) and were 1.8 (95% CI 
1.0-3.3) times more likely to be a new patient at the clinic (p=0.04). Across the reasons listed 
for not participating in Table 8, there was no difference in the mean age (F=1.13 p=0.35) or 
the proportion who were new patients in the clinic (χ2 with 5 df=4.76, p=0.45).  
TABLE 8. REASONS FOR NOT PARTICIPATING IN THE HPV-MSM-MMC STUDY 
Reason for not participating  
(multiple responses were permitted) 
n (%) Mean age 
(years) 
New patients  
n (%) 
Time 30 (39.0) 28.4 5 (16.7) 
Declined for other reasons  e.g depressed/eye infection 17 (22.1) 30.7 2  (11.8) 
English language not sufficient 14 (18.2) 27.1 4 (28.6) 
Anxious/upset 9 (11.7) 25.7 4 (44.4) 
Extra tests 4 (5.2) 26.8 1 (25.0) 
No reason given 3 (3.9) 27.7 1 (33.3) 
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RESPONSE RATE 
The flowchart in Figure 26 shows the available data in the study. All 522 men who 
participated in the study completed the questionnaire. Some men declined to give specific 
samples. The resulting number of samples available for analyses were: 512 anal and stored 
blood samples (98.1%); 521 external genital swabs (99.8%) and 182 oral samples (97.9% of 
the 186 men offered the oral sample). Overall, the questionnaire took between five and 15 
minutes to complete and it was generally completed in seven to ten minutes.  
MISSING DATA 
Missing surveys 
Eighteen (3.5%) questionnaires were not available for analysis (see page 99). The analyses 
were carried out on the 504 completed surveys. 
Item non-completion 
Most of the sample (98.0%) completed more than 46 of the 55 items that were asked to all 
participants. Table 9 lists the items that had more than 5% non-response. A fifth of the 
sample did not complete the three items asking about sex with a woman that were part of 
question 18 (Figure 25). Nearly two thirds of the sample did not give a reason for their 
intention to accept the HPV vaccine. This item was not missing at random as men who were 
less likely to accept the vaccine would be more likely to give a reason. All men were asked 
whether they had told their general practitioner (GP) their sexual orientation and 5.6% did 
not respond. This was question 52 of 62 so was near the end of the survey. There were 
three participants with more than 47 of the 101 questionnaire items (maximum including 
routed questions) missing. One of these men was described as “manic” by the research 
nurse and unable to sit down for long. There is no information as to why the other two men 
did not complete the questionnaire fully. The data from all three men were included in the 
analyses. 
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FIGURE 25. SCREENSHOT OF QUESTION 18 FROM THE CASI QUESTIONNAIRE 
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 FIGURE 26. FLOWCHART OF NUMBER OF MSM WITH AVAILABLE DATA AND BIOLOGICAL SPECIMENS 
513 with at least one adequate DNA specimen 
497 survey data 
 
511 with at least one adequate anogenital specimen 
495 survey data 
 
522 MSM recruited 
504 survey data 
Approximately 644 MSM approached 
166 adequate oral 
specimens 
165 survey data 
454 adequate anal 
specimens 
439 survey data 
  
446 adequate external 
specimens 
431 survey data 
486 adequate urine 
specimens 
470 survey data 
72/413 (17%) of MSM did not participate 
506 adequate 
serology specimens 
490 survey data 
177 oral specimens 
collected 
  
512 anal specimens 
collected 
  
521 external genital 
specimens collected 
  
522 urine specimens 
collected 
  
512 blood samples 
collected 
187 recruited on or after 7
th 
March 2012 
5 non-viable 1 non-viable 1 non-viable 
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TABLE 9. LIST OF VARIABLES WITH MORE THAN FIVE PERCENT OF MISSING DATA, DUE TO NON-
COMPLETION 
Question Number of non-responders/ 
Number of men asked question (%) 
When was the last time you had:   
Vaginal sex 110/504 (21.9) 
Oral sex with a woman 107/504 (21.2) 
Anal sex with a woman 109/504 (21.6)  
Please give reason below (Follow up to question: The HPV vaccine course is 3 
injections in a 6 month period. If you were offered the HPV vaccine in this clinic, how 
likely would you be to accept it?) 
324/504 (64.3) 
Please specify (Follow to response “Mixed/Other” from the ethnic group categories) 7/58 (12.1) 
In the last year, with how many men have you only had oral sex 40/494 (8.1) 
When you had anal sex without a condom in the last year, were you…always 
insertive, always receptive, versatile, mostly insertive, mostly receptive? 
36/326 (11.0) 
Age of partner 3 24/460 (5.2) 
How certain are you of their age? Partner 3 33/460 (7.2) 
Is this a regular (main) or a casual partner?   
Partner 2 27/483 (5.6) 
Partner 3 37/460 (8.0) 
How many partners do you think this partner has had in the last year? Partner 3 26/460 (5.7) 
How certain are you about the number of partners they have had?   
Partner 1 30/502 (6.0) 
Partner 2 37/483 (7.7) 
Partner 3 44/460 (9.6) 
When was the last time you had sex with this partner? (number)  
Partner 1 43/502 (8.6) 
Partner 2 53/483 (11.0) 
Partner 3 63/460 (13.7) 
When was the last time you had sex with this partner? Partner 3 (unit) 29/460 (6.3) 
When was the first time you had sex with this partner? (number)  
Partner 1 46/502 (9.2) 
Partner 2 56/483 (11.6) 
Partner 3 65/460 (14.1) 
When was the first time you had sex with this partner? Partner 3 (unit) 31/460 (6.7) 
What was the result of this [HIV] test? 27/475 (5.7) 
Please specify [Follows response to: Where did you last receive a DIAGNOSIS of 
genital or anal warts? “Other” category] 
1/5 (20.0) 
Where did you last receive TREATMENT for genital or anal warts? 13/145 (9.0) 
Please specify [Follows response to: Where did you last receive TREATMENT for 
genital or anal warts? “Other” category] 
1/9 (11.1) 
Have you told your GP your sexual orientation? 28/503 (5.6) 
Please specify [Follows response to: Where were you vaccinated? “Other” category] 4/35 (11.4) 
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Non-viable or missing samples 
Ten participants declined the anal swab, and ten a blood sample, so 512 of each were 
collected. One participant declined the external genital swab so 521 were collected and 
10/187 declined the oral specimen so 177 were collected (Figure 26). On arrival at the 
laboratory, five urine samples were non-viable, two having leaked and three having 
evidence of fungal growth. In addition, one anal and one external swab (from the same 
participant) had both leaked and could not be processed. 
PARTICIPANT CHARACTERISTICS 
Table 10 shows the services that were delivered to HPV-MSM-MMC participants at the 
study visit and is indicative of the breakdown of the sample in terms of reported behaviour 
and symptoms because specific symptoms would prompt specific investigations. For 
example, microscopy is recommended for MSM reporting symptoms and the sampling site 
relates to whether receptive or insertive behaviours were reported.  
TABLE 10. SERVICES PROVIDED TO HPV-MSM-MMC PARTICIPANTS AT THE STUDY VISIT, 
DETERMINED FROM SEXUAL HEALTH AND HIV ACTIVITY PROPERTY TYPES (SHAAPT) CODES. 
  N=522 
 
No. % 
Chlamydia, gonorrhoea, syphilis & HIV tests (full screen) 327 62.6 
Chlamydia, gonorrhoea and syphilis tests 30 5.8 
Chlamydia and gonorrhoea tests 19 3.6 
HSV test 18 3.5 
Hepatitis (A/ B/ C) tests 97 18.6 
Tested for gonorrhoea or syphilis using microscopy 47 9.0 
Genital, pharyngeal and rectal tests for chlamydia and gonorrhoea  246 47.1 
Referred via partner notification 25 4.8 
Hepatitis B vaccine dose 36 6.9 
HIV-related care 2 0.4 
Post-exposure prophylaxis 7 1.3 
Participants could receive more than one SHAAPT code, relating to the visit. 
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Table 11. shows demographic and lifestyle characteristics of study participants. The median 
age was 30 years (IQR 25-35), with 17 participants (3.3%) younger than 21. Nearly half (237; 
47.0%) were born in the UK and another 193 men (38.3%) had lived in the UK for at least 
three years. Figure 27 shows that countries in Europe as well as Brazil and South Africa were 
the most frequently reported countries of birth in 256 MSM who were born outside the UK.  
The majority of participants (382/501; 76.3%) were of white ethnicity and 91.5% identified 
as gay/homosexual. Most participants were employed (79.0%), with at least three years of 
education post-16 (68.3%). Two-thirds (328/498; 65.9%) reported higher risk drinking 
behaviour (identified using AUDIT-C, score ≥5), 17/498 (3.6%) hazardous and harmful 
drinking (AUDIT score 8–15) and a third (29.4%) were current smokers. A third (28.9%) of 
participants were circumcised, 28/522 (5.4%) had been diagnosed as HIV-positive and 
28/503 (5.6%) reported never having had an HIV test.  
FIGURE 27. WORLD MAP SHOWING THE FREQUENCY OF COUNTRY OF BIRTH OF 256 PARTICIPANTS 
WHO WERE NOT BORN IN THE UK 
 
11/267 participants did not answer the question asking for country of birth. 
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TABLE 11. SELECTED DEMOGRAPHIC AND LIFESTYLE CHARACTERISTICS OF PARTICIPANTS IN THE HPV-
MSM-MMC STUDY 
  N=522* 
  
N=504* 
 
No. % 
  
No. % 
Age group 
   
Currently smoke cigarettes 
  18-20 17 3.3 
 
No 355 70.6
21-25 119 23.3 
 
Yes 148 29.4 
26-30 127 24.9 
    31-35 140 27.4 
 
Alcohol use disorders identification test- AUDIT-C   
 36-40 108 21.1 
 
No risk drinking 170 34.1
    
Risk drinking 328 65.9 
     
  
 N=504* 
 
Currently employed   
Ethnicity 
   
No 106 21.0 
White 382 76.3 
 
Yes 398 79.0 
Black 31 6.2 
  
  
Asian & SE Asian 36 7.2 
 
Years of education since age 16     
Mixed/Other 52 10.4 
 
None  13 2.6 
 
  
 
Up to 2 years 62 12.3 
Born in the UK   
 
3 years or more 344 68.3 
No 267 53.0 
 
Still in education 85 16.9 
Yes 237 47.0 
  
  
    
Sexual orientation   
    
Gay/homosexual 460 91.5 
    
Bisexual 43 8.6 
*Total numbers vary for each question due to missing items: survey questions that were not asked (due to routing) or not 
answered. 
SEXUAL BEHAVIOUR 
Table 12 displays selected sexual behaviours of study participants. The majority of men 
(51.2%) reported first receptive anal sex between 16-20 years old. The median age at first 
oral, insertive anal, and receptive anal sex with a man was 18 (IQR 16-20), 19 (IQR 17-22), 
and 19 (IQR 17-23), respectively. HIV-positive MSM had first oral sex earlier (median=16 
years) compared with HIV-negative MSM (median=18; p=0.04) but there was no difference 
in age at first anal sex (receptive or insertive) by HIV status (Figure 28).  
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FIGURE 28. CUMULATIVE PERCENTAGE OF MSM ATTENDING MMC WHO HAD EXPERIENCED SEX WITH 
MEN BY AGE 
Two thirds of men (66.2%) had had more than 30 lifetime male sex (anal or oral) partners 
and only six men (1.2%) had had fewer than three lifetime partners. Of those who had an 
anal sex partner in the last year, 295/472 (62.5%) had sex with at least one partner without 
a condom. For each year increase in age, the odds of having more than 30 lifetime partners 
increased by 14.1% (95% CI 10.0-18.4) but there was no association between age and the 
number of partners, new partners, or partners without a condom in the last year. For 
example, the median number of male anal partners in the last year was six (IQR 3-15) in 
men aged 18-30 and eight (IQR 3-20) in men aged 31-40. Younger men, aged 18-30, were 
more likely to have had receptive anal sex in the last year than older men (86% vs 77%; OR 
1.8; 95 %CI 1.1-2.9). The proportion of men who had sex without a condom in the last year 
was higher among younger men (66% vs 58%; OR 1.4 95% CI 0.9-2.0) but this was not 
statistically significant. 
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TABLE 12. SELECTED SEXUAL BEHAVIOURS OF PARTICIPANTS IN THE HPV-MSM-MMC STUDY 
Number of partners 
 
Other  sexual behaviours 
 
 N=504* 
  
N=504* 
 
No. % 
  
No. % 
Total lifetime male partners oral and anal 
  
Age at first insertive anal sex (years) 
  Fewer than 20 99 19.7 
 
Up to 15  34 7.4 
21-30 71 14.1 
 
16-20  245 53.5 
31-100 170 33.8 
 
21-25  145 31.7 
101-500 163 32.4 
 
26-39  34 7.4 
     
  
Number of anal sex partners in the last year 
  
Age at first oral sex with man (years)  
0 1 0.2 
 
Up to 15  105 21.2 
1-4 179 37.6 
 
16-20  274 55.4 
5-10 136 28.6 
 
21-25  98 19.8 
11-30 113 23.7 
 
26-39  18 3.6 
More than 30 47 9.9 
  
  
    
Age at first receptive anal sex (years)  
Number of new anal sex partners in the last year 
 
Up to 15  36 7.8 
0 23 4.9 
 
16-20  235 51.2 
1-4 205 43.4 
 
21-25  141 30.7 
5-10 120 25.4 
 
26-39  47 10.2 
11-30 86 18.2 
  
  
More than 30 38 8.1 
 
Oral sex with man in the last year   
    
Yes 494 99.2 
Number of condom-less sex partners in the last year 
 
No 4 0.8 
0 178 37.6 
  
  
1-4 232 49.1 
 
Receptive anal sex in the last year   
5-10 40 8.5 
 
Yes 403 81.7 
11-30 16 3.4 
 
No 90 18.3 
More than 30 7 1.5 
  
  
    
Insertive anal sex (man) last year   
Number of exclusively oral sex partners in the last year 
 
Yes 435 89.9 
0 48 10.6 
 
No 49 10.1 
1-4 158 34.8 
  
  
5-10 148 32.6 
 
Position during condom-less sex in last year 
11-30 69 15.2 
 
Insertive 76 26.2 
More than 30 31 6.8 
 
Receptive 46 15.9 
    
Versatile 168 57.9 
       
 
   
Use of drugs in anus/rectum ever  
  
   
No 454 90.1 
   
Yes 50 9.9 
      
   
Concurrency between any of 3 most recent partners 
   
No 224 44.4 
   
Yes 280 55.6 
*Total numbers vary for each question due to missing items: survey questions that were not asked (due to routing) or not 
answered. Position/role during oral sex was not collected
109  
 
EXTERNAL COMPARISONS OF STUDY POPULATION 
HPV-MSM-MMC participants broadly mirrored that of MSM attending MMC during the 
recruitment period, in terms of age and ethnicity, but were slightly younger (Table 13). MSM 
attending other SHCs in England in 2010-2011 were younger and less ethnically diverse. 
Participants had more lifetime partners than MSM who had attended a SHC in the last five 
years in the Natsal-3 survey (British population in 2010-2012). Within Natsal-3, MSM who 
had attended a SHC had more lifetime partners than those who had not. For example, 93% 
of HPV-MSM-MMC participants reported >10 lifetime partners, compared to 78% of MSM 
who had attended a SHC in Natsal-3, and to 25% of MSM who had not attended. (Natsal-3 
team, personal communication). MSM participating in the GMSHS, recruiting from London 
social venues in 2011, had slightly fewer male anal partners in the last year and appeared to 
be less likely to have had anal sex in the last year than participants in the HPV-MSM-MMC 
study, although this was not formally tested156. 
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TABLE 13. COMPARISON OF DEMOGRAPHIC AND SEXUAL BEHAVIOUR DISTRIBUTIONS BETWEEN HPV-MSM-MMC PARTICIPANTS AND OTHER BRITISH MSM 
POPULATIONS. CONTINUED. 
 
HPV in MSM 
study 
population 
  
  
 
MSM aged 16-40 (GUMCAD. V2), 
attending during 2010-2011:  
MSM, aged 16-40, in the general British 
population 2010-2012 (Natsal-3): at least 
one male sexual partner (genital contact) in 
past 5 years  
 MSM  
(aged 18-40 )  
in GMSHS 2011 
   
MMC 2010-
2011  SHCs in England  
MSM attending a 
SHC in the last 5-
years   
MSM not 
attending a SHC in 
the last 5-years 
 
Total (N) 522 
  
4,376 
  
63,597 
  
43 
  
49 
 
 902  
 
n %
 
n %
 
n %
 
n %
 
n %  n % 
Age (years) 
              
   
18-20 17 3.3
 
124 2.8
 
5,237 8.2
 
5 10.6
 
14 28.2  47 5.2 
21-25 121 23.2 
 
728 16.6 
 
15,279 24.0 
 
9 21.8 
 
10 20.3  184 20.4 
26-30 133 25.5 
 
1,144 26.1 
 
16,580 26.1 
 
13 31.0 
 
17 34.4  264 29.3 
31-35 142 27.2 
 
1,182 27.0 
 
14,029 22.1 
 
11 24.9 
 
3 7.0  228 25.3 
36-40 109 20.9 
 
1,198 27.4 
 
12,472 19.6 
 
5 11.8 
 
5 10.2  179 19.8 
               
   
Ethnicity 
              
   
White 382 75.8
 
3,236 74.0
 
50,007 78.6
 
42 92.7
 
46 98.0  711 78.9 
Black 31 6.2 
 
231 5.3 
 
2,531 4.0 
 
0 0.0 
 
0 0.0  32 3.6 
Asian & SE Asian 36 7.1 
 
333 7.6 
 
3,629 5.7 
 
0 4.1 
 
2 0.0  71 7.9 
Mixed Other 52 10.3 
 
411 9.4 
 
3,994 6.3 
 
1 3.2 
 
2 2.0  87 9.7 
Not known / not stated 3 0.6 
 
165 3.8 
 
3,436 5.4 
 
0 0.0 
 
0 0.0  n/a n/a 
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TABLE 13. COMPARISON OF DEMOGRAPHIC AND SEXUAL BEHAVIOUR DISTRIBUTIONS BETWEEN HPV-MSM-MMC PARTICIPANTS AND OTHER BRITISH MSM 
POPULATIONS. CONTINUED. 
 
HPV in MSM 
study 
population 
  
  
 
MSM aged 16-40 (GUMCAD. V2), 
attending during 2010-2011:  
MSM, aged 16-40, in the general British 
population 2010-2012 (Natsal-3): at least 
one male sexual partner (genital contact) in 
past 5 years  
 MSM  
(aged 18-40 )  
in GMSHS 2011 
   
MMC 2010-
2011  SHCs in England  
MSM attending a 
SHC in the last 5-
years   
MSM not 
attending a SHC in 
the last 5-years 
 
Lifetime number of same-sex partners 
      
   
0 - 1 3 0.6  
Behavioural data not collected in 
GUMCAD v2 
  0 0.9  12 24.4  n/a n/a 2 - 4 15 3.0    7 16.7  17 35.2  n/a n/a 5 - 9 17 3.4    4 9.3  9 18.3  n/a n/a 10+   93.1    32 35.7  11 22.2  n/a n/a 10-20 64 12.7    13 0.9  4 8.8  n/a n/a 21-30 71 14.1    4 16.7  3 5.3  n/a n/a 31-100 170 33.8    11 9.3  1 1.6  n/a n/a >100 163 32.4    4 8.7  3 6.5  n/a n/a Anal sex in the last year              No 17 3.4    8 18.6  22 43.8  95 11.6 Yes 482 96.6    35 81.4  28 56.2  721 88.6 Number of anal partners without condom in last year (of those who report having had anal sex in the last year)     
0 178 37.6  
 
  0 0.0  0 0.0  286 42.3 1 128 27.1    14 72.9  11 63.1  228 33.7 2-4 104 22.0    4 20.3  5 27.7  120 17.7 5-10 40 8.5    0 0.0  2 9.2  25 3.7 >10 23 4.9    1 6.9  0 0.0  18 2.7 
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4.5 KEY FINDINGS 
The estimated participation rate in the HPV-MSM-MMC study was high at 81% and surveys 
were generally well completed with samples collected.  
Despite aiming to capture young MSM, there were few participants younger than 21. 
Participants were generally well-educated, alcohol drinkers with a high level of smoking and 
STI transmission behaviours. HIV prevalence (HIV positive diagnosis) was 5%. Rates of 
partner change and prevalence of HPV did not decline with age   
4.6 FINDINGS IN CONTEXT 
The MSM in this study reported high levels of sexual risk behaviour compared to MSM in 
the general population in the UK and MSM attending pubs and clubs in London. Smoking 
levels were similar (29% of participants) to men, aged 25-34, in the general population (30% 
of men159) and hazardous and harmful drinking  was higher at 49% compared to 32% in men 
in England in 2004160. 
4.7 STRENGTHS AND LIMITATIONS 
Participation bias 
There was a difference in the age and likelihood of being a first-time attendee between 
MSM participating in and declining from the study but this was not based on complete data. 
In contrast, when comparing to the MSM who attended MMC during the recruitment 
period, the age difference was reversed and did not appear to be significant.  
More MSM reported a language barrier to participation (18% of reasons reported) than was 
anticipated during study design. It is possible that reasons for not participating in the study 
would correlate with not being offered or accepting the HPV vaccine since translators would 
be required before consenting to vaccination and clinicians might avoid offering the vaccine 
to men who are excessively emotional or upset. This might result in a upwards bias in 
estimating vaccine intentions (chapter 8, page 201). 
Non-response bias 
A fifth of participants did not reply to the three items relating to sex with women. Although 
there may be other reasons for not replying to these items, it seems likely that participants 
did not feel that this question was relevant to them because they did not have sex with 
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women. Therefore, in the following results chapters, sex with women variables had missing 
items recoded as ‘never’ and sensitivity analyses were performed to examine the effect of 
recoding (results not shown). 
Additionally, there is some evidence of response fatigue. In the series of questions relating 
to the three most recent partners, each additional partner had a higher proportion of non-
response than its precedent. Furthermore, more questions at the end of the survey had 
more than five percent missing than those at the beginning. 
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5. HPV-MSM-MMC STUDY: HPV PREVALENCE, SPECIMEN 
AGREEMENT AND RISK FACTORS 
In this chapter, I present the primary results from the HPV-MSM-MMC study: HPV DNA 
prevalence and risk factors for HPV DNA detection. I first present HPV prevalence estimates 
and type distribution across specimen types. Then I report the age-specific HPV prevalence 
(for any HPV type, HR-HPV and vaccine-preventable HPV types) and risk factors for the 
detection of quadrivalent-vaccine types in anogenital specimens of any type. I then report 
risk factors for HR-HPV detection in each specimen type. 
I then turn to quantifying the relationship between HPV DNA detection and site, first 
reporting the contribution to vaccine-type prevalence from each specimen type, then 
formally estimating agreement and concordance for HPV detection between sites. I then 
focus on HPV16 in the anal and external genital swabs, comparing viral load and LCR 
variation. I report on risk factors that I identified for anogenital type-specific HPV 
concordance.  
 I then put the findings from this chapter into context by reviewing the literature up to mid-
2015, including random-effects meta-analyses. Finally I discuss potential bias within the 
study that should be considered when interpreting the findings presented in this chapter.  
5.1 OBJECTIVES  
1. To estimate the prevalence of detectable DNA of HPV, HR-HPV, vaccine-preventable 
HPV and individual HPV types by HIV status and specimen type in SHC-attending 
MSM in the UK 
2. To describe the relative HPV type distribution by specimen type 
3. To explore the association between HPV prevalence and age 
4. To identify associations between quadrivalent-vaccine type DNA detection and 
socio-demographic and behavioural variables at any anogenital site 
5. To identify associations between HR-HPV DNA detection and socio-demographic 
and behavioural variables at each anatomical site 
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6. To quantify the relationship between HPV DNA detection at different sites  
7. To compare HPV16 viral load and HPV16 variants in the anal and external specimens  
8. To identify associations between socio-demographic and behavioural variables and 
HR-HPV DNA detection at two or more (concordant) anogenital sites 
9. To discuss biases to be considered when interpreting the findings from this chapter 
METHODS 
The methods used to meet these objectives have been described in chapter 4. In particular, 
the collection, processing and testing of laboratory specimens are described on pages 90-93 
and statistical methods are described on pages 93-97. 
5.2 RESULTS 
Of 522 MSM participating in this study, at least one sample that was adequate for PCR was 
available for 513 MSM and at least one anogenital sample in 511 MSM. Data from the CASI 
survey were available for 497 of these MSM. Figure 26, in chapter 4 (page 102), shows that 
the number of adequate samples for anal, external, urine and oral was 454, 446, 486 and 
166, respectively. The median age of these 513 MSM was 30 (IQR: 25-35). Figure 29 
summarises the results presented in this chapter. 
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FIGURE 29. SUMMARY OF RESULTS TABLES AND FIGURES RELATING TO OBJECTIVES IN CHAPTER 5 
 Any 
anogenital 
Anal 
swab  
External 
genital 
swab 
Urine Oral Concordant 
anogenital  
HPV prevalence       
Any HPV 
Table 14 
 
HR-HPV 
 
Vaccine type HPV Table 15; Table 19 
 
Type-specific Table 16 
 
Relative type distribution 
 Figure 30 
 
Age-specific prevalence: 
     
 
Any HPV 
Figure 31     
 
HR-HPV 
 
Vaccine type HPV 
 
Social/demographic/behavioural risk factors for HPV:   
 
Quadrivalent-vaccine type HPV Table 17     
 
HR-HPV  
Figure 32 Figure 37 
Appendix IV, 
p.303,  
Appendix 
table 4 
Appendix IV, 
p.306, 
Appendix 
table 5 
Appendix 
IV, p.309,  
Appendix 
table 6 
HPV type-independent concordance  Table 20 
 
HPV type-specific concordance  
Figure 33, Figure 34, Figure 35 
 
HPV16 viral load in anal and external genital 
swabs Figure 36   
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HPV PREVALENCE 
HPV and HR-HPV prevalence 
Table 14 shows the prevalence of HPV DNA in different specimen types. The highest HPV 
DNA prevalence of 65.9% (95% CI 61.3-70.2) was found in the anal swab which was similar 
to the external genital swab (63.9%; 95% CI 59.3-68.4). HPV DNA prevalence was also similar 
in the oral cavity (12.7%; 95% CI 8.0-18.7) and urine (11.1%; 95% CI 8.5-14.2). This pattern 
was repeated for HR-HPV DNA with estimates of 40.5%, 38.8%, 5.1% and 5.4% for anal, 
external, urine and oral, respectively.   
At any anogenital site, the overall prevalence of HPV was 72.2% (95% CI 68.2-75.9). The 
prevalence was 71.1% (95% CI 66.8-75.1) in HIV-negative MSM and 92.6% (95% CI 75.7-
99.1) in HIV-positive MSM (χ2=5.90, p=0.02). The prevalence of detectable HR-HPV types 
was 47.2% (95% CI 42.9-51.5) overall, 45.7% (95% CI 41.2-50.2) in HIV-negative MSM and 
74.1% (95% CI 53.7-88.9) in HIV-positive MSM (χ2=8.28, p<0.01).  
Of the 13 HIV-positive MSM with an oral specimen adequate for HPV testing, none had HPV 
detected using the universal PCR probe. In HIV-negative MSM (n=151), the oral prevalence 
of any HPV was 13.7% (95%CI 8.7-20.2) and HR-HPV was 5.9% (95% CI 2.7-10.9). 
Vaccine-preventable HPV prevalence 
Table 15 shows that at any anogenital site, at least one quadrivalent-vaccine type 
(HPV6/11/16/18) was detected in 166/511 (32.5%) of participants; 18.4% (95% CI 15.3-22.0) 
had a bivalent-vaccine type(s) (HPV16/18); 71 (13.9%) had anogenital HPV 16/18 without 
HPV6/11; and 72 (14.1%) had HPV6/11 without HPV16/18. Table 15 shows that 1.4% of 
participants, with an adequate anogenital sample, had both bivalent types, none had all four 
quadrivalent types and 0.4% had more than three 9-valent vaccine types detected in 
anogenital specimens. In oral specimens (n=166), four (2.4%) had at least one quadrivalent 
type (one with both HPV6 and HPV18).  
For HIV-negative MSM (n=484), the prevalence of any bivalent, quadrivalent and 9-valent 
vaccine-preventable HPV types at any anogenital site was 17.4% (95% CI 14.1-21.0), 31.0% 
(95% CI 26.9-35.3) and 43.8% (95% CI 39.3-48.4), respectively. For HIV-positive MSM (n=27) 
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bivalent type prevalence was 37% (95% CI 19-58), quadrivalent-vaccine type prevalence was 
59% (95% CI 39-78) and 9-valent vaccine type prevalence was 74% (95% CI 54-89).  
HPV type-specific prevalence 
Table 16 shows that the most commonly detected HPV types were 16, 11 and 6 with 
anogenital  prevalence estimates of 13.5% (95% CI 10.8-16.8), 11.5% (95% CI 9.0-14.6) and 
9.4% (95% CI 7.1-12.3), respectively.  
For HIV-negative MSM the anogenital prevalence estimate for HPV6 was 9.7% (95% CI 7.2-
12.7), for HPV11 it was 10.7% (95% CI 8.1-13.8), for HPV16 it was 12.6% (95% CI 9.8-15.9) 
and for HPV18 it was 6.0% (95% CI 4.0-8.5). For HIV-positive MSM the prevalence estimates 
for HPV6, HPV11, HPV16 and HPV18 were 3.7% (95% CI 0.9-19.0), 25.9% (95% CI 11.1-46.3), 
29.6% (95% CI 13.8-50.2) and 11.1% (95% CI 2.4-29.2), respectively. 
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TABLE 14. PREVALENCE OF HPV DNA IN DIFFERENT SPECIMEN TYPES 
  Anogenital 
 
Oral   Anal N=454 External N=446 Urine N=486 ≥1 Anogenitala, b N=511    N=166  % 95% CI % 95% CI % 95% CI % 95% CI  % 95% CI Any bivalent HPV vaccine types (16/18) 16.1 (12.8-19.8) 13.7 (10.6-17.2) 1.9 (0.9-3.5) 18.4 (15.1-22.0)  1.2 (0.1-4.3) 
Any quadrivalent HPV vaccine types (6/11/16/18) 29.1 (24.9-33.5) 24.0 (20.1-28.2) 3.3 (1.9-5.3) 32.5 (28.6-36.7)  2.4 (0.7-6.1) 
HPV16/18 and HPV6/11 2.4 (1.2-4.3) 1.8 (0.8-3.5) 0.0 (0.0-0.1) 4.5 (2.9-6.7)  0.6 (0.02-3.3) 
HPV16/18 not HPV6/11 13.7 (10.6-17.2) 11.9 (9.0-15.3) 1.9 (0.9-3.5) 13.9 (11.0-17.2)  0.6 (0.02-3.3) 
HPV6/11 not HPV16/18  13.0 (10.0-16.4) 10.3 (7.7-13.5) 1.4 (0.6-2.9) 14.1  (11.1-17.4)  1.2 (0.1-4.3) 
Any 9-valent HPV vaccine types (6/11/16/18/31/33/45/52/58) 40.1 (35.5-44.8) 36.1 (31.6-40.7) 5.3 (3.5-7.7) 45.4 (41.0-49.8)  4.2 (1.7-8.5) 
High risk HPV types (HR-HPV)d 40.5 (36.0-45.2) 38.8 (34.2-43.5) 5.1 (3.4-7.5) 47.2 (42.8-51.6)   5.4 (2.5-10.0) 
Multiple HR typesd (2 or more) 11.5 (8.7-14.7) 9.4 (6.9-12.5) 0.4 (0.0-1.5) 17.4 (14.2-21.0)  0.0 (0.0-2.2) 
Any HPV typec 65.9 (61.3-70.2) 63.9 (59.3-68.4) 11.1 (8.5-14.2) 72.2 (68.1-76.1)  12.7 (8.0-18.7) 
Multiple types (2 or more) 20.9 (17.3-25.0) 19.3 (15.7-23.3) 1.0 (0.3-2.4) 29.2 (25.3-33.3)  0.6 (0.0-3.3) 
a27/511 were HIV-positive MSM in whom: 10 had any bivalent types,  16 any quadrivalent types, 20 any 9-valent types, 20 HR-HPV, 11 multiple HR types,  25 had detectable HPV and 16 had 
multiple HPV types. bHPV detected at anus (via swab) or external genitalia including penis (via swab) or urine. If any of the 3 sample types were adequate for DNA detection then included in the 
denominator. cReacted to the universal probe for HPV DNA. dHR-HPV classified according to International agency for research on cancer (IARC) monograph carcinogenic or probably 
carcinogenic10,11. 
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TABLE 15. NUMBER OF VACCINE-PREVENTABLE HPV TYPES DETECTED IN DIFFERENT SPECIMENS 
HPV type Anal swab External genital swab Urine ≥1 Anogenitala Oral 
 
N % N  % N  % N % N % 
 
Number of bivalent vaccine HPV types (16/18)                 
  
0 385 84.8 385 86.3 477 98.2 417 81.6 175 98.9 
1 69 15.2 59 13.2 9 1.9 87 17.0 2 1.1 
2 0 0.0 2 0.5 0 0.0 7 1.4 0 0.0 
           Number of quadrivalent vaccine HPV types 
(6/11/16/18)                 
  
0 322 70.9 339 76 470 96.7 345 67.5 173 97.7 
1 112 24.7 89 20 15 3.1 128 25.1 3 1.7 
2 20 4.4 17 3.8 1 0.2 34 6.7 1 0.6 
3 0 0.0 1 0.2 0 0.0 4 0.8 0 0.0 
4 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 
         
  
Number of 9-valent vaccine HPV 
types(6/11/16/18/31/33/45/52/58)                 
  
0 272 59.9 285 63.9 460 94.7 279 54.6 170 96.1 
1 144 31.7 124 27.8 24 4.9 157 30.7 6 3.3 
2 30 6.6 33 7.4 2 0.4 59 11.6 1 0.6 
3 7 1.5 4 0.9 0 0.0 14 2.7 0 0.0 
4 1 0.2 0 0.0 0 0.0 1 0.2 0 0.0 
5 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 
6 0 0.0 0 0.0 0 0.0 1 0.2 0 0.0 
7 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 
8 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 
9 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 
Total adequate samples 454   446   486   511   177  
aHPV detected at anus (via swab) or external genitalia including penis (via swab) or urine. If any of the 3 sample types were adequate for DNA detection then included in the denominator. 
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TABLE 16. HPV TYPE-SPECIFIC PREVALENCE IN DIFFERENT SPECIMEN TYPES 
 HPV type Anogenital  Oral  
  Anal N=454 External N=446 Urine N=486 ≥1 Anogenitala, b N=511   N=166 
16 12.6 (9.6-16.0) 10.1 (7.5-13.3) 1.2 (0.5-2.7) 13.5 (10.7-16.8)  0.6 (0.0-3.3) 
18 4.4 (2.7-6.7) 4.0 (2.4-6.3) 0.6 (0.1-1.8) 6.3 (4.3-8.7)  0.6 (0.0-3.3) 
31 1.3 (0.5-2.9) 0.7 (0.1-2.0) 0.2 (0.0-1.1) 1.6 (0.7-3.1)  0.0 (0.0-2.2) 
33 1.8 (0.8-3.4) 1.8 (0.8-3.5) 0.0 (0.0-0.8) 2.5 (1.4-4.3)  0.6 (0.0-3.3) 
35 2.9 (1.5-4.8) 1.8 (0.8-3.5) 0.2 (0.0-1.1) 3.3 (1.9-5.3)  0.0 (0.0-2.2) 
39 5.3 (3.4-7.8) 4.5 (2.8-6.8) 0.2 (0.0-1.1) 5.9 (4.0-8.3)  0.0 (0.0-2.2) 
45 7.5 (5.2-10.3) 7.0 (4.8-9.7) 0.8 (0.2-2.1) 9.0 (6.7-11.8)  0.6 (0.0-3.3) 
51 4.4 (2.7-6.7) 2.5 (1.2-4.4) 0.0 (0.0-0.8) 4.7 (3.0-6.9)  0.6 (0.0-3.3) 
52 4.8 (3.1-7.2) 6.1 (4.0-8.7) 1.2 (0.5-2.7) 7.8 (5.7-10.5)  0.6 (0.0-3.3) 
56 4.2 (2.5-6.5) 3.4 (1.9-5.5) 0.4 (0.0-1.5) 5.5 (3.7-7.8)  1.8 (0.4-5.2) 
58 1.5 (0.6-3.2) 1.6 (0.6-3.2) 0.0 (0.0-0.8) 2.3 (1.2-4.1)  0.0 (0.0-2.2) 
59 0.7 (0.1-1.9) 1.1 (0.4-2.6) 0.2 (0.0-1.1) 1.0 (0.3-2.3)  0.0 (0.0-2.2) 
68 4.8 (3.1-7.2) 6.1 (4.0-8.7) 0.4 (0.0-1.5) 7.8 (5.7-10.5)  0.0 (0.0-2.2) 
Possibly high risk HPV types 9.9 (7.3-13.0) 10.8 (8.0-14.0) 1.2 (0.5-2.7) 14.1 (11.3-17.4)   0.0 (0.0-2.2) 
26 1.1 (0.4-2.6) 1.1 (0.4-2.6) 0.2 (0.0-1.1) 1.6 (0.7-3.1)  0.0 (0.0-2.2) 
53 3.7 (2.2-5.9) 3.4 (1.9-5.5) 0.4 (0.0-1.5) 5.7 (3.8-8.0)  0.0 (0.0-2.2) 
66 0.7 (0.1-1.9) 0.0 (0.0-0.8) 0.0 (0.0-0.8) 0.6 (0.1-1.7)  0.0 (0.0-2.2) 
70 2.6 (1.4-4.6) 2.0 (0.9-3.8) 0.0 (0.0-0.8) 2.7 (1.5-4.6)  0.0 (0.0-2.2) 
73 2.9 (1.5-4.8) 4.9 (3.1-7.4) 0.6 (0.1-1.8) 4.9 (3.2-7.1)  0.0 (0.0-2.2) 
82 0.0 (0.0-0.8) 0.0 (0.0-0.8) 0.0 (0.0-0.8) 0.0 (0.0-0.7)  0.0 (0.0-2.2) 
Low risk HPV types                       
6 and/or 11 15.4 (12.2-19.1) 12.1 (9.2-15.5) 1.4 (0.6-2.9) 18.6 (15.3-22.2)  1.8 (0.4-5.2) 
6 8.6 (6.2-11.6) 5.4 (3.5-7.9) 0.2 (0.0-1.1) 9.4 (7.0-12.3)  1.8 (0.4-5.2) 
11 7.9 (5.6-10.8) 8.7 (6.3-11.8) 1.4 (0.6-2.9) 11.5 (8.9-14.6)  0.0 (0.0-2.2) a27/511 were HIV-positive MSM in whom: 8 had detectable HPV6/11.bHPV detected at anus (via swab) or external genitalia including penis (via swab) or urine. If any of the 3 sample types were 
adequate for DNA detection then included in the denominator. 
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RELATIVE TYPE DISTRIBUTION ACROSS SITES 
Figure 30 shows the relative contribution of each HPV type to overall genotyped HPV 
prevalence at each anatomical site. Each HPV type detected is treated independently; in 
multiple-type infections each HPV type contributes to the denominator. At all sites, the 
quadrivalent-vaccine types represented approximately 50% of the genotyped HPV detected. 
There was less diversity in the types detected at the oral site compared to the anogenital 
sites. At the oral site HPV6 and HPV56 were the most common types and HPV11 was not 
detected. The anogenital sites had similar HPV type distribution, particularly the anal and 
external sites. In GEE models, there was no interaction between anatomical site of HPV 
infection and type of HPV infection for HPV6/11/16/18 (p=0.41) or for all of the 21 HPV 
types tested (p=0.93). 
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FIGURE 30.THE RELATIVE DISTRIBUTION OF HPV TYPES DETECTED AT DIFFERENT ANATOMICAL SITES 
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AGE-SPECIFIC HPV PREVALENCE 
Figure 31 shows age-specific prevalence of HPV at any anogenital site. For any HPV type, and 
modelling age as a continuous variable (from 18 to 40 years), there was a 4.7% (95% CI 1.2-8.4) 
increase in the odds of an HPV infection per year. The effect was not significant when 
examining age as a categorical variable, except in the nonparametric test for trend (p<0.01), 
but confidence intervals are wide, and there were few participants in the youngest category in 
particular (17 in 18-20). There was no significant association between age and HR-HPV, 
bivalent, quadrivalent or 9-valent vaccine type detection, considered separately.  
FIGURE 31. HPV PREVALENCE IN ANY ANOGENITAL SAMPLE BY AGE 
 
 NB. Y axis scales differ between upper and lower panels. In 511 participants of the HPV-MSM-MMC study with at least one 
anogenital specimen that was adequate for HPV testing. Data for this figure are displayed in Appendix III, page 300. 
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SOCIAL, DEMOGRAPHIC AND BEHAVIOURAL RISK FACTORS FOR QUADRIVALENT-VACCINE TYPE 
HPV DNA DETECTION AT ANY ANOGENITAL SITE  
Table 17 and Table 18 show the association of socio-demographic and sexual behavioural 
variables with anogenital quadrivalent-vaccine type DNA detection. Table 18 shows that, at 
any anogenital site, detection of any quadrivalent-vaccine types was associated with number 
of lifetime anal or oral sex partners (aOR=2.6 in those with >100 compared to ≤20 partners), an 
HIV positive diagnosis (aOR=3.2; 95% CI 1.5-7.1) and rectal drug use (aOR=2.0; 95% CI 1.1-3.6). 
In MSM with fewer than 30 lifetime male partners, the mean number of partners was lower 
(16.6 partners) in those without quadrivalent-vaccine types than those with detectable 
quadrivalent HPV (mean=19.8; t=-2.1; p=0.04). Between one and 30 lifetime partners (n=166), 
the odds of having a detectable quadrivalent-vaccine type increased by 5% per partner 
(aOR=1.05; 95% CI 1.01-1.10). There were no other statistically significant associations 
between quadrivalent-vaccine type infection and demographic, health or behavioural 
variables, after adjusting for age. 
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TABLE 17. ASSOCIATION OF SOCIO-DEMOGRAPHIC FACTORS FOR QUADRIVALENT-VACCINE TYPE 
DETECTION AT ANY ANOGENITAL SITE 
 
Total 
 
HPV6/11/16/18 
prevalence     
 
Na 
 
n % 
 
Age-adjusted ORb 95% CI p value 
Demographic                  
Age group                
18-20 17   5 29.4   0.68 (0.22-2.07) 0.38 
21-25 119   35 29.4   0.68 (0.39-1.18)   
26-30 127   46 36.2   0.93 (0.55-1.58)   
31-35 140   39 27.9   0.63 (0.37-1.08)   
36-40 108   41 38.0   1 -   
Ethnicity                 
White 377   120 31.8   1 - 0.59 
Black 30   11 36.7   1.24 (0.57-2.68)   
Asian & SE Asian 28   8 28.6   0.78 (0.35-1.72)   
Mixed/Other 57   21 36.8   1.39 (0.76-2.55)   
Born in the UK                 
No 263   86 32.7   1 - 0.86 
Yes 232   74 31.9   0.97 (0.66-1.41)   
Currently employed                 
No 105   32 30.5   1 - 0.73 
Yes 390   128 32.8   1.09 (0.66-1.41)   
Years of education since age 16                
None  13   3 23.1   0.61 (0.16-2.25) 0.93 
Up to 2 years 58   19 32.8   1.01 (0.55-1.83)   
3 years or more 340   112 32.9   1 -   
Still in education 84   26 31.0   0.96 (0.55-1.67)   
Sexual orientation                 
Gay/homosexual 452   149 33.0   1 - 0.39 
Bisexual 42   11 26.2   0.73 (0.36-1.50)   
Health 
       
 
Self-rated general health 
       
 
Very good 253
 
87 34.4
 
1 - 0.20 
Good 216 
 
70 32.4 
 
0.92 (0.63-1.36)  
Fair 21 
 
3 14.3 
 
0.32 (0.09-1.13)  
Bad 4 
 
0 0.0 
 
1 (1.00-1.00)  
Circumcised 
       
 
No 349
 
111 31.8
 
1 - 0.66 
Yes 142 
 
48 33.8 
 
1.10 (0.72-1.66)  
Diagnosis of HIV 
       
 
No 484
 
150 31.0
 
1 - <0.01 
Yes 27 
 
16 59.3 
 
3.21 (1.45-7.08)  
Smoking, alcohol and substance use                
Currently smoke cigarettes              
No 349   118 33.8   1 - 0.31 
Yes 145   42 29.0   0.80 (0.53-1.23)   
Higher risk drinking (AUDIT-C )             
No 167   53 31.7   1 - 0.89 
Yes 322   104 32.3   1.03 (0.69-1.53)   
Use of drugs in anus/rectum ever               
No 446   137 30.7   1 - 0.03 
Yes 49   23 46.9   1.98 (1.09-3.60)   
aTotal numbers vary for each question due to missing items. For survey questions the total including missing items is 495. For age 
the total is 511. bAge is modelled continuously in adjusted models. Odds ratios presented for age group are unadjusted. 
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TABLE 18. ASSOCIATION OF SEXUAL BEHAVIOURS WITH QUADRIVALENT-VACCINE TYPES DETECTION AT 
ANY ANOGENITAL SITE. CONTINUED 
 Total  
HPV6/11/16/18 
prevalence 
    
 Na  n % 
 
Age-adjusted 
ORb 95% CI p value 
Number of sex partners  
   
 
  
 
Number of lifetime male partners (oral and anal sex) 
 
  
 
Fewer than 20 94 
 
20 21.3 
 
1 - 0.03 
21-30 73 
 
24 32.9 
 
1.86 (0.92-3.74)  
31-100 168 
 
53 31.6 
 
1.78 (0.96-3.29)  
101-500 159 
 
63 39.6 
 
2.56 (1.37-4.78)  
Number of anal sex partners in the last year  
 
   
0 1 
 
1 100.0 
 
omitted  0.10 
1-4 176 
 
45 25.6 
 
1 -  
5-10 135 
 
43 31.9 
 
1.36 (0.83-2.23)  
11-30 109 
 
38 34.9 
 
1.55 (0.92-2.61)  
More than 30 46 
 
20 43.5 
 
2.23 (1.14-4.33)  
Number of new anal sex partners in the last year  
 
   
0 22 
 
7 31.8 
 
1.15 (0.45-2.97) 0.43 
1-4 202 
 
58 28.7 
 
1 -  
5-10 119 
 
35 29.4 
 
1.03 (0.63-1.70)  
11-30 82 
 
30 36.6 
 
1.42 (0.83-2.45)  
More than 30 38 
 
16 42.1 
 
1.80 (0.88-3.68)  
Number of anal sex partners without a condom in the last year     
0 174 
 
44 25.3 
 
0.64 (0.41-1.00) 0.22 
1-4 228 
 
78 34.2 
 
1 -  
5-10 40 
 
16 40.0 
 
1.26 (0.63-2.52)  
11-30 15 
 
6 40.0 
 
1.29 (0.44-3.76)  
More than 30 7 
 
2 28.6 
 
0.76 (0.14-4.00)  
Age at first sex         
  
     
Age at first oral sex with man (years)         
  
      
Up to 15  101   34 33.7 
  
1 - 0.57 
16-20  270   89 33.0 
  
0.95 (0.59-1.55)   
21-25  98   26 26.5 
  
0.67 (0.36-1.26)   
26-39  17   6 35.3 
  
0.98 (0.33-2.96)   
Age at first receptive anal sex (years)       
  
     
Up to 15  34   11 32.4 
  
1 - 0.50 
16-20  232   77 33.2 
  
1.04 (0.48-2.24)   
21-25  140   42 30.0 
  
0.89 (0.39-2.02)   
26-39  47   20 42.6 
  
1.53 (0.58-4.02)   
Age at first insertive anal sex (years)       
  
     
Up to 15  34   11 32.4 
  
1 - 0.56 
16-20  238   84 35.3 
  
1.13 (0.53-2.44)   
21-25  145   43 29.7 
  
0.84 (0.37-1.89)   
26-39  33   13 39.4 
  
1.24 (0.44-3.50)   
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TABLE 18. ASSOCIATION OF SEXUAL BEHAVIOURS WITH QUADRIVALENT-VACCINE TYPES DETECTION AT 
ANY ANOGENITAL SITE. CONTINUED 
 Total  
HPV6/11/16/18 
prevalence 
    
 Na  n % 
 
Age-adjusted 
ORb 95% CI p value 
Sexual behaviour in the last year 
    
 
  
 
Receptive anal sex in last year 
   
 
  
 
No 89 
 
22 24.7 
 
1 - 0.08 
Yes 397 
 
134 33.8 
 
1.60 (0.94-2.71)  
Insertive anal sex in last year 
   
 
  
 
No 49 
 
17 34.7 
 
1 - 0.79 
Yes 426 
 
140 32.9 
 
0.92 (0.49-1.71)  
Position when having anal sex without condom in last year     
Insertive 75 
 
19 25.3 
 
1 - 0.07 
Receptive 46 
 
15 32.6 
 
1.47 (0.65-3.32)  
Versatile 164 
 
66 40.2 
 
2.01 (1.10-3.70)  
Condom use with most recent partner (incl oral)  
 
   
Always 237 
 
71 30.0 
 
1 - 0.10 
Sometimes 103 
 
29 28.2 
 
0.92 (0.55-1.54)  
Never 151 
 
59 39.1 
 
1.50 (0.98-2.31)  
Still having sex with most recent partner 
 
 
  
 
No 231 
 
66 28.6 
 
1 - 0.08 
Yes 260 
 
94 36.2 
 
1.41 (0.96-2.07)  
Last sex with most recent partner 
   
 
  
 
Up to 30 days ago 393 
 
133 33.8 
 
1 - 0.11 
31-90 days ago 28 
 
4 14.3 
 
0.33 (0.11-0.96)  
90-365 days ago 29 
 
8 27.6 
 
0.76 (0.33-1.76)  
Relationship type with most recent partner   
 
   
Regular 242 
 
83 34.3 
 
1 - 0.33 
Casual 236 
 
71 30.1 
 
0.83 (0.56-1.21)  
Concurrency between any of 3 most recent partners  
 
   
No 220 
 
66 30.0 
 
1 - 0.34 
Yes 275 
 
94 34.2 
 
1.20 (0.82-1.76)  
     
 
  
 aTotal numbers vary for each question due to missing items: survey questions that were not asked (due to routing) or not 
answered. For survey questions the total including missing items is 495. For STI diagnoses at visit the total is 511. bAge is modelled 
continuously in adjusted models. 
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SOCIAL, DEMOGRAPHIC AND BEHAVIOURAL RISK FACTORS FOR HR-HPV DNA DETECTION 
ACROSS ANATOMICAL SITES  
A total of ten socio-demographic and 21 sexual behaviour variables were examined for their 
association with HR-HPV DNA detection at each site and are displayed in Appendix table 4 
and Appendix table 5 in Appendix IV. Categorical variables that were statistically associated 
with HR-HPV DNA detection at any site are shown in Figure 32.  There was no association 
between age and HR-HPV detection at any site. An HIV positive diagnosis was associated 
with increased HR-HPV prevalence at all anogenital sites (anal aOR=2.29; 95% CI 1.46-3.60; 
external aOR=2.20; 95% CI 1.43-3.39; urine aOR=5.42; 95% CI 2.11-13.90). 
Comparison of risk factors for HR-HPV at anal and external genital sites 
Figure 32 and appendix IV (Appendix table 4) compare risk factors for HR-HPV detection in 
the two swabs. HR-HPV detection in the anal and the external genital swab had a similar risk 
profile. More than 30 lifetime partners increased the odds of HR-HPV detection in both the 
anal (aOR=1.97; 95% CI 1.38-2.82) and the external (aOR=1.48; 95% CI 1.04-2.10) swabs. 
Having had receptive anal sex in the last three months increased the odds of HR-HPV 
detection at both the anal (aOR=2.43; 95% CI 1.70-3.49) and external (aOR=1.61; 95% CI 
1.14-2.27) swabs. Compared to insertive anal sex, when having sex without a condom in the 
last year, receptive or versatile positioning increased the odds of HR-HPV detection at both 
the anal (aOR=2.00; 95% CI 1.27-3.16) and external (aOR=2.00; 95% CI 1.21-3.29) swabs. 
Having ever used drugs in the anus was also associated with HR-HPV at both sites (anal 
aOR=1.60; 95% CI 1.06-2.41; external aOR=1.63; 95% CI 1.10-2.41). 
Reporting insertive anal sex with a man in the last three months increased the odds of HR-
HPV detection in the external swab (aOR=1.52 95% CI 1.01-2.26) but not at other sites.  
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FIGURE 32. A FOREST PLOT SHOWING THE CATEGORICAL VARIABLES THAT WERE STATISTICALLY 
ASSOCIATED (P<0.05) WITH DETECTION OF HR-HPV DNA IN AT LEAST ONE SPECIMEN TYPE 
 
Logistic regression models fitted using GEE. Wald test P values. No HIV-positive participants were positive for oral HR-HPV and 
no men reporting anal sex in the last year with a woman were positive for HR-HPV in urine so odds ratios were not calculated.
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Risk factors for HR-HPV in oral and urine specimens 
The numbers of HR-HPV positive MSM were low for both urine and oral specimens 
(Appendix table 5). However some statistically significant associations were revealed for 
oral HR-HPV detection and these were shared with detection at the external swab. Fewer 
years of education (0-2 years) since the age of 16 compared to at least three years increased 
the odds of HR-HPV detection at the oral site (aOR=4.96; 95% CI 1.28-19.25) and at the 
external site (aOR=1.74; CI 1.21-2.50). HIV was the only statistically significant risk factor for 
HR-HPV DNA detection in urine (aOR=5.42; 95% CI 2.11-13.90). 
COMPARING SPECIMEN TYPES FOR THE DETECTION OF HPV DNA 
Table 19 shows the prevalence of vaccine-preventable HPV types by specimen type in 511 
MSM with an adequate anogenital specimen. 132 men (29.1%) had at least one detectable 
quadrivalent-vaccine type in the anal canal. A further 28 men had quadrivalent-vaccine 
types detected in the external genital swab so that the prevalence in these two samples was 
32.1%. Although only 16 men (3.3%) had detectable quadrivalent types in their urine, six of 
these infections were additional to the 160 detected in the two swabs.  
TABLE 19. INCREMENTAL CONTRIBUTION TO PREVALENCE OF VACCINE-PREVENTABLE HPV FROM EACH 
ANOGENITAL SPECIMEN TYPE IN MSM 
HPV type Anal swab External genital swab 
Anal or 
external 
genital swab 
Urine Any anogenital specimen 
 
N % N  % N % N  % N % 
16 57 12.6 45 10.1 66 13.3 6 1.2 69 13.5 
18 20 4.4 18 4.0 30 6.0 3 0.6 32 6.3 
16 and 18 4 0.9 2 0.5 7* 1.4 0 0.0 7 1.4 
16 or 18 69 15.2 59 13.2 82 16.5 9 1.9 87 17 
6 39 8.6 24 5.4 48 9.6 1 0.2 48 9.4 
11 36 7.9 39 8.7 58 11.7 7 1.4 59 11.5 
6 and 11 5 1.1 9 2.0 12 2.4 1 0.2 12 2.4 
6 or 11 65 14.3 45 10.1 82 16.5 6 1.2 83 16.2 
16 or 18 or 6 or 11 132 29.1 107 24.0 160 32.1 16 3.3 166 32.5 
31 or 33 or 45 or 52 or 58 74 16.3 70 15.7 103 20.7 11 2.3 110 21.5 
16 or 18 or 6 or 11 or 31 or 33 or 
45 or 52 or 58 182 40.1 161 36.1 224 45.0 26 5.4 232 45.4 
           Total adequate samples 454   446   498   486   511   
           *For rows measuring the frequency of both HPV types (HPV16&18 or HPV6&11), when combining specimen types, men were 
included in the numerator if one type was detected in one specimen (e.g anal) and the other type detected in another 
specimen (e.g. external) so that it is possible for the total to be greater than the sum of its parts. 
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Agreement of HPV DNA detection between sites 
HPV type-independent agreement and concordance 
The agreement for HPV type-independent detection, using the universal PCR probe, in the 
anal and external genital swabs was 76% (Κ = 0.45; 95% CI 0.36 - 0.54). Concordance 
between the swabs was 222/402 (55%) which was higher than that expected by chance 
(42%). HPV concordance was 41/423 (9.7%) for urine/external, 36/431 (8.4%) for urine/anal, 
9/138 (6.5%) for oral/anal and 8/148 (5.4%) for oral/external. 
TABLE 20. HPV TYPE-INDEPENDENT CONCORDANCE ACROSS SPECIMEN PAIRS 
Specimen pair a/N Percentage 
concordance 
Expected 
concordance (%) 
Anal/external genital 222/402 55.2 45.4 
urine/external genital 41/423 9.7 7.8 
urine/anal 36/431 8.4 7.6 
oral/anal 9/138 6.5 7.6 
oral/external genital 8/148 5.4 7.3 
 
HPV type-specific agreement and concordance 
The frequency of HPV detection and agreement across anogenital sites is displayed in Figure 
33. Pooled kappa for type-specific agreement for all 21 tested types for anal/external 
anal/urine and anal/oral agreement was 0.50 (95% CI 0.45-0.55), 0.03 (95% CI 0.00 - 0.07) 
and 0.11 (95% CI 0.07 - 0.16), respectively. Figure 34 shows that HR-HPV type-specific 
anogenital concordance was 29.4% (95% CI 24.9-34.2) compared to that expected by chance 
of 19.9%. 
See Statistical 
Methods, Box 6, 
page 96 for 
definitions of 
agreement, 
concordance and 
kappa. 
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FIGURE 33. NUMBER OF MSM WITH A SPECIFIC GENOTYPE OF HPV DNA (ALL 21 TESTED TYPES AND 
13 HR-HPV TYPES) DETECTED AT ONE OR MORE SITES IF ALL THREE SPECIMENS WERE ADEQUATE FOR 
PCR (N=381).  
 
Circle size represents frequency 
FIGURE 34. A BAR-CHART DISPLAYING HR-HPV TYPE-SPECIFIC CONCORDANCE (%) ACROSS 
ANATOMICAL SITES. 
 
Percent of men with same HR-HPV type (HPV16,18,31,33,35,39,45,51,52,56,58,59 or 68) in both specimens in men with both 
specimens adequate for HPV testing. Filled circles represent percentage concordance expected by chance. 
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Figure 35  shows the prevalence of HR-HPV and types 6/11 (LR-HPV) across specimen type 
pairs. There was no oral/anogenital type-specific concordance. There was higher 
anal/external concordance, especially for HPV16 (9.0%) and HPV45 (5.2%). Type-specific 
prevalence in urine was low, yet there was anogenital/urine concordance for some HPV 
types especially HPV6 (0.25%), HPV16 (1.26%) and HPV52 (1.51%).  
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FIGURE 35. HR-HPV AND HPV6/11 TYPE-SPECIFIC HPV DNA DETECTION: CONCORDANCE AND DISCORDANCE ACROSS ANOGENITAL SPECIMEN TYPES 
 
External=external genital swab. Anogenital concordance: at least two or three sites exhibit concordance. Denominator=both/all three samples in comparison were adequate for PCR. Possible HR-HPV 
types not shown.
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DNA quantification in anal and external swabs 
HPV16 was detected in 65/402 MSM in either the anal or external swab.  HPV16 was 
detected only in the anal swab in 21/65 (32%); the external swab only in 8/65 (12%); and in 
both swabs in 36/65 (55%). Agreement was 92.8% (Κ = 0.67; 95% CI 0.56 - 0.78) and anal 
samples were significantly more likely to detect HPV16 than external samples (OR=2.63; 
95% CI 1.12-6.85)  
Figure 36 shows that there were significantly more cells in the anal swab (median 636; IQR 
49-2,984 cells per reaction) than the external genital swab (median 9; IQR 5-76; z=2.46; 
p=0.01) and HPV16 DNA copies per reaction were higher in the anal (median 55,642; IQR 
1,893-642,028) than the external genital (median 152; IQR 8-4,047; z=4.93; p<0.01). 
Quantification of cellular and viral DNA was possible in both swabs in 14/36 concordant 
pairs and viral load (VL) was higher in the anal (median 952; IQR 80-2,771) compared to the 
external genital swab (median 48; IQR 1-220); a 7.7-fold difference in VL (IQR 2.1-637.6; 
z=2.61; p<0.01).  
Sequencing of the LCR 
Due to low HPV16 DNA copy number (especially in external samples), sequencing of the 
variable LCR was only possible in 10/36 concordant pairs and another 10/36 anal samples. 
There were 2/10 (20%) pairs that had different sequences in the paired samples and 1/20 of 
anal samples had a mixed variant infection. 
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FIGURE 36. KERNAL DENSITY PLOTS SHOWING THE DIFFERENCES IN CELL COUNTS, VIRAL DNA AND VIRAL LOAD BETWEEN ANAL AND EXTERNAL SWABS 
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Risk factors for anogenital concordant infections 
Appendix IV (Appendix table 6, page 309) shows the factors assessed for their association 
with anogenital concordant HR-HPV infections compared to not having a concordant 
infection (i.e HR-HPV infection at a single anogenital site or HPV negative) and to an HR-HPV 
infection at a single anogenital site.  The risk profile, shown in Figure 37, for concordant 
anogenital infections was similar to those at anal and external sites. HR-HPV type-specific 
concordant infections at anogenital sites were associated with at least ten male anal sex 
partners in the last year (aOR=1.69; 95% CI 1.15-2.49), at least ten new anal sex partners in 
the last year (aOR=1.56; 95% CI 1.06-2.30) receptive anal sex in the last three months 
(aOR=2.17; 95% CI 1.35-3.49) and receptive anal sex, compared to insertive sex, when 
having sex without a condom in the last year (aOR=2.84; 95% CI 1.45-5.57). 
Compared to a single infection, concordant anogenital HR-HPV infections were associated 
with reporting that the most recent relationship had ended (aOR=1.82; 95% CI 1.14-2.94). 
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FIGURE 37. SELECTED RISK FACTORS FOR HR-HPV TYPE-SPECIFIC CONCORDANCE AT ANOGENITAL 
SITES 
HIV status
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5.3 KEY FINDINGS 
Figure 38 simplifies data from Table 14 and Table 15 to show that two thirds (67.6%) of HPV-
MSM-MMC participants did not have any of the quadrivalent-vaccine types detected in 
anogenital specimens. A quarter had one type, 6.7% had two or three types and none had 
all four quadrivalent types detected. The prevalence of any HPV infection increased with age 
but no significant associations were detected when grouped HR-HPV, bivalent, quadrivalent 
or 9-valent vaccine-preventable HPV types were considered. There was no statistically 
significant association between detectable quadrivalent-vaccine type HPV or HR-HPV and 
age at first sex (Table 17 and Appendix table 4). 
Figure 39 shows the contribution of each anogenital site towards the overall anogenital 
prevalence of HPV16/18 and HPV6/11. The strongest agreement for HPV detection was 
between the anal and external swabs but with a pooled kappa was 0.50 was suggestive of 
only moderate agreement, and LCR sequencing revealed that some HPV16 positive pairs 
resulted from different variants. Furthermore, the two swabs had risk factors in common for 
HPV DNA detection. More cellular and viral DNA was harvested from anal swabs than 
external swabs and there was also higher viral load in the anal swabs. 
Urine was a poor marker for anogenital infection in MSM swabs. The lack of anogenital 
concordance with oral HPV infection might be attributed to the low prevalence of oral HPV 
DNA detection yet despite similarly low prevalence in urine there was some concordance 
between urine and anogenital swabs.  MSM with concordant anogenital HR-HPV infections 
were more likely to report their most recent relationship having ended than MSM with HR-
HPV at a single site.  
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FIGURE 38. DISTRIBUTION OF QUADRIVALENT-VACCINE TYPE HPV DNA DETECTION AT ANOGENITAL AND ORAL SITES IN 522 MSM ATTENDING MMC 
 
1 square= 1 participant. Upper panel displays the number of quadrivalent-vaccine HPV types detected across all specimens tested for DNA (oral, anal, external genital and urine) and is adapted from 
Table 15. Lower panel displays results that are adapted from Table 14 by including all participants (n= 522) in the denominator (not just MSM who have specimens adequate for HPV testing). HPVa/b= 
HPV type a and/or HPV type b. NB. Only a sub-sample (n=166) tested for oral HPV. 
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FIGURE 39. THE CONTRIBUTION OF EACH ANOGENITAL SAMPLE TO HPV6/11/16/18 PREVALENCE 
 
1 square= 1 participant. This figure expands on the lower panel of Figure 38 to show the breakdown of detectable quadrivalent-vaccine type DNA by specimen. Results are adapted from Table 19 by 
including all participants (n= 522) in the denominator (not just MSM who have specimens adequate for HPV testing) NB. only a sub-sample (n=166) tested for oral HPV.
143  
 
 
5.4 FINDINGS IN CONTEXT 
Figure 40 shows the HPV16 prevalence estimate for the HPV-MSM-MMC study highlighted 
in the results of a random-effects meta-analysis of estimates of HPV16 infection in the anal 
canal of HIV-negative MSM up to mid-2015. There was high heterogeneity between 
estimates from 18 studies and the pooled estimate was 12.4% (95% CI 10.5-14.2%). The 
pooled estimate from the seven studies in Europe was 12.5% (95% CI 10.5-14.4), had low 
heterogeneity (I2=32%) that was compatible with that expected by chance (p=0.18), and all 
European studies recruited from SHCs.  
In HIV-positive MSM, as shown in Figure 41, studies conducted in the US or Canada appear 
to have a higher prevalence than in other regions with overlapping confidence intervals.  
The random-effects pooled prevalence of HPV16 in HIV-positive MSM was estimated at 
28.6% (95% CI 25.3-31.8).  
The random-effects pooled estimate of HPV6 prevalence was 12.5% and 19.4% for HIV-
negative and HIV-positive MSM, respectively (Figure 42).  
There are no studies with directly comparable estimates for prevalence at the external 
genital swab because this is a composite of penile, scrotum and perianal sites. Two studies 
in HIV-negative MSM estimating penile HPV prevalence were both in young populations: in 
Melbourne, Australia, with a median age of 19, penile HPV16 prevalence was 1.5% (95% CI 
0.3-4.3)122, and it was 3.2% (95% CI 1.9-4.9) in the MSM vaccine trial population, described 
on page 238 (median age= 22 years)161. These studies also detected perianal HPV16 in 4.6% 
(95% CI 2.1-8.5) of young MSM in Melbourne and 6.0% (95% CI 4.2-8.2) of MSM vaccine trial 
participants. HPV16 prevalence at the scrotum in vaccine trial participants was estimated as 
2.2% (95% CI 2.2-3.7%). Therefore, despite the potential for double-counting, total perianal 
and penile HPV16 prevalence was lower in younger MSM in Sydney (6.1%) than in 
participants of the HPV-MSM-MMC study (10.1%). 
 
Methods for meta-
analysis in chapter 
3, page 56 
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In the MMC population, 29% were circumcised which may protect HIV-positive MSM from 
HR-HPV infection of the penis162.   
The estimate of oral HR-HPV prevalence for the HPV-MSM-MMC study of 5.4% (95% CI 2.5-
10.0) was higher than that of the global estimate in healthy men and women (3.5%; 95% 
3.0-4.1) yet the confidence intervals overlap134. In the large HPV in men (HIM) study, with 
predominantly heterosexual male participants in Mexico, Brazil and the US, the prevalence 
was 1.3%112. The estimate in this chapter lies within the range of estimates for HIV-negative 
MSM120,123,163. Figure 43 shows that updating the random-effects meta-analysis of 
prevalence of oral HPV16 infection from chapter 3, to include the estimate from this 
chapter, decreases the heterogeneity (I2=89% to I2=80%) and has negligible impact on the 
magnitude of the pooled estimate (3.6% to 1.9%). Likewise Figure 44 shows the result of 
including the findings from this chapter on the pooled estimate of oral HR-HPV prevalence 
(8.8% to 8.0%; I2=95% to I2=92%). As in the HPV-MSM-MMC study data, Kreimer et al found 
increasing educational level was associated with incident oral HPV infection, which they 
attributed to increased sexual mixing in educational environments113.  Kreimer et al and 
Beachler et al,  found that bisexual or heterosexual men had greater risk of incident oral 
HPV infection compared to homosexual MSM113,123. 
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FIGURE 40. RANDOM-EFFECTS META-ANALYSIS OF STUDIES ESTIMATING ANAL HPV16 PREVALENCE IN 
HIV-NEGATIVE MSM 
Abbreviations: Com=community, Res.=research, US= United States of America, SE=South East. Sadlier (2014)164, Van Aar 
(2013)165, Vriend (2013)166, Doná (2012)167,168, Van der Snoek (2003)62, Sayers (1998)60, Zou (2014)122, Vajdic (2009)84, Wiley 
(2013)169, Nyitray (2011)170, Berry (2009)171, Chin-Hong (2008)55, Friedman (1998)56, Palefsky (1998)57, Phanuphak (2013)50,172, 
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FIGURE 41. RANDOM-EFFECTS META-ANALYSIS OF STUDIES ESTIMATING ANAL HPV16 PREVALENCE IN 
HIV-POSITIVE MSM, BY REGION 
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FIGURE 42. RANDOM-EFFECTS META-ANALYSIS OF STUDIES ESTIMATING ANAL HPV6 PREVALENCE IN 
MSM POPULATIONS, BY HIV STATUS 
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FIGURE 43. RANDOM-EFFECTS META-ANALYSIS OF STUDIES ESTIMATING ORAL HPV16 PREVALENCE IN 
MSM POPULATIONS, BY HIV STATUS 
 
This figure updates the analysis in chapter 3, Figure 17, page 63 to include results from the HPV-MSM-MMC study. Weights are 
from random effects analyses. Beachler (2012)117,  Read (2012)120, Parisi (2011)124, Sirera (2006)63, Gaester (2014)127, Ong 
(2014)121 and Kreimer (2013)113. 
FIGURE 44. RANDOM-EFFECTS META-ANALYSIS OF STUDIES ESTIMATING ORAL HR-HPV PREVALENCE 
IN MSM POPULATIONS, BY HIV STATUS 
This figure updates the analysis in chapter 3, Figure 19, page 65 to include results from the HPV-MSM-MMC study. Weights are 
from random effects analyses. Mooij (2013)114, Beachler (2012)117,  Read (2012)120, Parisi (2011)124, Del Mistro (2012)125, Ong 
(2014)121 and Kreimer (2013)113. 
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The relative detection of HPV DNA between anatomical sites in the same man has been 
studied 63,65,66,118,124,191,192, but there are few studies in MSM collecting both anal and penile 
specimens 165,170,179,190,193,194, and fewer still reporting on type-specific concordance.  
In MSM in Amsterdam, infections at one anatomical site were detected more often than 
infections at multiple (at least two) anatomical sites. The prevalence of HPV type-specific 
concordant (at least two of anal/penile/oral) HR-HPV (HPV16/18/31/33/45/52/58) 
infections was 14% in HIV-positive and 10% in HIV-negative MSM116.  
Recently, Zou et al demonstrated that the incidence of anal HR-HPV DNA detection is over 
four times higher than penile195. That the anal sample is the most sensitive for HPV DNA 
detection in MSM has been found in several studies116,118 but in heterosexual men, the 
penile swab was the most sensitive65.  
The lack of concordance between oral and anogenital specimens was also found in HIV-
positive men reported by Videla et al (predominantly MSM)118 and Parisi et al124. However 
Edelstein et al found that 15/17 men (predominantly heterosexual) had the same type 
detected at oral and anogenital sites196. 
The lack of a significant association between circumcision status and external genital HPV 
detection (aOR 1.10, 95% CI 0.72-1.66), may be due to limited power. However, this was in 
contrast to the protective effect reported from international studies in men having sex with 
women197. There are inconsistent findings for the effect of circumcision status on HPV 
infection in MSM162,198,199.  
5.5 STRENGTHS AND LIMITATIONS 
In a cross-sectional study design, the clinical relevance of HPV detection and the temporal 
relationship between exposure variables and HPV infection cannot be determined and 
infections of longer duration are more likely to be detected. Additionally, not all men were 
tested for HIV at the clinic visit so there is potential for undiagnosed HIV. This potential 
misclassification would overestimate HPV prevalence in HIV-negative MSM. The sensitivity 
for the detection of HPV DNA in urine is lower than genital swabs200 and low HPV prevalence 
was observed in this specimen type.  
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The direct comparison across sites of factors associated with HR-HPV was hampered 
because there was considerably reduced power for the detection of risk factors in the oral 
and urine compared to the external and anal specimens. Furthermore, for anal and external 
genital swabs, where the prevalence of HR-HPV was approximately 40%, and for 
quadrivalent-vaccine types, at approximately 30%, the odds ratio considerably 
overestimates the relative risk. Therefore the ORs in this chapter should be interpreted as 
the ratio of HR-HPV odds given the exposure status and not as relative risk. 
Where the same risk factor was significantly associated with HPV detection (either 
quadrivalent or HR-HPV) at multiple sites, the likelihood of this being due to chance is 
reduced. Since many risk factor analyses were performed in this chapter, those factors that 
were statistically significant at only one site may well have arisen by chance. 
These type-specific estimates are subject to ‘masking’, where the predominant type is 
detected in multiple type infection overshadowing other types. This is of relevance if 
comparing the prevalence estimates in this chapter to post-vaccine prevalence estimates, 
where non-vaccine types may appear to increase as they are ‘unmasked’ by removal of the 
vaccine types.  
Testing all samples for HPV of each man in the same run reduced the effect of batch 
discrepancies when comparing between specimen sites. True differences in prevalence 
cannot be distinguished from differences in HPV testing specificity and sensitivity or DNA 
stability across specimens in this study. The relative detection of HPV between sites 
reported in this chapter would either support underlying differences in HPV tissue-tropism 
and epidemiology or differential specificity/sensitivity at different anatomical sites. 
Oral samples are particularly sensitive to sub-optimal DNA extraction methods201. Although 
oral rinse/gargle sampling is the optimal method for HPV detection, sensitivity is improved 
by combining with other sampling methods202. The oral prevalence estimates might 
therefore be biased downwards and increased oral-anogenital concordance would be 
expected with higher oral prevalence.  
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Perianal sampling using the external swab introduced the potential for contamination from 
the anal canal site. This potential bias would result in artificially high estimates of agreement 
between the swabs. Due to funding constraints, swabs could not be collected separately for 
each of the external genital sites.  
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6. HPV-MSM-MMC STUDY: HPV SEROLOGY 
In this chapter, I present the results from testing the serum for immunoglobulin (Ig) G 
(antibodies) specific to HPV16 and HPV18. I first present the prevalence of detectable 
IgG (seropositivity) in MSM; overall and by age. I then examine the antibody titre with 
respect to age and examine the associations of demographic and behavioural factors 
with HPV seropositivity. In addition, I report on the relationship between HPV 
seropositivity and HPV DNA detection. Finally, I put the chapter’s findings into context, 
comparing to those in the literature up to mid-2015. 
6.1 OBJECTIVES  
1. To estimate the seroprevalence of HPV16 and HPV18 in MSM attending MMC 
2. To estimate the age-specific seroprevalence in MSM  
3. To describe the relationship between IgG titres and age 
4. To explore demographic and behavioural risk factors for seropositivity in MSM  
5. To describe the association between HPV DNA detection and seropositivity 
6. To discuss biases to be considered when interpreting the findings from this 
chapter 
6.2 METHODS 
Methods used to meet the objectives are described in chapter 4. In particular, serology 
testing is described on page 93 and statistical methods on page 97. 
6.3 RESULTS 
Of the 522 participants in the study, 512 gave a blood sample and 506 had a sample that 
was adequate for serological tests (Figure 26, page 102). Of these 506 MSM, 496 also 
had an anogenital sample that was adequate for DNA testing. The median age of the 
506 MSM was 30 (IQR 25-35), 26/506 (5.1%; 95% CI 3.4-7.4) were diagnosed HIV-
positive and there were no differences in other demographic and behavioural 
characteristics from those reported in chapter 4, page 104. 
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SEROPREVALENCE 
Seroprevalence by HIV status is displayed in Table 21 and Figure 45. Approximately two-
thirds of participants had no detectable antibodies to the bivalent-vaccine types. 
Seroprevalence was higher in MSM diagnosed HIV-positive compared to HIV-negative.   
TABLE 21. HPV SEROPREVALENCE IN 506 MSM WITH SERUM SAMPLES ADEQUATE FOR TESTING 
HPV type N % 95% CI 
Anti-HPV16 144 28.5 (24.6-32.6) 
HIV-negative 129 26.9 (23.0-31.1) 
HIV-positive 15 57.7 (36.9-76.6) 
Anti-HPV18 87 17.2 (14.0-20.8) 
HIV-negative 78 16.3 (13.1-19.9) 
HIV-positive 9 34.6 (17.2-55.7) 
Anti-HPV16 or anti-HPV18 117 23.1 (19.5-27.0) 
HIV-negative 107 22.3 (18.6-26.3) 
HIV-positive 10 38.5 (20.2-59.4) 
Anti-HPV16 and anti-HPV18 57 11.3 (8.6-14.3) 
HIV-negative 50 10.4 (7.8-13.5) 
HIV-positive 7 26.9 (11.6-47.8) 
A total of 506 MSM were included in the denominator: 480 HIV-negative and 26 HIV-positive MSM. Data are displayed 
graphically in Figure 45. 
FIGURE 45. BAR CHART REPRESENTING HPV SEROPREVALENCE IN 506 MSM  
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AGE-SPECIFIC SEROPREVALENCE 
Figure 46 demonstrates that in HIV-negative MSM there was a significant relationship 
between seroprevalence and age for anti-HPV16 (OR=1.07 per year; 95% CI 1.03-1.11) 
and anti-HPV18 (OR per year=1.08; 95% CI 1.03-1.12). In HIV-positive MSM (n=26) there 
were wide confidence intervals and there was no statistically significant association 
(HPV16 OR per year=1.03 (95% CI 0.89-1.20); HPV18 OR per year=0.95 (95% CI 0.81-
1.11)). 
FIGURE 46. AGE-SPECIFIC HPV SEROPREVALENCE IN 480 HIV-NEGATIVE MSM 
Data for this figure and by HIV status, are displayed in Appendix III, Appendix table 2, page 301. 
ANTIBODY TITRES  
Figure 47, panel a, shows that the distributions of antibody titres in MSM seropositive 
for anti-HPV16 and anti-HPV18 were highly negatively skewed. Having log transformed 
these distributions, to improve their normality (panel b), there was no association 
between anti-HPV16 titre or anti-HPV18 titre (ELISA Units/ml) with age in seropositive 
MSM. Despite the residuals not being normally distributed, an assumption underlying 
the t test in ordinary linear regression, the plots of the fitted model to the observed 
data support the finding that age does not predict anti-HPV titre (Figure 48). 
Furthermore, there were no differences in the mean log titre across age groups for anti-
HPV16 (F(4, 136)=1.18, p=0.32) or anti-HPV18 (F(4, 80)=0.18, p=0.95). 
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FIGURE 47. HISTOGRAMS SHOWING THE DISTRIBUTIONS AND LOG-TRANSFORMED DISTRIBUTIONS 
OF ANTI-HPV16 TITRES IN 144 HPV16 SEROPOSITIVE MSM AND ANTI-HPV18 TITRES IN 87 
HPV18 SEROPOSITIVE MSM. 
 
Panels a and b represent histograms of the distributions and the log-transformed distributions of anti-HPV titres, 
respectively. 
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FIGURE 48. LINEAR REGRESSION MODELS OF AGE AND ANTI-HPV TITRES IN HPV SEROPOSITIVE 
MSM 
  
RISK FACTORS FOR BIVALENT-VACCINE HPV TYPE SEROPOSITIVITY IN MSM 
Table 22 and Table 23 show the socio-demographic and behavioural factors that were 
assessed for their association with HPV16 and, separately, for HPV18 in univariate 
analyses. Age, HIV status (HPV16 OR=3.71; 95% CI 1.66-8.29; HPV18 OR=2.73; 95% CI 
1.17-6.34), at least ten anal partners (altogether and new) in the last year,  increasing 
number of lifetime partners (HPV16 p-trend <0.01; HPV18 p-trend <0.01), having had 
receptive anal sex in the last three months (HPV16 OR=3.26; 95% CI 1.98-5.36; HPV18 
OR=2.20; 95% CI 1.24-3.90), having ever used drugs anally (HPV16 OR=2.16; 95% CI 
1.18-3.97; HPV18 OR=2.75; 95% CI 1.43-5.29) and overlapping of any of the three most 
recent partners (HPV16 OR=1.56; 95% CI 1.04-2.33; HPV18 OR=1.78; 95% CI 1.08-2.91) 
were statistically significantly associated with both HPV16 and HPV18 seropositivity. 
In addition, HPV16 seropositivity was associated with having at least ten anal partners 
without a condom in the last year (OR=2.88; 95% CI 1.35-6.16), position during 
condomless receptive anal sex in the last year and age of most recent partner (OR per 
year=1.04; 95% CI 1.01-1.06). There were no factors independently associated with 
HPV18 seropositivity. 
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TABLE 22. UNIVARIATE ANALYSES OF SOCIO-DEMOGRAPHIC, AND HIV STATUS, RISK FACTORS FOR HPV16 AND, SEPARATELY, FOR HPV18 ANTIBODY DETECTION. 
 HPV16  HPV18 
Risk factor Seronegative 
n (%) 
Seropositive 
n (%) 
OR 95% CI P   Seronegative 
n (%) 
Seropositive 
n (%) 
OR 95% CI p 
Each additional year in age 1.06 (1.03-1.10) <0.01    1.07 (1.02-1.11) <0.01 
Ethnic group            
White 268 (72.0) 104 (28.0) 1 - 0.68  307 (82.5)  65 (17.5) 1 - 0.89 
Black  45 (68.2)  21 (31.8) 1.20 (0.68-2.12)    56 (84.8)  10 (15.2) 0.84 (0.41-1.74)  
Asian & SE Asian  37 (75.5)  12 (24.5) 0.84 (0.42-1.67)    41 (83.7)   8 (16.3) 0.92 (0.41-2.06)  
Born in the UK            
No 185 (70.9)  76 (29.1) 1 - 0.62  220 (84.3)  41 (15.7) 1 - 0.37 
Yes 167 (72.9)  62 (27.1) 0.90 (0.61-1.34)   186 (81.2)  43 (18.8) 1.24 (0.78-1.99)  
Currently smoke            
No 248 (72.3)  95 (27.7) 1 - 0.69  286 (83.4)  57 (16.6) 1 - 0.62 
Yes 103 (70.5)  43 (29.5) 1.09 (0.71-1.67)   119 (81.5)  27 (18.5) 1.14 (0.69-1.89)  
Increasing or higher risk alcohol drinking (AUDIT-C)        
No 117 (70.9)  48 (29.1) 1 - 0.71  136 (82.4)  29 (17.6) 1 - 0.91 
Yes 232 (72.5)  88 (27.5) 0.92 (0.61-1.40)   265 (82.8)  55 (17.2) 0.97 (0.59-1.60)  
Currently employed            
No  80 (75.5)  26 (24.5) 1 - 0.35   91 (85.8)  15 (14.2) 1 - 0.36 
Yes 272 (70.8) 112 (29.2) 1.27 (0.77-2.08)   315 (82.0)  69 (18.0) 1.33 (0.73-2.43)  
Years of education post-16         
None    9 (69.2)   4 (30.8) 1 - 0.13*   11 (84.6)   2 (15.4) 1 - 0.40* 
Up to 2 years  45 (72.6)  17 (27.4) 0.85 (0.23-3.13)    51 (82.3)  11 (17.7) 1.19 (0.23-6.12)  
3 years or more 230 (69.3) 102 (30.7) 1 (0.30-3.32)   270 (81.3)  62 (18.7) 1.26 (0.27-5.84)  
Still in education  68 (81.9)  15 (18.1) 0.50 (0.13-1.83)    74 (89.2)   9 (10.8) 0.67 (0.13-3.51)  
Sexual orientation            
Gay/homosexual 316 (70.9) 130 (29.1) 1 - 0.15  369 (82.7)  77 (17.3) 1 - 0.87 
Bisexual  35 (81.4)   8 (18.6) 0.56 (0.25-1.23)    36 (83.7)   7 (16.3) 0.93 (0.40-2.17)  
Circumcised            
No 252 (72.8)  94 (27.2) 1 - 0.43  291 (84.1)  55 (15.9) 1 - 0.20 
Yes  97 (69.3)  43 (30.7) 1.19 (0.77-1.83)   111 (79.3)  29 (20.7) 1.38 (0.84-2.28)  
HIV positive diagnosis            
No 351 (73.1) 129 (26.9) 1 - <0.01  402 (83.8)  78 (16.3) 1 - 0.02 
Yes  11 (42.3)  15 (57.7) 3.71 (1.66-8.29)    17 (65.4)   9 (34.6) 2.73 (1.17-6.34)  
Seronegative  : IgG antibodies were not detected in the serum;  Seropositive : IgG antibodies were detected in the serum. *P value from Fisher’s exact test 
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TABLE 23. UNIVARIATE ANALYSES OF SEXUAL BEHAVIOUR RISK FACTORS FOR HPV16 AND, SEPARATELY, FOR HPV18 ANTIBODY DETECTION. CONTINUED 
 HPV16  HPV18 
Risk factor Seronegative n (%) Seropositive n (%) OR 95% CI P   Seronegative n (%) Seropositive n (%) OR 95% CI p 
Number of lifetime male partners (anal and oral sex)        
Fewer than 20  87 (88.8)  11 (11.2) 1 - <0.01   91 (92.9)   7 (7.1) 1 - <0.01 
21-30  54 (78.3)  15 (21.7) 2.20 (0.94-5.13)    59 (85.5)  10 (14.5) 2.20 (0.79-6.11)  
31-100 118 (71.5)  47 (28.5) 3.15 (1.54-6.42)   146 (88.5)  19 (11.5) 1.69 (0.68-4.18)  
101-500  93 (58.9)  65 (41.1) 5.53 (2.74-11.16)   110 (69.6)  48 (30.4) 5.67 (2.45-13.14)  
Number of male sex partners in the last year         
Male anal sex partners           
<10 213 (81.3)  49 (18.7) 1 - <0.01  230 (87.8)  32 (12.2) 1 - <0.01 
>=10 119 (58.9)  83 (41.1) 3.03 (2.00-4.61)   152 (75.2)  50 (24.8) 2.36 (1.45-3.85)  
New anal sex partners            
<10 239 (78.1)  67 (21.9) 1 - <0.01  261 (85.3)  45 (14.7) 1 - 0.02 
>=10  91 (59.1)  63 (40.9) 2.47 (1.62-3.76)   118 (76.6)  36 (23.4) 1.77 (1.08-2.89)  
Anal sex partners without a condom          
<10 315 (72.9) 117 (27.1) 1 - 0.01  359 (83.1)  73 (16.9) 1 - 0.06 
>=10  14 (48.3)  15 (51.7) 2.88 (1.35-6.16)    20 (69.0)   9 (31.0) 2.21 (0.97-5.05)  
Exclusively oral sex partners          
<10 229 (75.1)  76 (24.9) 1 - 0.06  260 (85.2)  45 (14.8) 1 - 0.07 
>=10  91 (66.4)  46 (33.6) 1.52 (0.98-2.36)   107 (78.1)  30 (21.9) 1.62 (0.97-2.71)  
Each additional year of age at first sex with a man        
Oral    0.97 (0.92-1.02)     0.97 (0.91-1.04)  
Receptive anal   0.97 (0.92-1.02) 0.23    0.97 (0.92-1.03) 0.40 
Oral sex with a man in last 3 months     0.19   
No  12 (75.0)   4 (25.0) 1 - 0.77*   16 (100.0)   0 (0.0) n/a - 0.09* 
Yes 335 (71.6) 133 (28.4) 1.19 (0.38-3.76)   386 (82.5)  82 (17.5) n/a n/a  
Receptive anal sex with a man in last 3 months        
No 139 (85.8)  23 (14.2) 1 - <0.01  145 (89.5)  17 (10.5) 1 - 0.01 
Yes 206 (65.0) 111 (35.0) 3.26 (1.98-5.36)   252 (79.5)  65 (20.5) 2.20 (1.24-3.90)  
Insertive anal sex with a man in last 3 months        
No  82 (78.8)  22 (21.2) 1 - 0.09   90 (86.5)  14 (13.5) 1 - 0.33 
Yes 258 (70.5) 108 (29.5) 1.56 (0.93-2.63)   302 (82.5)  64 (17.5) 1.36 (0.73-2.54)  
Vaginal sex in last year        
No 258 (73.5)  93 (26.5) 1 - 1.00  291 (82.9)  60 (17.1) 1 - 0.20* 
Yes  23 (74.2)   8 (25.8) 0.96 (0.42-2.23)    29 (93.5)   2 (6.5) 0.33 (0.08-1.44)  
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TABLE 23. UNIVARIATE ANALYSES OF SEXUAL BEHAVIOUR RISK FACTORS FOR HPV16 AND, SEPARATELY, FOR HPV18 ANTIBODY DETECTION. CONTINUED 
 HPV16  HPV18 
Risk factor Seronegative n (%) Seropositive n (%) OR 95% CI P   Seronegative n (%) Seropositive n (%) OR 95% CI p 
Oral sex with a woman in the last year        
No 259 (72.8)  97 (27.2) 1 - 0.52  294 (82.6)  62 (17.4) 1 - 0.06* 
Yes  23 (79.3)   6 (20.7) 0.70 (0.28-1.76)    28 (96.6)   1 (3.4) 0.17 (0.02-1.27)  
Anal sex with a woman in the last year        
No 276 (73.4) 100 (26.6) 1 - 0.91*  315 (83.8)  61 (16.2) 1 - 1.00* 
Yes   5 (71.4)   2 (28.6) 1.10 (0.21-5.78)     6 (85.7)   1 (14.3) 0.86 (0.10-7.28)  
Position when having anal sex without a condom in the last year        
Insertive only  63 (86.3)  10 (13.7) 1 - <0.01   62 (84.9)  11 (15.1) 1 - 0.53 
Receptive only  32 (69.6)  14 (30.4) 2.76 (1.10-6.89)    36 (78.3)  10 (21.7) 1.57 (0.61-4.05)  
Versatile  98 (60.5)  64 (39.5) 4.11 (1.97-8.60)   128 (79.0)  34 (21.0) 1.50 (0.71-3.15)  
Each additional year at first attending a sexual health clinic 1.00 (0.96-1.05)     1.03 (0.98-1.08)  
Use of drugs in anus/rectum ever        
No 325 (73.5) 117 (26.5) 1 - 0.01  374 (84.6)  68 (15.4) 1 - <0.01 
Yes  27 (56.3)  21 (43.8) 2.16 (1.18-3.97)    32 (66.7)  16 (33.3) 2.75 (1.43-5.29)  
Condom use with most recent partner        
Always 166 (69.7)  72 (30.3) 1 - 0.53  196 (82.4)  42 (17.6) 1 - 0.43 
Sometimes  74 (73.3)  27 (26.7) 0.84 (0.50-1.42)    88 (87.1)  13 (12.9) 0.69 (0.35-1.35)  
Never 110 (74.8)  37 (25.2) 0.78 (0.49-1.23)   119 (81.0)  28 (19.0) 1.10 (0.65-1.86)  
Most recent male partner (oral or anal)        
Each additional year of age of partner 1.04 (1.01-1.06) 0.01    1.01 (0.98-1.04) 0.42 
Each additional day since last having sex with partner 1.00 (0.99-1.00) 0.11    1.00 (1.00-1.01) 0.50 
Relationship type with most recent partner        
Regular 172 (72.3)  66 (27.7) 1 - 0.91  198 (83.2)  40 (16.8) 1 - 0.97 
Casual 168 (71.8)  66 (28.2) 1.02 (0.68-1.53)   195 (83.3)  39 (16.7) 0.99 (0.61-1.61)  
Relationship is continuing with most recent partner        
No 171 (73.7)  61 (26.3) 1 - 0.37  194 (83.6)  38 (16.4) 1 - 0.61 
Yes 178 (70.1)  76 (29.9) 1.20 (0.80-1.78)   208 (81.9)  46 (18.1) 1.13 (0.70-1.81)  
Concurrency between any of the 3 most recent partners        
No 168 (76.7)  51 (23.3) 1 - 0.03  191 (87.2)  28 (12.8) 1 - 0.02 
Yes 184 (67.9)  87 (32.1) 1.56 (1.04-2.33)   215 (79.3)  56 (20.7) 1.78 (1.08-2.91)  
Seronegative  : IgG antibodies were not detected in the serum;  Seropositive : IgG antibodies were detected in the serum. *P value from Fisher’s exact test 
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FIGURE 49. ASSOCIATION OF SELECTED RISK FACTORS FOR HPV SEROPOSITIVITY IN LOGISTIC 
REGRESSION MODELS 
  
Odds ratios are adjusted for lifetime number of partners and age, except for lifetime partners which is adjusted for age. Only 
MSM who had oral sex with another man in the last 3 months had detectable anti-HPV18 
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Categorical socio-demographic and behavioural risk factors identified in previous chapters 
and those statistically significantly associated with seropositivity, having adjusted for age 
and lifetime number of partners, are displayed in the forest plot on page 160 (Figure 49). In 
addition, Table 24 shows all of the socio-demographic and HIV variables examined for their 
association with seropositivity and Table 25 shows all of the sexual behavioural factors, 
having adjusted for age and lifetime number of partners.  
Table 24 shows that after adjustment for number of lifetime partners, the association 
between age and seropositivity, was no longer statistically significant (aOR per year 
HPV16=1.03; 95% CI 0.99-1.07; aOR per year HPV18=1.03; 95% CI 0.99-1.08). On the other 
hand, after adjustment for age, the association with number of lifetime partners remained 
associated with seropositivity; MSM with >100 partners were 4.7-4.8 times more likely than 
those with ≤20 lifetime partners to be seropositive (Table 25). 
An HIV-positive diagnosis remained a significant predictor of HPV16 seropositivity after 
adjusting for age and lifetime number of partners (aOR=3.16; 95% CI 1.37-7.28) but not for 
HPV18 seropositivity (aOR=2.04; 95% CI 0.84-4.92) even though the point estimates for 
HPV18 are approximately 2-fold higher in HIV-positive MSM compared to in HIV-negative 
MSM.  
After adjustment, reporting receptive anal sex in the last three months remained associated 
with HPV16 seropositivity (aOR=3.39; 95% CI 2.01-5.71) and HPV18 (aOR=2.14; 95% CI 1.18-
3.90). Use of drugs anally was no longer associated with HPV16 seropositivity (aOR=1.65; 
95% CI 0.88-3.09) but remained associated with HPV18 seropositivity (aOR=2.07; 95% CI 
1.05-4.10) and overlapping of any of the three most recent partners was no longer 
associated with seropositivity. Position during condomless receptive anal sex in the last year 
remained associated with HPV16 seropositivity with MSM reporting versatility having 4.6 
times greater odds than those who were only insertive (95% CI 2.1-9.9). 
The finding that there was a significant association between number of anal partners in the 
last year (total and new)  and HPV16 seropositivity, having adjusted for age and lifetime 
partners, should be interpreted in the context of probable collinearity between number of 
lifetime partners (oral and anal) and number of anal partners in the last year. In a model 
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with age, lifetime partners and total anal partners in the last year as predictors for HPV16 
seropositivity, lifetime number of partners was no longer significant (p=0.10) suggesting 
that number of partners in the last year were more important predictors than those over a 
year ago. Number of lifetime partners was considered an a priori confounder because it was 
expected that cumulative risk of HPV exposure would predict serostatus rather than recent 
exposure. 
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TABLE 24. SOCIO-DEMOGRAPHIC AND HIV STATUS RISK FACTORS FOR HPV 
SEROPOSITIVITY, HAVING ADJUSTED FOR AGE AND LIFETIME NUMBER OF PARTNERS 
 HPV16    HPV18    
Risk factor aOR 95% CI P value  aOR 95% CI P value 
Each additional year in agea 1.03 (0.99-1.07) 0.15 1.03 (0.99-1.08) 0.18 
Ethnic group       
White 1 -  0.46 1 -  0.97 
Black 1.41 (0.78-2.56)   0.93 (0.44-1.98)   
Asian & SE Asian 0.88 (0.43-1.80)  0.92 (0.40-2.11)  
Born in the UK         
No 1 -  0.70 1 -  0.26 
Yes 0.92 (0.61-1.39)   1.32 (0.81-2.16)   
Currently smoke           
No 1 - 0.62 1 - 0.47 
Yes 1.12 (0.72-1.74)  1.21 (0.72-2.06)  
Increasing or higher risk alcohol drinking (AUDIT-C)      
No 1 -  0.64 1 -  0.71 
Yes 0.90 (0.59-1.39)   0.91 (0.54-1.52)   
Currently employed           
No 1 - 0.64 1 - 0.49 
Yes 1.14 (0.67-1.92)  1.25 (0.66-2.37)  
Years of education post-16       
None  1 -  0.75 1 -  0.92 
Up to 2 years 1.03 (0.27-3.88)   1.36 (0.25-7.27)   
3 years or more 1.18 (0.35-4.00)  1.48 (0.31-7.05)  
Still in education 0.83 (0.21-3.19)   1.18 (0.21-6.55)   
Sexual orientation           
Gay/homosexual 1 - 0.80 1 - 0.36 
Bisexual 0.90 (0.38-2.09)  1.53 (0.61-3.83)  
Circumcised         
No 1 -  0.48 1 -  0.34 
Yes 1.18 (0.75-1.84)   1.29 (0.77-2.17)   
HIV positive diagnosis           
No 1 - 0.01 1 - 0.11 
Yes 3.16 (1.37-7.28)   2.04 (0.84-4.92)   
Abbreviations: aOR=adjusted odds ratio, SE Asian=South East Asian, AUDIT-C= Alcohol Use Disorders 
Identification Test Consumption, HIV=Human Immunodeficiency virus. aAdjusted for lifetime number of partners 
only 
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TABLE 25. SEXUAL BEHAVIOUR RISK FACTORS FOR HPV SEROPOSITIVITY, ADJUSTED FOR AGE AND 
LIFETIME NUMBER OF PARTNERS. CONTINUED. 
 HPV16    HPV18    
Risk factor aOR 95% CI P  aOR 95% CI p 
Number of lifetime male partners (anal and oral sex)a       
Fewer than 20  1 - <0.01 1 - <0.01 
21-30 2.07 (0.88-4.86)  2.06 (0.74-5.74)   
31-100 2.79 (1.34-5.79)   1.47 (0.58-3.72)  
101-500 4.74 (2.29-9.85)  4.77 (1.99-11.44)   
Number of male sex partners in the last year      
Male anal sex partners       0.26 
<10 1 - <0.01 1 -  
>=10 2.19 (1.34-3.57)  1.40 (0.78-2.50)   
New anal sex partners      0.94 
<10 1 -  0.02 1 -    
>=10 1.77 (1.10-2.85)   1.02 (0.58-1.80)  
Anal sex partners without a condom     0.50 
<10 1 - 0.08 1 -  
>=10 2.02 (0.91-4.50)  1.35 (0.56-3.25)   
Exclusively oral sex partners      0.96 
<10 1 -  0.96 1 -    
>=10 0.99 (0.61-1.60)  0.99 (0.56-1.74)  
Each additional year of age at first sex with a man       
Oral  0.98 (0.92-1.04) 0.52 1.00 (0.93-1.07) 0.95 
Receptive anal 0.95 (0.89-1.01) 0.07 0.96 (0.90-1.03) 0.26 
       Oral sex with a man in last 3 months        
No 1 - 0.72    
Yes 0.80 (0.24-2.66)        
Receptive anal sex with a man in last 3 months      
No 1 -  <0.01 1 -  0.01 
Yes 3.39 (2.01-5.71)   2.14 (1.18-3.90)   
Insertive anal sex with a man in last 3 months      
No 1 - 0.38 1 - 0.88 
Yes 1.27 (0.74-2.20)  1.05 (0.55-2.03)  
Vaginal sex in last year       
No 1 -  0.33 1 -  0.32 
Yes 1.58 (0.62-4.01)   0.46 (0.10-2.12)   
Oral sex with a woman in the last year      
No 1 - 0.94 1 - 0.16 
Yes 1.04 (0.38-2.82)  0.23 (0.29-1.77)  
Anal sex with a woman in the last year      
No 1 -  0.71 1 -  0.96 
Yes 1.40 (0.23-8.57)   0.95 (0.09-9.78)   
Position when having anal sex without a condom in the last year      
Insertive only 1 - <0.01 1 - 0.43 
Receptive only 3.52 (1.34-9.23)   1.95 (0.70-5.45)   
Versatile 4.61 (2.14-9.93)  1.45 (0.66-3.17)  
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TABLE 25. SEXUAL BEHAVIOUR RISK FACTORS FOR HPV SEROPOSITIVITY, ADJUSTED FOR AGE AND 
LIFETIME NUMBER OF PARTNERS. CONTINUED. 
 HPV16    HPV18    
Risk factor aOR 95% CI P  aOR 95% CI p 
Each additional year at first attending a 
sexual health clinic 
0.98 (0.93-1.03) 0.46 1.02 (0.96-1.08) 0.57 
Use of drugs in anus/rectum ever     
No 1 -  0.12 1 -  0.04 
Yes 1.65 (0.88-3.09)   2.07 (1.05-4.10)   
Condom use with most recent partner      
Always 1 - 0.53 1 - 0.51 
Sometimes 0.91 (0.53-1.57)  0.71 (0.36-1.43)   
Never 0.76 (0.47-1.23)  1.09 (0.63-1.90)  
Most recent male partner (oral or anal)         
Each additional year of age of partner 1.02 (0.98-1.06) 0.12 1.00 (0.98-1.08) 0.82 
Each additional day since last having 
sex with partner 
1.00 (0.98-1.06) 0.51 1.00 (1.00-1.01) 0.14 
Relationship type with most recent partner     
Regular 1 -  0.88 1 -  0.86 
Casual 1.03 (0.68-1.57)   0.96 (0.58-1.58)   
Relationship is continuing with most recent partner      
No 1 - 0.50 1 - 0.58 
Yes 1.15 (0.76-1.75)  1.15 (0.70-1.88)  
Concurrency between any of the 3 most recent partners      
No 1 -  0.14 1 -  0.10 
Yes 1.37 (0.90-2.08)  1.54 (0.92-2.56)  
  Abbreviation: aOR=adjusted odds ratio.  aAdjusted for age only 
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RELATIONSHIP BETWEEN HPV SEROPOSITIVITY AND HPV DNA DETECTION 
Table 26 examines HPV-type specificity for the association between DNA and seropositivity. 
Seropositivity for anti-HPV16 was associated with anogenital HPV16 DNA detection 
(OR=3.81; 95% CI 2.24-6.46) and this association remained after adjusting for age and 
lifetime number of partners (aOR=3.58; 95% CI 2.05-6.23). There were 37/499 participants 
(7.4%) seropositive for HPV16 with detectable anogenital HPV16 DNA, 327 (65.5%) 
participants with neither DNA nor seropositivity for HPV16, 30 (6.0%) participants who had 
detectable DNA with undetectable anti-HPV16 and 105 (21.0%) participants with 
undetectable DNA but who were seropositive. 
Similarly, seropositivity for anti-HPV18 was associated with anogenital HPV18 DNA 
detection (OR=3.21; 95% CI 1.51-6.86; aOR=2.71; 95% CI 1.17-6.27). Separately, anti-HPV18 
seropositivity was associated with HPV16 DNA (OR=1.98; 95% CI 1.09-3.62) but not after 
adjusting for age and lifetime partners (aOR=1.71; 95% CI 0.90-3.24). 
Table 27 describes the associations between HPV type groupings and seropositivity for 
HPV16/18 to further examine the type specificity of these associations. Quadrivalent-
vaccine type infection at anogenital sites was associated with HPV16/18 seropositivity, even 
after adjusting for age and lifetime partner numbers (aOR=1.79; 95% CI 1.19-2.71). 101/506 
(20.0%) participants were seropositive for HPV16/18 without any detectable anogenital 
quadrivalent-vaccine type DNA and 73/506 (14.4%) were seropositive for HPV16/18 with 
detectable anogenital quadrivalent-vaccine type DNA. The association between anal 
HPV16/18 DNA detection and HPV16/18 seropositivity (aOR=3.05; 95% CI 1.75-5.30) was 
stronger than for external genital (aOR=2.03; 95% CI 1.13-3.65). Anogenital LR-HPV 
(aOR=1.09; 95% CI 0.67-1.79) and external genital quadrivalent-vaccine type DNA detection 
(aOR=1.55; 95% CI 0.96-2.50) were not associated with HPV16/18 seropositivity. 
Furthermore there were no associations between DNA detection in oral and urine 
specimens (HPV16, HPV18, bivalent-vaccine types, LR-HPV, quadrivalent-vaccine types, 9-
valent vaccine types and HR-HPV) and seropositivity. 
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TABLE 26. ASSOCIATION OF HPV DNA DETECTION WITH HPV ANTIBODY DETECTION IN MSM, FOR ANTI-HPV16 AND, SEPARATELY, FOR ANTI-
HPV18 
 
 HPV16 HPV18 
 Seronegative 
n (%) 
Seropositive 
n (%) 
OR 95% CI aORa  95% CI Seronegative 
n (%) 
Seropositive 
n (%) 
OR 95% CI aORa 95% CI 
HPV16 DNA detected             
Anal             
No 295 (76.2) 92 (23.7) 1 - 1 - 324 (83.7) 63 (16.3) 1 - 1 - 
Yes 21 (38.2) 34 (61.8) 5.19 (2.87-9.39) 4.84 (2.62-8.96) 39 (70.9) 16 (29.09) 2.11 (1.11-4.01) 1.81 (0.92-3.56) 
External genital             
No 284 (72.8) 106 (27.2) 1 - 1 - 325 (83.3) 65 (16.7) 1 - 1 - 
Yes 21 (47.7) 23 (52.3) 2.93 (1.56-5.52) 2.78 (1.43-5.44) 34 (77.3) 10 (22.7) 1.47 (0.69-3.12) 1.24 (0.55-2.82) 
Any anogenital siteb             
No 324 (75.5) 105 (24.5) 1 - 1 - 362 (84.4) 67 (15.6) 1 - 1 - 
Yes 30 (44.8) 37 (55.2) 3.81 (2.24-6.46) 3.58 (2.05-6.23) 49 (73.1) 18 (26.9) 1.98 (1.09-3.62) 1.71 (0.90-3.24) 
Oral             
No 120 (71.4)  48 (28.6) N/A    138 (82.1)  30 (17.9) N/A    
Yes   1 (100.0)   0 (0.0) N/A N/A N/A N/A   1 (100.0)   0 (0.0) N/A N/A N/A N/A 
HPV18 DNA detected             
Anal             
No 305 (72.3) 117 (27.7) 1 - 1 - 351 (83.2) 71 (16.8) 1 - 1 - 
Yes 11 (55.0) 9 (45.0) 2.13 (0.86-5.28) 1.62 (0.59-4.44) 12 (60.0) 8 (40.0) 3.30 (1.30-8.36) 2.59 (0.89-7.53) 
External genital             
No 293 (70.4) 123 (29.6) 1 - 1 - 347 (83.4) 69 (16.6) 1 - 1 - 
Yes 12 (66.7) 6 (33.3) 1.19 (0.44-3.25) 1.04 (0.34-3.18) 12 (66.7) 6 (33.3) 2.51 (0.91-6.93) 1.84 (0.59-5.72) 
Any anogenital siteb             
No 334 (72.0) 130 (28.0) 1 - 1 - 391 (84.3) 73 (15.7) 1 - 1 - 
Yes 20 (62.5) 12 (37.5) 1.54 (0.73-3.24) 1.29 (0.57-2.91) 20 (62.5) 12 (37.5) 3.21 (1.51-6.86) 2.71 (1.17-6.27) 
Oral             
No 121 (71.6)  48 (28.4) N/A    139 (82.2)  30 (17.8) N/A    
Yes 0 (0.0) 0 (0.0) N/A N/A N/A N/A 0 (0.0) 0 (0.0) N/A N/A N/A N/A 
Abbreviations: aOR=adjusted odds ratio, N/A= not applicable.  aAdjusted for age and lifetime number of partners. bIn MSM with at least one anogenital sample adequate for PCR and adequate serum 
sample. Bold formatting represents HPV type-specific associations. 
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TABLE 27. ASSOCIATION OF HPV DNA DETECTION WITH ANTI-HPV16/18 ANTIBODY DETECTION IN 
MSM  
 HPV16/18 
Risk factor Seronegative  
n (%) 
Seropositive  
n (%) 
OR 95% CI aORa  95% CI 
Bivalent- vaccine type HPV DNA detected       
Anal (N=442)       
No 303 (69.7) 132 (30.3) 1 - 1 - 
Yes 29 (40.8)  42 (59.2) 3.48 (2.06-5.87) 3.05 (1.75-5.30) 
External genital (N=434)       
No 303 (67.9) 143 (32.1) 1 - 1 - 
Yes 29 (48.3)  31 (51.7) 2.21 (1.27-3.83) 2.03 (1.13-3.65) 
Any anogenital siteb  (N=496)       
No 289 (69.8) 125 (30.2) 1 - 1 - 
Yes 43 (46.7)  49 (53.3) 2.63 (1.66-4.18) 2.38 (1.46-3.89) 
LR-HPV (HPV6/11) DNA detected       
Anal       
No 291 (66.4) 147 (33.6) 1 - 1 - 
Yes 41 (60.3)  27 (39.7) 1.33 (0.78-2.26) 1.16 (0.66-2.04) 
External genital       
No 298 (65.8) 155 (34.2) 1 - 1 - 
Yes 34 (64.2)  19 (35.8) 1.03 (0.57-1.88) 1.07 (0.57-2.00) 
Any anogenital siteb       
No 274 (66.3) 139 (33.7) 1 - 1 - 
Yes 58 (62.4)  35 (37.6) 1.18 (0.74-1.89) 1.09 (0.67-1.79) 
Quadrivalent- vaccine type HPV DNA detected     
Anal       
No 267 (70.6) 111 (29.4) 1 - 1 - 
Yes 65 (50.8)  63 (49.2) 2.49 (1.63-3.81) 2.15 (1.37-3.37) 
External genital       
No 273 (68.1) 128 (31.9) 1 - 1 - 
Yes 59 (56.2)  46 (43.8) 1.62 (1.03-2.54) 1.55 (0.96-2.50) 
Any anogenital siteb       
No 243 (70.6) 101 (29.4) 1 - 1 - 
Yes 89 (54.9)  73 (45.1) 1.98 (1.34-2.91) 1.79 (1.19-2.71) 
9-valent- vaccine type HPV DNA detected       
Anal       
No 238 (72.3)  91 (27.7) 1 - 1 - 
Yes 94 (53.1)  83 (46.9) 2.56 (1.71-3.83) 2.11 (1.38-3.23) 
External genital       
No 245 (70.4) 103 (29.6) 1 - 1 - 
Yes 87 (55.1)  71 (44.9) 1.93 (1.29-2.90) 1.66 (1.08-2.55) 
Any anogenital siteb       
No 203 (72.8)  76 (27.2) 1 - 1 - 
Yes 129 (56.8)  98 (43.2) 2.04 (1.40-2.97) 1.73 (1.16-2.58) 
HR-HPV DNA detected       
Anal       
No 237 (72.7)  89 (27.3) 1 - 1 - 
Yes 95 (52.8)  85 (47.2) 2.66 (1.77-3.98) 2.19 (1.43-3.36) 
External genital       
No 240 (71.4)  96 (28.6) 1 - 1 - 
Yes 92 (54.1)  78 (45.9) 2.14 (1.43-3.20) 1.81 (1.18-2.78) 
Any anogenital siteb       
No 204 (75.8)  65 (24.2) 1 - 1 - 
Yes 128 (54.0) 109 (46.0) 2.71 (1.84-3.97) 2.28 (1.53-3.42) 
Analyses were restricted to MSM with respective DNA and serum samples adequate for HPV testing.There were no statistically 
significant associations between urine or oral HPV DNA detection and HPV16/18 seropositivity (for HPV16, HPV18, bivalent 
HPV types, HPV6/11, quadrivalent HPV types, 9-valent HPV types and HR-HPV types). aAdjusted for age and lifetime number of 
partners. bIn MSM with at least one anogenital sample adequate for PCR and adequate serum sample. Bold formatting 
represents HPV type-specific associations. 
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6.4 KEY FINDINGS 
65.6% of HPV-MSM-MMC participants had no detectable antibodies to HPV16 and/or 
HPV18 (Table 21). Of the 174 HPV16/18 seropositive MSM, 49 (28.2%) also had detectable 
anogenital bivalent-vaccine type HPV DNA and 73 (42.0%) also had detectable quadrivalent-
vaccine type HPV DNA in at least one anogenital specimen (Table 27). Using the results from 
Table 27, Figure 50 shows that in the overall sample of 522 MSM, 174 (33.3%) were 
seropositive (anti-HPV16/18) and 101/522 (19.3%) were seropositive in the absence of any 
detectable HPV DNA (HPV6/11/16/18) at any site. Having accounted for the 170 MSM with 
HPV DNA detected at one or more sites in chapter 5 (Table 15), the remaining 251/522 
(48.1%) had no detectable markers for HPV6/11/16/18 in any specimen type (Figure 50).  
HIV status, number of anal partners in the last year, recent receptive anal sex and position 
during condomless sex in the last year were associated with seropositivity after adjusting for 
age and lifetime number of partners. Number of lifetime partners was associated with 
seropositivity after adjusting for age but not after adjusting for number of anal partners in 
the last year, suggesting that recent partners are more important predictors of HPV16/18 
seropositivity than partners over a year ago. 
Anogenital HPV DNA detection was strongly associated with same HPV type seropositivity 
and for HPV16 this effect was stronger for DNA detected in the anal sample compared to 
the external genital sample. 
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FIGURE 50. DISTRIBUTION OF QUADRIVALENT-VACCINE TYPE HPV DNA AND HPV16/18 SEROPOSITIVITY IN 522 HPV-MSM-MMC PARTICIPANTS 
 
1 square= 1 participant. This chart updates  Figure 38, page 141 to include serology results in HPV-MSM-MMC participants. Results are adapted from Table 27 by including all participants (n= 522) in 
the denominator (not just MSM who have specimens adequate for HPV testing). Abbreivations: HPVa/b= HPV type a and/or HPV type b. NB. The denominator includes all participants, so those with 
no evidence of HPV include those men without a complete set of adequate samples. All participants had at least one adequate serum, oral or anogenital sample. 
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6.5 FINDINGS IN CONTEXT 
Figure 51 shows a random-effects meta-analysis of eight studies measuring HPV16 serum 
antibodies in MSM and includes the findings from this chapter. Three of these studies 
sampled from MSM populations in the Netherlands. The random-effects pooled meta-
analysis revealed high heterogeneity between study estimates, even within each HIV 
stratum, that was partly explained by the median age of study participants in a meta-
regression (adjusted R2=40%; p=0.05). 
Different assays for antibody detection are likely to introduce heterogeneity to results. Not 
only is the type of antibody response being measured variable, depending on target 
epitope(s), so that the efficacy of detected antibodies may be different, but also the variable 
reagents and methods have prevented the establishment of standardised cut-off values for 
detection resulting in variable assay sensitivity203. 
6.6 STRENGTHS AND LIMITATIONS 
There are no estimates of the sensitivity and specificity of seropositivity for detecting recent 
or lifetime HPV infections. Only one study has estimated the rate of HPV seroconversion in 
men. Following penile HPV16 infection in heterosexual men, only 13% (95% CI 6.6%-24.8%) 
seroconverted by 24 months post-infection85. This is likely to be a considerable 
underestimate of seroconversion rate for MSM, in whom anal HPV infections predominate, 
compared to heterosexual men, in whom the majority of infections are penile65,179, with anal 
infections having a stronger association with seropositivity than penile infections204. If the 
estimate of HPV16 seroprevalence in this chapter of 28% only represents 13% of those 
exposed in the last two years, with no waning immunity, this would predict the entire MSM 
at MMC population having been twice exposed in that time.  There are no data on duration 
of detectable serum antibodies in men, but they are thought to last for years in women205. 
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FIGURE 51. STUDIES MEASURING HPV16 SEROPREVALENCE IN MSM 
  
+Studies conducted in Amsterdam, The Netherlands. References: Alberts (2015)206, Mooij (2013)207, van Rijn (2014)116, Goldstone (2011) quadrivalent-vaccine trial population was selected as low-risk 
on age, lifetime number of partners (<5) and history of HPV-related disease variables193.  Hagensee (1997)88, Sharma (2013)208, Lu (2011)209, Heilenberg (2010)210. Bubble size represents sample size.
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7. HPV-MSM-MMC STUDY: HPV6/11, ANOGENITAL WARTS 
& OTHER SEXUALLY TRANSMITTED INFECTIONS  
In this chapter, I present results relating to anogenital warts (AGW) as a proxy measure for 
exposure to HPV6/11. I first present prevalence estimates of AGW and examine the burden 
of unreported AGW. I then examine factors associated with AGW, including HPV infection 
and other STIs and HPV seropositivity. 
7.1 OBJECTIVES  
1. To estimate the prevalence of AGW in MSM attending MMC 
2. To estimate the sensitivity and specificity of a patient-suspected episode of AGW for 
the  detection of diagnosed and SHAAPT-coded AGW cases 
3. To estimate the age-specific prevalence of anogenital HPV6/11 DNA detection and 
AGW diagnoses 
4. To examine demographic and behavioural associations with AGW 
5. To examine the association between AGW and current HPV infection and HPV16/18 
seropositivity  
6. To estimate the prevalence of STIs in MSM attending MMC 
7. To examine the association between STIs and markers for HPV exposure, including 
current anogenital HPV infection (HPV6/11 and HR-HPV), and prior exposure 
(history of AGWs and HPV16/18 seropositivity) 
8. To discuss biases to be considered when interpreting the findings from this chapter  
7.2 METHODS 
Methods employed to meet the objectives are described in chapter 4. In particular, the 
statistical methods are described on page 97. 
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7.3 RESULTS 
DIAGNOSED AND SUSPECTED ANOGENITAL WARTS 
In total 157/522 (30.2%; 95% CI 26.3-34.3) MSM had received or reported having received 
an AGW diagnosis in their lifetime and 48 men (9.4%; 95% CI 7.0-12.3) reported having had 
an AGW diagnosis in the last year (Table 28 and Figure 52). Of 504 participants, 98 (19%) 
reported that they had had AGW episodes in their lifetime for which they did not access 
health services. 
TABLE 28. PREVALENCE OF DIAGNOSED AND SUSPECTED AGW EPISODES IN 522 HPV-MSM-MMC 
PARTICIPANTS 
 Total; N=522 
 n % (of total) 95% CI 
TOTAL DIAGNOSED AGW 157 30.2 26.3-34.3 
Over a year ago  without a diagnosis at visit 100 19.2 15.9-22.8 
Over a year ago  with a diagnosis at visit 4 0.8 0.2-2.0 
In the last year without a diagnosis at visit 36 6.9 4.9-9.4 
In the last year with a diagnosis at visit 12 2.3 1.2-4.0 
New diagnosis at visit (never before) 4 0.8 0.2-2.0 
New diagnosis at visit with missing questionnaire data 1 0.2 0.0-1.1 
    
 n % (of 504) 95% CI 
TOTAL SUSPECTED  undiagnosed AGW in lifetime 98 19.4 16.1-23.2 
Abbreviations: AGW=anogenital warts. Suspected AGW = Participant reported having had symptoms of AGW for which they 
did not access health services so did not receive a diagnosis.   
175  
 
FIGURE 52. DISTRIBUTION OF AGW DIAGNOSES IN 522 HPV-MSM-MMC PARTICIPANTS 
As a result of missing CASI survey data and item non-response, there was inconsistency in the size of the denominator for each 
measure of AGW. Abbreviations: AGW= anogenital warts, MSM= men who have sex with men. 
In order to estimate the proportion of those episodes without health service use which 
represent “true” AGW episodes, the association of suspected AGW with diagnosed AGW 
episodes was examined. Fifty-three men (10.7%; 95% CI 8.3-13.8) attended the clinic 
because they suspected they had genital warts of whom 13 (25%) received a warts diagnosis 
at the visit. In the patient records of the 40 MSM without a corresponding AGW SHAAPT 
code, it was recorded that at least five had had AGW visualised on exam. Where AGWs were 
not seen on exam, among a variety of lesions, haemorrhoids and anal tags were recorded.  
A further seven men received a warts diagnosis having attended the clinic for other reasons. 
A suspected AGW at visit was 65% sensitive (95% CI 40.8-84.6) and 92% specific (95% CI 
88.9-94.1) for the detection of a diagnosed and SHAAPT-coded AGW episode (Box 7).  
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BOX 7. SENSITIVITY AND SPECIFICITY OF A SUSPECTED AGW EPISODE FOR THE DETECTION OF A 
DIAGNOSED AND SHAAPT-CODED AGW EPISODE 
          
  Diagnosis of AGW at visit  
 
Suspec
ted AG
W 
  
 +ve -ve Total  𝑆𝑆𝐴𝐴𝑛𝑛𝑠𝑠𝑠𝑠𝐴𝐴𝑠𝑠𝑆𝑆𝑠𝑠𝐴𝐴𝑆𝑆 = 1313 + 7 = 0.65 
 +ve 13 38 51  
 -ve 7 431 438  𝑆𝑆𝑝𝑝𝐴𝐴𝑐𝑐𝑠𝑠𝑆𝑆𝑠𝑠𝑐𝑐𝑠𝑠𝐴𝐴𝑆𝑆 = 43138 + 431 = 0.92 
  Total 20 469 489         
Figure 53 shows that in MSM with an AGW diagnosis before the clinic visit, the median 
number of diagnosed episodes was one (IQR 1-2) and the median number of AGW 
treatments was one, with a wider distribution (IQR 1-3) indicating that the number of 
treatments per episode was greater than one. In the 98 participants who reported at least 
one suspected AGW episode (without accessing health services), the median number of 
suspected episodes was one (IQR: 1-2).  
FIGURE 53. HISTOGRAMS SHOWING THE DISTRIBUTION OF LIFETIME NUMBER OF AGW EPISODES  
 
*Of MSM reporting at least one lifetime diagnosis of AGW (n=152, not including those diagnosed at study visit). **Of MSM 
reporting at least one suspected AGW episode in their lifetime (n=97) 
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AGE-SPECIFIC PREVALENCE OF AGW 
In chapter 5, the prevalence of HPV6/11 was 18.6% (Table 14, page 119). Figure 54 shows 
the lack of an age-association with a current anogenital HPV6/11 infection or AGW 
diagnoses at study visit. Eighteen percent (3/17) of 18 to 20 year old MSM received an AGW 
diagnosis at the study visit with wide confidence intervals (95% CI 4-43) compared to 3.5% 
of those older than 20 (18/505; 95% CI 2.1-5.6%). As expected, increasing age group was 
associated with a history of AGW (p-trend 0.03). 
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FIGURE 54. AGE-SPECIFIC PREVALENCE OF ANOGENITAL HPV6/11 INFECTION AND DIAGNOSED AGW 
 
Data is available in Appendix III, Appendix table 3, page 302.  
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FACTORS ASSOCIATED WITH AGW 
Variables examined for their association with AGW history are displayed in Table 29 and 
Table 30. Variables found to be associated with AGW or other markers of HPV exposure are 
displayed in Figure 55. In this section, age was modelled as a continuous variable and was 
again shown to be significantly associated with a history of anogenital warts (OR=1.06; 95% 
CI 1.02-1.09) but the association was not statistically significant after adjusting for lifetime 
partner numbers (OR=1.04; 95% CI 1.00-1.07). No other demographic or lifestyle factors 
were associated with a history of AGW. 
Table 30 shows that a number of sexual behaviour factors were associated with a history of 
AGW. More than 30 lifetime partners was associated with a history of AGW (OR=2.83; 95% 
CI 1.80-4.46) even after adjusting for age (aOR=2.49; 95% CI 1.55-3.99).  
Increasing partner numbers were associated with AGW: at least ten anal partners (in total 
(OR=1.68; 95% CI 1.14-2.49), new partners (OR=1.80; 95% CI 1.20-2.70) and partners 
without a condom (OR=2.87; 95% CI 1.38-6.00) in the last year. Number of recent partners 
was correlated with lifetime partners and, after adjusting for age and lifetime partners, total 
anal partners and new anal partners in the last year were no longer statistically significantly 
associated with AGW (aOR=1.20; 95% CI 0.77-1.85 and aOR=0.91-2.15, respectively). 
However, recent condomless partner numbers remained significant predictors of AGW 
(aOR=2.29; 1.08-4.86). 
Age of most recent partner (OR per year=1.05; 95% CI 1.03-1.08; aOR per year=1.04; 95% CI 
1.02-1.07) and overlapping of any of the three most recent partnerships (OR=1.67; 95% CI 
1.13-2.46; aOR=1.56; 95% CI 1.04-2.32) increased the odds of AGW. 
Vaginal sex in the last year (OR=1.79; 95% CI 0.85-3.79; aOR=3.09; 95% CI 1.34-7.15) and 
oral sex with a woman in the last year (OR=2.05; 95% CI 0.95-4.42; aOR=3.55; 95% CI 1.52-
8.30) were associated with a history of AGW, but only after adjusting for age and number of 
lifetime partners. 
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TABLE 29. DEMOGRAPHIC AND LIFESTYLE RISK FACTORS FOR AGW  
 
Risk factor History of diagnosed AGWa   
 
No  
N (%) 
Yes  
n (%) OR 95% CI aORb 95% CI 
Each additional year in age   1.06 (1.02-1.09) 1.04 (1.00-1.07) 
Ethnic group       
White 266 (69.8) 115 (30.2) 1 - 1 - 
Black  41 (61.2)  26 (38.8) 1.47 (0.86-2.51) 1.75 (1.00-3.08) 
Asian & SE Asian  36 (70.6)  15 (29.4) 0.96 (0.51-1.83) 1.07 (0.55-2.07) 
Born in the UK       
No 186 (70.2)  79 (29.8) 1 - 1 - 
Yes 160 (67.5)  77 (32.5) 1.13 (0.78-1.65) 1.14 (0.77-1.68) 
Currently smoke       
No 249 (70.3) 105 (29.7) 1 - 1 - 
Yes  96 (65.3)  51 (34.7) 1.26 (0.84-1.90) 1.32 (0.86-2.01) 
Increasing or higher risk alcohol drinking (AUDIT-C)     
No 118 (69.4)  52 (30.6) 1 - 1 - 
Yes 225 (69.0) 101 (31.0) 1.02 (0.68-1.52) 1.04 (0.69-1.57) 
Currently employed       
No  79 (75.2)  26 (24.8) 1 - 1 - 
Yes 267 (67.3) 130 (32.7) 1.48 (0.91-2.42) 1.29 (0.77-2.15) 
Years of education post-16       
None   10 (76.9)   3 (23.1) 1 - 1 - 
Up to 2 years  43 (69.4)  19 (30.6) 1.47 (0.36-5.96) 1.79 (0.44-7.38) 
3 years or more 225 (65.6) 118 (34.4) 1.75 (0.47-6.47) 2.03 (0.54-7.59) 
Sexual orientation       
Gay/homosexual 317 (69.2) 141 (30.8) 1 - 1 - 
Bisexual  29 (67.4)  14 (32.6) 1.09 (0.56-2.12) 1.72 (0.84-3.55) 
Circumcised       
No 243 (68.6) 111 (31.4) 1 - 1 - 
Yes 102 (70.3)  43 (29.7) 0.92 (0.61-1.41) 0.96 (0.62-1.48) 
Abbreviations: AGW= anogenital warts, SE Asian=South East Asian, AUDIT-C=Alcohol Use Disorders Identification Test 
Consumption.  aincludes episodes diagnosed at study visit. baOR is adjusted for age and lifetime number of partners, except for 
age where only adjusted for lifetime number of partners 
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TABLE 30. SEXUAL BEHAVIOUR RISK FACTORS FOR AGW DIAGNOSES CONTINUED.  
 
Risk factor History of diagnosed AGWa   
 
No  
n (%) 
Yes 
n (%) OR 95% CI aORb 95% CI 
Number of lifetime male partners (anal and oral sex)    
<31 139 (82.2)  30 (17.8) 1 - 1 - 
>=31 206 (62.0) 126 (38.0) 2.83 (1.80-4.46) 2.49 (1.55-3.99) 
Number of male sex partners in the last year       
Male anal sex partners       
<10 196 (73.7)  70 (26.3) 1 - 1 - 
>=10 130 (62.5)  78 (37.5) 1.68 (1.14-2.49) 1.20 (0.77-1.85) 
New anal sex partners       
<10 228 (73.1)  84 (26.9) 1 - 1 - 
>=10  95 (60.1)  63 (39.9) 1.80 (1.20-2.70) 1.40 (0.91-2.15) 
Anal sex partners without a condom       
<10 310 (70.3) 131 (29.7) 1 - 1 - 
>=10  14 (45.2)  17 (54.8) 2.87 (1.38-6.00) 2.29 (1.08-4.86) 
Exclusively oral sex partners       
<10 226 (72.2)  87 (27.8) 1 - 1 - 
>=10  88 (63.3)  51 (36.7) 1.51 (0.98-2.30) 1.11 (0.70-1.76) 
Each additional year of age at first sex with a man    
Oral    0.99 (0.94-1.04) 0.99 (0.94-1.05) 
Receptive anal   1.00 (0.96-1.05) 0.99 (0.94-1.05) 
Oral sex with a man in last 3 months       
No  12 (75.0)   4 (25.0) 1 - 1  
Yes 330 (68.8) 150 (31.3) 1.36 (0.43-4.30) 1.12 (0.34-3.64) 
Receptive anal sex with a man in last 3 months    
No 121 (72.9)  45 (27.1) 1 - 1 - 
Yes 218 (67.1) 107 (32.9) 1.32 (0.87-1.99) 1.31 (0.85-2.01) 
Insertive anal sex with a man in last 3 months    
No  75 (69.4)  33 (30.6) 1 - 1 - 
Yes 255 (68.2) 119 (31.8) 1.06 (0.67-1.69) 0.90 (0.55-1.45) 
Vaginal sex in the last year       
No 258 (71.3) 104 (28.7) 1 - 1 - 
Yes  18 (58.1)  13 (41.9) 1.79 (0.85-3.79) 3.09 (1.34-7.15) 
Oral sex with a woman in the last year       
No 263 (71.7) 104 (28.3) 1 - 1 - 
Yes  16 (55.2)  13 (44.8) 2.05 (0.95-4.42) 3.55 (1.52-8.30) 
Anal sex with a woman in the last year       
No 275 (71.1) 112 (28.9) 1 - 1 - 
Yes   4 (57.1)   3 (42.9) 1.84 (0.41-8.36) 2.50 (0.51-12.34) 
Position when having anal sex without a condom in the last year    
Insertive only  56 (73.7)  20 (26.3) 1 - 1 - 
Receptive or versatile 133 (62.1)  81 (37.9) 1.71 (0.95-3.05) 1.73 (0.95-3.16) 
 
182  
 
TABLE 30. SEXUAL BEHAVIOUR RISK FACTORS FOR AGW DIAGNOSES CONTINUED.  
 
Risk factor History of diagnosed AGWa   
 
No  
n (%) 
Yes 
n (%) OR 95% CI aORb 95% CI 
Each additional year at first attending a sexual health clinic 0.97 (0.93-1.00) 0.90 (0.86-0.95) 
Use of drugs in anus/rectum ever       
No 317 (70.0) 136 (30.0) 1 - 1 - 
Yes  29 (59.2)  20 (40.8) 1.61 (0.88-2.94) 1.27 (0.68-2.35) 
Condom use with most recent partner       
Always 163 (67.4)  79 (32.6) 1 - 1 - 
Not always 182 (70.8)  75 (29.2) 0.85 (0.58-1.24) 0.89 (0.60-1.32) 
Most recent male partner (oral or anal) 
 
      
Each additional year of age of partner   1.05 (1.03-1.08) 1.04 (1.02-1.07) 
Each additional day since last having sex with partner  1.00 (0.99-1.00) 1.00 (0.99-1.00) 
Relationship type with most recent partner       
Regular 170 (68.8)  77 (31.2) 1 - 1 - 
Casual 167 (70.2)  71 (29.8) 0.94 (0.64-1.38) 0.93 (0.63-1.39) 
Relationship is continuing with most recent partner    
No 172 (73.2)  63 (26.8) 1 - 1 - 
Yes 173 (65.5)  91 (34.5) 1.44 (0.98-2.11) 1.39 (0.94-2.06) 
Concurrency between any of the 3 most recent partners    
No 167 (74.9)  56 (25.1) 1 - 1 - 
Yes 179 (64.2) 100 (35.8) 1.67 (1.13-2.46) 1.56 (1.04-2.32) 
Abbreviations: AGW= anogenital warts.  aincludes episodes diagnosed at study visit. baOR=adjusted odds ratio; adjusted for age 
and lifetime number of partners. 
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FIGURE 55. SELECTED FACTORS AND THEIR ASSOCIATION WITH A HISTORY OF DIAGNOSED AGW 
 
Models adjusted for lifetime number of partners (anal and oral) and age, except for lifetime partners which was only adjusted 
for age. 
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ASSOCIATION BETWEEN AGW AND OTHER MEASURES OF HPV INFECTION 
Of the 157 MSM with a lifetime diagnosis of AGW, 53 (33.8%) did not have detectable 
HPV6/11/16/18 DNA or antibodies in any specimen, 64 (40.8%) also had an anogenital 
HPV6/11/16/18 infection, one (0.64%) had an oral HPV6/11/16/18 infection and 68 (43.3%) 
were seropositive for HPV16/18.  
In Table 31, a history of AGW is separated into episodes at visit and older episodes (over a 
year ago), to introduce time since diagnosis into the relationship between markers for HPV 
exposure and AGW. A current anogenital HPV6/11 infection was associated with a history of 
AGW (OR=2.11; 95% CI 1.33-3.34; aOR=2.03; 95% CI 1.25-3.29) and an AGW diagnosis at 
visit (OR=3.52; 95% CI 1.44-8.62; aOR=3.94; 95% CI 1.57-9.93) even after adjusting for age 
and lifetime number of partners. A current anogenital HPV6/11 infection was not associated 
with an AGW diagnosis over a year ago. There were 12 participants with an AGW diagnosis 
at visit who had undetectable anogenital HPV6/11.  
On the other hand a current anogenital HPV16/18 infection was not associated with a 
history of AGW (OR=1.09 95% CI 0.67-1.78; aOR=1.04 95% CI 0.63-1.71) or a diagnosis at 
visit (OR=1.18; 95% CI 0.48-2.91; aOR=1.31; 95% CI 0.51-3.39). There were too few cases of 
oral HPV infection to assess the association with AGW.  
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TABLE 31. ASSOCIATION OF HPV DNA OR ANTIBODY DETECTION WITH DIAGNOSED AGW IN MSM  
 MSM with AGW history  
(including a diagnosis at visit) 
AGW diagnosis at visit AGW diagnosis over a year ago 
Risk factor No 
(n) 
Yes 
(n) 
OR 95% CI aOR
a  
95% CI No 
(n) 
Yes 
(n) 
OR 95% CI aO
Ra  
95% CI No 
(n) 
Yes 
(n) 
OR 95% CI aORa  95% CI 
HPV16/18 serum antibody detectedb                  
No 246 84 1 - 1 - 319 13 1 - 1 - 240 53 1 - 1 - 
Yes 106 68 1.88 1.27-2.78 1.49 0.98-2.25 166 8 1.18 0.48-2.91 1.31 0.51-3.39 101 36 1.61 1.00-2.62 1.10 0.66-1.83 
Anogenital HPV16/18 DNA detectedc                   
No 290 125 1 - 1 - 399 18 1 - 1 - 281 73 1 - 1 - 
Yes 64 30 1.09 0.67-1.76 0.99 0.60-1.63 91 3 0.73 0.21-2.53 0.79 0.22-2.75 62 18 1.12 0.62-2.01 0.98 0.53-1.81 
Anogenital HPV6/11 DNA detectedc 
                  
No 301 113 1 - 1 - 404 12 1 - 1 - 292 79 1 - 1 - 
Yes 53 42 2.11 1.33-3.34 2.03 1.25-3.29 86 9 3.52 1.44-8.62 3.94 1.57-9.93 51 12 0.87 0.44-1.71 0.70 0.35-1.42 
Oral HPV16/18 DNA detectedd 
                  
No 110 53     154 10     110 26     
Yes 2 0 n/a n/a n/a n/a 2 0 n/a n/a n/a n/a 2 0 n/a n/a n/a n/a 
Oral HPV6/11 DNA detectedd                   
No 110 52 1 - 1 - 153 10     110 26     
Yes 2 1 1.06 0.09-11.93 0.87 0.07-10.41 3 0 n/a n/a n/a n/a 2 0 n/a n/a n/a n/a 
HPV16/18 serum or anogenital HPV16/18e                    
No 209 71 1 - 1 - 270 12 1 - 1 - 203 44 1 - 1 - 
Yes 135 79 1.72 1.17-2.54 1.31 0.87-1.99 205 9 0.99 0.41-2.39 1.08 0.43-2.76 132 43 1.50 0.94-2.41 1.01 0.61-1.67 
HPV16/18 serum & anogenital HPV16/18e                    
No 312 133 1 - 1 - 428 19 1 - 1 - 306 78 1 - 1 - 
Yes 32 17 1.25 0.67-2.32 1.22 0.63-2.34 47 2 0.96 0.22-4.24 1.03 0.23-4.62 29 9 1.22 0.55-2.68 1.09 0.48-2.47 
a Adjusted for age and lifetime number of partners. b In MSM with an adequate serum sample. c In MSM with at least one anogenital sample adequate for PCR. dIn MSM with an adequate oral sample. 
eIn MSM with both an adequate anogenital sample and an adequate serum sample. MSM with missing observations for any AGW variable were excluded.
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PREVALENCE OF SEXUALLY TRANSMITTED INFECTIONS 
Table 32 displays the prevalence of individual STIs in participants. Gonorrhoea was the most 
common STI diagnosed at the visit, in 11.7% of MSM (95% CI 9.1-14.8) followed by HIV 
(5.4%; 95% CI 3.6-7.7), herpes simplex virus (HSV; 2.7%; 95% CI 1.5-4.5), chlamydia (2.7%; 
95% CI 1.5-4.5), and syphilis, (1.0%; 95% CI 0.3-2.2). There were two diagnoses of primary, 
one of secondary and two of early latent syphilis. The prevalence of other STIs diagnosed at 
visit was 50/522 (9.6%; 95% 7.0-12.1). 
TABLE 32. PREVALENCE OF STI DIAGNOSES IN THE LAST YEAR AND AT VISIT IN 522 HPV-MSM-MMC 
PARTICIPANTS 
 N n % 95% CI 
HIV diagnosis ever 522 28 5.4 3.6-7.7 
Diagnosis code at visit    
Gonorrhoea 522 61 11.7 9.1-14.8 
Chlamydia 522 14 2.7 1.5-4.5 
HSV 522 14 2.7 1.5-4.5 
Syphilis 522 5 1.0 0.3-2.2 
Multiple (≥2) STIsa 522 6 1.2 0.4-2.5 
Other STIb 522 50 9.6 7.2-12.4 
Reported diagnosis in the last year    
Gonorrhoea 489 87 17.8 14.5-21.5 
Chlamydia 489 70 14.3 11.3-17.7 
HSV 489 20 4.1 2.5-6.3 
Syphilis 489 18 3.7 2.2-5.8 
Multiple (≥2) STIsa 489 40 7.7 5.5-10.3 
Diagnosis code at visit and reported diagnosis in the last year   
Gonorrhoea 489 16 3.3 1.9-5.3 
Chlamydia 489 6 1.2 0. 5-2.7 
HSV 489 5 1.0 0.3-2.4 
Syphilis 489 1 0.2 0.0-1.1 
Multiple (≥2) STIsa 489 1 0.2 0.0-1.1 
Total diagnoses in the last year (including visit)   
Gonorrhoea 522 132 25.3 21.6-29.3 
Chlamydia 522 78 14.9 12.0-18.3 
HSV 522 29 5. 6 3.8-7.9 
Syphilis 522 22 4.2 2.7-6.3 
Multiple (≥2) STIsa 522 54 10.3 7.9-13.3 
Abbreviations: N=denominator, n=numerator, CI=Confidence Interval, HIV=Human Immunodeficiency Virus, HSV=Herpes 
Simplex Virus, STI=Sexually Transmitted Infection. a Two or more of Gonorrhoea/Chlamydia/HSV/Syphilis. b SHAAPT code at 
visit for an STI that was not Gonorrhoea/Chlamydia/HSV/Syphilis. 
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ASSOCIATION BETWEEN STIS AND HPV 
Table 33 shows the association of STIs with AGWs and anogenital HPV6/11 infection. HIV 
status was associated with a history of AGW (OR=2.44; 95% CI 1.13-5.25) but not after 
adjusting for age and lifetime number of partners (aOR=1.83; 95% CI 0.83-4.05). Anogenital 
HPV6/11 was not associated with HIV status (OR=1.87; 95% CI 0.80-4.39; aOR=1.70; 95% CI 
0.71-4.06). A syphilis diagnosis at visit was not associated with a history of AGW (Fisher’s 
exact p=0.17) and was associated with anogenital HPV6/11 infection (Fisher’s exact p=0.04). 
Associations between STIs diagnosed in the same time period as AGW were possible from 
data presented in Table 34. The number of participants was too small to establish whether 
there was an association with STIs diagnosed at visit and an AGW diagnosis at visit, or in the 
last year. Table 34 also shows that there were associations between reporting a diagnosis of 
gonorrhoea (OR=2.61; 95% CI 1.36-5.00; aOR=2.56; 95% CI 1.31-5.01), HSV (OR=3.30; 95% CI 
1.14-9.53; aOR=3.24; 95% CI 1.10-9.53), syphilis (OR=6.67; 95% CI 2.45-18.15; aOR=6.20; 
95% CI 2.26-16.99) and reporting a diagnosis of AGW in the last year. Attending a SHC in the 
last year was not measured so it was not possible to adjust for this potential confounder.  
Table 35 shows the association of STIs with HPV16/18 seropositivity and anogenital HR-HPV 
infection.  An HIV-positive diagnosis was strongly associated with detection of HPV16/18 
antibodies (OR=3.89; 95% CI 1.69-8.91; aOR=3.26; 95% CI 1.38-7.73) and anogenital HR-HPV 
detection (OR=3.09; 95% CI 1.33-7.15; aOR=2.54; 95% CI 1.08-5.98) even after adjusting for 
age and lifetime partner numbers. A HSV diagnosis at visit was associated with detectable 
HPV16/18 antibodies (Fisher’s exact p=0.01). 
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TABLE 33. ASSOCIATIONS OF INDIVIDUAL STIS WITH DIAGNOSED AGW AND ANOGENITAL HPV6/11 INFECTION 
 History of diagnosed AGW (including visit) Anogenital HPV6/11 DNA detection 
 Yes 
(n)a 
No 
 (n) OR 95% CI 
aOR 95% CI Yes 
(n)b 
No 
 (n) OR 95% CI 
aOR 95% CI 
HIV diagnosis ever 14 14 2.44 (1.13-5.25) 1.83 (0.83-4.05) 8 20 1.87 (0.80-4.39) 1.70 (0.71-4.06) 
Diagnosis code at visit              
Gonorrhoea 20 41 1.15 (0.65-2.03) 1.29 (0.70-2.36) 15 46 1.55 (0.83-2.92) 1.52 (0.78-2.95) 
Chlamydia 6 8 1.76 (0.60-5.17) 1.97 (0.61-6.36) 3 11 1.23 (0.34-4.51) 1.38 (0.37-5.20) 
HSV 4 10 0.92 (0.29-2.99) 0.92 (0.27-3.11) 1 13 0.34 (0.04-2.62) 0.36 (0.05-2.86) 
Syphilis 3 2 3.52 (0.58-21.25) 2.54 (0.41-15.76) 3 2 6.93 (1.14-42.06) 6.34 (1.03-38.94) 
Reported diagnosis in the last year              
Gonorrhoea 32 55 1.41 (0.87-2.30) 1.20 (0.72-2.00) 20 67 1.52 (0.86-2.67) 1.39 (0.78-2.48) 
Chlamydia 29 41 1.76 (1.04-2.96) 1.45 (0.84-2.51) 15 55 1.34 (0.72-2.50) 1.19 (0.62-2.26) 
HSV 9 11 1.92 (0.78-4.73) 1.83 (0.71-4.72) 1 19 0.24 (0.03-1.80) 0.24 (0.03-1.83) 
Syphilis 10 8 2.98 (1.15-7.70) 2.53 (0.95-6.72) 5 13 1.85 (0.64-5.34) 1.68 (0.58-4.86) 
Total reported diagnosis in the last year (including visit            
Gonorrhoea 45 84 1.33 (0.87-2.04) 1.24 (0.79-1.94) 30 102 1.47 (0.90-2.39) 1.39 (0.83-2.31) 
Chlamydia 31 46 1.69 (1.03-2.80) 1.46 (0.86-2.48) 16 62 1.19 (0.65-2.17) 1.13 (0.61-2.09) 
HSV 12 16 1.79 (0.83-3.88) 1.63 (0.73-3.63) 1 28 0.15 (0.02-1.13) 0.15 (0.02-1.14) 
Syphilis 13 9 3.54 (1.48-8.48) 2.94 (1.20-7.22) 8 14 2.71 (1.10-6.66) 2.47 (1.00-6.12) 
Abbreviations AWG=anogenital warts, HSV=Herpes simplex virus, HIV=Human immunodeficiency virus, OR=odds ratio. aOR= adjusted OR; adjusted for lifetime number of sexual partners and age 
(continuous). aIn the total of 522 MSM, 157 had a history of AGW and in the 489 MSM with available survey data (diagnoses in the last year), 149 had a history of AGW.  bIn all 522 MSM, 95 had 
detectable anogenital HPV6/11 DNA and in those 489 MSM with available survey data, 86 had detectable anogenital HPV6/11 DNA. 
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TABLE 34. ASSOCIATIONS OF INDIVIDUAL STIS WITH AN AGW DIAGNOSIS AT VISIT AND A SELF-REPORTED AGW DIAGNOSIS IN THE LAST YEAR 
 AGW diagnosis at visit Reported AGW diagnosis in the last year 
 Yes 
(n)a 
No 
 (n) OR 95% CI 
aOR 95% CI Yes 
(n)b 
No 
 (n) OR 95% CI 
aOR 95% CI 
HIV diagnosis ever 1 27 0.88 (0.11-6.79) 0.98 (0.12-7.80) 5 23 2.11 (0.76-5.84) 1.95 (0.69-5.48) 
Diagnosis code at visit              
Gonorrhoea 3 58 1.27 (0.36-4.45) 1.46 (0.41-5.23) 4 53 0.67 (0.23-1.93) 0.68 (0.23-1.98) 
Chlamydia 1 13 1.88 (0.23-15.06) 2.34 (0.28-19.25) 1 12 0.76 (0.10-5.98) 0.76 (0.10-6.04) 
HSV 2 12 4.29 (0.90-20.53) 4.59 (0.93-22.65) 1 12 0.76 (0.10-5.98) 0.73 (0.09-5.79) 
Syphilis 0 5 n/a n/a n/a n/a 3 2 14.63 (2.38-89.89) 13.01 (2.08-81.29) 
Reported diagnosis in the last year              
Gonorrhoea 5 82 1.57 (0.56-4.45) 1.76 (0.61-5.11) 16 71 2.61 (1.36-5.00) 2.56 (1.31-5.01) 
Chlamydia 5 65 2.07 (0.73-5.89) 2.40 (0.82-7.09) 10 60 1.67 (0.79-3.53) 1.59 (0.74-3.43) 
HSV 1 19 1.25 (0.16-9.81) 1.17 (0.15-9.47) 5 15 3.30 (1.14-9.53) 3.24 (1.10-9.53) 
Syphilis 1 17 1.40 (0.18-11.07) 1.36 (0.17-10.89) 7 11 6.67 (2.45-18.15) 6.20 (2.26-16.99) 
Total reported diagnosis in the last year (including visit)            
Gonorrhoea 8 124 1.87 (0.76-4.62) 2.26 (0.88-5.80) 18 110 1.81 (0.97-3.37) 1.79 (0.94-3.39) 
Chlamydia 5 73 1.83 (0.65-5.15) 2.17 (0.74-6.35) 11 66 1.69 (0.82-3.48) 1.62 (0.77-3.40) 
HSV 3 26 3.04 (0.84-11.00) 3.09 (0.83-11.46) 6 22 2.72 (1.05-7.08) 2.62 (1.00-6.90) 
Syphilis 1 21 1.14 (0.15-8.93) 1.12 (0.14-8.90) 10 12 9.41 (3.82-23.20) 8.74 (3.51-21.74) 
Abbreviations AWG=anogenital warts, HSV=Herpes simplex virus, HIV=Human immunodeficiency virus, OR=odds ratio. aOR= adjusted OR; adjusted for lifetime number of sexual partners and age 
(continuous). In the total of 522 MSM, 21 had a diagnosis code for AGW at visit. In the 489 MSM with available survey data , 48 reported a diagnosis in the last year.   
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TABLE 35. ASSOCIATIONS OF INDIVIDUAL STIS WITH HPV16/18 SEROPOSITIVITY AND ANOGENITAL HR-HPV INFECTION 
 HPV16/18 seropositivity Anogenital HR-HPV DNA detection 
 Yes (n)a No 
 (n) OR 95% CI 
aOR 95% CI Yes 
(n)b 
No 
 (n) OR 95% CI 
aOR 95% CI 
HIV diagnosis ever 17 9 3.89 (1.69-8.91) 3.26 (1.38-7.73) 20 8 3.09 (1.33-7.15) 2.54 (1.08-5.98) 
Diagnosis code at visit              
Gonorrhoea 23 35 1.29 (0.74-2.27) 1.31 (0.72-2.41) 32 29 1.33 (0.78-2.27) 1.45 (0.82-2.56) 
Chlamydia 6 8 1.45 (0.49-4.24) 1.16 (0.35-3.86) 6 8 0.87 (0.30-2.55) 0.94 (0.30-2.94) 
HSV 9 4 4.47 (1.36-14.74) 5.72 (1.48-22.15) 9 5 2.14 (0.71-6.48) 2.72 (0.81-9.18) 
Syphilis 1 3 0.63 (0.07-6.14) 0.53 (0.05-5.18) 4 1 4.73 (0.52-42.57) 3.96 (0.43-36.31) 
Reported diagnosis in the last year              
Gonorrhoea 35 47 1.56 (0.96-2.54) 1.35 (0.81-2.26) 45 42 1.27 (0.80-2.02) 1.1 (0.68-1.78) 
Chlamydia 28 39 1.47 (0.87-2.49) 1.16 (0.67-2.02) 35 35 1.16 (0.70-1.92) 0.97 (0.57-1.65) 
HSV 10 9 2.22 (0.88-5.58) 2.01 (0.77-5.24) 12 8 1.74 (0.70-4.34) 1.71 (0.67-4.39) 
Syphilis 10 8 2.51 (0.97-6.48) 2.13 (0.80-5.70) 13 5 3.07 (1.08-8.75) 2.69 (0.93-7.77) 
Abbreviations AWG=anogenital warts, HSV=Herpes simplex virus, HIV=Human immunodeficiency virus, OR=odds ratio. aOR= adjusted OR; adjusted for lifetime number of sexual partners and age 
(continuous). aIn the 506 MSM with adequate serum samples, 174 were seropositive for HPV16 and/or HPV18 and in the 475 MSM with available survey data (diagnoses in the last year), 162 were 
seropositive for HPV16 and/or HPV18.  bIn all 522 MSM, 241 had detectable anogenital HR-HPV DNA and in those 489 MSM with available survey data, 229 had detectable anogenital HR-HPV DNA. 
191  
 
7.4 KEY FINDINGS 
Figure 56 updates Figure 38, page 141, and Figure 50, page 170, to show that 6.9% of 
participants in the HPV-MSM-MMC study had a history of AGW and detectable 
quadrivalent-vaccine type DNA, a further 5.6% were also seropositive to HPV16/18. A 
separate 8.4% were seropositive and had a history of AGW and a further 10.2% had a 
history of AGW in the absence of any other markers for HPV exposure. Therefore in HPV-
MSM-MMC participants, 38% had no evidence of quadrivalent-vaccine type HPV exposure 
using the combined markers of HPV DNA testing, anti-HPV16/18 serum testing and a history 
of AGW. 
 AGW episodes were a significant burden with a third of participants having had an AGW 
diagnosis in their lifetime. There was an indication of additional burden in MSM not 
accessing health services: only 25% of MSM attending the SHC because they suspected 
having an AGW episode had it confirmed with a diagnosis at visit. If 25% of suspected cases 
are indeed AGW, then 5% (25% of 19%) of this population had had additional AGW episodes 
for which they did not access health services.  
There was no indication that MSM in a particular age range were more or less at risk of 
having an anogenital HPV6/11 infection or an AGW diagnosis. The cumulative number of 
lifetime partners, which increases with age, explained the increase in prior AGW episodes 
with age.  
Number of lifetime anal, oral and condomless anal sex partners in the last year, age of most 
recent partner and concurrency within the three most recent partnerships were associated 
with a history of AGW.  
A history of AGW and a diagnosis at visit were associated with a current anogenital HPV6/11 
infection but not with an HPV16/18 infection. However there were 12 AGW diagnoses at 
visit with undetectable anogenital HPV6/11. One possible explanation for this non-
concordance could be that swabbing the surface of an AGW does not capture the HPV types 
within and responsible for lesion development211.  That current anogenital HPV6/11 
detection was not associated with AGW episodes over a year ago is supported by estimates 
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of HPV6/11 duration of infection in longitudinal studies in men, in which the median time to 
clearance is six months212. 
HIV status was not associated with an anogenital HPV6/11 infection and, after adjusting for 
age and lifetime number of partners, was not associated with a history of AGW. There were 
few statistically significant associations between STI diagnoses and markers for HPV 
exposure and the numbers for these analyses were small.  However some associations were 
identified: syphilis was associated with HPV6/11 infection and a reported AGW diagnosis in 
the last year, HSV was associated with a reported AGW diagnosis in the last year and 
HPV16/18 seropositivity and a gonorrhoea diagnosis in the last year was associated with an 
AGW diagnosis in the last year. 
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FIGURE 56. DISTRIBUTION OF HPV DNA DETECTION, SEROPOSITIVITY AND HISTORY OF AGW IN 522 HPV-MSM-MMC PARTICIPANTS 
 
1 square= 1 participant. This chart updates Figure 50, page 170, to include AGW results in HPV-MSM-MMC participants. Relevant AGW results are described on page 184 and all participants (n= 522) 
are included in the denominator. 
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7.5 FINDINGS IN CONTEXT 
The estimate of AGW prevalence of 4.1% in HPV-MSM-MMC participants was similar to that 
in MSM attending a SHC in Melbourne, Australia, between 2002 and 2013 (4.0%), despite 
Australia’s routine use of the quadrivalent vaccine in girls since 2008 and boys since 2013213. 
In 40 SHCs in the US, between 2010 and 2011, the prevalence of AGW was 7.5% in an MSM 
population with 18.2% HIV prevalence214. In HIV-positive MSM in the CARH-MEN cohort in 
Spain, the prevalence of AGW was considerably higher at 27.9%215.  
The estimate of a history of AGW of 30.2% in HPV-MSM-MMC participants is more than that 
in an internet sample of MSM in Denmark (25.2%)216 and considerably more than that 
reported by men in Britain in the Natsal-2 survey (3.6%) 217. 
It is estimated that 1/12 MSM living in London are in infected with HIV and that in England 
in 2014, among male SHC attendees, 86% (3,477/ 4,054) of syphilis diagnoses, 68% (18,029/ 
26,575) of gonorrhoea diagnoses, 21% (11,468/ 55,807) of chlamydia diagnoses, 12% 
(1,474/ 11,889) of genital herpes diagnoses and 9% (3,456/ 39,349) of genital warts 
diagnoses were among MSM218.  
7.6 STRENGTHS AND LIMITATIONS 
The denominator was not consistent across the three AGW measurements (Figure 52) so 
combining these measurements into a single measure (a history of AGW), with missing 
observations for some measures in some participants, has potential to underestimate the 
AGW burden.  
There was some potential misclassification for SHAAPT coding because all MSM who 
attended with suspected AGW are likely to have been examined but it is not routine to 
examine men for AGWs if they do not report symptoms. There was also evidence for 
incomplete reporting of AGW episodes through SHAAPT codes. Incomplete SHAAPT coding 
is more likely for AGW, which is diagnosed from clinical symptoms, than for bacterial STIs, 
such as chlamydia, which are diagnosed from laboratory tests. The data were too sparse to 
adjust for potential confounders when examining the associations of STIs and AGWs and, as 
in chapters 5 and 6, associations with behaviours that were of high prevalence would be 
difficult to detect. 
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8. HPV-MSM-MMC STUDY: POTENTIAL VACCINE UPTAKE AND 
COVERAGE  
In this chapter, I present results relating to potential vaccine uptake and health service use in 
MSM in order to inform estimates of potential vaccine coverage. I begin by estimating the 
age at first attendance at a SHC, which represents the earliest opportunity to vaccinate, and 
relate this to the age at first sexual experience. I then examine the population of first time 
attenders in terms of HPV exposure. Participants’ preferred health service for AGW diagnosis 
and treatment and Hepatitis B virus vaccination is then explored. Finally I explore potential 
uptake and barriers to uptake via HPV knowledge, STI risk perception, HBV vaccine uptake 
and reported likelihood of, and reasons for, accepting the vaccine.  
8.1 OBJECTIVES  
1. To estimate age of first attending a SHC in the UK  and examine its association with 
HPV infection, HPV seropositivity  and AGW  
2. To estimate the prevalence of HPV infection, HPV seropositivity and AGW in MSM 
attending a SHC in the UK for the first time and compare these in repeat attenders 
3. To describe types of health services used for HBV vaccination and AGW diagnosis 
and treatment in MSM attending a SHC 
4. To describe HPV knowledge, in particular, risk and expectation of HPV vaccine 
outcomes, and explore the association with HPV infection 
5. To describe reported HBV virus vaccine uptake, STI risk perception and likelihood of 
accepting an HPV vaccine and explore associations with HPV infection 
6. To examine reasons for and against reported likelihood of accepting an HPV vaccine 
 
8.2 METHODS 
Methods employed to meet the objectives are described in chapter 4. In particular, the 
basis for asking questions relating to use of health services, risk perception, vaccine 
outcome expectancy and perceived self-efficacy is described on page 82 and the 
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development of knowledge items on page 82. Furthermore, the statistical methods are 
described on page 98. 
8.3 RESULTS 
AGE AT FIRST ATTENDANCE AT SHC  
The median age at first attending a SHC in the UK was 24 (IQR 20-27) (Figure 57). Table 36 
shows that there was no difference in the mean age of first attending a SHC in the UK 
between MSM with and without detectable anogenital HPV6/11 (t=0.48, p=0.63), HPV16/18 
(t=-0.21, p=0.83), serum anti-HPV16/18 (t=-1.28, p=0.20) or suspected AGW (t=-0.55, 
p=0.58) or a history of diagnosed AGW (t=1.73, p=0.08). MSM diagnosed with AGW at study 
visit reported attending a SHC for the first time an average of two years earlier (mean=22 
years) than MSM without a diagnosis at visit (mean=24 years, t=2.18, p=0.03). 
FIGURE 57. HISTOGRAM OF AGE AT FIRST ATTENDING A SHC IN THE UK 
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TABLE 36. MEAN AGE AT FIRST ATTENDING AN SHC IN THE UK, BY MARKERS FOR HPV EXPOSURE 
Marker  of HPV exposure Mean age at first 
attending a SHC in 
the UK (95% CI) 
t-statistic p-value 
Anogenital LR-HPV DNA detection    
No (n=393)  24.3 (23.9-24.8) 0.48 0.63 
Yes (n=91) 24.1 (23.0-25.1)   
Anogenital bivalent-vaccine type DNA detection    
No (n=395) 24.3 (23.8-24.8) -0.21 0.83 
Yes (n=89) 24.4 (23.3-25.5)   
Anogenital quadrivalent-vaccine type DNA detection    
No (n=326)  24.3 (23.7-24.8) -0.19 0.85 
Yes (n=158) 24.4 (23.6-25.2)   
Anogenital 9-valent-vaccine type DNA detection    
No (n=264) 24.3 (23.7-24.9) 0.04 0.97 
Yes (n=220) 24.3 (23.6-25.0)   
Anogenital HPV16/18 seropositivity    
No (n=317) 24.1 (23.5-24.6) -1.28 0.20 
Yes (n=163) 24.7 (23.9-25.5)   
Suspected AGW at visit    
No (n=442) 24.2 (23.8-24.7) -0.55 0.58 
Yes (n=51) 24.6 (23.2-26.1)   
Diagnosed AGW at visit    
No (n=473) 24.4 (23.9-24.8) 2.18 0.03 
Yes (n=20) 21.9 (19.8-24.0)   
Diagnosed AGW in the last year    
No (n=431) 24.2 (23.8-24.7) -0.47 0.64 
Yes (n=48) 24.6 (23.1-26.1)   
History of AGW    
No (n=338) 24.5 (24.0-25.1) 1.73 0.08 
Yes (n=154) 23.7 (22.9-24.4)   
Abbreviations: SHC=sexual health clinic, LR-HPV=HPV6/11, bivalent HPV=HPV16/18, quadrivalent HPV=HPV6/11/16/18, 9-
valent HPV=HPV6/11/16/18/31/33/45/52/58, AGW= anogenital wart. 
HPV MEASUREMENT IN FIRST TIME ATTENDERS 
Of the 40 (8%) MSM who were attending a SHC in the UK for the first time when they 
participated in the study, five (13%) had detectable anogenital HPV6/11, seven (18%) had 
anogenital HPV16/18 (two with both HPV6/11 and HPV16/18), four (10%) were HPV16/18 
seropositive, one attended because he suspected he had an episode of AGW, none had an 
AGW diagnosis, and two had an AGW diagnosis over a year ago, elsewhere. Over half 
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(27/40) of first-time attenders had no evidence of exposure to quadrivalent–vaccine type 
HPV, considering history of diagnosed AGW, anogenital HPV6/11/16/18 and seropositivity 
to HPV16/18.  
Table 37 shows the distribution of markers for HPV exposure in first-time SHC attenders 
compared to repeat SHC attenders. There was no statistically significant difference in the 
detection of HR-HPV (OR=1.10; 95% CI 0.57-2.11) or quadrivalent-vaccine type (OR=1.48; 
95% CI 0.70-3.11) DNA at anogenital sites. There was a significant difference in the 
proportion seropositive for HPV16/18 who were first-time attenders compared to repeat 
attenders (Fisher’s exact p<0.05) and in the proportion reporting a history of AGW (Fisher’s 
exact p<0.05). 
TABLE 37. DISTRIBUTION OF MARKERS FOR HPV EXPOSURE, IN FIRST-TIME SHC ATTENDERS 
COMPARED TO REPEAT SHC ATTENDERS. 
 First time attenders (N=40)  
n (%) 
Repeat attenders  
n/N (%) 
Anogenital HR-HPV DNA detectiona   
No 22 (55.0) 239/454 (52.6) 
Yes 18 (45.0) 215/454 (47.4) 
Anogenital quadrivalent vaccine type DNA detectiona   
No 30 (75.0) 304/454 (67.0) 
Yes 10 (25.0) 150/454 (33.0) 
Seropositive for HPV16/18b   
No 36 (90.0) 285/449 (63.5) 
Yes 4 (10.0) 164/449 (36.5) 
History of AGW   
No 38 (95.0) 308/462 (66.7) 
Yes 2 (5.0) 154/462 (33.3) 
aAmong MSM with at least one anogenital sample adequate for PCR. bAmong MSM with a serum specimen adequate for HPV 
ELISA testing. 
TYPES OF HEALTH SERVICES USED BY MSM AT MMC 
Table 38 shows that in MSM with survey data and an anogenital sample adequate for HPV 
testing, 77.1% (381/494) had visited their GP in the last year but only 43.8% (167/381) of 
these had disclosed their sexuality. Of the 130 MSM who had ever been treated for AGW, 
the large majority 116 (89.2%) were treated at a SHC, five (3.9%) were last treated at a GP, 
and nine (6.9%) at another service reported as “… hospital” or a doctor/clinic outside the 
UK. 438/502 (87.3%) of participants had received at least one dose of HBV vaccine and the 
median number of doses received was 3 (IQR: 2-3), including booster doses.  Most HBV 
vaccinations (335/429; 78.1%) were administered in a SHC with 16.3% (70/429) being 
delivered by a GP and 7.5% (32/429) at another service, for example, in other countries. 
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HPV KNOWLEDGE 
For each knowledge question, the proportion of respondents who selected the correct 
answer is displayed in Figure 59. Only 1.2% of the sample answered all nine knowledge 
items correctly. The median number of correct answers was 5 (IQR: 3-6; mean=4.4) (Figure 
58). Difficult questions, based on lower number correctly responding, related to the efficacy 
and safety of the HPV vaccine. 
FIGURE 58. DISTRIBUTION OF THE NUMBER OF CORRECT ANSWERS AMONG THE 487 MSM WHO 
ANSWERED ALL NINE KNOWLEDGE QUESTIONS 
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FIGURE 59. DISTRIBUTION OF ANSWERS TO THE KNOWLEDGE QUESTIONS ABOUT HPV 
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ASSOCIATION OF DETERMINANTS OF VACCINE UPTAKE WITH ANOGENITAL QUADRIVALENT-
VACCINE HPV TYPE INFECTION 
There were no significant differences in health-seeking behaviour, HPV knowledge, STI risk 
perception, or expected vaccine acceptance between those with anogenital quadrivalent-
vaccine type DNA detected and those without quadrivalent-vaccine type DNA detected 
(Table 38 and Table 39).  
REPORTED LIKELIHOOD OF ACCEPTING THE HPV VACCINE 
The distribution of likelihood of accepting the 3-dose, 6-month, HPV vaccine if it was offered 
is displayed in Figure 60. Only 21/503 (4.2%) of MSM reported that they would probably or 
definitely refuse the HPV vaccine if it was offered and 292/503 (58.1%) reported that they 
would definitely accept it. Overall, 438/502 (87.3%) had received the HBV vaccine. In MSM 
who would definitely or probably accept the HPV vaccine, 371/418 (88.8%) had been 
vaccinated for HBV, in those who would possibly accept, 49/63 (78%) had received HBV 
vaccine, and for those would probably not or definitely not, 14/15 (93%) and 4/6 (67%) had 
received the HBV vaccine, respectively. History of HBV vaccination was associated with 
intention for HPV vaccine uptake (nonparametric test for trend p=0.02).  
All participants were asked to give a reason for this intention. If the response was 
“definitely”/ “probably”/ “possibly” then 168/482 (34.9%) of MSM gave a reason but if 
response was “probably not” or “definitely not” then 8/15 (57%) and 4/6 (67%) gave a 
reason, respectively. Figure 61 displays the frequency of the groups that arose from the 
open-ended free text field in which participants gave their reasons for their intentions. 
Some participants described more than one theme.  
REASONS FOR VACCINE UPTAKE LIKELIHOOD 
The most common reason, reported 98 times by the 145 MSM in the definitely/probably 
group, was for the expected outcomes (protection and health benefit). Reasons reported 
less frequently included trust in the clinic and its staff, feeling at higher risk of STIs, the 
benefit to others (reducing onward transmission) and general positivity, for example “no 
reason not to”. However this group also reasoned that more information would be needed 
before decision-making and would need evidence on vaccine safety.  
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Of the 23 MSM who gave a reason for possibly accepting the vaccine, 16 required more 
information and 10 mentioned vaccine safety. Three MSM reasoned that they were at lower 
risk so did not consider themselves in need of protection. Of the 12 MSM who wouldn’t 
accept the vaccine, and gave a reason, barriers included practical inconvenience, for 
example “I am leaving the UK in a few weeks”, general views on vaccination, for example “I 
do not take vaccines”, understanding the vaccine to be a trial drug, low risk perception and 
needing more information on vaccine safety. One man reported already having received the 
vaccine privately however he was not seropositive to HPV16/18. 
FIGURE 60. DISTRIBUTION OF REPORTED LIKELIHOOD OF ACCEPTING THE HPV VACCINE COURSE IF A, 
3-DOSE, 6-MONTH COURSE WAS OFFERED AT A SHC.  
 
Prevalence of response category is displayed with 95% CI. Denominator= 503 respondents. 
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TABLE 38. HEALTH SERVICE USE, BY ANOGENITAL QUADRIVALENT-VACCINE TYPE DETECTION, IN 495 
HPV-MSM-MMC PARTICIPANTSa 
 
Total 
 
HPV Not 
detectedb HPV Detected
b 
     
 
 
Nc % 
 
Nc % Nc % 
 
aOR 95% CI p 
Age at first attendance at UK SHC (years)      
15 to 18  54 11.2 
 
34 10.4 20 12.7 
 
1.27 (0.62-2.59) 0.50 
19 to 24  211 43.6 
 
147 45.1 64 40.5 
 
0.92 (0.56-1.53)  
25 to 29 136 28.1 
 
91 27.9 45 28.5 
 
1 -  
30 to 35  74 15.3 
 
46 14.1 28 17.7 
 
1.20 (0.66-2.19)  
36 to 39 9 1.9  8 2.5 1 0.6  0.24 (0.03-2.00)  
Visited GP in last year 
          
 
No 85 17.2
 
60 18.0 25 15.6
 
1 - 0.82 
Yes 381 77.1 
 
255 76.4 126 78.8 
 
1.18 (0.71-1.98)  
Not registered with GP 28 5.7 
 
19 5.7 9 5.6 
 
1.13 (0.45-2.84)  
Told GP sexuality 
          
 
No 285 61.2
 
191 60.6 94 62.3
 
1 - 0.74 
Yes 181 38.8 
 
124 39.4 57 37.8 
 
0.93 (0.63-1.39)  
Ever had an HIV test   
          
 
No 28 5.7
 
20 6.0 8 5.0
 
1 - 0.70 
Yes 466 94.3 
 
314 94.0 152 95.0 
 
1.18 (0.51-2.76)  
Most recent test 
          
 
In the last year 360 78.6
 
241 78.3 119 79.3
 
1 - 0.77 
More than a year ago 98 21.4 
 
67 21.8 31 20.7 
 
0.93 (0.58-1.51)  
Ever had HBV vaccine 
          
 
No 63 12.8
 
47 14.1 16 10.1
 
1 - 0.23 
Yes 430 87.2 
 
287 85.9 143 89.9 
 
1.46 (0.80-2.67)  
Where received the HBV vaccine  
 
    
 
   
GP 62 14.5 
 
46 16.0 16 11.3 
 
1 - 0.46 
Sexual health clinic (SHC) 325 75.8 
 
215 74.9 110 77.5 
 
1.48 (0.79-2.75)  
SHC & GP 8 1.9 
 
4 1.4 4 2.8 
 
2.87 (0.64-12.86)  
Other 32 7.5 
 
22 7.7 10 7.0 
 
1.31 (0.51-3.36)  
Other & SHC 2 0.5 
 
0 0.0 2 1.4 
 
   
Number of HBV vaccine doses received      
 
   
1 37 8.8 
 
25 8.8 12 8.6 
 
1 - 0.62 
2 62 14.7 
 
42 14.8 20 14.3 
 
0.99 (0.42-2.38)  
3 138 32.6 
 
90 31.8 48 34.3 
 
1.11 (0.51-2.40) 
 4 60 14.2 
 
36 12.7 24 17.1 
 
1.39 (0.59-3.31) 
 Not sure 126 29.8 
 
90 31.8 36 25.7 
 
0.84 (0.38-1.84) 
 Abbreviations: aOR=age-adjusted odds ratio, SHC=sexual health clinic, GP= general practitioner, HIV= human immunodeficiency 
virus, HBV=hepatitis B virus. aA total of 495 MSM had complete survey data and at least one anogenital sample that was 
adequate for HPV testing. bDetection of HPV DNA of quadrivalent-vaccine types  in any anogenital specimen.  cTotal numbers 
vary for each question due to missing items: survey questions that were not asked (due to routing) or not answered.  
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TABLE 39. HPV KNOWLEDGE, RISK PERCEPTION AND VACCINE ACCEPTANCE, BY ANOGENITAL 
QUADRIVALENT-VACCINE TYPE DETECTION, IN 495 HPV-MSM-MMC PARTICIPANTSa 
 
Total  HPV Not detectedb HPV Detectedb 
 
   
 
Nc % 
 
Nc % Nc % 
 
aOR 95% CI p 
Knowledge about HPV            
0 to 4 correct answers 218 45.5  148 45.7 70 45.2  1 - 0.89 
5 to 9 correct answers 261 54.5  176 54.3 85 54.8  1.03 (0.70-1.51)  
Risk perception-compared to other people same age       
Much below average 19 3.9 
 
14 4.2 5 3.1 
 
1 - 0.16 
Below average 66 13.4 
 
53 15.9 13 8.2 
 
0.68 (0.21-2.23) 
 Average 193 39.2 
 
128 38.3 65 40.9 
 
1.42 (0.49-4.12) 
 Above average 173 35.1 
 
114 34.1 59 37.1 
 
1.44 (0.49-4.18) 
 Much above average 42 8.5 
 
25 7.5 17 10.7 
 
1.89 (0.57-6.23) 
 Risk perception- compared to other MSM same age 
 
 
Much below average 34 7.0 
 
26 7.9 8 5.2 
 
1 - 0.57 
Below average 119 24.5 
 
83 25.2 36 23.2 
 
1.40 (0.58-3.39)  
Average 232 47.8 
 
159 48.2 73 47.1 
 
1.48 (0.64-3.43)  
Above average 75 15.5 
 
46 13.9 29 18.7 
 
2.02 (0.81-5.08)  
Much above average 25 5.2 
 
16 4.9 9 5.8 
 
1.84 (0.59-5.75)  
Self-perceived likelihood of accepting the 3-dose HPV vaccine schedule  
Definitely 288 58.3 
 
186 55.7 102 63.8 
 
1 - 0.40 
Probably 124 25.1 
 
87 26.1 37 23.1 
 
0.78 (0.49-1.23)  
Possibly 62 12.6 
 
47 14.1 15 9.4 
 
0.58 (0.31-1.10) 
 Probably not 14 2.8 
 
9 2.7 5 3.1 
 
1.01 (0.33-3.10) 
 Definitely not 6 1.2 
 
5 1.5 1 0.6 
 
0.37 (0.04-3.17) 
 Abbreviations: aOR=age-adjusted odds ratio aA total of 495 MSM had complete survey data and at least one anogenital sample 
that was adequate for HPV testing. bDetection of HPV DNA of quadrivalent-vaccine types  in any anogenital specimen.  c In 
participants with survey responses and adequate anogenital samples for HPV testing.Total numbers vary for each question due 
to missing items: survey questions that were not asked (due to routing) or not answered.  
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FIGURE 61. FREQUENCY OF REASONS CITED FOR INTENTION TO ACCEPT/NOT TO ACCEPT THE HPV 
VACCINE, STRATIFIED BY SELF-REPORTED LIKELIHOOD OF ACCEPTING THE VACCINE.  
 
 
NB.Different  X-axis scales  between upper and lower panels after excluding the most common reason (protection/safety/health 
benefit). 
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8.4 KEY FINDINGS 
The average age at first attendance at a SHC was 24 years, representing the earliest age, on 
average, at which HPV vaccination would occur, assuming that SHC service use patterns 
would not change due to vaccine availability. Average age of first attendance was an 
average of five years after the initiation of anal sex. One in three MSM aged 18 to 24 had 
detectable quadrivalent-vaccine type DNA. In MSM attending MMC, SHCs were the 
predominant service type used for AGW diagnosis and treatment and for HBV vaccine 
uptake.  
HPV knowledge, relating to HPV vaccine outcomes and safety and to HPV risk, was low. 
However, MSM had strong intentions to accept the vaccine if it was offered, with reported 
barriers being a lack of information, particularly about vaccine safety, reflecting the findings 
from the knowledge questions. There remain a small minority of MSM who would not 
accept the vaccine, due to negative attitudes to vaccines in general. 
8.5 FINDINGS IN CONTEXT 
Studies examining the attitudes of MSM towards the HPV vaccine were systematically 
reviewed in 2014219. There were 18 studies identified, with only two in Europe (Italy and 
Sweden) and eight in the US where vaccines are not always free at the point of care as they 
would be in the UK’s NHS. In twelve studies, only half would accept the vaccine (mean=56%, 
median=65%, range 0–86%), a substantially lower estimate than that reported in the HPV-
MSM-MMC participants. This difference might be because the vaccine would be free in the 
NHS but also because HPV-MSM-MMC participants were engaged with and more likely to 
trust the NHS as demonstrated by their access to the clinic and their participation in the 
research study. This proactivity towards health and trust in the clinic (a reason cited for 
intending to accept the vaccine) is likely to influence the positive intentions to accept the 
vaccine compared to MSM who do not attend SHCs. The only study in the review that 
recruited from a SHC (New York) and quantified likelihood of acceptance estimated 86% 
would accept220.    
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8.6 STRENGTHS AND LIMITATIONS 
This study recruited from the potential target population for HPV vaccination and 
represents the only estimate, to date, of HPV vaccine uptake in MSM attending SHCs in the 
UK. However there is likely to be a correlation between participation in the study and 
attitude to health systems such as trust in the clinic and its staff, which were cited as 
reasons for intending to accept the vaccine. MSM who did not consent to participate have 
different engagement with healthcare and health research which is likely to be reflected in 
their attitudes to vaccination. This potential bias would result in overestimation of vaccine 
acceptance in the population of MSM attending SHCs. Considering the worst-case scenario, 
where all of the MSM who declined to take part in the study would opt out of HPV 
vaccination, 20% of MSM at MMC would not receive the vaccine; which would still 
represent high expected uptake. 
In this study, reported likelihood of accepting the HPV vaccine was used as a marker for 
intention to accept it. In most social cognition models, intention is the strongest 
determinant of behaviour yet it does not directly translate into behaviour because it 
interacts with other determinants that were not measured in this study. For example, in the 
theory of planned behaviour, “perceived behavioural control” works in combination with 
intention to predict behaviour221. In this study we measured HBV vaccine uptake as a 
marker for predicted HPV vaccine uptake behaviour and found the gap between intention 
and behaviour to be only 7% (96% intention-89% HBV vaccine uptake). 
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9. MATHEMATICAL MODEL OF HPV16 AND ANAL CANCER IN 
MSM ATTENDING SEXUAL HEALTH CLINICS IN THE UK: IMPACT 
OF HPV VACCINATION  
In this chapter, I present a preliminary estimation of vaccine effectiveness against HPV16 
and related anal cancer using a static, deterministic, compartmental cohort model. I first 
describe the model, its parameters and underlying assumptions, before presenting results of 
the model output compared to the observed data followed by the expected reduction in 
HPV16 prevalence and anal cancer, by age, resulting from different vaccine scenarios. 
9.1 OBJECTIVES  
1. To develop a deterministic compartmental model of HPV16 infection and anal 
cancer in MSM attending SHCs in the UK that can inform other dynamic probabilistic 
transmission models of HPV in MSM 
2. To perform a preliminary analysis to estimate the vaccine-associated reduction in 
HPV16 prevalence and related anal cancer incidence in MSM attending SHCs. 
9.2 METHODS 
OVERVIEW 
A compartmental model for anal HPV16, with progression to anal cancer, was developed. A 
total of 100,000 hypothetical HIV-negative boys aged ten, who would report having sex with 
men at least once during their lifetime, and would attend a SHC between the ages of 16 and 
40, were followed in the model until age 77. Available data constrained the age ranges in 
the model. Model compartments represent HPV16 infection/immune status, stratified by 
HIV status, and, when HPV16-infected, endpoints specific to anal cancer and its precursors. 
The sequence of transition through model compartments, the model structure (Figure 62), 
was developed to represent the natural history of anal HR-HPV infection while maintaining 
the balance of model-complexity with utility. There was a monthly deterministic probability, 
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corresponding to the current compartment (i.e. no model memory), of transitioning from 
one compartment to the next. 
Model parameter values were assigned following in-depth literature searches in 2011 and 
updated as and when more data became available until January 2014. Some parameter 
values were inferred following fitting of the model to available data. The model was 
calibrated to both HPV prevalence and anal cancer incidence. Data sources included the 
HPV-MSM-MMC study (previous chapters), age-specific prevalence estimates in MSM 
identified via a published systematic literature review and cancer registry data from the 
Office of National Statistics (ONS). Model equations and state variables can be found in 
Appendix V, page 312. 
210  
 
FIGURE 62. SCHEMATIC OF THE HPV16 AND ANAL CANCER MODEL STRUCTURE 
 
Compartments are represented by rectangles: Infected=HPV16 infection with normal or ASCUS histology, LSIL= low-grade squamous intraepithelial lesion, HSIL= high-grade squamous intraepithelial 
lesion, Cancer=anal squamous cell carcinoma and superscript h (h) represents HIV infection. Transition parameters, represented by arrows, are defined in the following sections. 
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DEMOGRAPHIC FACTORS 
The size of the closed model population was only influenced by mortality. From the age of 
10, boys/men had an age-specific risk of mortality, parameterised from ONS data, which 
determined the transition into the “dead” compartment (Table 40). See below for the 
additional risk of mortality associated with HIV and anal cancer.  
TABLE 40. DEMOGRAPHIC AND ANAL SEX DEBUT PARAMETER NAMES, DEFINITIONS, VALUES AND DATA 
SOURCES 
Parameter 
name 
Definition Default value Source  
𝐴𝐴(𝑎𝑎)  Natural mortality Age-specific 2005-2007 data from UK life tables, Office for 
National Statistics, UK222  
𝛼𝛼  Probability of having anal sex with 
another man for the first time in lifetime 
between the a and a+1  
8.9x10-3 See section entitled “Initiation of anal sex”, below, 
for details.  
INITIATION OF ANAL SEX 
At age 10, all boys were assumed to be HPV-naïve, HIV-negative with no sexual history and 
were in the “virgins” compartment with potential to initiate anal sex. All men in the model 
were assumed to have sex exclusively with men. Age of anal sex debut, collected in 
respondents older than 12 in the Natsal-2 survey, was used to derive the probability of 
transitioning from the “virgin” into the “susceptible” compartment (α; Table 40). The 
expected proportion of “virgins” (V) was assumed to decline annually at a constant rate, α, 
as shown in Equation 3, where 𝑎𝑎 equals age in years. The value of annual α was estimated 
by fitting age-specific expected proportion of “virgins” in men who will have sex with men to 
that observed in Natsal-2 by minimising the sum of squares of the differences (Figure 63). 
Annual transition probabilities were converted to monthly using:  1-𝐴𝐴−𝛼𝛼12  
EQUATION 3. AGE RELATIONSHIP OF EXPECTED PROPORTION OF “VIRGINS” 
𝑉𝑉𝑎𝑎 = 𝑉𝑉𝑎𝑎−1 − 𝛼𝛼𝑉𝑉𝑎𝑎−1 
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FIGURE 63. COMPARING OBSERVED AND EXPECTED PERCENTAGE OF ANAL SEX VIRGINS, BY AGE, AT 
THE MINIMUM SUM OF SQUARED DIFFERENCES 
 
Expected proportion of virgins in boys who will have sex with men fitted to observed behavioural data on initiation of anal sex 
from Natsal-2. The minimum value of sum of squares of the differences was achieved when 𝛼𝛼 =8.9x10-3/ month. 
HUMAN IMMUNODEFICIENCY VIRUS INFECTION 
HIV-related parameter names, definitions, values and sources are displayed in Table 41. 
Observed age-specific HIV prevalence was derived by applying the age distribution of HIV 
prevalence in the GMSHS between 2000 and 2008223 to the estimated aggregate prevalence 
of HIV infection in MSM (including undiagnosed), aged 20-44 years, attending SHCs in 
England and Wales (6.7%)224. Prevalence was assumed to remain at this level after 44 years 
(Figure 64). 
FIGURE 64. HIV PREVALENCE IN MSM ATTENDING SHCS IN ENGLAND, ADJUSTED TO THE AGE PROFILE 
OF HIV PREVALENCE IN MSM IN PUBS AND CLUBS IN LONDON 2000-2008. 
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 In the model, HIV infection did not occur until age 18 and expected age-specific HIV 
prevalence was fitted to observed prevalence by changing the parameters of a gamma 
distribution of the force of infection (FOI) for HIV. HIV incidence per month was calculated 
by multiplying the FOI and the number of HIV-negative MSM that month.  
HIV-positive MSM were at additional risk of dying (d; HIV-specific mortality rate) 
representing HIV-related deaths. HPV infection and disease progression parameters were 
modified by HIV status but HIV FOIs were unaffected by HPV status. 
TABLE 41. HIV PARAMETER NAMES, DEFINITIONS, VALUES AND DATA SOURCES 
Name Definition Default 
value 
Source  
λ𝐻𝐻𝐻𝐻𝐻𝐻  Probability of 
acquiring HIV 
infection between a 
and a+1  
Gamma-distributed by age: values of alpha and beta parameters of the gamma 
distribution were estimated during calibration by fitting  to observed age-specific HIV 
prevalence, see section entitled “Human immunodeficiency virus infection”, above, for 
details. 
d Probability of HIV-
related death 
between a and a+1 
5.1x10-4 Bhaskaran et al estimated HIV-associated fatality among HIV-positive 
individuals, at risk between 2004-2006, in a large multinational collaboration 
of HIV seroconverter cohorts (CASCADE). Mortality following HIV 
seroconversion was compared with expected mortality, calculated by 
applying general population death rates matched on demographic factors225. 
Monthly parameter value derived from 6.1/1000 excess deaths being 
attributed to HIV per year by dividing by 12. 
HUMAN PAPILLOMAVIRUS INFECTION 
HPV infection related parameter names, definitions, values and sources are displayed in 
Table 42. After initiating anal sex activity, represented by transition into the “susceptible” to 
HPV16 compartment, the risk of becoming infected with HPV (FOI) was age specific and HIV 
status specific. The FOI for HPV16 was gamma distributed by age and the parameter values 
(α and β) were determined by fitting the proportion of MSM in infected compartments 
(including those with disease progression) in the number of alive MSM to the observed anal 
HPV16 prevalence (Figure 31-page 124, Figure 65 and Figure 66)  using maximum likelihood 
estimation (MLE) (Model calibration, page 222).  
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FIGURE 65. OBSERVED AGE-SPECIFIC ESTIMATES OF ANAL HPV16 PREVALENCE IN INTERNATIONAL 
POPULATIONS OF HIV-NEGATIVE MSM 
 
HPV16 estimates are plotted at the average age of the study population, or age group if age-specific estimates were available. 
During calibration, observed prevalence was assumed across the age range of each study. Berry (2009)171, Chin-Hong (2004)54, 
Friedman (1998)56, Gao (2010)174, Goldstone (2011)193, Palefsky (1998)57, Sayers (1998)60, Vajdic (2009)84, Zou (2014)122 and Van 
der Snoek (2005)226. 
FIGURE 66. OBSERVED AGE-SPECIFIC ESTIMATES OF ANAL HPV16 PREVALENCE IN INTERNATIONAL 
POPULATIONS OF HIV-POSITIVE MSM 
 
NB. Axis scales differ from Figure 65. Berry (2009)171, Damay (2010)182, Friedman (1998)56, Gao (2010)174, Lacey 
(1999)59,Palefsky (1997)64,  Palefsky (1998)57, Piketty (2003)227, Salit (2010)228, Sayers (1998)60, Sirera (2006)63, Vajdic (2009)84, 
de Pokomandy (2009)93 and Van der Snoek (2005)226. 
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TABLE 42. HPV INFECTION PARAMETER NAMES, DEFINITIONS, VALUES AND DATA SOURCES 
Parameter 
name 
Definition Default 
value 
Source  
λ𝐻𝐻𝐻𝐻𝐻𝐻,     
λ𝐻𝐻𝐻𝐻𝐻𝐻ℎ 
HIV-dependent risk of 
becoming infected (I) with 
HPV16 at time a+1 if 
susceptible at time a.  
Gamma-distributed by age: values of alpha and beta parameters of the gamma 
distribution were estimated during calibration as described in section entitled 
“Model calibration”, below 
µ  HIV-independent probability 
of effective natural immunity 
to HPV16 waning in 1 month.  
0.5 Duration of effective natural immunity is unknown. See section 
entitled “Scenario analyses”, below, for details on varying this 
parameter from the default value of 0.5 to 0, 0.25 and 1 
(representing duration of natural immunity ranging from 1 month-
lifelong). 
ϕ,ϕℎ    
 
HIV-dependent probability of 
resolving an HPV16 infection, 
with normal or ASCUS 
cytology/histology between a 
and a+1 
0.065, 
0.008 
See Box 8, below, for details 
𝜌𝜌,𝜌𝜌ℎ HIV-dependent probability of 
clearing HPV16 infection, with 
detectable LSIL/LGAIN, 
between a and a+1. 
0.003, 
0.001 
 
π,πℎ HIV-dependent probability of 
clearing an HPV16 infection, 
with detectable HSIL/HGAIN, 
between a and a+1. 
0.013, 
0.001 
Resolution of infections occurred with a probability that was independent of age but 
dependent on HIV status (Box 8) and resulted in a period of natural immunity represented 
by the “resistant” compartment. There was an age-independent probability of waning 
natural immunity (see section entitled “Scenario analyses”, below, page 222) when MSM 
returned to the “susceptible” compartment. No partial immunity was modelled. 
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BOX 8. ESTIMATION OF THE CLEARANCE RATE OF HPV16 INFECTION  
   
 Total anal HPV16 infection clearance rate:  Relative contribution of HPV16 infection stages (I, LSIL and HSIL) to clearance rate:  
    HIV-negative MSM 
MSM in the HIM study 
(N=156), that recruited 
from low HIV prevalence 
communities in Mexico, 
Florida and Brazil (2005), 
were assessed for type-
specific clearance, which 
was defined as a anal type-
specific HPV infection with 
prevalent HPV16 at 
enrolment (N=11) that was 
then undetectable at the 6-
month visit (N=3) 229. 
Therefore, in HIV-negative 
MSM, the total clearance 
rate from HPV 16 infections 
(including those associated 
with cancer pre-cursors) 
was estimated at 
0.045/month. 
 HIV-positive MSM 
Clearance rate was assessed in HIV-
positive MSM, participating in the 
HIPVIRG cohort study, which recruited 
from 4 HIV clinics in Montreal, Canada 
(2002-2005). Clearance of a prevalent 
anal type-specific HPV infection at 
baseline was considered to have occurred 
at the first follow-up visit at which that 
infection was no longer detected 
Clearance and incidence rates by type 
were determined using appropriate 
incidence density calculation based on 
person-time denominators (person-
months). At enrolment, 92 MSM had 
HPV16 detected and 28 of these cleared 
during the 2286 person-months of follow-
up93. Therefore, in HIV-positive MSM, the 
total clearance rate from both clinically 
undetectable and detectable HPV 16 
infections was estimated at 0.012 
/month. 
 
 Overall prevalence 
A meta-analysis estimated the pooled prevalence on HPV16, LSIL and HSIL by HIV status in MSM. The pooled 
prevalence of HPV16 infection was 12.5% in HIV-negative and 35.4% in HIV-positive MSM. This estimate was 
assumed to include infections associated with cancer pre-cursors.  The pooled prevalence estimate of LSIL was 6.6% 
in HIV-negative and 27.5% in HIV-positive MSM and of HSIL was 2.7% (HIV-negative) and 6.7% (HIV-positive)230. 
 
  Proportion of LSIL/HSIL associated with HPV16 
There have been two systematic reviews of the literature of the HPV-association with anal cancer and its pre-
cursors. The first, up until July 2007, was not stratified by HIV status but did have an estimate for the proportion of 
LSIL associated with HPV16 of 7.3% in men32. The other, searching records until 200833, estimated that 76.6% of HSIL 
was HPV16-associated in HIV-negative (or unreported) male populations and 55.3% in HIV-positive male 
populations.  
 
  Prevalence of HPV16-associated HSIL/LSIL 
Therefore, it was assumed that the prevalence of HSIL adjusted for HPV16-association was 0.76*2.7=2.05% for HIV-
negative MSM and 0.55*6.7=5.1% for HIV-positive MSM. 
It was assumed that the prevalence for HPV16-associated LSIL was 0.07*6.6=0.46% in HIV-negative MSM and 
0.07*27.5=1.9% in HIV-positive MSM. 
 
  Prevalence of HPV16-associated with normal/ASCUS cytology/histology 
It follows that the ratio of HPV16 infection prevalence of normal/ASCUS: LSIL: HSIL was 9.99:0.46:2.05 in HIV-
negative MSM and 29.8:1.9:3.7 in HIV-positive MSM. 
 
    Clearance rate calculations. clearance probability per month for HPV16 infection can be calculated as follows:  
    with normal/ASCUS cytology or histology= 
 (Prevalence of I/Total HPV16 prevalence)*total 
clearance rate 
𝜙𝜙 =(9.99/12.5)*0.045=0.065, 𝜙𝜙ℎ 
=(29.8/35.4)*0.01=0.008 
 With associated LSIL=  
(Prevalence of LSIL/Total HPV16 
prevalence)*total clearance rate 
𝜌𝜌 =(0.46/12.5)*0.045=0.003,  
𝜌𝜌ℎ=(1.9/35.4)*0.012=0.001 
 With associated HSIL= 
 (Prevalence of HSIL/Total HPV16 prevalence)*total clearance rate 
π =(2.05/12.5)*0.045=0.013,  πℎ==(3.7/35.4)*0.012=0.001 
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ANAL CANCER DEVELOPMENT 
Anal cancer related parameters are displayed in Table 43. Following infection, MSM could 
progress sequentially to compartments representing low-grade or high-grade lesions, or 
revert to the immune state (“resistant”), depending on a set of age-independent 
parameters. However, the progression from a high-grade lesion to anal cancer was assumed 
to be age-associated: p(HSIL to anal cancer)=μ1𝐴𝐴
�μ2a�. Expected anal cancer incidence was 
calculated by multiplying the number of new cases per 100,000 months by the inverse 
probability of anal cancer being attributed to HPV16 (SCC16). Values for μ were estimated by 
fitting the expected to the observed anal cancer incidence using MLE (Model calibration, 
page 222). 
TABLE 43. ANAL CANCER PARAMETER DEFINITIONS AND DATA SOURCES 
Name Definition Default 
value 
Source  
σ,σℎ  The probability a man develops 
LSIL/LGAIN at time a+1 if he 
HPV16 infection (I, Ih) at time a. 
0.006, 
0.028 
Derived from annual transition probabilities in Czoski-Murray et 
al231 which are based on data from Palefsky et al, 199873. 
Annual transition from normal/ ASCUS to LGAIN if HIV-negative= 
0.079 and if HIV-positive=0.338. 
𝓍𝓍,𝓍𝓍ℎ  The probability a man develops 
HSIL/HGAIN at time a+1 if he 
had LSIL/LGAIN (L, Lh) at time a.  
0.013, 
0.018 
Derived from annual transition probabilities in Czoski-Murray et 
al231 (Box 9). 
δ(𝑎𝑎), δℎ(𝑎𝑎) HIV-dependent probability of 
developing cancer at time a+1 if 
had HSIL/HGAIN (H) at time a.  
Age-dependent: mu1*exp^(mu2*age) 
Values of mu estimated via calibration 
SCC16 Proportion of cancer cases 
caused by HPV16 
0.761 De Vuyst et al.33 and Abramowitz et al  have similar estimates. 
No significant difference between HIV-negative and HIV-
positive232. 
ψ  Case fatality rate for anal 
cancer 
0.004 Risk of dying from anal cancer was 36.2%  at 12-years in the 
treated arm of an RCT of anal cancer treatment conducted in 
the UK233. 
Monthly risk was calculated (assuming a constant probability of 
dying over the 12 years), as follows: 
Annual=0.362/12 
Monthly=0.362/(12x12) 
τ=1- ψ HIV-independent probability of 
surviving anal cancer between a 
and a+1 
0.996 
 
It was assumed that survival coincides with clearance of HPV. It 
was assumed that all anal cancers are diagnosed and treated 
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The cancer registry for England 2010234, did not collect behavioural or sexual orientation 
data to determine the observed incidence of anal cancer specific to MSM. The age-
distribution of anal cancer incidence in all men in England in 2010 was applied to pooled 
estimates for anal cancer incidence in HIV-negative (Figure 67) and HIV-positive MSM 
(Figure 68) from a global meta-analysis of anal cancer incidence in MSM (Box 10)230. Poisson 
distributed 95% confidence intervals were determined around the observed counts of anal 
cancer in 100,000 person years using STATA v13.1. 
FIGURE 67. OBSERVED AGE-SPECIFIC ANAL CANCER INCIDENCE ESTIMATES IN HIV-NEGATIVE MSM IN 
THE UK, COMPARED TO MEN IN ENGLAND  
Age-specific weights, derived from cancer registry estimates for anal cancer incidence in men, were attached to the aggregate 
estimate of anal cancer incidence in HIV-negative MSM (Box 10), to provide age-specific observed anal cancer incidence. 
Poisson-distributed 95% CI. 
FIGURE 68. OBSERVED AGE-SPECIFIC ANAL CANCER INCIDENCE ESTIMATES IN MSM IN THE UK, 
COMPARED TO MEN IN ENGLAND, BY HIV STATUS 
 
Due to inconsistent referral patterns from primary care services in the UK, anal cancer onset 
was assumed to coincide with diagnosis and treatment, which informed the parameters for 
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additional risk of anal cancer-related mortality and probability of recovering from anal 
cancer. Recovery was represented by transition to the “resistant” compartment, which 
assumed that recovery coincided with clearing of the HPV16 infection. Relapse was not 
modelled. Men with anal cancer were not offered the vaccine. 
BOX 9. SOURCE OF PARAMETER VALUES FOR DEVELOPING HGAIN/HSIL 
The monthly probability of developing HSIL/HGAIN from LSIL/LGAIN was calculated by Czoski-Murray et al (2010) 231.  
Calculations were based on data from the San Francisco cohort of MSM, presented by Palefsky et al (2008) 73.   
Person-years at risk were estimated assuming: 
• Men who develop HGAIN had half of the follow-up of those who do not develop HGAIN 
• Half of the observed cases of HGAIN (in individuals with no AIN at baseline) experienced prior LG-AIN. 
Annual incidence rates for HG-AIN by HIV status  
n No HGAIN HGAIN Person-years 
Person-years at risk 
 
Per non-
HGAIN 
case                             
Per HGAIN 
case 
Summary data     
HIV negative 221 188 33 671 3.3 1.65 
HIV positive 277 170 107 593 2.7 1.35 
LGAIN to HGAIN annual transition probabilities  
LSIL at baseline n No HGAIN HGAIN  Total person-years at risk    
 
  Mean 
HIV negative 17 10 7  44.3 0.158  
HIV positive 90 43 47  218.2 0.215  
Source: Czoski-Murray et al (2010) 231. Abbreviations: HGAIN=High grade anal 
intraepithelial neoplasia, LGAIN=Low grade AIN, LSIL= Low grade squamous intraepithelial 
lesion 
𝓍𝓍 = 0.15812 = 0.013 
 𝓍𝓍ℎ = 0.21512 = 0.018 
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BOX 10. ANAL CANCER INCIDENCE ESTIMATES FROM A RANDOM-EFFECTS META-ANALYSIS OF STUDIES 
IN HIV-NEGATIVE AND HIV-POSITIVE MSM POPULATIONS 
A systematic review and meta-analysis in 2012 identified two studies of anal cancer incidence in HIV-
negative MSM giving a pooled estimate of 5.1/100,000 person years compared to that from nine 
studies in HIV-positive MSM of 45.9/100,000 person years. Incidence in HIV-positive MSM has risen 
from 21.8/100,000 person years since the introduction of highly active anti-retroviral therapy 
(HAART) in 1996 to 77.8/100,000 person years which is attributed to the reduction in HIV-related 
mortality resulting in a longer period at risk of anal cancer230. 
 
Source: Machalek et al. (2012)230 
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SHC ATTENDANCE AND VACCINATION 
In all scenarios both HIV-negative and HIV-positive MSM populations were eligible for 
vaccination. Vaccine coverage depended on SHC attendance rate which was modelled in 
two scenarios in HIV-negative MSM:  first-time attendance and at first time or any 
subsequent attendance (any attendance). For first-time attendance only, the age-specific 
probability of attending a SHC for the first time was parameterised using data from the HPV 
in MSM study (chapter 7). A six-month lag was introduced to represent the delay in 
completing the vaccine dosing schedule. For the scenario in which HIV-negative MSM were 
offered the vaccine at any attendance (including first time), an average period of one year 
between attendances was assumed. HIV-positive MSM were offered the vaccine at any visit. 
It was assumed that in 76% of HIV-positive MSM the diagnosis had been made and they 
attended a SHC/HIV clinic 7.3 times per year23,235. Dosing schedule period was not modelled 
in scenarios where vaccine was offered at any attendance. 
Likelihood of accepting the vaccine, if offered during a SHC/HIV clinic attendance, was 
estimated from the HPV in MSM study as 96% (chapter 7). All MSM were assumed to 
complete the 3-dose vaccine course. If MSM received the vaccine, they either transitioned 
into vaccine success (effectively immunised) or vaccine failure (vaccinated but not immune) 
compartments with probabilities of vaccine efficacy (VE) and 1-VE, respectively.  The course 
and probability of HPV infection was unaltered in MSM in whom the vaccine was not 
effective. 
Effective vaccination resulted in MSM in the uninfected (“susceptible”, “virgin” and 
“resistant”) compartments transitioning to corresponding “vaccine success” compartments 
where there was no risk of HPV infection. The course of infection was unaltered for MSM in 
the infected compartments who responded successfully to vaccination, but following 
recovery, they remained in “vaccine success” compartments representing immunity to re-
infection.  
Vaccine immunity was assumed to wane independently of natural immunity, when men 
transit from a “vaccine success” compartment to the corresponding “vaccine failure” 
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compartment with a probability of one divided by average duration of effective vaccine 
immunity. 
MODEL CALIBRATION 
It was assumed that anal HPV16 DNA would be detected for all infected states in observed 
prevalence estimates. Expected HPV16 prevalence was therefore equal to the sum of all 
infected compartments in the total alive population. Expected age-specific HPV16 
prevalence, HIV prevalence and anal cancer incidence were simultaneously deterministically 
fitted to all observed estimates by minimising the negative log likelihood (Box 11) using the 
generalized reduced gradient (GRG) nonlinear solving method in Microsoft Office Excel’s 
add-in program, Solver.  
BOX 11. LIKELIHOOD CALCULATIONS 
 likelihood calculation  Negative log likelihood  
Binomial  
(prevalence) 
𝑝𝑝𝑖𝑖
𝓍𝓍𝑖𝑖(1 − 𝑝𝑝𝑖𝑖)𝑛𝑛𝑖𝑖−𝓍𝓍𝑖𝑖 
−�𝓍𝓍𝑖𝑖 ln𝑝𝑝𝑖𝑖 + (𝑛𝑛𝑖𝑖 − 𝓍𝓍𝑖𝑖) ln(1 − 𝑝𝑝𝑖𝑖)𝑁𝑁
𝑖𝑖=1
 
𝑝𝑝=Observed prevalence  
𝓍𝓍=Number with HPV16 infection 
𝑛𝑛=Sample size 
𝑠𝑠=age-specific observed estimate 
𝑁𝑁=Number of age-specific observed 
estimates 
Poisson  
(anal cancer 
incidence) 
λ𝜅𝜅
𝜅𝜅! 𝐴𝐴−𝜆𝜆 
 
−�𝜅𝜅 ln 𝜆𝜆 − 𝜆𝜆 − ln𝜅𝜅! λ= number of cancers in model in age 
range (cohort of 100,000) 
𝜅𝜅 =count= number of cancers in cancer 
registry data in age range/100,000 
 
SCENARIO ANALYSES 
Due to scarcity of data, uncertainty was introduced to the model from natural history 
parameters, particularly, the duration of effective natural immunity.  The monthly 
probability of losing natural resistance (μ) was varied in scenarios (0, 0.25, 0.5, 0.75 and 1), 
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with re-calibration for each scenario, to examine the effect on expected anal cancer 
incidence and HPV16 prevalence.  
VACCINE SCENARIOS 
Vaccine efficacy against HPV16 infection was modelled at 50% (MSM in the intention-to-
treat analysis with history of HPV infection), 75% and 100%. Average duration of vaccine-
induced effective immunity was modelled at 20, 40, 60 and 1000 years (lifelong).  
9.3 RESULTS 
CALIBRATION  
The comparison between observed and modelled anal cancer incidence and HPV16 
prevalence are displayed in Figure 69 and between observed and modelled HIV prevalence 
in Figure 70. The modelled mean HPV16 prevalence in HIV-negative MSM was 11.3%. 
Prevalence increased with age, peaked at 14.4% at 46 years, and thereafter declined with 
age to 11.4% at 77 years. The mean prevalence in HIV-positive MSM was 38.0%. Prevalence 
was underestimated by the model in HIV-positive MSM aged 18-40 years (mean 8.3%), 
compared to the estimate of 29.6% in the same age-group in HIV-positive MSM in the HPV-
MSM-MMC study. Above 45 years, where no observed estimates were available to restrain 
the model, the estimated HPV16 prevalence in HIV-positive MSM was very high years (mean 
66.2%).  
Mean anal cancer incidence was 7 and 112 per 100,000 person years for HIV-negative and 
HIV-positive MSM, respectively. In MSM aged 60 years and older, incidence was 18/100,000 
years for HIV-negative and 288/100,000 person years for HIV-positive MSM. Modelled mean 
HIV prevalence was 7.7%.  
 
224  
 
FIGURE 69. COMPARISON OF MODEL OUTPUT AND OBSERVED ESTIMATES FOR ANAL CANCER INCIDENCE AND ANAL HPV16 PREVALENCE 
 
Model outputs (expected) are displayed as lines and observed estimates are displayed as points with 95% CIs. For observed HIV-negative HPV16 prevalence, black points represent estimates from the 
HPV-MSM-MMC study and grey points represent estimates from other published studies. Anal cancer observed estimates as in Figure 68, page 218. 
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FIGURE 70. COMPARISON OF MODEL OUTPUT AND OBSERVED ESTIMATES FOR HIV PREVALENCE 
 
Observed estimates displayed with 95% confidence intervals calculated using the binomial exact method. 
FIGURE 71. PROPORTION OF MSM ATTENDING A SEXUAL HEALTH CLINIC WHO WOULD RECEIVE THE 
HPV VACCINE, BY AGE 
 
Any attendance=first and any subsequent visit to SHC, assumed to occur annually. In all scenarios both HIV-negative and HIV-
positive MSM were eligible for vaccination. 
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PROPORTION OF MSM VACCINATED  
Figure 71 shows that if offered the vaccine at first SHC attendance, with 96% uptake, a 
maximum of 43% of HIV-negative MSM would receive the vaccine by the age of 39 years. If 
offered at any attendance, assuming 96% uptake, the vaccine would be administered to 
95% of HIV-negative MSM attending SHCs by the age of 40 years and 99% of HIV-positive 
MSM by the age of 29 years.  
FIGURE 72. PROPORTION OF MSM WITH EFFECTIVE PROTECTION AGAINST HPV16, BY AGE, AS A 
RESULT OF DIFFERENT VACCINATION SCENARIOS 
 
Abbreviations: VE= vaccine efficacy, Years duration= average duration of vaccine protection (years). Any attendance=first and 
any subsequent visit to SHC, assumed to occur annually. In all scenarios both HIV-negative and HIV-positive MSM were eligible 
for vaccination. 
PROPORTION OF MSM EFFECTIVELY IMMUNISED 
Figure 72 shows that for HIV-negative MSM increasing vaccine efficacy increased the 
proportion of immune MSM, and increasing the duration of protection increased both the 
maximum proportion of immune MSM and the time to reach that maximum.  Modelling 
lifelong immunity at 75% efficacy resulted in the highest proportion of HPV16 immune MSM 
for the longest period. In HIV-negative MSM, from age 60 years, whether vaccine was given 
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at first or at any visit, increasing vaccine duration of protection from 40 to 60 years 
compensated for the reduction in efficacy from 100 to 75%. From approximately age 40, 
increasing the duration of protection from 20 to 40 years compensated for a reduction in 
efficacy from 75 to 50%.  
For HIV-positive MSM, the proportion immune was influenced more by vaccine efficacy than 
by duration of protection. The highest proportion of immune MSM, sustained for the 
longest period, resulted from a vaccine efficacy of 100% lasting for 40 years. Above the age 
of 60, increasing duration of protection from 40 years to lifelong compensated for a 
reduction in efficacy from 100 to 75%, and increasing duration of protection from 20 to 40 
years compensated for an efficacy reduction from 75 to 50%. 
FIGURE 73. MODELLED MEAN HPV16 PREVALENCE IN HIV SUBPOPULATIONS OF MSM ATTENDING 
SHCS, BY VACCINE SCENARIO, WHEN VACCINATING ALL MSM. 
 
Abbreviations: VE= vaccine efficacy, Years duration= average duration of vaccine protection (years). Any attendance=first and 
any subsequent visit to SHC, assumed to occur annually. In all scenarios both HIV-negative and HIV-positive MSM were eligible 
for vaccination. 
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IMPACT OF VACCINATION ON ANAL CANCER INCIDENCE 
Figure 73 shows that the mean HPV16 prevalence was reduced from 11.3% to 8.5% for HIV-
negative MSM, with vaccine efficacy of 75% and lifelong protection, and if the vaccine was 
offered only at the first clinic attendance in their lifetime. Prevalence was reduced to 4.0% if 
HIV-negative MSM were offered the vaccine at any annual visit. For HIV-positive MSM, 
prevalence was reduced from 38.0% to 13.4% with vaccine efficacy of 75% and lifelong 
protection.  
Figure 74 shows that the mean anal cancer incidence was reduced from 6.9 to 5.0/100,000 
person years for HIV-negative MSM, with vaccine efficacy of 75% and lifelong protection, 
and if the vaccine was offered only at the first clinic attendance in their lifetime. Incidence 
was reduced to 2.4/100,000 person years if HIV-negative MSM were offered the vaccine at 
any annual visit. For HIV-positive MSM, incidence was reduced from 112.3 to 38.3/100,000 
person years with vaccine efficacy of 75% and lifelong protection. 
FIGURE 74. MODELLED MEAN ANAL CANCER INCIDENCE, BY HIV STATUS, RESULTING FROM DIFFERENT 
VACCINE SCENARIOS, WHEN VACCINATING ALL MSM  
 Abbreviations: VE= vaccine efficacy, Years duration= average duration of vaccine protection (years). Any attendance=first and 
any subsequent visit to SHC, assumed to occur annually. In all scenarios both HIV-negative and HIV-positive MSM were eligible 
for vaccination. 
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FIGURE 75. PERCENT REDUCTION IN MEAN ANAL CANCER INCIDENCE AND HPV16 PREVALENCE, BY 
HIV STATUS, RESULTING FROM DIFFERENT HPV VACCINE SCENARIOS.  
Abbreviations: VE=Vaccine efficacy, YD= average years duration of protection. HIV-negative and HIV-positive MSM populations 
were both eligible for vaccination in all scenarios. 
Figure 75 shows the relative reduction in mean anal cancer incidence and HPV16 
prevalence. For HIV-negative MSM, lifelong immunity has the greatest impact on anal 
cancer incidence (27% reduction for first-time attendance; 65% for any attendance) and is 
the only scenario in which as much relative reduction occurs for HIV-negative as for HIV-
positive MSM (66% reduction for HIV-positive MSM). HPV16 prevalence relative reduction is 
similar for HIV-positive and HIV-negative MSM if they are offered the vaccine at any visit.  
Figure 76 displays age-specific HPV16 prevalence under different vaccination scenarios and 
reflects the proportion of immune MSM in Figure 72.  The impact of vaccination on HPV16 
prevalence was greater and earlier in the scenarios where the vaccine was offered at any 
attendance compared to when HIV-negative MSM were only offered the vaccine at their 
first SHC attendance. Figure 77 shows that, for HIV-negative MSM, a longer duration of 
protection has more impact as age increases and as anal cancer incidence increases, so 
having more relative impact in older age.  
0
20
40
60
80
%
 re
du
ct
io
n
40 YD; 50% VE 40 YD; 75% VE 40 YD; 100% VE 20 YD; 75% VE 60 YD; 75% VE 1000 YD;75% VE
Mean anal cancer incidence
0
20
40
60
80
%
 re
du
ct
io
n
40 YD; 50% VE 40 YD; 75% VE 40 YD; 100% VE 20 YD; 75% VE 60 YD; 75% VE 1000 YD;75% VE
Mean HPV16 prevalence
      
HIV negative: first attendance HIV negative: any attendance HIV positive
230  
 
FIGURE 76. THE EFFECT OF THE HPV VACCINE ON AGE-SPECIFIC HPV16 PREVALENCE, OVER A 67-
YEAR PERIOD, IN A COHORT OF 100,000 MSM 
 
 
 
Abbreviations: VE= vaccine efficacy, Years duration= average duration of vaccine protection (years). Any attendance=first and 
any subsequent visit to SHC, assumed to occur annually. In all scenarios both HIV-negative and HIV-positive MSM were eligible 
for vaccination. 
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FIGURE 77. EFFECT OF THE HPV16 VACCINE ON ABSOLUTE AGE-SPECIFIC ANAL CANCER INCIDENCE, 
OVER A 67-YEAR PERIOD, IN A COHORT OF 100,000 MSM 
 
Abbreviations: VE= vaccine efficacy, Years duration= average duration of vaccine protection (years). Any attendance=first and 
any subsequent visit to SHC, assumed to occur annually. In all scenarios both HIV-negative and HIV-positive MSM were eligible 
for vaccination. 
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SENSITIVITY ANALYSIS: RISK OF WANING NATURAL IMMUNITY 
The results of model re-calibration to different values of monthly probability of losing 
natural immunity are displayed in Figure 78 and Figure 79. The fit of model output to 
observed data was improved, especially for HIV-positive MSM, when the probability was 
reduced from the default (0.5 per month to 0.25 per month).  When lifelong natural 
immunity was modelled (monthly probability of losing natural immunity=0) the model 
output did not fit well to observed data. Increasing the probability of losing natural 
immunity above 0.5 per month had little impact on the model fit to observed data. Figure 
80 shows that the relative reduction in mean anal cancer incidence and HPV16 prevalence 
was not sensitive to the waning natural immunity rate, even below 0.5 per month. 
FIGURE 78. EFFECT OF VARYING THE RATE OF WANING NATURAL IMMUNITY ON MODELLED HPV16 
PREVALENCE AND ANAL CANCER INCIDENCE IN HIV-NEGATIVE MSM 
 
For observed HIV-negative HPV16 prevalence (upper panel): Black points represent age-specific estimates from the HPV-MSM-
MMC study and grey points represent estimates from other published studies. 
233  
 
FIGURE 79. EFFECT OF VARYING THE RATE OF WANING NATURAL IMMUNITY ON MODELLED HPV16 
PREVALENCE AND ANAL CANCER INCIDENCE IN HIV-POSITIVE MSM.  
 
 
NB. Axis scales differ from Figure 78. 
234  
 
FIGURE 80. EFFECT OF WANING NATURAL IMMUNITY RATE ON THE PERCENT REDUCTION OF MEAN 
ANAL CANCER INCIDENCE AND HPV16 PREVALENCE, BY HIV STATUS  
 
Vaccine efficacy=75%, 40 years average duration of protection 
KEY FINDINGS 
This preliminary modelling study has shown that HIV-positive MSM would benefit more 
than HIV-negative MSM from a vaccine against HPV16 to prevent anal cancer, assuming that 
vaccine efficacy is not reduced in HIV infection or due to antiretroviral treatment. A strategy 
in which the vaccine was offered to HIV-negative MSM at any SHC attendance would be 
more effective than targeting first-time attenders. Values of waning natural immunity 
between 0 and 0.5 per month are likely to result in better fitting models than values above 
0.5 per month.   
9.4 STRENGTHS AND LIMITATIONS 
The model population was restricted to MSM attending SHCs in the UK and no HPV 
transmission was modelled. Therefore the impact of vaccination will have been 
underestimated because the indirect effects of vaccination on unvaccinated MSM in the 
model, and on the wider MSM population not modelled, could not be estimated.  
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Current HPV vaccines also protect against HPV18 infection and future vaccines will expand 
to cover more HPV types associated with anal cancer. The model was not designed to assess 
the additional reduction in anal cancer that would result from broader spectrum vaccines, 
or from cross-protection against other HPV types, and has therefore underestimated 
potential vaccine impact.  
There was substantial uncertainty surrounding the parameters values for many of the 
natural history parameters for HPV16 infection and anal cancer development in MSM. For 
example, the clearance rate estimation from different stages of HPV infection for HIV-
negative MSM was only based on 11 prevalent cases. Further refinement of this model 
would involve updating these parameter values, with their distributions, from the recent 
literature. A probabilistic uncertainty analysis, in which the inputted uncertainty is 
translated into output credibility, should also be incorporated into future models of HPV in 
MSM.  
Furthermore, there is now data suggesting that detection of HPV DNA on the  surface does 
not directly correspond to detection within the lesion211. Given that, in addition to the ‘I’ 
compartment,  HSIL, LSIL and cancer compartments contributed to modelled HPV16 
prevalence, which was fitted to observed data, HPV16 prevalence may have been 
underestimated by the model. 
This model was calibrated to age-specific estimates of anal cancer incidence, HPV 
prevalence and HIV prevalence. These point estimates are affected by cohort effects and 
may have introduced bias. For example, older HIV-positive MSM in the UK have had 
continued improvement in the efficacy of HIV therapy during their lifetimes, when HIV-
related mortality would have been higher than if they had lived in the current generation. 
Therefore the observed HIV prevalence in the older ages is likely to have been 
underestimated. Furthermore, these men, who were prematurely removed from the MSM 
population, did not contribute to the anal cancer incidence data in older age. The current 
generation’s diagnosed HIV-positive MSM population will live longer, contributing to the 
person-time at risk in the older age groups, where effective ART does not reduce anal 
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cancer risk. This would result in higher anal cancer incidence than observed in 2010 at older 
ages.  
This model assumes that HIV-positive MSM attend SHC/HIV clinics more frequently than 
HIV-negative MSM, regardless of whether they are diagnosed. Given the high uptake (95% 
in 2014) for HIV testing in SHCs25, the proportion undiagnosed may be lower than in MSM in 
the general population, however this bias in attendance rate should be considered when 
interpreting these findings.   
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10. DISCUSSION 
In this chapter, I summarise the main findings presented in this thesis and describe how they 
underpin estimates of HPV vaccine effectiveness in MSM who attend SHCs in the UK. To do 
so, I add context, particularly an update of the literature on vaccine efficacy in men and 
specifically MSM, which has accrued since 2009, when the PhD was conceptualised. At the 
end of each results chapter, I have identified specific strengths and limitations. Here I discuss 
the strengths and limitations of this thesis as a whole. The structure of this discussion 
updates the literature and then addresses the following questions: 
1. Is a prophylactic HPV vaccine programme targeted at MSM attending SHCs likely to 
intervene too late in their lifetime to be effective? 
2. To what extent can an MSM-targeted SHC-delivered HPV vaccine programme 
interrupt HPV transmission in the wider MSM population (including those who do 
not attend SHCs) in the UK? 
3. What are the estimates for effectiveness and cost-effectiveness of an MSM-targeted 
SHC-delivered HPV vaccine programme? 
10.1 SUMMARY OF THESIS 
This thesis addresses the question of whether a targeted HPV vaccine programme for MSM 
in the UK, delivered in SHCs, would be effective (page 21).  Data collected from 522 MSM 
attending a central London SHC (MMC) were analysed to define the SHC-attending MSM 
population in the UK in terms of HPV exposure (including estimates of current, prior and 
future HPV risk) and to estimate vaccine uptake. A mathematical model of HPV16 infection 
and anal cancer was developed and used to estimate vaccine effectiveness.  
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10.2 THE EVOLVING CONTEXT SURROUNDING ESTIMATES OF HPV VACCINE 
EFFECTIVENESS 
Since 2009 there have been significant changes in the context and data to inform the 
research question. These include: 
• Quadrivalent vaccine trials in men 
• Adoption of gender-neutral vaccination programmes by some countries 
• Population-level estimates of vaccine effectiveness  
• An increase in studies measuring current HPV infection (reviewed in chapter 5, 
page 142) and seropositivity in MSM (reviewed in chapter 6, page 171)  
Here, the current estimates of vaccine efficacy and safety and population-level 
estimates of vaccine effectiveness, with respect to men and MSM are reviewed. 
VACCINE EFFICACY, EFFECTIVENESS AND SAFETY 
Vaccine trials in men and MSM 
The quadrivalent vaccine has now been tested in male populations (Table 44 displays 
estimates of efficacy and Table 45 displays estimates of effectiveness).  Between 2004 
and 2008 a randomised, placebo-controlled, double-blind, multicentre (71 sites), 
international (18 countries) trial in 4065 healthy boys and men, including 602 HIV-
negative MSM, was conducted. Results were reported by Giuliano et al in 2011236 and 
are displayed in Table 44. It showed substantial efficacy against persistent HPV infection, 
external genital lesions (EGL; predominantly AGW) and AIN. There were no reported 
vaccine-related serious adverse events and there was a lower reported rate of adverse 
events than reported in the trials in young women. Almost all vaccinees seroconverted 
for vaccine type HPV antibodies by seven months after starting the course of 
vaccination. Heterosexual men had higher peak mean antibody concentration than 
MSM; men of black ethnicity had higher mean antibody concentration than those of 
white or Asian ethnicity; and the vaccine was less immunogenic in older men than 
younger men. The clinical significance of these differences in antibody concentration 
was thought to be negligible based on the efficacy results237.  
In MSM, aged 16-26 years, irrespective of baseline HPV status or vaccine course 
completion (ITT population), the quadrivalent vaccine was 70% efficacious against EGL 
and 55% against HPV16/18-related AIN238. Confidence intervals of vaccine efficacy 
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estimates in this trial in men overlap with the estimates from the trial in women, so the 
authors suggest that vaccine efficacy was similar in the two sexes236. 
The MSM population was restricted to those younger than 27 reporting fewer than six 
lifetime male or female partners to represent men at low risk of having already been 
exposed to HPV. These efficacy estimates are therefore limited in their generalisability 
to other MSM populations.  
Vaccine-related reductions in AIN and AGWs have been demonstrated in older, 
previously HPV-exposed MSM attending an anorectal surgery practice in New York239,240  
and vaccine-induced HPV seroconversion and safety have been demonstrated in HIV-
positive MSM (Table 45)241. In HIV-positive MSM the vaccine increased the antibody 
levels in those with pre-existing antibodies, and ART use at vaccination was associated 
with higher concentration. After adjustment, CD4 cell count, nadir CD4 count and age 
were not associated with antibody concentrations241.  
Cross-protection 
Currently available vaccines are designed to protect against types 6, 11, 16 and 18 but in 
clinical trials also conferred partial cross-protection (production of cross-neutralising 
antibodies that offer protection against non-vaccine HPV types) against persistent 
infection with types 31, 33, 45 and 52242–245. In Australia, repeat cross-sectional HPV 
surveillance demonstrated partial vaccine effectiveness against types 31, 33 and 45 
(58%; 95% CI 27-76) following the introduction of the quadrivalent vaccine246. 
9-valent vaccine 
Given the limited effectiveness of cross-protection, extending the valency of VLPs offers 
an alternative strategy for preventing infection and disease caused by a wider range of 
HR-HPV types. In December 2014, a 9-valent vaccine was licensed for use following 
evidence that the induced antibody responses to HPV6, 11, 16 and -18 were non-inferior 
to the quadrivalent vaccine and that it additionally prevented disease related to HPV 
types 31, 33, 45, 52, and 58. There was no evidence of cross-protection against non-
vaccine types15,247.  
Two-dose schedule 
Reduction in the original three-dose vaccine schedule to two doses has recently been 
assessed. Immunogenicity trials demonstrated non-inferior antibody titres in young 
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participants receiving two doses of the quadrivalent vaccine compared to the full three-
dose course248,249.  
Long-term safety and efficacy 
After nearly ten years of follow-up, the HPV vaccine trials in women demonstrate 
sustained efficacy and a continued excellent safety record. Short-lived reactions at 
injections sites are common but serious vaccine-attributable adverse events, such as 
anaphylaxis, are rare96,250.  
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TABLE 44. STUDIES ASSESSING THE EFFICACY OF THE QUADRIVALENT VACCINE IN MEN 
Study design Publication Recruitment period Follow-up Endpoint ATP-VE (95% CI) ITT-VE (95% CI) 
1. 3463 heterosexual healthy boys and men aged 16-23. Excluded if history/baseline anogenital lesions, including those caused by other STI. ATP=seronegative and DNA negative for vaccine types at 
baseline until 7 months with no protocol violations. ITT population=irrespective of baseline HPV /did not complete the full vaccine course (minimum 1 dose) & returned for follow-up.  
Randomised, placebo-controlled, 
double-blind, multicenter 
(71 sites), international (18 
countries) 
Giuliano (2011)236 2004-2008  Median=2.9 years. 
Incident external genital lesions 
(EGL=AGW & penile, perianal or 
perineal neoplasia or cancer) 
92.4% (69.6-99.1) 63.7% (39.3-79.1) 
2. Subsample of above trial: 602 HIV-negative MSM (oral or anal sex with boy/man in last year) aged 16-26.Thirty-three MSM were diagnosed with HIV during the trial and were included in the 
analyses. 
 Giuliano (2011)   
Incident EGL (AGW & penile, perianal or 
perineal neoplasia or cancer) 
 
79.0% (97.9-99.6) 70.2% (23.0-90.2) 
 
Palefsky (2011)238 
 
Mean=2.2 years 
Persistent HPV6/11/16/18 infection 94.9% (80.4-99.4) 59.4% (43.0-71.4) 
  HPV6/11/16/18 detection at any time 84.0% (68.6-92.7) 48.5% (32.3-61.1) 
  AIN  54.9% (8.4-79.1) 25.7% (-1.1-45.6) 
  HPV6/11/16/18-related AIN 77.5% (39.6-93.3) 50.3% (25.7-67.2) 
  HPV16/18-related AIN 78.6% (-0.4-97.7) 55.2 % (8.5-79.3) 
3. 112 HIV-positive men > 18 years old, cytology=normal/ASCUS/LSIL & stable HIV-infection (no low CD4 counts or high viral loads, on or off ART). Excluded if both HPV16 &HPV18 detected/current 
or history of HSIL (or cell dysplasia suggestive of)/HGAIN/anal or perianal carcinoma. ATP= seronegative and DNA negative for endpoint HPV type at baseline; ITT=irrespective of baseline HPV 
status 
Multicentre (8 sites in US), 
single-arm, open-label, pilot trial 
Wilkin et al 
(2010)241 2008 18 months 
HPV6 seroconversion at week 28 98% (1-sided, 92%) 97% (NR) 
HPV11  99% (1-sided, 93%) 98% (NR) 
HPV16  100% (1-sided, 95%) 99% (NR) 
HPV18  95% (1-sided, 89%) 96% (NR) 
Abbreviations: ATP =According to protocol; VE= Vaccine efficacy; CI=Confidence Interval;  ITT=Intention-to-treat; EGL=External genital lesions; HPV=Human papillomavirus; AGW=anogenital warts; 
AIN=anal intra-epithelial neoplasia; HGAIN=High-grade AIN; ASCUS= Atypical Squamous Cells of Undetermined Significance; LSIL=Low-grade squamous intraepithelial lesion; ART=antiretroviral 
therapy; HSIL=high-grade squamous intraepithelial lesion; NR=Not reported 
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TABLE 45. STUDIES ASSESSING THE EFFECTIVENESS OF THE QUADRIVALENT VACCINE IN MSM 
Study design Publication Recruitment period Follow-up Endpoint ATP-HR (95% CI) ITT-HR (95% CI) 
1. 202 HIV-negative MSM, > 18 years old, history of biopsy-proven treated HGAIN. Mean age 40.4 years. ATP= all participants ITT=anal oncogenic HPV detected at baseline or 8 months before 
vaccination. Cox proportional hazards analysis 
Single-site (anorectal surgery 
practice in NY, US), non-
concurrent cohort study 
Swedish (2012)239 2007-2010 
median unvaccinated =722 
days; vaccinated= 489 
days 
Recurrent HGAIN 1 year 0.42 (0.22-0.82) 0.40 (0.19-0.86) 
Recurrent HGAIN 2 years 0.50 (0.26-0.98) 0.47 (0.22-1.00) 
Recurrent HGAIN 3 years 0.52 (0.27-1.02) 0.48 (0.22-1.04) 
2. 313 HIV-negative MSM, > 26 years old, No prior anal condyloma (AGW) or previously-treated and recurrence-free for 12 months prior to study entry. Mean age 42.1years. ATP= all participants. 
Cox proportional hazards analysis 
Single-site (anorectal surgery 
practice in NY, US), non-
concurrent cohort study 
Swedish & 
Goldstone 
(2014)240 
2007-2010 
median unvaccinated =1039 
days; vaccinated=880 
days 
Anal condyloma (AGW) 
0.49 (0.24-0.98) NR 
aHR=0.45 (0.22-0.92) NR 
Abbreviations: ATP =According to protocol; HR=hazard ratio; CI=Confidence Interval;  ITT=Intention-to-treat; HPV=Human papillomavirus; AGW=anogenital warts; AIN=anal intra-epithelial neoplasia; 
HGAIN=High-grade AIN; aHR=adjusted hazard ratio; ASCUS= Atypical Squamous Cells of Undetermined Significance; LSIL=Low-grade squamous intraepithelial lesion; HSIL=high-grade squamous 
intraepithelial lesion; NR=Not reported 
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10.3 POPULATION-LEVEL ESTIMATES OF VACCINE EFFECTIVENESS 
Population-level estimates of vaccine effectiveness have recently been systematically 
reviewed by Drolet et al251. Of the 52 countries that have implemented HPV vaccine 
programmes (41% of high-income countries; 15% of low/middle-income countries), time-
series studies had been conducted in nine high-income countries that were eligible for 
inclusion in the review. In general, high-income countries started programmes in 2007/8 
using the quadrivalent vaccine. The UK was an exception, starting with the bivalent vaccine 
in 2008 and switching to the quadrivalent in 2012. The UK, Australia, Canada and New 
Zealand opted for school-based programmes and Denmark, Germany and the US for 
primary care/community-based programmes. Catch-up programmes for older girls were 
also implemented in most cases. Coverage estimates were variable. Overall, school-based 
programmes had higher coverage and the UK reached 84-90% of school girls252. The US 
began vaccinating boys, and MSM aged 22-26 years, in 2011 and Australia included all boys 
in their school-based programme from 2013. 
These ecological studies, with inherent difficulties in determining causal association, were 
able to capture the indirect effects of female vaccination including the reduction in non-
vaccine HPV types. Consistent with transmission model predictions19, countries with high 
vaccine coverage (>50%) showed both direct and indirect effects one to four years after 
implementation: at least a 60% reduction in HPV16/18 and AGW in girls younger than 20 
years, cross-protection against HPV 31/33/45 and a reduction in AGW in men and older 
women. Countries with low coverage only showed direct effects, with the magnitude 
correlating with coverage (dose-response relationship),  with no evidence of cross-
protection or herd immunity251. In SHCs in Australia, where school-based coverage was high 
(70%), the proportion of AGW-related consultations reduced in heterosexual men but not in 
MSM two years after implementation (Figure 81) with greater reduction in men after five 
years253,254. 
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FIGURE 81. PREVALENCE OF AGW IN MEN ATTENDING SHCS IN AUSTRALIA BEFORE AND AFTER THE 
INTRODUCTION OF THE QUADRIVALENT VACCINE TO WOMEN AGED 12-27 IN 2007.  
 
Adapted from Donovan et al,  2011254. P test for trend within the pre-vaccine period or the vaccine period (grey region). 
 
10.4 WOULD A TARGETED HPV VACCINE PROGRAMME FOR MSM IN THE UK, 
DELIVERED IN SHCS, BE LIKELY TO BE COST-EFFECTIVE? 
10.4.1  IS A PROPHYLACTIC HPV VACCINE PROGRAMME TARGETED AT MSM 
ATTENDING SEXUAL HEALTH CLINICS LIKELY TO INTERVENE TOO LATE IN THEIR LIFETIME TO 
BE EFFECTIVE? 
SHCs are arguably the most feasible setting to deliver MSM-targeted vaccines in the 
National Health Service (NHS) yet they serve an MSM population that differs in terms of 
HPV-exposure, sexual experience, age and setting from the MSM vaccine trial population 
(page 238238). Because of the age-relationship of HPV infection in women, there is a high-
level assertion in this field that age is the most important variable to consider for targeting 
the HPV vaccine in other populations (including MSM) because of four underlying 
assumptions: 
A. The vaccine is not therapeutic and current HPV infection in women is related to age; this has 
been taken to imply that the vaccine is wasted on those already infected and that those 
infected are older (current HPV infection) 
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B. Age is related to cumulative risk of exposure and intervention is most effective prior to 
exposure, so vaccine programmes have not been considered worthwhile in populations  with 
prior exposure (prior HPV exposure) 
C. HPV incidence declines with age reducing the need for preventive interventions (future risk 
of HPV infection) 
D. Following infection, HPV-related cancer takes years to develop; vaccines would be wasted in 
older populations who would be more likely to die of other causes before developing HPV-
related cancer. (future risk of HPV-related disease) 
Considering the findings from this thesis, and those of others, the strength of these 
assumptions, in relation to MSM populations, is discussed below and summarised at the end 
of this section (Box 12, page 253). 
A. CURRENT HPV INFECTION: HPV INFECTION ONLY PARTIALLY REDUCES VACCINE 
EFFICACY AND HR-HPV INFECTION IS NOT RELATED TO AGE IN MSM  
HPV vaccines do not alter the course of a pre-existing infection97–101. In HIV-positive MSM, 
detection of anal HPV11 DNA at baseline was associated with lower post-vaccine anti-
HPV11 concentrations and likewise for HPV16241. Therefore MSM infected with any vaccine-
preventable type at the time of intervention would continue to be at risk of developing HPV-
related diseases unless the infection clears. However, if vaccinated while infected, following 
clearance there is evidence that the vaccine confers protection against re-infection from the 
cleared types239,243,255. Furthermore, MSM infected with some, but not all, of the vaccine 
types may still be protected against the other vaccine types and even those HPV types not 
targeted by the vaccine because of cross-protection256,257. 
As shown in chapter 5, of 522 MSM attending MMC, 68% had no detectable vaccine-type 
(6/11/16/18) HPV DNA at any tested anatomical site with the potential to be protected 
against all four vaccine types; 75% had one or fewer vaccine types detected with potential 
to be protected against the remaining three types; and 100% of the population had fewer 
than four vaccine types detected, therefore having potential to be protected against at least 
one other HPV type. In addition, each additional sexual partner increased the odds of a 
current anogenital infection (quadrivalent HPV type), after adjusting for age. However, 
there was no association between age and HR-HPV detection so, based on current infection, 
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there was no age group (between 18 and 40 years) in which the vaccine should be targeted 
or avoided.  
B. PRIOR HPV INFECTION: THE IMPACT OF PRIOR EXPOSURE ON REDUCING VACCINE 
EFFICACY IS LIKELY TO BE SMALL  
Cumulative exposure to HPV infection cannot be determined from DNA detection because 
the majority of infections are transient. In chapters 6 and 7, in addition to those with a 
current HPV6/11/16/18 infection (32%), a further 30% of the MMC MSM had evidence of 
prior exposure to HPV, either detected because of seroconversion (HPV types 16/18) (Table 
27, page 168) or a diagnosis of AGWs (LR-HPV; Table 31, page 185).  Having already been 
exposed to HPV, or having a pre-existing infection at the time of vaccination (current, as 
above) would reduce vaccine effectiveness if: 
• That exposure had resulted in effective lifelong immunity against all vaccine types, 
in which case there would be no need for vaccine-induced immunity; the vaccine 
would be redundant.  
• Prior exposure to HPV resulted in an infection that did not resolve, but instead a 
state of viral latency, and the vaccine was not efficacious at preventing re-
activation.  
• Exposure to and clearance of HPV interferes with the mechanism that leads to 
vaccine-induced immunogenicity.   
Here, the complexity in measuring prior exposure is discussed and the assumption that prior 
exposure substantially reduces vaccine effectiveness is challenged by describing the 
duration and effectiveness of the immune response to HPV and the effectiveness estimates 
in previously-exposed populations. 
Seropositivity as a marker for prior exposure 
Antibody detection lacks sensitivity for measuring previous HPV exposure because of low 
seroconversion rates85,236,258,259 and unknown duration of detection. For example, only 8% of 
HIV-negative MSM with detectable anogenital HPV16 DNA in Amsterdam seroconverted to 
HPV16 within a year259. It is likely that HPV infection-induced antibodies in MSM are short-
lived. In chapter 6, the strong association that was found between type-specific 
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seropositivity and anogenital DNA positivity would be present if both duration of infection 
and duration of detectable antibodies following infection were short-lived. On the other 
hand, if antibodies remained at detectable concentrations for life and there was a high 
turnover of infections, there would be no association with current infection.   
If seropositivity (detectable IgG) reverts to seronegativity (undetectable IgG) within a couple 
of years of exposure, due to waning serum antibodies, then estimates of seroprevalence are 
poor markers for cumulative risk. Prior exposure to the bivalent vaccine types in the HPV-
MSM-MMC population would have been substantially underestimated.  
History of AGW as a marker for prior exposure 
History of AGW is also likely to be an insensitive marker for prior exposure to LR-HPV 
infection because not all LR-HPV infections will develop into AGW, not all AGW episodes will 
be detected by the individual and not all detected episodes will be diagnosed. In addition, in 
the HPV-MSM-MMC study, recall bias would have been likely as men were reporting on 
lifetime diagnoses, perhaps in the context of a complex STI history, which could have 
introduced confusion. The specificity of an AGW diagnosis for LR-HPV infection should be 
considered as some cases may be misdiagnosed and there is some evidence that HR-HPV is 
also associated with AGW260,261. It is probable that all diagnosed AGW are caused by LR-HPV 
but that in 20-50% of cases there are multiple type infections which include HR-HPV262. 
Effectiveness of natural immunity against re-infection 
It is not clear that antibodies resulting from infection are efficacious against re-infection as 
they are found at much lower concentrations than vaccine-induced antibodies and 
seroconversion is not necessary for clearance of an HPV infection. In MSM in the 
Netherlands, seropositivity, resulting from natural infection, regardless of antibody 
concentration at baseline, was not associated with a reduction in incident HR-HPV infections 
after a year263.  
Cell-mediated immune responses (CMI) were not measured in the HPV-MSM-MMC study. 
Considering that HIV infection, which depletes T cell function, increases HPV 
susceptibility264, CMI is likely to be important in the successful resolution of HPV infections. 
The extent to which CMI is important in preventing re-infection, including by other HPV 
248 
 
types, is not known. It is therefore difficult both to measure prior exposure to HPV and to 
establish the protective value of having successfully resolved an HPV infection. 
Relevance of prior exposure to expected vaccine effectiveness 
In the HPV-MSM-MMC study, the median age of first attending a SHC in the UK was 24 
years, an average of five years after anal sex debut. During that five-year period, MSM are 
likely to have been exposed to the common HPV types, which may not be detectable from 
measuring seropositivity and/or AGW history.  
Not only is prior exposure to HPV infection difficult to measure but it is also of questionable 
relevance to expected vaccine effectiveness. HPV exposure does not result in effective 
lifelong immunity against all vaccine types, and there are expected fluctuations in CMI 
competency during a lifetime, especially if infected with HIV. So there is benefit in 
immunising previously exposed MSM to prevent infections with HPV types to which they 
have not yet been exposed and to prevent re-infections, especially during periods when 
natural immunity has waned or is impaired. The probability that prior HPV exposure does 
not strongly influence vaccine effectiveness is supported by evidence that the quadrivalent 
HPV vaccine is efficacious in preventing recurrent high-grade AIN in older MSM with a 
history of HPV-related AIN239.  
C. FUTURE RISK OF HPV INFECTION: VACCINES ARE STILL NEEDED IN OLDER MSM WHO 
REMAIN AT HIGH RISK OF HPV INFECTION 
The remaining risk of infection after a specific age is determined by the subsequent lifetime 
cumulative incidence. Cumulative incidence, the number of new infections in a population 
in a given time period, can be estimated from age-specific HPV prevalence, age-specific STI 
transmission behaviours, and age-specific HPV seroprevalence (cumulative HPV infection). It 
can also be directly measured in longitudinal studies of incidence and duration of HPV 
infection.  
HIV infection increases susceptibility to HPV infection which increases the frequency of HPV 
detection in HIV-positive populations, either as incident infections or reactivations from 
latency264. HPV incidence in MSM will therefore also depend on the prevalence of HIV 
infection in the MSM population.  
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Estimating age-specific incidence 
Age-specific cumulative risk of infection, measured as seroprevalence or history of AGW, 
cannot accurately predict age-specific incidence because sensitivity and specificity for HPV 
infection are too low and duration of infections and frequency of re-infections, which would 
be counted once as seropositive, are unknown. 
In both chapters 6 and 7, the age relationship with seropositivity and AGW was confounded 
by lifetime number of partners, which also predicted current HPV infection. The study found 
that recent (last year) high rates of partner change were more influential than lifetime 
partner numbers in predicting current and prior HPV infection, so number of partners in the 
last year may represent a useful proxy measure for HPV transmission and associated 
incidence. In chapter 4, number of partners in the last year in the HPV-MSM--MMC study 
was not associated with age; a high rate of partner change was maintained between 16 and 
40 years old. Behavioural measures in the HPV-MSM-MMC study therefore do not suggest 
that there would be a decline in HPV incidence with age.  
Incidence can be estimated from current HPV prevalence, provided the duration of infection 
is known. The distribution of duration of infection is likely to change with age and due to 
other co-factors such as HIV infection. The finding in chapter 5 that HR-HPV prevalence was 
not associated with age could suggest that duration of infection and  incidence of HR-HPV 
are constant with age, or that duration of infections increase with age, whilst incidence 
declines.  
In men the median time to clearance of genital HPV16 or any HR-HPV  was estimated to be 
12.2 and 7.2 months, respectively265.  In HIV-positive MSM in Montreal, the mean duration 
of anal HPV16 infection was 35.8 months93. 
Longitudinal studies measuring incidence  
Cross-sectional assessments of HPV prevalence cannot provide estimates for the dynamic 
processes underlying the spread of HPV infection. Longitudinal studies of anogenital HPV 
infection have estimated HPV type-specific incidence and suggests a high turnover of 
infections. For example,  HIV-negative MSM in Thailand had a 12-month cumulative 
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incidence of 7.2% (95% CI 3.0-17.5%) and 33.9% (21.1-54.5%) for HPV16 and HR-HPV, 
respectively172. 
Recently, in young MSM (median 19 years), in Melbourne, Australia, the incidence of anal 
HPV16 and HPV16/18 DNA detection was 10.2 and 22.1 per 100 person-years, respectively. 
It was 40.8 per 100 person-years for any quadrivalent vaccine types and 55.2 for any 9-
valent type. For definite infections, those detected at two or more consecutive visits, the 
incidence estimates were 13.6, 31.3 and 34.9 per 100 person-years for bivalent, 
quadrivalent and 9-valent vaccine types, respectively. The authors identified that the 
incidence rates in young MSM were three to four times higher than those in women of the 
same age195.  
In older HIV-negative MSM (median 38 years) in Amsterdam, the incidence of anal HPV16 
DNA detection was 9.7 per 100 person-years263, similar to that in the young Australian MSM 
population. In an HIV-positive MSM population (mean age 45 years), in San Francisco, the 
incidence of anal HPV16 DNA detection was 14.8 per 100 person-years and in HIV-positive 
MSM in Montreal, Canada (median age 43 years), it was 13.0 per 100 person-years93.  
In the young Australian MSM population, penile incidence was lower than anal incidence 
and simulation, using the vaccine trial population as sexual partners, resulted in estimates of 
the per-partner transmission probabilities by HPV type and according to whether sex was 
insertive or receptive. Approximately 46% of receptive anal sex partnerships resulted in 
transmission of HPV16 and HPV11 infections (63% for HPV18 and HPV6). The transmission 
risk was much lower for insertive anal sex partnerships (range=0.8-9.3%). This is consistent 
with findings from chapter 5, where positioning during condomless sex and receptive anal 
sex, but not insertive anal sex, were risk factors for HPV detection. 
The incidence of oral HPV infections was higher in HIV-positive than HIV-negative MSM in 
Amsterdam. For example, the incidence of detectable HPV16 DNA in the oral cavity was 4.2 
per 100 person-years in HIV-positive MSM and 1.1 in HIV-negative MSM266.  
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Given these high rates of new infections in MSM populations of all ages, the expected 
cumulative lifetime risk would remain high in older MSM compared to in older women, 
where incidence declines after a peak in the youngest age group (18-24 years)71. 
Factors other than age and rate of partner change that affect HPV infection risk 
Cumulative incidence is also influenced by factors, other than age and lifetime partner 
number, that increase susceptibility to HPV. For example HIV and smoking are thought to 
alter the risk and progression of HPV infection262. In the HPV-MSM-MMC population, 
current smoking was measured and prevalence was similar (29.4%) to that in men aged 25-
34 in the general population (30.4%159) and there was no association with HPV status. In 
fact, few demographic and behavioural factors were associated with HPV infection (chapter 
5) or history of infection (chapters 7 and 8). The factors found to associated with HPV 
exposure were HIV status, number of partners, use of drugs in the anus, recent receptive 
anal intercourse and positioning during condomless receptive anal sex. There were high 
levels of correlated STI transmission behaviours reported among participants in the HPV-
MSM-MMC study, and because these risk factors were not broadly distributed, it was 
difficult to establish which specific behaviours were associated with markers for HPV.  
In chapter 7 it was shown that 5% of HPV-MSM-MMC participants had been diagnosed as 
HIV-positive, which is similar to that estimated for MSM in London (6.6% diagnosed) but 
higher than the estimate outside London (2.5% diagnosed)267. The median age of HIV 
diagnosis for MSM in the UK was 34 in 2013268, so HPV-MSM-MMC participants were still at 
risk of HIV infection which would result in a lower HIV prevalence estimate in this younger 
population. It is estimated, using the GMSHS, that 20% of MSM in the UK have undiagnosed 
HIV224,267. In a SHC, where annual testing is promoted, with 83% offered and 95% uptake in 
2014269, this proportion is likely to be lower, however there is still potential for HIV-positive 
MSM to have been misclassified as HIV-negative in this study. 
As a cohort of MSM ages, those with higher STI transmission behaviours are more likely to 
become HIV-positive, which increases their future risk of HPV. The residual HIV-negative 
population is also affected, becoming smaller with lowered average risk behaviour.  These 
changes in the denominator for HIV-negative and HIV-positive MSM over time should be 
considered when exploring the associations of HPV with age in MSM. 
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Furthermore, recent changes in HIV treatment guidelines will impact on HPV epidemiology 
in HIV-positive populations. In the UK, and elsewhere, ART is now initiated earlier in HIV 
infection, at higher CD4+ T cell counts, than in the cohorts studied for HPV-related cancer 
incidence in this thesis270. HPV-related diseases are expected to be less likely in HIV-positive 
cohorts who started ART at higher CD4+ T cell counts. This is partly because the population-
average nadir CD4+ count will be higher, so there will be less loss of immune system 
functionality following ART-related immune reconstitution, which may result in increased 
HPV clearance and reduced HPV-related disease progression271.  
Relevance of future risk of HPV infection to expected vaccine effectiveness 
The future risk of HPV infection was estimated in the HPV-MSM-MMC study to be constant 
across the age-range of participants (18-40 years), having measured both age-specific STI 
transmission behaviours, for example number of anal sex partners in the last year, and 
markers for HPV exposure, including current infection. This leads to the conclusion that 
there is significant remaining risk of HPV infection in MSM attending SHCs in the UK, which 
could be prevented by HPV vaccines. This is in contrast to women who reduce partner 
change rates after a peak age (approximately 24 years) with an associated decline in HPV 
prevalence. 
D. FUTURE RISK OF DEVELOPING HPV-RELATED DISEASE: THE EXPECTED PERIOD OF 
REMAINING LIFE FOLLOWING FIRST SHC ATTENDANCE IS SUFFICIENT FOR ANAL CANCER 
DEVELOPMENT 
The earlier vaccination occurs the more the potential it has to benefit the MSM population, 
not only because of the greater the size of the HPV-naïve portion and the greater the future 
risk of infection but also because of the slow rate of disease progression for HPV-related 
cancers. Following HPV infection, the probability of dying from other causes, before the 
onset of carcinoma, increases with age and reduces the benefit of vaccination. 
If anal cancer, like cervical cancer,  takes approximately 30 years to develop272, in an average 
80 year lifetime273, the opportunity to prevent considerable disease burden remains after 
age 24, the median age of first attending a SHC (Chapter 8). 
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BOX 12. SUMMARY: SUBSTANTIAL BURDEN OF VACCINE-PREVENTABLE HPV IN MSM, AFTER SEXUAL 
DEBUT, HPV EXPOSURE AND SHC-ATTENDANCE 
A: Current infection 
 • Whilst the vaccine is not therapeutic, the reduction in re-infections and the prevention of other 
type infections does not preclude its use in MSM with pre-existing infections 
• Current HR-HPV infections are not associated with age in MSM so only considering current 
infection, there are no age groups, between 16-40 years, that should be targeted 
B: Prior exposure  
 • Cumulative risk of HPV exposure is associated with lifetime number of partners, which is 
associated with age 
• Seropositivity and history of AGWs provide underestimates of prior HPV exposure  
• Whilst vaccine effectiveness is optimal in HPV-naïve populations, MSM attending SHCs are 
unlikely to be naïve to all vaccine types 
• The reduction in vaccine effectiveness related to prior exposure is likely to be small 
C: Future risk of HPV infection:  
 • MSM remain at high risk of HPV infection after attending SHCs, at least until the age of 40  
D: Future risk of HPV-related cancer development 
 • After first SHC attendance, MSM have sufficient remaining life years to develop HPV-related 
AGW and cancer 
 
 
  
254 
 
10.4.2  INTERRUPTION OF HPV TRANSMISSION IN MSM IN THE UK 
Having established that there is an opportunity to prevent a significant amount of HPV 
infection and disease in MSM younger than 40 years, attending SHCs (Box 12, page 253), the 
question remains: what coverage of the MSM population could be expected in terms of 
proportion expected to receive the HPV vaccine at SHCs and HPV transmission 
characteristics of those vaccinated? This question is addressed in terms of: 
• Expected direct effects of an SHC HPV vaccine programme, including; 
o expected vaccine uptake at SHCs,  
o expected attendance at SHCs , and 
• Expected indirect effects of the proposed vaccine programme. 
VACCINE UPTAKE 
Nearly all (96%) of HPV-MSM-MMC participants reported that they would probably or 
definitely accept the HPV vaccine at a SHC, as shown in chapter 8. Misconceptions relating 
to vaccine safety and requirement of additional information were the most frequently 
reported potential barriers to uptake. Furthermore, knowledge relating to risk of HPV 
exposure and lack of treatment for infection was poor and likely to result in falsely low 
perception of HPV risk, a determinant of vaccine uptake. Given these findings, it is likely that 
an educational component to a vaccine programme would improve HPV vaccine uptake in 
MSM at SHCs.    
MSM USE OF HEALTH SERVICES 
There is a suggestion that use of SHCs is increasing in MSM with 30% (95% CI 20.1–41.2%) 
reporting attending a SHC in the last 5 years in Natsal-1 in 1990, 36% (95% CI 27.2–44.9%) in 
Natsal-2 in 2000 and 45% (95% CI 35.0–55.5) in Natsal-3 in 2010-20128,274. Also, attendance 
appears to be higher in MSM populations in cities: of MSM participating in the GMSHS in 
2011 in London 457/834 (55%) attended an STI clinic in the previous year156. In 2010, 
between 40 and 44% of respondents to the European MSM internet survey living in 
Birmingham (135/338; 40%), Manchester (241/586; 41%) and London (2100/4816; 44%) 
reported an STI screen in the last year275. Considering these data, it is reasonable to 
estimate that at least half of the UK’s young MSM population today will access an SHC in 
their lifetime.  
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Furthermore, the findings in chapter 8 suggest that other services would not be successful 
at reaching at-risk MSM. For HPV-MSM-MMC participants, the SHC was the preferred 
service for AGW diagnosis and treatment and for HBV vaccination. For example, less than 
half of participants that visited their GP in the last year had disclosed their sexuality.  
In addition, it is possible that younger MSM would attend specifically to access the HPV 
vaccine if it was known to be available and this would result in a lower median age at first 
attendance, increased capture of HPV-naïve MSM and increased vaccine effectiveness. 
Unlike the HBV vaccine, the cervical cancer HPV vaccine promotion activities are likely to 
have resulted in widespread awareness of HPV vaccines, especially in school-age children, 
and could provide additional motivation to get protected. Younger men, including MSEW, 
may be more likely to attend for HPV vaccination, especially as health promotion has 
targeted younger ages. 
MSM AND THE INDIRECT OF EFFECTS OF HPV VACCINATION  
‘High’ HPV vaccine coverage was defined as coverage of at least half of the population in a 
recent meta-analysis of population-level impacts of HPV vaccination251. Quantifying vaccine 
coverage does not take into account the heterogeneity of populations with respect to STI 
transmission risk behaviours. Vaccinating sub-populations with more network connections 
and higher Rn more efficiently interrupts transmission compared to vaccinating sub-
populations, such as those who do not attend SHCs with lower rates of partner change. 
Assuming that they are not already immune, vaccination of SHC-attending MSM probably 
represents the most efficient way to interrupt HPV transmission in MSM because it targets 
those at highest risk of acquiring and transmitting HPV and therefore will maximise direct 
and indirect protective effects. 
SHC-attending MSM, especially those in London, probably have a higher HPV Rn than the 
wider MSM population. High STI transmission behaviour (chapter 4) and high prevalence of 
syphilis (chapter 7), a marker for increased STI transmission276, were found in the HPV-MSM-
MMC population compared to other MSM populations in the UK. The higher HPV Rn in SHC-
attending MSM is probable, not only because SHC-attending individuals are health-seeking, 
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in part, because of perceived risk, which is likely to reflect “risky” behaviour156, but also 
because living in London is associated with a variety of complex individual and socio-cultural 
influences that increase STI transmission risk behaviour277. This London bias should be 
considered when generalising the results in this thesis beyond London MSM populations. 
Heterogeneity in the value of HPV Rn across MSM sub-populations has implications for HPV 
control, and these depend on the amount of sexual mixing between men residing in 
different geographical regions, including outside the UK. By lowering the disproportionately 
large Rn of the SHC-attending MSM sub-population, through vaccination, the overall Rn 
should be efficiently lowered. The SHC-attending MSM population is probably dynamically 
important in the UK’s MSM sexual network.  Interrupting transmission in this part of the 
network would therefore confer substantial indirect benefits to MSM with fewer STI 
transmission risk behaviours in the wider MSM population.  
The SHC-attending MSM population might also receive small indirect benefits from the 
current routine vaccination programme in girls since 8% of HPV-MSM-MMC participants 
reported having had vaginal sex in the last year. Findings from the meta-analysis in chapter 
3, where there was no evidence that MSM were at increased risk of oral HPV compared to 
heterosexual men were supported in chapter 5, where anal sex with women was associated 
with oral HPV infection in the MSM at MMC. The latter should be interpreted with caution 
given the low oral HPV prevalence and reduced sample size for this analysis. There is a 
possibility that the indirect consequences of female vaccination in MSM would be greater at 
the oral site than the anogenital.   
At MMC, 85% of MSM had lived in the UK for more than three years (38%) or were born 
there (47%). Migration in and out of the UK would impact on vaccine effectiveness and cost-
effectiveness. If MSM entered from regions with gender-neutral HPV vaccine programmes 
herd immunity would increase but would decrease if MSM entered from unvaccinated 
regions with high HPV prevalence. Vaccinated MSM leaving the UK would reduce cost-
effectiveness of a targeted HPV vaccine programme at SHCs.  
Over half of HPV-MSM-MMC participants (256/504) were born outside the UK, of whom 
three-quarters (193/256) had lived in the UK for more than three years (chapter 4, page 
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104). This indicator of migration is unlikely to be generalizable to the rest of the UK, because 
London represents a unique multicultural setting, but highlights an important consideration.  
Migration should be considered when comparing vaccine coverage of the MSM population 
through a gender-neutral school-based programme to a targeted SHC-delivered 
programme. HPV vaccine programme effectiveness would be over-estimated if the 
emigration of vaccinated MSM and the immigration of unvaccinated MSM were not 
included in assessments, which effectively reduce vaccine coverage. Vaccinating MSM at 
SHCs would be cheaper than a gender-neutral programme and, given migration patterns, 
might also result in higher coverage of the MSM population. This is especially significant 
given that a gender-neutral programme would only be considered for the prevention of 
disease in MSM.  
Given the enthusiasm for the HPV vaccine and the exceptionally high STI transmission risk 
behaviours demonstrated in the HPV-MSM-MMC study as well as the frequent use of SHCs 
by MSM in the UK, approximately half of the UK’s MSM population, representing the ‘inner 
core’ of the MSM core risk group, could be expected to receive the HPV vaccine at SHCs and 
this should have significant effects on MSM who do not attend SHCs. 
ESTIMATES FOR MSM-TARGETED SHC-DELIVERED HPV VACCINE PROGRAMME 
EFFECTIVENESS AND COST-EFFECTIVENESS. 
Vaccine effectiveness 
In chapter 9, percentage reduction in anal HPV16 prevalence and anal cancer incidence 
were estimated as measures of vaccine effectiveness in a cohort of MSM from age 10 to 77. 
Given that the expected vaccine impact on other HPV types, on other HPV-related diseases 
at other anatomical sites, in MSM older than 77 and those not attending SHCs, and women 
in the UK, were not modelled, these estimates represent the minimum potential reduction. 
Substantial reductions in anal cancer incidence were projected, with HIV-positive MSM 
benefiting to a greater extent than HIV-negative MSM, probably due to higher vaccine 
coverage estimates. Targeting HIV-negative MSM at their first SHC attendance was not as 
effective as targeting MSM at any attendance and duration of vaccine-induced immunity 
significantly influenced estimates.  
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The preliminary work presented in chapter 9 has been expanded and refined by colleagues 
at PHE to include transmission, parameter uncertainty, all quadrivalent vaccine types and 
additional outcomes, including AGWs and penile, oropharyngeal and oral cancers yet the 
results remain confidential (Appendix VII, page 335).  
Vaccine cost-effectiveness  
For a vaccine programme to be implemented, it has not only to be feasible with substantial 
expected effectiveness, but also affordable. In the UK, decisions are influenced by the 
incremental cost-effectiveness ratio, a measure of the cost-effectiveness of an intervention 
strategy; relative costs and effects of vaccine programme implementation compared to no 
vaccine programme278.  
The direct healthcare costs associated with no vaccine programme (the status quo) are a 
function of incidence of, and costs associated with, vaccine-preventable outcomes. Anal 
cancer is rare in HIV-negative MSM but more common in HIV-positive MSM and, when 
diagnosed, is associated with expensive treatment (approximately £15, 000 per cancer case 
in the NHS in 2009) which may include surgery279,280. In contrast, as shown in chapter 7, 
AGWs are very common in MSM and each episode is estimated to cost the NHS £113281.  
The costs associated with implementing a vaccine programme include both programme 
costs: vaccine price, delivery, administration and health promotion, and costs associated 
with breakthrough disease. Here, breakthrough disease refers to cases in MSM who were 
not vaccinated, in MSM in whom the vaccine was not effective and cases resulting from 
non-vaccine types. The proportion of anal cancer attributed to vaccine-type HPV infections 
is lower than that for AGW and therefore proportionally more breakthrough cases of anal 
cancer might be expected. 
The effects of no vaccine programme are usually measured using the reduction in quality-
adjusted life years (QALY), which measure both the quality and quantity of life lived. Similar 
to the pattern with cost, anal cancer is less frequent and associated with greater reduction 
in quality and length of life compared to AGWs, which are more frequent with less, but 
significant, reduction of quality of life282. The effects of the vaccine programme depend on 
vaccine coverage, the number of cases averted and the QALYs gained.  
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The rate of disease progression is higher for AGW than for cancer and this is relevant for 
estimating costs and benefits because the reduction in AGW will occur sooner after vaccine 
introduction than the reduction in cancer. In economic models, future costs and benefits are 
standardised to present values by attaching declining weights to future events (discounting). 
Therefore, the QALYs gained by averting cancer cases (that take approximately 30 years to 
develop) will, in discounted models, be reduced more than the QALYs gained by averting 
AGW cases raising the influence of AGW prevention in the contribution to overall vaccine 
effectiveness. 
This is important when comparing a school-based gender-neutral vaccine programme, 
which would intervene, on average, a decade earlier than an SHC-based vaccine 
programme. The accrual of cancer-related benefits, using a SHC-based programme, would 
occur, approximately a decade earlier than a school-based programme. The cancer-related 
benefits would therefore be significantly more discounted in a school-based model 
(discount factor=0.36; discounting to 3.5%) compared to a SHC-based model (discount 
factor=0.50; discounting to 3.5%). 
HPV vaccine policy in the UK 
As displayed in Box 13, in the UK, in 2008, the Joint Committee on Vaccination and 
Immunisation (JCVI), acknowledged a lack of evidence to assess the value of an HPV vaccine 
programme targeted at MSM. In 2012, the routine programme in girls switched to the 
quadrivalent vaccine and the JCVI issued a call for evidence for potential benefits of HPV 
vaccine for those not currently offered immunisation, particularly men who have sex with 
men (MSM)283. In 2014, the JCVI recommended a switch from the three-dose to a two-dose 
schedule for the quadrivalent vaccine in girls aged younger than 15 years284.  
The JCVI has now assessed the MSM-targeted HPV vaccine programme (October 2014). The 
Committee discussed prevalence estimates from chapter 5 alongside the transmission 
model of HPV infection in MSM, developed by PHE. The JCVI’s interim position, subject to 
consultation, was that the evidence indicates that a targeted programme undertaken in SHC 
and HIV clinics, using the quadrivalent vaccine, could be cost-effective, subject to availability 
of the vaccine and delivery at an appropriate price. The committee advised that it would be 
very important to closely monitor vaccine coverage and completion and the impact of the 
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programme if implemented, as the outcome would also influence the consideration of a 
programme for adolescent boys. The JCVI is currently developing its final advice to the 
Secretary of State for Health. 
BOX 13. HISTORY OF JCVI RECOMMENDATIONS AND CALLS FOR EVIDENCE 
2008 • Lack of evidence to assess the value of an HPV vaccine programme targeted at MSM 
• School-based programme in girls using bivalent vaccine (& catch-up in older girls) 
2012 • Call for evidence for potential benefits of HPV vaccine for those not currently offered 
immunisation, particularly men who have sex with men (MSM) 
• Girls school-based programme switch to the quadrivalent vaccine 
2014 • Meeting to assess the MSM-targeted HPV vaccine programme 
• Girls school-based programme switched to 2-dose schedule 
 
Further policy recommendations 
Whilst the findings of this thesis support the introduction of a targeted HPV vaccine 
programme for MSM at SHCs, further consideration of a school-based gender-neutral 
programme is warranted given that the vaccine is efficacious in girls (and probably boys) 
using a two-dose schedule, which will alter the cost: benefit ratio. Furthermore, there is 
improved data availability for other HPV disease outcomes and vaccine coverage that could 
inform an updated assessment of including boys in the current routine school-based 
programme19. If a gender-neutral programme is recommended then a catch-up programme 
in MSM would still be likely to be beneficial. 
The UK’s central government would need to procure the HPV vaccine in order to negotiate 
the lowest price. This has implications for a targeted programme that would be delivered as 
part of integrated sexual health services, which are commissioned by local governments, 
and possibly as part of HIV treatment and care services, which are commissioned by NHS 
England285. The commissioning system would therefore need to be adapted in order to 
deliver a targeted vaccine programme, having procured the vaccine at the minimum cost. 
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If a targeted HPV vaccine programme is implemented, both programme evaluation and 
monitoring would be required for continued strategic decision-making. Programme 
evaluation aims to assess the overall relevance, efficiency, effectiveness, sustainability or 
impact of the programme design, implementation and outcomes. Plans for targeted HPV 
vaccine programme evaluation will need to be developed alongside plans for 
implementation.   
Monitoring is an ongoing system of gathering information and tracking programme 
performance. Indicators, such as the cross-sectional measures of HPV prevalence presented 
in this thesis, are used to measure progress.  The findings from this thesis provide not only 
detailed baseline data prior to HPV vaccine programme implementation, but also data on 
the relative detection of HPV DNA at different anatomical sites, which suggest that in MSM, 
the optimal sample for monitoring HPV infection is the anal swab. 
Conclusion 
This thesis aimed to inform the policy decision of whether to vaccinate MSM attending SHCs 
in the UK (page 21). It provides strong evidence for HPV vaccine effectiveness in MSM 
attending SHCs in the UK and has provided evidence of effectiveness to the JCVI for their 
decision-making. A substantial burden of HPV infection could be prevented after sexual 
debut, after HPV exposure and after first SHC attendance in MSM. A third of HPV-MSM-
MMC participants had no evidence of HPV infection, an additional third showed evidence of 
prior infection, which may have little reduction on vaccine efficacy, and a further third had 
current infection with one or more of the quadrivalent vaccine types so could still benefit 
from protection from re-infection from those type(s) and infection from other vaccine HPV 
types.  
At least half of the UK’s MSM population could be expected to receive the HPV vaccine at 
SHCs and these men represent those at high risk of acquiring and transmitting HPV 
infection, so would efficiently interrupt HPV transmission. 
Building on these data and on the anal cancer model in chapter 9, a refined transmission 
model was developed by PHE that estimated that the targeted programme is also expected 
to be cost-effective. If the JCVI now recommends this programme, the UK’s complex health 
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commissioning system would need to be adapted in order to procure the vaccine at the 
lowest price. A programme that includes public engagement, including education, should be 
developed to enhance uptake. Monitoring and evaluation of such a programme would be 
needed, and would include measuring HPV prevalence and medium- to long-term cancer 
incidence in MSM.  
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APPENDIX II. RESULTS FROM THE QUESTIONNAIRE PILOT 
Pilot 1 Could not answer open-ended “Altogether in your life so far, with how many men have 
you had sex (that is anal or oral sex)?” 
Could not even guess “Number of partner’s partners”. Need a don’t know option 
 
Pilot 2 Wanted to know the answers to the knowledge questions at the end 
Pilot 3 Could not answer open-ended “Altogether in your life so far, with how many men have 
you had sex (that is anal or oral sex)?” 
Wanted more information for the vaccine likelihood question. Asked if this could be an 
option 
 
Pilot 4 Could not answer open-ended “Altogether in your life so far, with how many men have 
you had sex (that is anal or oral sex)?” 
Suggested simplifying the “new partners in the last year” section 
Age of partner needs to be a category 
Certain of age? Needs to be in line 
Change order: partner’s partners to after age of partner 
HIV test question. Make clearer 
 
Pilot 5 Could not answer open-ended “Altogether in your life so far, with how many men have 
you had sex (that is anal or oral sex)?” 
Wanted more information for the vaccine likelihood question. Asked if this could be an 
option 
Pilot 6 Could not answer open-ended “Altogether in your life so far, with how many men have 
you had sex (that is anal or oral sex)?” Ranges would work. 
Number of condomless partners: need to remind that this still applies to exclusively oral 
sex partners 
Partner’s partners estimation: Allow free text e.g. "a lot", could guess if ranges were 
given 
Risk perception: need another question. Compared to other MSM your age… 
Where HBV vaccinated. Need to convert to tick all that apply. 
 
Pilot 7 Could not answer open-ended “Altogether in your life so far, with how many men have 
you had sex (that is anal or oral sex)?” Ranges would work. 
Partners altogether and last year oral: Needs to be approximately. 
Number of condomless partners: need to remind that this still applies to exclusively oral 
sex partners 
Partner’s partners estimation: Allow free text e.g. "a lot", could guess if ranges were 
given 
Last time you had sex with…: Layout needs to be clearer 
Knowledge questions: split over 2 pages 
Compared with (not to) 
 
Pilot 8 Order partners in the last year. New partners above condomless so it is clear is includes 
all. 
Pilot 9 No issues identified 
Pilot 10 Could not answer open-ended “Altogether in your life so far, with how many men have 
you had sex (that is anal or oral sex)?” Ranges would work. 
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APPENDIX III. AGE-SPECIFIC PREVALENCE DATA  
APPENDIX TABLE 1. AGE-SPECIFIC ANOGENITAL HPV DATA IN 511 MSM (DATA FOR FIGURE 31) 
HPV type Age Prevalence (%) 95% CI 
Frequency of detecting HPV DNA 
in any anogenital specimen in 
participants of the HPV-MSM-
MMC study with at least one 
anogenital sample that was 
adequate for HPV testing 
(n=511). 
Data are displayed graphically in 
chapter 5, Figure 31, page 124. 
any HPV 
18-20 58.8 32.9-81.6 
21-25 68.1 58.9-76.3 
26-30 67.7 58.8-75.7 
31-35 74.3 66.2-81.3 
36-40 81.5 72.9-88.3 
    
HR-HPV 
18-20 41.2 18.4-67.1 
21-25 40.3 31.4-49.7 
26-30 48.0 39.1-57.1 
31-35 50.0 41.4-58.6 
36-40 50.9 41.1-60.7 
    
Quadrivalent vaccine type HPV 
18-20 29.4 10.3-56.0 
21-25 29.4 21.4-38.5 
26-30 36.2 27.9-45.2 
31-35 27.9 20.6-36.1 
36-40 38.0 28.8-47.8 
    
9-valent vaccine type HPV 
18-20 41.2 18.4-67.1 
21-25 40.3 31.4-49.7 
26-30 49.6 40.6-58.6 
31-35 41.4 33.2-50.1 
36-40 51.9 42.0-61.6 
    
HPV6 
18-20 17.6 3.8-43.4 
21-25 6.7 2.9-12.8 
26-30 9.4 5.0-15.9 
31-35 10.0 5.6-16.2 
36-40 10.2 5.2-17.5 
    
HPV11 
18-20 17.6 3.8-43.4 
21-25 13.4 7.9-20.9 
26-30 11.0 6.2-17.8 
31-35 6.4 3.0-11.9 
36-40 15.7 9.4-24.0 
    
HPV16 
18-20 0.0 0.0-19.5 
21-25 13.4 7.9-20.9 
26-30 17.3 11.2-25.0 
31-35 13.6 8.4-20.4 
36-40 11.1 5.9-18.6 
    
HPV18 
18-20 11.8 1.5-36.4 
21-25 5.9 2.4-11.7 
26-30 5.5 2.2-11.0 
31-35 5.0 2.0-10.0 
36-40 8.3 3.9-15.2 
    
HPV31/33/45/52/58 
18-20 17.6 3.8-43.4 
21-25 16.8 10.6-24.8 
26-30 27.6 20.0-36.2 
31-35 20.0 13.7-27.6 
36-40 22.2 14.8-31.2 
    
HPV16/18 
18-20 11.8 1.5-36.4 
21-25 16.8 10.6-24.8 
26-30 21.3 14.5-29.4 
31-35 17.9 11.9-25.2 
36-40 18.5 11.7-27.1 
    
HPV6/11 
18-20 23.5 6.8-49.9 
21-25 17.6 11.3-25.7 
26-30 19.7 13.2-27.7 
31-35 13.6 8.4-20.4 
36-40 24.1 16.4-33.3 
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APPENDIX TABLE 2. AGE-SPECIFIC HPV SEROPREVALENCE IN 506 MSM (DATA FOR FIGURE 46) 
  TOTAL (N=506) HIV negative (N=480) HIV positive (N=26) 
HPV type Age 
Prevalence 
(%) 95% CI 
Prevalence 
(%) 95% CI 
Prevalence 
(%) 95% CI 
HPV16  
seropositive 
 
18-20 6.3 0.2-30.2 6.3 0.2-30.2   
21-25 19.8 13.0-28.3 18.9 12.1-27.5 40.0 5.3-85.3 
26-30 30.8 23.0-39.5 28.5 20.7-37.3 71.4 29.0-96.3 
31-35 29.5 22.1-37.8 26.9 19.5-35.4 66.7 29.9-92.5 
36-40 37.1 27.9-47.1 37.0 27.6-47.2 40.0 5.3-85.3 
    
    
HPV18  
seropositive 
 
18-20 6.3 0.2-30.2 6.3 0.2-30.2   
21-25 9.5 4.8-16.3 8.1 3.8-14.8 40.0 5.3-85.3 
26-30 14.6 9.0-21.9 13.0 7.6-20.3 42.9 9.9-81.6 
31-35 24.5 17.6-32.5 23.8 16.8-32.1 33.3 7.5-70.1 
36-40 21.0 13.6-30.0 21.0 13.5-30.3 20.0 0.5-71.6 
 
   
    
HPV16 and/or 18  
seropositive 
 
18-20 12.5 1.6-38.3 12.5 1.6-38.3   
21-25 21.6 14.5-30.1 20.7 13.6-29.5 40.0 5.3-85.3 
26-30 34.6 26.5-43.5 32.5 24.4-41.6 71.4 29.0-96.3 
31-35 41.7 33.4-50.4 38.5 30.1-47.4 88.9 51.8-99.7 
36-40 41.9 32.3-51.9 42.0 32.2-52.3 40.0 5.3-85.3 
 
   
  
  
HPV16 and 18  
seropositive 
 
18-20 0.0 0.0-20.6 0.0 0.0-20.6   
21-25 7.8 3.6-14.2 6.3 2.6-12.6 40.0 5.3-85.3 
26-30 10.8 6.0-17.4 8.9 4.5-15.4 42.9 9.9-81.6 
31-35 12.2 7.3-18.9 12.3 7.2-19.2 11.1 0.3-48.2 
36-40 16.2 9.7-24.7 16.0 9.4-24.7 20.0 0.5-71.6 
Data (total, N=506) are displayed graphically in chapter 6, Figure 46, page 154 
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APPENDIX TABLE 3. AGE-SPECIFIC ESTIMATES FOR LR-HPV AND AGW PREVALENCE (DATA FOR 
FIGURE 54) 
HPV type Age Prevalence (%) 95% CI 
Anogenital HPV6/11 
 
18-20 23.5 6.8-49.9 
21-25 17.4 11.1-25.3 
26-30 18.8 12.5-26.5 
31-35 13.4 8.3-20.1 
36-40 23.9 16.2-33.0 
  
  
AGW warts diagnosis at study visit 
 
18-20 17.6 3.8-43.4 
21-25 4.1 1.4-9.4 
26-30 0.8 0.0-4.1 
31-35 4.2 1.6-9.0 
36-40 5.5 2.0-11.6 
 
 
  
History of AGW 
 
18-20 17.6 3.8-43.4 
21-25 23.1 16.0-31.7 
26-30 25.8 18.5-34.1 
31-35 37.6 29.6-46.1 
36-40 35.8 26.8-45.5 
 
 
  
Data are displayed graphically in chapter 7, Figure 54, page 178 
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APPENDIX IV. RISK FACTOR ANALYSES TABLES 
ANAL AND EXTERNAL GENITAL SWABS 
 APPENDIX TABLE 4. RISK FACTORS FOR THE DETECTION OF HR-HPV DNA IN THE ANAL AND EXTERNAL GENITAL SWABS CONTINUED 
 ANAL EXTERNAL 
 Number of MSM     Number of MSM     
Risk factor HR-HPV 
neg. (n) 
HR-HPV 
pos. (n) 
OR 95% CI aOR 95% CI HR-HPV 
neg. (n) 
HR-HPV 
pos.(n) 
OR 95% CI aOR 95% CI 
HIV positive diagnosis             
no 253 167 1  1  255 154 1  1  
yes 9 13 2.33 (1.48-3.66) 2.29 (1.46-3.60) 9 16 2.21 (1.43-3.40) 2.20 (1.43-3.39) 
Each additional year in age   1.02 (0.99-1.04) N/A N/A   1.01 (0.98-1.03) N/A N/A 
Ethnic group             
White 188 147 1  1  198 130 1  1  
Black 40 18 0.63 (0.39-1.04) 0.64 (0.39-1.04) 36 17 0.78 (0.49-1.27) 0.79 (0.49-1.27) 
Asian & SE Asian 30 13 0.63 (0.36-1.11) 0.64 (0.36-1.12) 30 17 0.81 (0.49-1.33) 0.81 (0.49-1.34) 
Born in the UK             
no 143 92 1  1  150 84 1  1  
yes 118 86 1.03 (0.77-1.37) 1.04 (0.78-1.38) 116 81 1.12 (0.84-1.49) 1.12 (0.83-1.49) 
Currently smoke             
no 189 118 1  1  190 114 1  1  
yes 72 59 1.10 (0.80-1.50) 1.12 (0.82-1.53) 75 51 1.05 (0.76-1.44) 1.06 (0.77-1.45) 
Increasing or higher risk alcohol drinking (AUDIT-C)            
No 86 67 1  1  89 56 1  1  
Yes 172 108 0.91 (0.68-1.24) 0.91 (0.68-1.24) 174 107 0.88 (0.65-1.19) 0.88 (0.65-1.20) 
Currently employed             
no 54 38 1  1  54 35 1  1  
yes 207 140 0.99 (0.69-1.41) 0.93 (0.65-1.34) 212 130 0.83 (0.59-1.17) 0.80 (0.57-1.14) 
Years of education post-16             
0-2 years  35 26 1.40 (0.94-2.07) 1.42 (0.96-2.11) 28 33 1.73 (1.21-2.48) 1.74 (1.21-2.50) 
3 years or more 182 117 1  1  192 106 1  1  
Sexual orientation             
Gay/homosexual 235 168 1  1  238 154 1  1  
Bisexual 25 10 0.48 (0.23-0.97) 0.49 (0.24-1.00) 27 11 0.71 (0.40-1.27) 0.72 (0.40-1.30) 
Circumcised             
No 175 130 1  1  186 118 1  1  
Yes 83 47 0.92 (0.66-1.26) 0.91 (0.66-1.26) 78 45 0.93 (0.67-1.29) 0.93 (0.67-1.29) 
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 APPENDIX TABLE 4. RISK FACTORS FOR THE DETECTION OF HR-HPV DNA IN THE ANAL AND EXTERNAL GENITAL SWABS CONTINUED 
 ANAL EXTERNAL 
 Number of MSM     Number of MSM     
Risk factor HR-HPV 
neg. (n) 
HR-HPV 
pos. (n) 
OR 95% CI aOR 95% CI HR-HPV 
neg. (n) 
HR-HPV 
pos.(n) 
OR 95% CI aOR 95% CI 
Number of lifetime male partners (anal and oral sex)           
<31 107 44 1  1  99 40 1  1  
>=31 153 134 1.97 (1.40-2.77) 1.97 (1.38-2.82) 167 125 1.48 (1.05-2.06) 1.48 (1.04-2.10) 
Number of male sex partners in the last year            
male anal sex partners             
<10 156 79 1  1  156 67 1  1  
>=10 88 92 1.54 (1.14-2.06) 1.51 (1.13-2.04) 95 89 1.87 (1.38-2.53) 1.86 (1.38-2.52) 
New anal sex partners             
<10 173 102 1  1  175 87 1  1  
>=10 69 68 1.35 (1.00-1.82) 1.33 (0.99-1.81) 74 68 1.51 (1.11-2.04) 1.50 (1.11-2.03) 
Anal sex partners without a condom             
<10 230 154 1  1  236 139 1  1  
>=10 11 17 1.43 (0.86-2.39) 1.42 (0.85-2.36) 13 16 1.62 (1.00-2.62) 1.61 (0.99-2.61) 
Exclusively oral sex partners             
<10 175 98 1  1  176 89 1  1  
>=10 65 60 1.25 (0.90-1.72) 1.23 (0.89-1.71) 64 58 1.42 (1.03-1.95) 1.41 (1.03-1.95) 
Each additional year of age at first sex with a man            
Oral    0.97 (0.93-1.01) 0.96 (0.92-1.00)   0.97 (0.93-1.00) 0.96 (0.92-1.00) 
Receptive anal   0.98 (0.95-1.02) 0.97 (0.93-1.01)   0.97 (0.93-1.00) 0.96 (0.92-1.00) 
Oral sex with a man in last 3 months             
No 9 2 1  1  10 2 1  1  
Yes 248 175 3.23 (0.68-15.45) 3.22 (0.67-15.37) 253 161 2.07 (0.61-7.06) 2.10 (0.62-7.16) 
Receptive anal sex with a man in last 3 months            
No 106 38 1  1  92 40 1  1  
Yes 149 137 2.35 (1.64-3.37) 2.43 (1.70-3.49) 168 124 1.57 (1.12-2.20) 1.61 (1.14-2.27) 
Insertive anal sex with a man in last 3 months            
No 62 31 1  1  63 29 1  1  
Yes 185 141 1.41 (0.96-2.06) 1.39 (0.95-2.03) 196 128 1.52 (1.02-2.27) 1.52 (1.01-2.26) 
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 APPENDIX TABLE 4. RISK FACTORS FOR THE DETECTION OF HR-HPV DNA IN THE ANAL AND EXTERNAL GENITAL SWABS CONTINUED 
 ANAL EXTERNAL 
 Number of MSM     Number of MSM     
Risk factor HR-HPV 
neg. (n) 
HR-HPV 
pos. (n) 
OR 95% CI aOR 95% CI HR-HPV 
neg. (n) 
HR-HPV 
pos.(n) 
OR 95% CI aOR 95% CI 
Vaginal sex in the last year             
No 194 122 1  1  198 114 1  1  
Yes 16 8 0.91 (0.46-1.78) 0.92 (0.47-1.79) 20 8 0.75 (0.37-1.49) 0.75 (0.37-1.49) 
Oral sex with a woman in the last year            
No 195 126 1  1  199 118 1  1  
Yes 16 6 0.71 (0.33-1.53) 0.72 (0.33-1.55) 20 6 0.63 (0.29-1.35) 0.63 (0.29-1.36) 
Anal sex with a woman in the last year            
No 208 130 1  1  214 121 1  1  
Yes 2 1 0.66 (0.08-5.53) 0.62 (0.07-5.21) 2 3 2.24 (0.84-5.98) 2.26 (0.85-6.05) 
Position when having anal sex without a condom in the last year          
Insertive only 44 23 1  1  50 15 1  1  
Receptive or versatile 94 96 1.95 (1.24-3.08) 2.00 (1.27-3.16) 103 89 1.99 (1.21-3.28) 2.00 (1.21-3.29) 
Each additional year at first attending a sexual health clinic 0.99 (0.96-1.02) 0.97 (0.93-1.00)   1.01 (0.98-1.03) 1.00 (0.96-1.04) 
Use of drugs in anus/rectum ever             
No 242 153 1  1  244 139 1  1  
Yes 19 25 1.63 (1.08-2.45) 1.60 (1.06-2.41) 22 26 1.64 (1.11-2.43) 1.63 (1.10-2.41) 
Condom use with most recent partner             
Always 121 86 1  1  124 82 1  1  
Not always 138 91 0.94 (0.70-1.25) 0.95 (0.71-1.26) 139 82 0.88 (0.66-1.17) 0.88 (0.66-1.17) 
Most recent male partner (oral or anal)             
Each additional year of age of partner  1.01 (0.99-1.03) 1.00 (0.98-1.02)   1.00 (0.98-1.02) 1.00 (0.98-1.02) 
Each additional day since last having sex with partner 1.00 (0.99-1.00) 1.00 (0.99-1.00)   1.00 (1.00-1.00) 1.00 (1.00-1.00) 
Relationship type with most recent partner           
Regular 121 97 1  1  135 80 1  1  
Casual 131 74 0.85 (0.63-1.14) 0.85 (0.63-1.14) 123 78 1.19 (0.88-1.60) 1.19 (0.89-1.60) 
Relationship is continuing with most recent partner            
No 131 76 1  1  119 75 1  1  
Yes 128 102 1.20 (0.90-1.60) 1.19 (0.89-1.59) 144 90 0.88 (0.66-1.18) 0.88 (0.66-1.17) 
Concurrency between any of the 3 most recent partners           
No 121 70 1  1  124 66 1  1  
Yes 140 108 1.24 (0.92-1.66) 1.22 (0.91-1.64) 142 99 1.21 (0.90-1.63) 1.21 (0.90-1.63) 
Abbreviations: HR-HPV neg.=DNA of HR-HPV types not detected. HR-HPV pos.=DNA of at least one HR-HPV type detected. aOR=age-adjusted odds ratio. N/A=Not applicable. Logistic regression 
models fitted using the generalised equation estimation (GEE) method. 
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ORAL AND URINE SPECIMENS 
APPENDIX TABLE 5. RISK FACTORS FOR THE DETECTION OF HR-HPV DNA IN THE ORAL AND URINE SPECIMENS CONTINUED 
 ORAL URINE 
 Number of MSM     Number of MSM     
Risk factor HR-HPV 
neg. (n) 
HR-HPV 
pos. (n) 
OR 95% CI aOR 95% CI HR-HPV 
neg. (n) 
HR-HPV 
pos. (n) 
OR 95% CI aOR 95% CI 
HIV positive diagnosis             
no 140 7 1    441 20 1  1  
yes 12 0 N/A N/A N/A N/A 20 5 5.35 (2.09-13.69) 5.42 (2.11-13.90) 
Each additional year in age   0.96 (0.86-1.08) N/A N/A   0.99 (0.93-1.06) N/A N/A 
Ethnic group             
White 117 6 1  1  341 19 1  1  
Black 21 2 1.79 (0.37-8.54) 1.69 (0.35-8.15) 53 5 1.48 (0.53-4.15) 1.48 (0.53-4.15) 
Asian & SE Asian 17 1 1.14 (0.14-9.00) 1.13 (0.14-8.96) 49 0 N/A N/A N/A N/A 
Born in the UK             
No 77 6 1  1  240 12 1  1  
Yes 79 3 0.50 (0.13-1.95) 0.50 (0.13-1.93) 206 12 1.16 (0.51-2.60) 1.16 (0.51-2.60) 
Currently smoke             
No 114 7 1  1  316 17 1  1  
Yes 42 2 0.78 (0.17-3.64) 0.75 (0.16-3.50) 129 7 1.09 (0.45-2.61) 1.09 (0.45-2.63) 
Increasing or higher risk alcohol drinking (AUDIT-C)            
No 51 2 1  1  151 12 1  1  
Yes 103 7 1.69 (0.36-7.83) 1.67 (0.36-7.76) 289 12 0.63 (0.28-1.44) 0.63 (0.28-1.44) 
Currently employed             
No 30 3 1  1  92 8 1  1  
Yes 126 6 0.50 (0.13-1.93) 0.55 (0.13-2.40) 354 16 0.51 (0.22-1.19) 0.49 (0.20-1.17) 
Years of education post-16             
0-2 years 20 4 4.97 (1.28-19.25) 4.96 (1.28-19.25) 65 4 1.10  (0.36-3.35) 1.08 (0.35-3.33) 
3 years or more 114 4 1  1  305 16 1  1  
Sexual orientation             
Gay/homosexual 142 7 1  1  411 20 1  1  
Bisexual 14 2 2.68 (0.58-12.46) 2.60 (0.56-12.11) 34 4 2.07 (0.67-6.41) 2.09 (0.67-6.55) 
Circumcised             
No 104 4 1  1  311 18 1  1  
Yes 51 5 2.42 (0.67-8.74) 2.37 (0.65-8.56) 131 6 0.88 (0.35-2.21) 0.88 (0.35-2.21) 
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APPENDIX TABLE 5. RISK FACTORS FOR THE DETECTION OF HR-HPV DNA IN THE ORAL AND URINE SPECIMENS CONTINUED 
 ORAL URINE 
 Number of MSM     Number of MSM     
Risk factor HR-HPV 
neg. (n) 
HR-HPV 
pos. (n) 
OR 95% CI aOR 95% CI HR-HPV 
neg. (n) 
HR-HPV 
pos. (n) 
OR 95% CI aOR 95% CI 
Number of lifetime male partners (anal and oral sex)           
<31 56 4 1  1  147 7 1  1  
>=31 100 5 0.71 (0.20-2.58) 0.80 (0.21-3.09) 298 17 1.33 (0.54-3.29) 1.37 (0.52-3.57) 
Number of male sex partners in the last year           
Male anal sex partners             
<10 75 5 1  1  231 14 1  1  
>=10 71 3 0.65 (0.16-2.62) 0.66 (0.16-2.68) 189 8 0.89 (0.37-2.11) 0.88 (0.37-2.11) 
New anal sex partners             
<10 89 7 1  1  274 16 1  1  
>=10 56 1 0.24 (0.03-1.85) 0.25 (0.03-1.92) 142 6 0.98 (0.40-2.41) 0.98 (0.40-2.41) 
Anal sex partners without a condom             
<10 135 7 1  1  390 20 1  1  
>=10 11 1 1.69 (0.22-13.17) 1.78 (0.23-13.88) 27 2 2.03 (0.57-7.18) 2.03 (0.57-7.17) 
Exclusively oral sex partners             
<10 92 7 1  1  276 15 1  1  
>=10 40 1 0.34 (0.04-2.65) 0.36 (0.05-2.76) 125 7 1.10 (0.45-2.70) 1.12 (0.46-2.74) 
Each additional year of age at first sex with a man           
Oral    1.01 (0.86-1.19) 1.03 (0.86-1.23)   0.96 (0.85-1.07)   
Receptive anal   0.97 (0.82-1.14) 0.99 (0.82-1.19)   1.00 (0.90-1.10)   
Oral sex with a man in last 3 months             
No 4 1 1  1  15 0     
Yes 152 8 0.25 (0.03-1.90) 0.23 (0.03-1.78) 427 23     
Receptive anal sex with a man in last 3 months           
No 49 4 1  1  148 8 1  1  
Yes 102 5 0.62 (0.17-2.23) 0.57 (0.16-2.09) 290 15 1.09 (0.45-2.64) 1.08 (0.44-2.64) 
Insertive anal sex with a man in last 3 months           
No 27 3 1  1  97 3 1  1  
Yes 123 5 0.39 (0.10-1.58) 0.39 (0.09-1.56) 331 20 2.09 (0.59-7.40) 2.10 (0.59-7.41) 
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APPENDIX TABLE 5. RISK FACTORS FOR THE DETECTION OF HR-HPV DNA IN THE ORAL AND URINE SPECIMENS CONTINUED 
 ORAL URINE 
 Number of MSM     Number of MSM     
Risk factor HR-HPV 
neg. (n) 
HR-HPV 
pos. (n) 
OR 95% CI aOR 95% CI HR-HPV 
neg. (n) 
HR-HPV 
pos. (n) 
OR 95% CI aOR 95% CI 
Vaginal sex in the last year             
No 118 5 1  1  328 14     
Yes 10 1 2.25 (0.27-18.49) 2.25 (0.27-18.89) 25 1 0.82 (0.09-7.47) 0.80 (0.09-7.27) 
Oral sex with a woman in the last year           
No 118 5 1  1  333 15     
Yes 10 1 2.25 (0.27-18.49) 2.24 (0.27-18.84) 24 1 0.82 (0.09-7.31) 0.80 (0.09-7.11) 
Anal sex with a woman in the last year           
No 126 5 1  1  349 16 N/A    
Yes 1 1 13.58 (1.60-115.07) 14.14 (1.57-127.21) 6 0 N/A N/A N/A N/A 
Position when having anal sex without a condom in the last year           
Insertive only 21 3 1  1  68 5 1  1  
Receptive or versatile 72 2 0.21 (0.04-1.24) 0.22 (0.04-1.27) 191 9 0.80 (0.25-2.58) 0.81 (0.25-2.64) 
Each additional year at first attending a sexual health clinic 1.05 (0.92-1.20) 1.18 (0.95-1.46) 161  1.02 (0.94-1.11)   
Use of drugs in anus/rectum ever             
No 138 7 1  1  404 21 1  1  
Yes 18 2 2.08 (0.45-9.67) 2.38 (0.49-11.47) 42 3 1.72 (0.57-5.23) 1.73 (0.57-5.26) 
Condom use with most recent partner             
Always 71 4 1  1  213 12 1  1  
Not always 83 5 1.07 (0.30-3.85) 1.09 (0.30-3.92) 230 11 1.01 (0.44-2.32) 1.01 (0.44-2.31) 
Most recent male partner (oral or anal)             
Each additional year of age of partner 1.02 (0.94-1.11) 1.04 (0.95-1.13)   1.02 (0.97-1.07) 1.02 (0.97-1.08) 
Each additional day since last having sex with partner 0.90 (0.77-1.05) 0.90 (0.77-1.05)   1.00 (0.99-1.01) 1.00 (0.99-1.01) 
Relationship type with most recent partner            
Regular 82 4 1  1  221 13 1  1  
Casual 68 5 1.48 (0.41-5.32) 1.50 (0.41-5.40) 211 10 0.83 (0.36-1.91) 0.83 (0.36-1.91) 
Relationship is continuing with most recent partner           
No 70 4 1  1  205 11 1  1  
Yes 84 5 1.04 (0.29-3.75) 1.05 (0.29-3.78) 237 13 1.01 (0.45-2.27) 1.01 (0.45-2.27) 
Concurrency between any of the 3 most recent partners           
No 76 5 1  1  198 10 1  1  
Yes 80 4 0.77 (0.21-2.78) 0.82 (0.22-3.03) 248 14 1.27 (0.56-2.90) 1.27 (0.56-2.91) 
Abbreviations: HR-HPV neg.=DNA of HR-HPV types not detected. HR-HPV pos.=DNA of at least one HR-HPV type detected. aOR=age-adjusted odds ratio. N/A=Not applicable. Logistic regression 
models fitted using the generalised equation estimation (GEE) method. 
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ANOGENITAL CONCORDANCE 
 APPENDIX TABLE 6. RISK FACTORS FOR HR-HPV TYPE-SPECIFIC ANOGENITAL CONCORDANT INFECTIONS IN MSM CONTINUED.  
 ANOGENITAL CONCORDANCE ANOGENITAL CONCORDANCE compared to SINGLE INFECTION 
Risk factor HR-HPV 
detected at 
<2 sites (n) 
HR-HPV 
detected at 
≥2 sites (n) 
OR 95% CI aOR 95% CI MSM with 
HR-HPV 
detected at 
one site (n) 
HR-HPV 
detected at 
≥2 sites (n) 
OR 95% CI aOR 95% CI 
Each additional year in age   0.99 (0.96-1.02) N/A N/A   0.97 (0.93-1.02) N/A N/A 
Ethnic group             
White 194 88 1  1  74 88 1  1  
Black 33 10 0.69 (0.36-1.31) 0.69 (0.36-1.31) 10 10 0.96 (0.42-2.19) 0.96 (0.42-2.20) 
Asian & SE Asian 31 8 0.69 (0.35-1.35) 0.69 (0.35-1.35) 11 8 0.95 (0.40-2.24) 0.95 (0.40-2.24) 
Born in the UK             
No 154 53 1  1  54 53 1  1  
Yes 107 53 1.16 (0.80-1.68) 1.16 (0.80-1.68) 42 53 1.04 (0.65-1.66) 1.04 (0.65-1.67) 
Currently smoke             
No 186 70 1  1  70 70 1  1  
Yes 74 36 1.14 (0.77-1.69) 1.13 (0.76-1.68) 25 36 1.24 (0.75-2.06) 1.19 (0.71-2.00) 
Increasing or higher risk drinking (AUDIT-C)             
No 86 42 1  1  35 42 1  1  
Yes 172 62 0.77 (0.53-1.12) 0.76 (0.52-1.11) 60 62 0.78 (0.48-1.27) 0.76 (0.47-1.25) 
Currently employed             
No 50 25 1  1  18 25 1  1  
Yes 211 81 0.77 (0.51-1.18) 0.78 (0.50-1.21) 78 81 0.87 (0.50-1.51) 0.93 (0.52-1.64) 
Years of education post-16             
0 to 2 years  48 22 1.72 (1.07-2.77) 1.70 (1.06-2.74) 15 23 1.34 (0.75-2.42) 1.33 (0.74-2.42) 
3 years or more 275 64 1  1  89 67 1  1  
Sexual orientation             
Gay/homosexual 238 100 1  1  87 100 1  1  
Bisexual 22 6 0.60 (0.26-1.41) 0.59 (0.25-1.39) 9 6 0.72 (0.26-2.01) 0.70 (0.25-1.96) 
Circumcised             
No 174 79 1  1  65 79 1  1  
Yes 84 26 0.73 (0.47-1.12) 0.73 (0.47-1.12) 30 26 0.67 (0.39-1.13) 0.66 (0.39-1.13) 
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 APPENDIX TABLE 6. RISK FACTORS FOR HR-HPV TYPE-SPECIFIC ANOGENITAL CONCORDANT INFECTIONS IN MSM CONTINUED.  
 ANOGENITAL CONCORDANCE ANOGENITAL CONCORDANCE compared to SINGLE INFECTION 
Risk factor HR-HPV 
detected at 
<2 sites (n) 
HR-HPV 
detected at 
≥2 sites (n) 
OR 95% CI aOR 95% CI MSM with 
HR-HPV 
detected at 
one site (n) 
HR-HPV 
detected at 
≥2 sites (n) 
OR 95% CI aOR 95% CI 
Number of lifetime male partners (anal and oral sex)            
<31 89 26 1  1  22 26 1  1  
>=31 172 80 1.40 (0.91-2.14) 1.52 (0.96-2.40) 74 80 0.66 (0.38-1.17) 0.74 (0.40-1.35) 
Number of male sex partners in the last year             
Male anal sex partners             
<10 146 44 1  1  48 44 1  1  
>=10 101 56 1.67 (1.14-2.45) 1.69 (1.15-2.49) 46 56 1.16 (0.71-1.88) 1.17 (0.71-1.91) 
New anal sex partners             
<10 170 55 1  1  63 55 1  1  
>=10 75 45 1.55 (1.05-2.27) 1.56 (1.06-2.30) 30 45 1.43 (0.87-2.34) 1.47 (0.89-2.41) 
Anal sex partners without a condom             
<10 228 90 1  1  82 90 1  1  
>=10 16 10 1.4 (0.74-2.63) 1.41 (0.75-2.65) 11 10 0.77 (0.36-1.66) 0.79 (0.36-1.71) 
Exclusively oral sex partners             
<10 170 59 1  1  56 59 1  1  
>=10 70 36 1.19 (0.79-1.80) 1.19 (0.79-1.81) 30 36 0.88 (0.52-1.48) 0.89 (0.53-1.51) 
Each additional year of age at first sex with a man            
Oral    0.97 (0.92-1.02) 0.96 (0.85-1.08)   1.01 (0.94-1.09) 0.97 (0.92-1.02) 
Receptive anal   0.98 (0.94-1.03) 1.00 (0.89-1.11)   1.01 (0.95-1.07) 0.99 (0.94-1.04) 
Oral sex with a man in last 3 months             
No 6 1 1  1  1 1 1  1  
Yes 252 105 2.47 (0.32-19.03) 2.47 (0.32-19.05) 93 105 0.69 (0.04-11.07) 0.77 (0.05-12.46) 
Receptive anal sex with a man in last 3 months            
No 89 21 1  1  22 21 1  1  
Yes 166 84 2.17 (1.35-3.49) 2.17 (1.35-3.50) 73 84 1.06 (0.57-1.97) 1.01 (0.54-1.88) 
Insertive anal sex with a man in last 3 months             
No 59 16 1  1  19 16 1  1  
Yes 193 84 1.64 (0.96-2.81) 1.65 (0.96-2.82) 75 84 1.18 (0.61-2.29) 1.19 (0.61-2.32) 
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 APPENDIX TABLE 6. RISK FACTORS FOR HR-HPV TYPE-SPECIFIC ANOGENITAL CONCORDANT INFECTIONS IN MSM CONTINUED.  
 ANOGENITAL CONCORDANCE ANOGENITAL CONCORDANCE compared to SINGLE INFECTION 
Risk factor HR-HPV 
detected at 
<2 sites (n) 
HR-HPV 
detected at 
≥2 sites (n) 
OR 95% CI aOR 95% CI MSM with 
HR-HPV 
detected at 
one site (n) 
HR-HPV 
detected at 
≥2 sites (n) 
OR 95% CI aOR 95% CI 
Vaginal sex in the last year             
No 276 70 1  1  90 70 1  1  
Yes 25 4 0.7 (0.25-1.94) 0.69 (0.25-1.93) 7 4 0.73 (0.25-2.12) 0.79 (0.27-2.33) 
Oral sex with a woman in the last year             
No 280 72 1  1  93 72 1  1  
Yes 24 3 0.54 (0.17-1.76) 0.54 (0.17-1.75) 6 3 0.48 (0.13-1.78) 0.52 (0.14-1.96) 
Anal sex with a woman in the last year             
No 297 74 N/A  N/A  96 74 N/A  N/A  
Yes 6 0 N/A N/A N/A N/A 4 0 N/A N/A N/A N/A 
Position when having anal sex without a condom in the last year           
Insertive only 49 9 1  1  18 9 1  1  
Receptive or versatile 106 61 2.88 (1.47-5.64) 2.84 (1.45-5.57) 47 61 2.29 (1.00-5.25) 2.22 (0.96-5.14) 
Each additional year at first attending a sexual health clinic  0.99 (0.96-1.03) 1.04 (0.93-1.16)   1.00 (0.95-1.05) 1.00 (0.95-1.05) 
Use of drugs in anus/rectum ever             
No 238 90 1  1  84 90 1  1  
Yes 23 16 1.63 (0.98-2.69) 1.64 (0.99-2.72) 12 16 1.06 (0.56-2.03) 1.07 (0.56-2.06) 
Condom use with most recent partner             
Always 121 52 1  1  45 52 1  1  
Not always 138 53 0.89 (0.61-1.28) 0.89 (0.61-1.29) 51 53 0.92 (0.57-1.47) 0.90 (0.56-1.45) 
Most recent male partner (oral or anal)             
Each additional year of age of partner   1.01 (0.98-1.03) 1.02 (0.97-1.08)   0.99 (0.96-1.03) 1.01 (0.98-1.04) 
Each additional day since last having sex with partner  1.00 (1.00-1.01) 1.00 (0.99-1.01)   1.02 (1.01-1.03) 1.00 (1.00-1.01) 
Relationship type with most recent partner             
Regular 136 54 1  1  59 54 1  1  
Casual 117 47 1.12 (0.77-1.64) 1.12 (0.77-1.63) 34 47 1.56 (0.96-2.53) 1.57 (0.96-2.55) 
Relationship is continuing with most recent partner            
No 113 52 1  1  30 52 1  1  
Yes 146 54 0.78 (0.54-1.12) 0.78 (0.54-1.13) 66 54 0.54 (0.34-0.86) 0.55 (0.34-0.88) 
Concurrency between any of the 3 most recent partners            
No 115 43 1  1  33 43 1  1  
Yes 146 63 1.18 (0.81-1.71) 1.18 (0.81-1.73) 63 63 0.88 (0.54-1.43) 0.88 (0.54-1.43) 
Abbreviations: aOR=age-adjusted odds ratio. N/A=Not applicable. Logistic regression models fitted using the generalised equation estimation (GEE) method. 
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APPENDIX V. MATHEMATICAL MODEL STATE VARIABLE DEFINITIONS AND EQUATIONS  
APPENDIX TABLE 7. MATHEMATICAL MODEL STATE VARIABLE DEFINITIONS 
 State Variable Definition 
UNVACCINATED  
(no subscript) 
N The number of HIV negative men who have not been vaccinated and have not had anal sex with a man in their lifetime. S, Sℎ  The number of HIV negative/positive MSM who have not been vaccinated and are susceptible to HPV16 infection  R, Rℎ  The number of HIV negative/positive MSM who have not been vaccinated and have effective natural immunity to HPV16 infection  I, Iℎ  The number of HIV negative/positive MSM who have not been vaccinated and are infectious with HPV16 and have normal or ASCUS 
cytology/histology   L𝑡𝑡, L𝑡𝑡ℎ  The number of HIV negative/positive MSM who have not been vaccinated and are infectious with HPV16, with detectable LSIL/LGAIN  H𝑡𝑡, H𝑡𝑡ℎ  The number of HIV negative/positive MSM who have not been vaccinated and are infectious with HPV16, with detectable HSIL/HGAIN  C𝑡𝑡, Cℎ  The number of HIV negative/positive MSM who have not been vaccinated and are infectious with HPV16, with HPV-related anal cancer that is 
diagnosed and treated 
SUCCESSFULLY VACCINATED 
 (V/subscript v) 
V, Vℎ  The number of HIV negative /positive MSM who have been successfully vaccinated and are immune to HPV16 infection. S𝑣𝑣, S𝑣𝑣ℎ  The number of HIV negative /positive MSM who have been successfully vaccinated and are immune to HPV16 infection, have no natural 
immunity and are not infectious. R𝑣𝑣,𝑅𝑅𝑣𝑣ℎ  The number of HIV negative /positive MSM who have been successfully vaccinated and are immune to HPV16 infection and have natural 
immunity to HPV16 infection. I𝑣𝑣, 𝐼𝐼𝑣𝑣ℎ  The number of HIV negative/positive MSM that is successfully vaccinated is infectious with HPV16 and has normal or ASCUS cytology/histology  L𝑣𝑣,𝐿𝐿𝑣𝑣𝑡𝑡ℎ  The number of HIV negative/positive MSM that is successfully vaccinated, is infectious with HPV16, with detectable LSIL/LGAIN 
𝐻𝐻𝑣𝑣,𝐻𝐻𝑣𝑣𝑡𝑡ℎ  The number of HIV negative/positive MSM that is successfully vaccinated, is infectious with HPV16, with detectable HSIL/HGAIN C𝑣𝑣,𝐶𝐶𝑣𝑣ℎ  The number of HIV negative/positive MSM that is successfully vaccinated, is infectious with HPV16, with HPV-related anal cancer that is 
diagnosed and treated 
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 State Variable Definition 
VACCINE FAILURES 
(F/subscript f) 
F, Fℎ  The number of HIV negative /positive MSM who have been vaccinated but do not have vaccine-induced immunity to HPV16 infection. S𝑓𝑓 , S𝑓𝑓ℎ  The number of HIV negative /positive MSM who have been vaccinated but are susceptible to HPV16 infection. R𝑓𝑓 ,𝑅𝑅𝑓𝑓ℎ  The number of HIV negative /positive MSM who have natural immunity to HPV16 infection. No vaccine-induced immunity despite having 
received vaccine.  I𝑓𝑓 , 𝐼𝐼𝑓𝑓ℎ  The number of HIV negative/positive MSM who have been vaccinated  and are infectious with HPV16 and have normal or ASCUS 
cytology/histology  L𝑓𝑓 ,𝐿𝐿𝑓𝑓𝑡𝑡ℎ  The number of HIV negative/positive MSM who have been vaccinated  and are infectious with HPV16, with detectable LSIL/LGAIN 
𝐻𝐻𝑓𝑓 ,𝐻𝐻𝑓𝑓𝑡𝑡ℎ  The number of HIV negative/positive MSM who have been vaccinated  and are infectious with HPV16, with detectable HSIL/HGAIN C𝑓𝑓 ,𝐶𝐶𝑓𝑓ℎ  The number of HIV negative/positive MSM who have been vaccinated  and are infectious with HPV16, with HPV-related anal cancer that is 
diagnosed and treated 
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HPV16 AND ANAL CANCER MODEL EQUATIONS 
UNVACCINATED-HIV NEGATIVE N(𝑎𝑎=0) = 100,000 S(𝑎𝑎=0) = R(𝑎𝑎=0) = I(𝑎𝑎=0) = 𝐿𝐿(𝑎𝑎=0)𝑎𝑎 = 𝐿𝐿(𝑎𝑎=0)𝑏𝑏 = 𝐿𝐿(𝑎𝑎=0)𝑐𝑐 = 𝐻𝐻(𝑎𝑎=0)𝑎𝑎 = 𝐻𝐻(𝑎𝑎=0)𝑏𝑏 = 𝐻𝐻(𝑎𝑎=0) 𝑐𝑐 = 𝐶𝐶(𝑎𝑎=0) = 0 
 
N(𝑎𝑎+1) = �1 − α(𝑎𝑎) − m(𝑎𝑎)�N(𝑎𝑎) − γ1nyN(𝑎𝑎) − (1 − γ1)nyN(𝑎𝑎) S(𝑎𝑎+1) = �1 − λ𝐻𝐻𝐻𝐻𝐻𝐻𝑖𝑖(𝑎𝑎) − m(𝑎𝑎) − λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎)�S(𝑎𝑎) + α(𝑎𝑎)N(𝑎𝑎) + µR(𝑎𝑎) − 𝛾𝛾1ng(𝑎𝑎)𝑆𝑆 (𝑎𝑎) − (1 − γ1)ng(𝑎𝑎)𝑆𝑆 (𝑎𝑎)  R(𝑎𝑎+1) = �1 − µ − m(𝑎𝑎) − λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎)�R(𝑎𝑎) + 𝜌𝜌𝐿𝐿(𝑎𝑎)𝑡𝑡  + π𝐻𝐻(𝑎𝑎)𝑡𝑡 + τC(𝑎𝑎) + ϕI(𝑎𝑎) − 𝛾𝛾1𝑛𝑛g(𝑎𝑎)𝑅𝑅(𝑎𝑎)  − (1 − 𝛾𝛾1)𝑛𝑛g(𝑎𝑎)𝑅𝑅(𝑎𝑎)  
I(𝑎𝑎+1) = �1 − σ − ϕ − m(𝑎𝑎) − λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎)�I(𝑎𝑎) + λ𝐻𝐻𝐻𝐻𝐻𝐻𝑖𝑖(𝑎𝑎)S(𝑎𝑎) − 𝛾𝛾2𝑛𝑛g(𝑎𝑎)𝐼𝐼(𝑎𝑎) − (1 − 𝛾𝛾2)𝑛𝑛g(𝑎𝑎)𝐼𝐼(𝑎𝑎)  
 
 𝐿𝐿(𝑎𝑎)𝑡𝑡 = 𝐿𝐿(𝑎𝑎)𝑎𝑎 + 𝐿𝐿(𝑎𝑎)𝑏𝑏 + 𝐿𝐿(𝑎𝑎)𝑐𝑐  
𝐿𝐿(𝑎𝑎+1)𝑎𝑎 = �1 − 2𝓍𝓍– ρ − m(𝑎𝑎) − λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎)�𝐿𝐿(𝑎𝑎)𝑎𝑎 + σI(𝑎𝑎) − 𝛾𝛾2𝑛𝑛g(𝑎𝑎) 𝐿𝐿(𝑎𝑎)𝑎𝑎 − (1 − 𝛾𝛾2)𝑛𝑛g(𝑎𝑎)𝐿𝐿(𝑎𝑎)𝑎𝑎  
𝐿𝐿(𝑎𝑎+1)𝑏𝑏 = �1 − 2𝓍𝓍– ρ − m(𝑎𝑎) − λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎)�𝐿𝐿(𝑎𝑎)𝑏𝑏 + 𝓍𝓍𝐿𝐿(𝑎𝑎)𝑎𝑎  − 𝛾𝛾2𝑛𝑛g(𝑎𝑎) 𝐿𝐿(𝑎𝑎)𝑏𝑏 − (1 − 𝛾𝛾2)𝑛𝑛g(𝑎𝑎)𝐿𝐿(𝑎𝑎)𝑏𝑏  
𝐿𝐿(𝑎𝑎+1)𝑐𝑐 = �1 − 𝓍𝓍– ρ − m(𝑎𝑎) − λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎)�𝐿𝐿(𝑎𝑎)𝑐𝑐 + 𝓍𝓍𝐿𝐿(𝑎𝑎)𝑏𝑏  − 𝛾𝛾2𝑛𝑛g(𝑎𝑎) 𝐿𝐿(𝑎𝑎)𝑐𝑐 − (1 − 𝛾𝛾2)𝑛𝑛g(𝑎𝑎)𝐿𝐿(𝑎𝑎)𝑐𝑐  
 
𝐻𝐻(𝑎𝑎)𝑡𝑡 = 𝐻𝐻(𝑎𝑎)𝑎𝑎 + 𝐻𝐻(𝑎𝑎)𝑏𝑏 + 𝐻𝐻(𝑎𝑎)𝑐𝑐  
𝐻𝐻(𝑎𝑎+1)𝑎𝑎 = �1 − 2δ(𝑎𝑎)–π − m(𝑎𝑎) − λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎)�𝐻𝐻(𝑎𝑎)𝑎𝑎 + 𝓍𝓍𝐿𝐿(𝑎𝑎)𝑡𝑡 − 𝛾𝛾2𝑛𝑛g(𝑎𝑎) 𝐻𝐻(𝑎𝑎)𝑎𝑎 − (1 − 𝛾𝛾2)𝑛𝑛g(𝑎𝑎)𝐻𝐻(𝑎𝑎)𝑎𝑎  
𝐻𝐻(𝑎𝑎+1)𝑏𝑏 = �1 − 2δ(𝑎𝑎)–π − m(𝑎𝑎) − λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎)�𝐻𝐻(𝑎𝑎)𝑏𝑏 + δ(𝑎𝑎)𝐻𝐻(𝑎𝑎)𝑎𝑎 − 𝛾𝛾2𝑛𝑛g(𝑎𝑎) 𝐻𝐻(𝑎𝑎)𝑏𝑏 − (1 − 𝛾𝛾2)𝑛𝑛g(𝑎𝑎)𝐻𝐻(𝑎𝑎)𝑏𝑏  
𝐻𝐻(𝑎𝑎+1)𝑐𝑐 = �1 − δ(𝑎𝑎)–π − m(𝑎𝑎) − λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎)�𝐻𝐻(𝑎𝑎)𝑐𝑐 + δ(𝑎𝑎)𝐻𝐻(𝑎𝑎)𝑏𝑏 − 𝛾𝛾2𝑛𝑛g(𝑎𝑎) 𝐻𝐻(𝑎𝑎)𝑐𝑐 − (1 − 𝛾𝛾2)𝑛𝑛g(𝑎𝑎)𝐻𝐻(𝑎𝑎)𝑐𝑐  
 
C(𝑎𝑎+1) = �1– τ–ψ − m(𝑎𝑎) − λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎) �C(𝑎𝑎) + +δ(𝑎𝑎)𝐻𝐻(𝑎𝑎)𝑡𝑡    
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UNVACCINATED-HIV POSITIVE (superscript h) S(𝑎𝑎=0)ℎ = R(𝑎𝑎=0)ℎ = I(𝑎𝑎=0)ℎ = L(𝑎𝑎=0)ℎ𝑎𝑎 = L(𝑎𝑎=0)ℎ𝑏𝑏 = L(𝑎𝑎=0)ℎ𝑐𝑐 = 𝐻𝐻(𝑎𝑎=0)ℎ𝑎𝑎 = 𝐻𝐻(𝑎𝑎=0)ℎ𝑏𝑏 = 𝐻𝐻(𝑎𝑎=0)ℎ𝑐𝑐 = C(𝑎𝑎=0)ℎ = 0 
 
S(𝑎𝑎+1)ℎ = �1 − λ𝐻𝐻𝐻𝐻𝐻𝐻𝑖𝑖ℎ(𝑎𝑎) − m(𝑎𝑎) − d�S(𝑎𝑎)ℎ + λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎)𝑆𝑆(𝑎𝑎) + µℎR(𝑎𝑎) − 𝛾𝛾3nzS(𝑎𝑎)ℎ − (1 − 𝛾𝛾3)nzS(𝑎𝑎)ℎ   R(𝑎𝑎+1)ℎ = �1 − µℎ − m(𝑎𝑎) − d�R(𝑎𝑎)ℎ + 𝜌𝜌ℎ𝐿𝐿(𝑎𝑎)ℎ𝑡𝑡  + πℎ𝐻𝐻(𝑎𝑎)ℎ𝑡𝑡 +  τℎC(𝑎𝑎)ℎ + ϕℎI(𝑎𝑎)ℎ  + λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎)𝑅𝑅(𝑎𝑎) − 𝛾𝛾3nzR(𝑎𝑎)ℎ − (1 −
𝛾𝛾3)nzR(𝑎𝑎)ℎ   I(𝑎𝑎+1)ℎ = �1 − σℎ − ϕℎ − m(𝑎𝑎) − d�I(𝑎𝑎)ℎ + λ𝐻𝐻𝐻𝐻𝐻𝐻𝑖𝑖ℎ(𝑎𝑎)S(𝑎𝑎)ℎ + λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎)I(𝑎𝑎) − 𝛾𝛾4nzI(𝑎𝑎)ℎ − (1 − 𝛾𝛾4)nzI(𝑎𝑎)ℎ   
 
 𝐿𝐿(𝑎𝑎)ℎ𝑡𝑡 = 𝐿𝐿(𝑎𝑎)ℎ𝑎𝑎 + 𝐿𝐿(𝑎𝑎)ℎ𝑏𝑏 + 𝐿𝐿(𝑎𝑎)ℎ𝑐𝑐  
𝐿𝐿(𝑎𝑎+1)ℎ𝑎𝑎 = �1 − 2𝓍𝓍ℎ– ρℎ − m(𝑎𝑎) − d�𝐿𝐿(𝑎𝑎)ℎ𝑎𝑎 + σℎI(𝑎𝑎)ℎ  + λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎)L(𝑎𝑎)𝑎𝑎 − 𝛾𝛾4𝑛𝑛z 𝐿𝐿(𝑎𝑎)ℎ𝑎𝑎 − (1 − 𝛾𝛾4)𝑛𝑛z𝐿𝐿(𝑎𝑎)ℎ𝑎𝑎  
𝐿𝐿(𝑎𝑎+1)ℎ𝑏𝑏 = �1 − 2𝓍𝓍ℎ– ρℎ − m(𝑎𝑎) − d�𝐿𝐿(𝑎𝑎)ℎ𝑏𝑏 + 𝓍𝓍ℎ𝐿𝐿(𝑎𝑎)ℎ𝑎𝑎  + λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎)L(𝑎𝑎)𝑏𝑏 − 𝛾𝛾4𝑛𝑛z 𝐿𝐿(𝑎𝑎)ℎ𝑏𝑏 − (1 − 𝛾𝛾4)𝑛𝑛z𝐿𝐿(𝑎𝑎)ℎ𝑏𝑏  
𝐿𝐿(𝑎𝑎+1)ℎ𝑐𝑐 = �1 − 𝓍𝓍ℎ– ρℎ − m(𝑎𝑎) − d�𝐿𝐿(𝑎𝑎)ℎ𝑐𝑐 + 𝓍𝓍ℎ𝐿𝐿(𝑎𝑎)ℎ𝑏𝑏  + λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎)L(𝑎𝑎)𝑐𝑐 − 𝛾𝛾4𝑛𝑛z 𝐿𝐿(𝑎𝑎)ℎ𝑐𝑐 − (1 − 𝛾𝛾4)𝑛𝑛z𝐿𝐿(𝑎𝑎)ℎ𝑐𝑐  
 
𝐻𝐻(𝑎𝑎)ℎ𝑡𝑡 = 𝐻𝐻(𝑎𝑎)ℎ𝑎𝑎 + 𝐻𝐻(𝑎𝑎)ℎ𝑏𝑏 + 𝐻𝐻(𝑎𝑎)ℎ𝑐𝑐  
𝐻𝐻(𝑎𝑎+1)ℎ𝑎𝑎 = �1 − 2δℎ(𝑎𝑎)–πℎ − m(𝑎𝑎) − d�𝐻𝐻(𝑎𝑎)ℎ𝑎𝑎 + 𝓍𝓍ℎ𝐿𝐿(𝑎𝑎)ℎ𝑡𝑡 + λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎)H(𝑎𝑎)𝑎𝑎 − 𝛾𝛾4𝑛𝑛z 𝐻𝐻(𝑎𝑎)ℎ𝑎𝑎 − (1 − 𝛾𝛾4)𝑛𝑛z𝐻𝐻(𝑎𝑎)ℎ𝑎𝑎  
𝐻𝐻(𝑎𝑎+1)ℎ𝑏𝑏 = �1 − 2δℎ(𝑎𝑎)–πℎ − m(𝑎𝑎) − d�𝐻𝐻(𝑎𝑎)ℎ𝑏𝑏 + δℎ𝑗𝑗𝐻𝐻(𝑎𝑎)ℎ𝑎𝑎 + λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎)H(𝑎𝑎)𝑏𝑏 − 𝛾𝛾4𝑛𝑛z 𝐻𝐻(𝑎𝑎)ℎ𝑏𝑏 − (1 − 𝛾𝛾4)𝑛𝑛z𝐻𝐻(𝑎𝑎)ℎ𝑏𝑏  
𝐻𝐻(𝑎𝑎+1)ℎ𝑐𝑐 = �1 − δℎ(𝑎𝑎)–πℎ − m(𝑎𝑎) − d�𝐻𝐻(𝑎𝑎)ℎ𝑐𝑐 + δℎ𝑗𝑗𝐻𝐻(𝑎𝑎)ℎ𝑏𝑏 + λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎)H(𝑎𝑎)𝑐𝑐 − 𝛾𝛾4𝑛𝑛z 𝐻𝐻(𝑎𝑎)ℎ𝑐𝑐 − (1 − 𝛾𝛾4)𝑛𝑛z𝐻𝐻(𝑎𝑎)ℎ𝑐𝑐  
 
C(𝑎𝑎+1)ℎ = �1– τℎ–ψ − m(𝑎𝑎) − d �C(𝑎𝑎)ℎ + δℎ(𝑎𝑎)𝐻𝐻(𝑎𝑎)ℎ𝑡𝑡 + λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎)C(𝑎𝑎)  
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SUCCESSFULLY VACCINATED-HIV NEGATIVE N𝑣𝑣(𝑎𝑎=0) = S𝑣𝑣(𝑎𝑎=0) = R𝑣𝑣(𝑎𝑎=0) = I𝑣𝑣(𝑎𝑎=0) = 𝐿𝐿𝑣𝑣(𝑎𝑎=0)𝑎𝑎 = 𝐿𝐿𝑣𝑣(𝑎𝑎=0)𝑏𝑏 = 𝐿𝐿𝑣𝑣(𝑎𝑎=0)𝑐𝑐 = 𝐻𝐻𝑣𝑣(𝑎𝑎=0)𝑎𝑎 = 𝐻𝐻𝑣𝑣(𝑎𝑎=0)𝑏𝑏 = 𝐻𝐻𝑣𝑣(𝑎𝑎=0) 𝑐𝑐= 𝐶𝐶𝑣𝑣(𝑎𝑎=0) = 0 V(𝑎𝑎) = N𝑣𝑣(𝑎𝑎) + R𝑣𝑣(𝑎𝑎) + I𝑣𝑣(𝑎𝑎) + L𝑣𝑣(𝑎𝑎)𝑡𝑡 + 𝐻𝐻𝑣𝑣(𝑎𝑎)𝑡𝑡 + S𝑣𝑣(𝑎𝑎) 
 
N𝑣𝑣(𝑎𝑎+1) = �1 − α(𝑎𝑎) − m(𝑎𝑎)�N𝑣𝑣(𝑎𝑎) + γ1nyN(𝑎𝑎) − ωN𝑣𝑣(𝑎𝑎) S𝑣𝑣(𝑎𝑎+1) = �1 − m(𝑎𝑎) − λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎)�S𝑣𝑣(𝑎𝑎) + α(𝑎𝑎)N𝑣𝑣(𝑎𝑎) + µR𝑣𝑣(𝑎𝑎) + 𝛾𝛾1ng(𝑎𝑎)𝑆𝑆 (𝑎𝑎) − ω𝑆𝑆 𝑣𝑣(𝑎𝑎)  R𝑣𝑣(𝑎𝑎+1) = �1 − µ − m(𝑎𝑎) − λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎)�R𝑣𝑣(𝑎𝑎) + 𝜌𝜌𝐿𝐿𝑣𝑣(𝑎𝑎)𝑡𝑡  + π𝐻𝐻𝑣𝑣(𝑎𝑎)𝑡𝑡 + τC𝑣𝑣(𝑎𝑎) + ϕI𝑣𝑣(𝑎𝑎) + 𝛾𝛾1𝑛𝑛g(𝑎𝑎)𝑅𝑅(𝑎𝑎)  − 𝜔𝜔𝑅𝑅𝑣𝑣(𝑎𝑎)  
I𝑣𝑣(𝑎𝑎+1) = �1 − σ − ϕ − m(𝑎𝑎) − λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎)�I𝑣𝑣(𝑎𝑎) + 𝛾𝛾2𝑛𝑛g(𝑎𝑎)𝐼𝐼(𝑎𝑎) −𝜔𝜔𝐼𝐼𝑣𝑣(𝑎𝑎)  
 
 𝐿𝐿𝑣𝑣(𝑎𝑎)𝑡𝑡 = 𝐿𝐿𝑣𝑣(𝑎𝑎)𝑎𝑎 + 𝐿𝐿𝑣𝑣(𝑎𝑎)𝑏𝑏 + 𝐿𝐿𝑣𝑣(𝑎𝑎)𝑐𝑐  
𝐿𝐿𝑣𝑣(𝑎𝑎+1)𝑎𝑎 = �1 − 2𝓍𝓍– ρ − m(𝑎𝑎) − λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎)�𝐿𝐿𝑣𝑣(𝑎𝑎)𝑎𝑎 + σI𝑣𝑣(𝑎𝑎) + 𝛾𝛾2𝑛𝑛g(𝑎𝑎) 𝐿𝐿(𝑎𝑎)𝑎𝑎 − 𝜔𝜔𝐿𝐿𝑣𝑣(𝑎𝑎)𝑎𝑎  
𝐿𝐿𝑣𝑣(𝑎𝑎+1)𝑏𝑏 = �1 − 2𝓍𝓍– ρ − m(𝑎𝑎) − λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎)�𝐿𝐿𝑣𝑣(𝑎𝑎)𝑏𝑏 + 𝓍𝓍𝐿𝐿𝑣𝑣(𝑎𝑎)𝑎𝑎 + 𝛾𝛾2𝑛𝑛g(𝑎𝑎) 𝐿𝐿𝑣𝑣(𝑎𝑎)𝑏𝑏 − 𝜔𝜔𝐿𝐿𝑣𝑣(𝑎𝑎)𝑏𝑏  
𝐿𝐿𝑣𝑣(𝑎𝑎+1)𝑐𝑐 = �1 − 𝓍𝓍– ρ − m(𝑎𝑎) − λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎)�𝐿𝐿𝑣𝑣(𝑎𝑎)𝑐𝑐 + 𝓍𝓍𝐿𝐿𝑣𝑣(𝑎𝑎)𝑏𝑏 + 𝛾𝛾2𝑛𝑛g(𝑎𝑎) 𝐿𝐿(𝑎𝑎)𝑐𝑐 − 𝜔𝜔𝐿𝐿𝑣𝑣(𝑎𝑎)𝑐𝑐  
 
𝐻𝐻𝑣𝑣(𝑎𝑎)𝑡𝑡 = 𝐻𝐻𝑣𝑣(𝑎𝑎)𝑎𝑎 + 𝐻𝐻𝑣𝑣(𝑎𝑎)𝑏𝑏 + 𝐻𝐻𝑣𝑣(𝑎𝑎)𝑐𝑐  
𝐻𝐻𝑣𝑣(𝑎𝑎+1)𝑎𝑎 = �1 − 2δ(𝑎𝑎)–π − m(𝑎𝑎) − λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎)�𝐻𝐻𝑣𝑣(𝑎𝑎)𝑎𝑎 + 𝓍𝓍𝐿𝐿𝑣𝑣(𝑎𝑎)𝑡𝑡 + 𝛾𝛾2𝑛𝑛g(𝑎𝑎) 𝐻𝐻(𝑎𝑎)𝑎𝑎 − 𝜔𝜔𝐻𝐻𝑣𝑣(𝑎𝑎)𝑎𝑎  
𝐻𝐻𝑣𝑣(𝑎𝑎+1)𝑏𝑏 = �1 − 2δ(𝑎𝑎)–π − m(𝑎𝑎) − λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎)�𝐻𝐻𝑣𝑣(𝑎𝑎)𝑏𝑏 + δ(𝑎𝑎)𝐻𝐻𝑣𝑣(𝑎𝑎)𝑎𝑎 + 𝛾𝛾2𝑛𝑛g(𝑎𝑎) 𝐻𝐻(𝑎𝑎)𝑏𝑏 − 𝜔𝜔𝐻𝐻𝑣𝑣(𝑎𝑎)𝑏𝑏  
𝐻𝐻𝑣𝑣(𝑎𝑎+1)𝑐𝑐 = �1 − δ(𝑎𝑎)–π − m(𝑎𝑎) − λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎)�𝐻𝐻𝑣𝑣(𝑎𝑎)𝑐𝑐 + δ(𝑎𝑎)𝐻𝐻𝑣𝑣(𝑎𝑎)𝑏𝑏 + 𝛾𝛾2𝑛𝑛g(𝑎𝑎) 𝐻𝐻(𝑎𝑎)𝑐𝑐 − 𝜔𝜔𝐻𝐻𝑣𝑣(𝑎𝑎)𝑐𝑐  
 
C𝑣𝑣(𝑎𝑎+1) = �1– τ–ψ − m(𝑎𝑎) − λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎) �C𝑣𝑣(𝑎𝑎) + δ(𝑎𝑎)𝐻𝐻𝑣𝑣(𝑎𝑎)𝑡𝑡    
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SUCCESSFULLY VACCINATED -HIV POSITIVE (superscript h) S𝑣𝑣(𝑎𝑎=0)ℎ + R𝑣𝑣(𝑎𝑎=0)ℎ + I𝑣𝑣(𝑎𝑎=0)ℎ + L𝑣𝑣(𝑎𝑎=0)ℎ𝑎𝑎 + L𝑣𝑣(𝑎𝑎=0)ℎ𝑏𝑏 + L𝑣𝑣(𝑎𝑎=0)ℎ𝑐𝑐 + 𝐻𝐻𝑣𝑣(𝑎𝑎=0)ℎ𝑎𝑎 + 𝐻𝐻𝑣𝑣(𝑎𝑎=0)ℎ𝑏𝑏 + 𝐻𝐻𝑣𝑣(𝑎𝑎=0)ℎ𝑐𝑐 + C𝑣𝑣(𝑎𝑎=0)ℎ = 𝑉𝑉(𝑎𝑎=0)ℎ= 0 
 
S𝑣𝑣(𝑎𝑎+1)ℎ = �1 − m(𝑎𝑎) − d�S𝑣𝑣(𝑎𝑎)ℎ + λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎)𝑆𝑆𝑣𝑣(𝑎𝑎) + µℎR𝑣𝑣(𝑎𝑎)ℎ + 𝛾𝛾3nzS(𝑎𝑎)ℎ − ωS𝑣𝑣(𝑎𝑎)ℎ   R𝑣𝑣(𝑎𝑎+1)ℎ = �1 − µℎ − m(𝑎𝑎) − d�R𝑣𝑣(𝑎𝑎)ℎ + 𝜌𝜌ℎ𝐿𝐿𝑣𝑣(𝑎𝑎)ℎ𝑡𝑡  + πℎ𝐻𝐻𝑣𝑣(𝑎𝑎)ℎ𝑡𝑡 + τℎC𝑣𝑣(𝑎𝑎)ℎ + ϕℎI𝑣𝑣(𝑎𝑎)ℎ  + λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎)𝑅𝑅𝑣𝑣(𝑎𝑎) + 𝛾𝛾3nzR(𝑎𝑎)ℎ −
ωR𝑣𝑣(𝑎𝑎)ℎ   I𝑣𝑣(𝑎𝑎+1)ℎ = �1 − σℎ − ϕℎ − m(𝑎𝑎) − d�I𝑣𝑣(𝑎𝑎)ℎ + λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎)I𝑣𝑣(𝑎𝑎) + 𝛾𝛾4nzI(𝑎𝑎)ℎ − ωI𝑣𝑣(𝑎𝑎)ℎ   
 
 𝐿𝐿𝑣𝑣(𝑎𝑎)ℎ𝑡𝑡 = 𝐿𝐿𝑣𝑣(𝑎𝑎)ℎ𝑎𝑎 + 𝐿𝐿𝑣𝑣(𝑎𝑎)ℎ𝑏𝑏 + 𝐿𝐿𝑣𝑣(𝑎𝑎)ℎ𝑐𝑐  
𝐿𝐿𝑣𝑣(𝑎𝑎+1)ℎ𝑎𝑎 = �1 − 2𝓍𝓍ℎ– ρℎ − m(𝑎𝑎) − d�𝐿𝐿𝑣𝑣(𝑎𝑎)ℎ𝑎𝑎 + σℎI𝑣𝑣(𝑎𝑎)ℎ  + λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎)L𝑣𝑣(𝑎𝑎)𝑎𝑎 + 𝛾𝛾4𝑛𝑛z 𝐿𝐿(𝑎𝑎)ℎ𝑎𝑎 − 𝜔𝜔𝐿𝐿𝑣𝑣(𝑎𝑎)ℎ𝑎𝑎  
𝐿𝐿𝑣𝑣(𝑎𝑎+1)ℎ𝑏𝑏 = �1 − 2𝓍𝓍ℎ– ρℎ − m(𝑎𝑎) − d�𝐿𝐿𝑣𝑣(𝑎𝑎)ℎ𝑏𝑏 + 𝓍𝓍ℎ𝐿𝐿𝑣𝑣(𝑎𝑎)ℎ𝑎𝑎  + λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎)L𝑣𝑣(𝑎𝑎)𝑏𝑏 + 𝛾𝛾4𝑛𝑛z 𝐿𝐿(𝑎𝑎)ℎ𝑏𝑏 − 𝜔𝜔𝐿𝐿𝑣𝑣(𝑎𝑎)ℎ𝑏𝑏  
𝐿𝐿𝑣𝑣(𝑎𝑎+1)ℎ𝑐𝑐 = �1 − 𝓍𝓍ℎ– ρℎ − m(𝑎𝑎) − d�𝐿𝐿𝑣𝑣(𝑎𝑎)ℎ𝑐𝑐 + 𝓍𝓍ℎ𝐿𝐿𝑣𝑣(𝑎𝑎)ℎ𝑏𝑏  + λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎)L𝑣𝑣(𝑎𝑎)𝑐𝑐 + 𝛾𝛾4𝑛𝑛z 𝐿𝐿(𝑎𝑎)ℎ𝑐𝑐 − 𝜔𝜔𝐿𝐿𝑣𝑣(𝑎𝑎)ℎ𝑐𝑐  
 
𝐻𝐻𝑣𝑣(𝑎𝑎)ℎ𝑡𝑡 = 𝐻𝐻𝑣𝑣(𝑎𝑎)ℎ𝑎𝑎 + 𝐻𝐻𝑣𝑣(𝑎𝑎)ℎ𝑏𝑏 + 𝐻𝐻𝑣𝑣(𝑎𝑎)ℎ𝑐𝑐  
𝐻𝐻𝑣𝑣(𝑎𝑎+1)ℎ𝑎𝑎 = �1 − 2δℎ(𝑎𝑎)–πℎ − m(𝑎𝑎) − d�𝐻𝐻𝑣𝑣(𝑎𝑎)ℎ𝑎𝑎 + 𝓍𝓍ℎ𝐿𝐿𝑣𝑣(𝑎𝑎)ℎ𝑡𝑡 + λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎)H𝑣𝑣(𝑎𝑎)𝑎𝑎 + 𝛾𝛾4𝑛𝑛z 𝐻𝐻(𝑎𝑎)ℎ𝑎𝑎 − 𝜔𝜔𝐻𝐻𝑣𝑣(𝑎𝑎)ℎ𝑎𝑎  
𝐻𝐻𝑣𝑣(𝑎𝑎+1)ℎ𝑏𝑏 = �1 − 2δℎ(𝑎𝑎)–πℎ − m(𝑎𝑎) − d�𝐻𝐻𝑣𝑣(𝑎𝑎)ℎ𝑏𝑏 + δℎ𝑗𝑗𝐻𝐻𝑣𝑣(𝑎𝑎)ℎ𝑎𝑎 + λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎)H𝑣𝑣(𝑎𝑎)𝑏𝑏 + 𝛾𝛾4𝑛𝑛z 𝐻𝐻(𝑎𝑎)ℎ𝑏𝑏 − 𝜔𝜔𝐻𝐻𝑣𝑣(𝑎𝑎)ℎ𝑏𝑏  
𝐻𝐻𝑣𝑣(𝑎𝑎+1)ℎ𝑐𝑐 = �1 − δℎ(𝑎𝑎)–πℎ − m(𝑎𝑎) − d�𝐻𝐻𝑣𝑣(𝑎𝑎)ℎ𝑐𝑐 + δℎ𝑗𝑗𝐻𝐻𝑣𝑣(𝑎𝑎)ℎ𝑏𝑏 + λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎)H𝑣𝑣(𝑎𝑎)𝑐𝑐 + 𝛾𝛾4𝑛𝑛z 𝐻𝐻(𝑎𝑎)ℎ𝑐𝑐 − 𝜔𝜔𝐻𝐻𝑣𝑣(𝑎𝑎)ℎ𝑐𝑐  
 
C𝑣𝑣(𝑎𝑎+1)ℎ = �1– τℎ–ψ − m(𝑎𝑎) − d �C𝑣𝑣(𝑎𝑎)ℎ + δℎ(𝑎𝑎)𝐻𝐻𝑣𝑣(𝑎𝑎)ℎ𝑡𝑡 + λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎)C𝑣𝑣(𝑎𝑎)  
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VACCINE FAILURES-HIV NEGATIVE N𝑓𝑓(𝑎𝑎=0) + S𝑓𝑓(𝑎𝑎=0) + R𝑓𝑓(𝑎𝑎=0) + I𝑓𝑓(𝑎𝑎=0) + L𝑓𝑓(𝑎𝑎=0)𝑎𝑎 + L𝑓𝑓(𝑎𝑎=0)𝑏𝑏 + L𝑓𝑓(𝑎𝑎=0)𝑐𝑐 + 𝐻𝐻𝑓𝑓(𝑎𝑎=0)𝑎𝑎 + 𝐻𝐻𝑓𝑓(𝑎𝑎=0)𝑏𝑏 + 𝐻𝐻𝑓𝑓(𝑎𝑎=0)𝑐𝑐 + C𝑓𝑓(𝑎𝑎=0)= 𝐹𝐹(𝑎𝑎=0) = 0 
 
N𝑓𝑓(𝑎𝑎+1) = �1 − α(𝑎𝑎) − m(𝑎𝑎)�N𝑓𝑓(𝑎𝑎) + (1 − γ1)nyN(𝑎𝑎) + ωN𝑣𝑣(𝑎𝑎) S𝑓𝑓(𝑎𝑎+1) = �1 − m(𝑎𝑎) − λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎) − λ𝐻𝐻𝐻𝐻𝐻𝐻,𝑖𝑖(𝑎𝑎)�S𝑓𝑓(𝑎𝑎) + α(𝑎𝑎)N𝑓𝑓(𝑎𝑎) + µR𝑓𝑓(𝑎𝑎) + (1 − 𝛾𝛾1)ng(𝑎𝑎)𝑆𝑆 (𝑎𝑎) + ω𝑆𝑆 𝑣𝑣(𝑎𝑎)  R𝑓𝑓(𝑎𝑎+1) = �1 − µ − m(𝑎𝑎) − λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎)�R𝑓𝑓(𝑎𝑎) + 𝜌𝜌𝐿𝐿𝑓𝑓(𝑎𝑎)𝑡𝑡  + π𝐻𝐻𝑓𝑓(𝑎𝑎)𝑡𝑡 +  τC𝑓𝑓(𝑎𝑎) + ϕI𝑓𝑓(𝑎𝑎) + [(1 − 𝛾𝛾1)]𝑛𝑛g(𝑎𝑎)𝑅𝑅(𝑎𝑎) +
𝜔𝜔𝑅𝑅𝑣𝑣(𝑎𝑎)  I𝑓𝑓(𝑎𝑎+1) = �1 − σ − ϕ − m(𝑎𝑎) − λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎)�I𝑓𝑓(𝑎𝑎) + λ𝐻𝐻𝐻𝐻𝐻𝐻,𝑖𝑖(𝑎𝑎)S𝑓𝑓(𝑎𝑎) + (1 − 𝛾𝛾2)𝑛𝑛g(𝑎𝑎)𝐼𝐼(𝑎𝑎) + 𝜔𝜔𝐼𝐼𝑣𝑣(𝑎𝑎)  
 
 𝐿𝐿𝑓𝑓(𝑎𝑎)𝑡𝑡 = 𝐿𝐿𝑓𝑓(𝑎𝑎)𝑎𝑎 + 𝐿𝐿𝑓𝑓(𝑎𝑎)𝑏𝑏 + 𝐿𝐿𝑓𝑓(𝑎𝑎)𝑐𝑐  
𝐿𝐿𝑓𝑓(𝑎𝑎+1)𝑎𝑎 = �1 − 2𝓍𝓍– ρ − m(𝑎𝑎) − λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎)�𝐿𝐿𝑓𝑓(𝑎𝑎)𝑎𝑎 + σI𝑓𝑓(𝑎𝑎) + (1 − 𝛾𝛾2)𝑛𝑛g(𝑎𝑎) 𝐿𝐿(𝑎𝑎)𝑎𝑎 + 𝜔𝜔𝐿𝐿𝑣𝑣(𝑎𝑎)𝑎𝑎  
𝐿𝐿𝑓𝑓(𝑎𝑎+1)𝑏𝑏 = �1 − 2𝓍𝓍– ρ − m(𝑎𝑎) − λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎)�𝐿𝐿𝑓𝑓(𝑎𝑎)𝑏𝑏 + 𝓍𝓍𝐿𝐿𝑓𝑓(𝑎𝑎)𝑎𝑎 + (1 − 𝛾𝛾2)𝑛𝑛g(𝑎𝑎) 𝐿𝐿𝑣𝑣(𝑎𝑎)𝑏𝑏 + 𝜔𝜔𝐿𝐿𝑣𝑣(𝑎𝑎)𝑏𝑏  
𝐿𝐿𝑓𝑓(𝑎𝑎+1)𝑐𝑐 = �1 − 𝓍𝓍– ρ − m(𝑎𝑎) − λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎)�𝐿𝐿𝑓𝑓(𝑎𝑎)𝑐𝑐 + 𝓍𝓍𝐿𝐿𝑓𝑓(𝑎𝑎)𝑏𝑏 + (1 − 𝛾𝛾2)𝑛𝑛g(𝑎𝑎) 𝐿𝐿(𝑎𝑎)𝑐𝑐 + 𝜔𝜔𝐿𝐿𝑣𝑣(𝑎𝑎)𝑐𝑐  
 
𝐻𝐻𝑓𝑓(𝑎𝑎)𝑡𝑡 = 𝐻𝐻𝑓𝑓(𝑎𝑎)𝑎𝑎 + 𝐻𝐻𝑓𝑓(𝑎𝑎)𝑏𝑏 + 𝐻𝐻𝑓𝑓(𝑎𝑎)𝑐𝑐  
𝐻𝐻𝑓𝑓(𝑎𝑎+1)𝑎𝑎 = �1 − 2δ(𝑎𝑎)–π − m(𝑎𝑎) − λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎)�𝐻𝐻𝑓𝑓(𝑎𝑎)𝑎𝑎 + 𝓍𝓍𝐿𝐿𝑓𝑓(𝑎𝑎)𝑡𝑡 + (1 − 𝛾𝛾2)𝑛𝑛g(𝑎𝑎) 𝐻𝐻(𝑎𝑎)𝑎𝑎 + 𝜔𝜔𝐻𝐻𝑣𝑣(𝑎𝑎)𝑎𝑎  
𝐻𝐻𝑓𝑓(𝑎𝑎+1)𝑏𝑏 = �1 − 2δ(𝑎𝑎)–π − m(𝑎𝑎) − λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎)�𝐻𝐻𝑓𝑓(𝑎𝑎)𝑏𝑏 + δ(𝑎𝑎)𝐻𝐻𝑓𝑓(𝑎𝑎)𝑎𝑎 + (1 − 𝛾𝛾2)𝑛𝑛g(𝑎𝑎) 𝐻𝐻(𝑎𝑎)𝑏𝑏 + 𝜔𝜔𝐻𝐻𝑣𝑣(𝑎𝑎)𝑏𝑏  
𝐻𝐻𝑓𝑓(𝑎𝑎+1)𝑐𝑐 = �1 − δ(𝑎𝑎)–π − m(𝑎𝑎) − λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎)�𝐻𝐻𝑓𝑓(𝑎𝑎)𝑐𝑐 + δ(𝑎𝑎)𝐻𝐻𝑓𝑓(𝑎𝑎)𝑏𝑏 + (1 − 𝛾𝛾2)𝑛𝑛g(𝑎𝑎) 𝐻𝐻(𝑎𝑎)𝑐𝑐 + 𝜔𝜔𝐻𝐻𝑣𝑣(𝑎𝑎)𝑐𝑐  
 
C𝑓𝑓(𝑎𝑎+1) = �1– τ–ψ − m(𝑎𝑎) − λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎) �C𝑓𝑓(𝑎𝑎) + δ(𝑎𝑎)𝐻𝐻𝑓𝑓(𝑎𝑎)𝑡𝑡   
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 𝐿𝐿𝑓𝑓(𝑎𝑎)ℎ𝑡𝑡 = 𝐿𝐿𝑓𝑓(𝑎𝑎)ℎ𝑎𝑎 + 𝐿𝐿𝑓𝑓(𝑎𝑎)ℎ𝑏𝑏 + 𝐿𝐿𝑓𝑓(𝑎𝑎)ℎ𝑐𝑐  
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𝐿𝐿𝑓𝑓(𝑎𝑎+1)ℎ𝑐𝑐 = �1 − 𝓍𝓍ℎ– ρℎ − m(𝑎𝑎) − d�𝐿𝐿𝑓𝑓(𝑎𝑎)ℎ𝑐𝑐 + 𝓍𝓍ℎ𝐿𝐿𝑓𝑓(𝑎𝑎)ℎ𝑏𝑏  + λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎)L𝑓𝑓(𝑎𝑎)𝑐𝑐 + (1 − 𝛾𝛾4)𝑛𝑛z 𝐿𝐿(𝑎𝑎)ℎ𝑐𝑐 + 𝜔𝜔𝐿𝐿𝑣𝑣(𝑎𝑎)ℎ𝑐𝑐  
 
𝐻𝐻𝑓𝑓(𝑎𝑎)ℎ𝑡𝑡 = 𝐻𝐻𝑓𝑓(𝑎𝑎)ℎ𝑎𝑎 + 𝐻𝐻𝑓𝑓(𝑎𝑎)ℎ𝑏𝑏 + 𝐻𝐻𝑓𝑓(𝑎𝑎)ℎ𝑐𝑐  
𝐻𝐻𝑓𝑓(𝑎𝑎+1)ℎ𝑎𝑎 = �1 − 2δℎ(𝑎𝑎)–πℎ − m(𝑎𝑎) − d�𝐻𝐻𝑓𝑓(𝑎𝑎)ℎ𝑎𝑎 + 𝓍𝓍ℎ𝐿𝐿𝑓𝑓(𝑎𝑎)ℎ𝑡𝑡 + λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎)H𝑓𝑓(𝑎𝑎)𝑎𝑎 + (1 − 𝛾𝛾4)𝑛𝑛z 𝐻𝐻(𝑎𝑎)ℎ𝑎𝑎 + 𝜔𝜔𝐻𝐻𝑣𝑣(𝑎𝑎)ℎ𝑎𝑎  
𝐻𝐻𝑓𝑓(𝑎𝑎+1)ℎ𝑏𝑏 = �1 − 2δℎ(𝑎𝑎)–πℎ − m(𝑎𝑎) − d�𝐻𝐻𝑓𝑓(𝑎𝑎)ℎ𝑏𝑏 + δℎ(𝑎𝑎)𝐻𝐻𝑓𝑓(𝑎𝑎)ℎ𝑎𝑎 + λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎)H𝑓𝑓(𝑎𝑎)𝑏𝑏 + (1 − 𝛾𝛾4)𝑛𝑛z 𝐻𝐻(𝑎𝑎)ℎ𝑏𝑏 + 𝜔𝜔𝐻𝐻𝑣𝑣(𝑎𝑎)ℎ𝑏𝑏  
𝐻𝐻𝑓𝑓(𝑎𝑎+1)ℎ𝑐𝑐 = �1 − δℎ(𝑎𝑎)–πℎ − m(𝑎𝑎) − d�𝐻𝐻𝑓𝑓(𝑎𝑎)ℎ𝑐𝑐 + δℎ(𝑎𝑎)𝐻𝐻𝑓𝑓(𝑎𝑎)ℎ𝑏𝑏 + λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎)H𝑓𝑓(𝑎𝑎)𝑐𝑐 + (1 − 𝛾𝛾4)𝑛𝑛z 𝐻𝐻(𝑎𝑎)ℎ𝑐𝑐 + 𝜔𝜔𝐻𝐻𝑣𝑣(𝑎𝑎)ℎ𝑐𝑐  
 
C𝑓𝑓(𝑎𝑎+1)ℎ = �1– τℎ–ψ − m(𝑎𝑎) − d �C𝑓𝑓(𝑎𝑎)ℎ + δℎ(𝑎𝑎)𝐻𝐻𝑓𝑓(𝑎𝑎)ℎ𝑡𝑡 + λ𝐻𝐻𝐻𝐻𝐻𝐻(𝑎𝑎)C𝑓𝑓(𝑎𝑎) 
 Where: 
λ =Force of Infection  
ω =Waning natural immunity  
φ = I_R, The probability of clearing a disease-free HPV16 infection between t and t+1. 
ρ =The probability of clearing an infection with symptoms of LSIL between t and t+1.  
π =HSIL_R, The probability of clearing an infection with symptoms of HSIL between t and t+1.  
τ =C_R , The probability of surviving anal cancer between t and t+1 
m =Probability of dying naturally  
γ=Vaccine efficacy 
κ=Vaccine uptake 
ν=Duration of vaccine-induced immunity (months) 
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APPENDIX VII. JCVI INTERIM POSITION STATEMENT ON HPV 
The advice of JCVI is made with reference to the UK immunisation programme and may not 
necessarily transfer to other epidemiological circumstances 
JCVI interim position statement on HPV vaccination of men who have 
sex with men (MSM) 
Introduction 
In 2008 following a detailed review of the cost-effectiveness and impact of HPV 
vaccination in adolescents, JCVI recommended a universal programme of HPV 
vaccination in girls aged 12-13 years of age in schools, along with a catch up 
programme for girls 13 to under 18 years of age. At this time JCVI agreed that the 
evidence indicated vaccinating boys was unlikely to be cost-effective, as vaccine 
efficacy was high, and high coverage in girls would provide herd protection for 
boys, meaning that a programme which included boys would provide little 
additional benefit. 
JCVI has kept the HPV vaccination programme under review and in 2012 
identified concerns that men who have sex with men (MSM) are a group at high risk 
for HPV infection and associated disease who receive very little health benefit from 
the current HPV vaccination programme. JCVI subsequently issued a call for evidence, 
and indicated a need for modelling of the impact and cost-effectiveness of a 
targeted programme of vaccinating MSM. 
Although not the subject of this position statement, the Committee recognises the 
importance of the on-going assessment of HPV vaccination of adolescent boys. 
The Committee is disappointed that modelling work on the impact and cost-
effectiveness of this programme by PHE is not able to begin until early 2015, due to 
its dependence on modelling work that will not be completed until then, but JCVI 
members agree that it would be inadvisable to take shortcuts which could undermine 
the validity of the results in order to expedite this work. In addition the Committee 
notes that were a targeted programme for MSM to go ahead, then consideration 
would need to be given as to whether other groups should have access to HPV 
vaccination, for example unimmunised women over 17 years of age and non-MSM 
individuals attending Genito-Urinary Medicine (GUM) clinics. Further data have been 
requested so that consideration can be given to whether these additional groups 
might be included in the HPV vaccination programme and so that the Department of 
Health has an evidence base on which to consider the issue of equity in 
vaccination. 
JCVI and the HPV sub-committee have now considered evidence on the impact and 
cost-effectiveness of a targeted programme of vaccinating MSM. The evidence 
indicates that a targeted programme undertaken in GUM and HIV clinics could be 
cost-effective, subject to implementation at a cost-effective price. This statement 
sets out the key evidence and describes the considerations and interim position of the 
JCVI in this regard. As with all significant decisions, the JCVI is issuing its interim 
findings for consultation to ensure that the most appropriate and up-to-date 
evidence has been used, and that reasonable assumptions have been made where 
evidence is limited or unavailable. Once the consultation is completed, the JCVI 
will develop its final advice to the Secretary of State for Health. 
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Background 
Previous deliberations on HPV vaccination programmes  
5. JCVI began consideration of HPV vaccination in 2006. JCVI considered all available 
evidence before development of a recommendation for the introduction of an HPV 
vaccination programme in the UK, including: 
vaccine efficacy studies, 
burden of disease resulting from HPV infection (epidemiology), 
the expected health benefits of introducing an HPV vaccination programme, 
whether the programme would be cost-effective, 
attitudinal work, and 
the suitability of a routine immunisation programme. 
At the October 2007 meeting JCVI concluded that a universal HPV vaccination programme for 
girls aged 12 to 13 years would be cost-effective. In addition to this, the Committee also 
recommended a time-limited ‘catch up’ vaccination of girls aged 13 to 17 years. In July 2008 a 
full statement on HPV vaccination was issued1. 
JCVI did not recommend vaccinating boys at this time as it was considered unlikely to be 
cost-effective. The Committee considered that high coverage in girls would provide herd 
protection to boys, and that vaccination of boys would generate little additional benefit to 
the prevention of cervical cancer, which was the main aim of the programme. Additionally, 
JCVI agreed that there was insufficient evidence on the protective effects of the vaccine 
against cancers affecting males such as anal, head and neck cancers. JCVI agreed that 
when more data became available, high-risk groups such as MSM would be considered. 
Review of the existing programme  
The HPV immunisation programme was introduced in 2008 with girls aged 12-13 years routinely 
offered a course of three doses of vaccine. A catch-up campaign offered vaccine to girls aged 
13 to 17 years of age. The vaccine used routinely from 2008 to September 2012 was the 
bivalent vaccine, Cervarix®, which provides protection against HPV types 16 and 18. Since 
September 2012 the quadrivalent vaccine Gardasil® has been used, which in addition to 
providing protection against HPV types 16 and 18 also provides protection against HPV 
types 6 and 11 responsible for the majority of cases of genital warts in the UK. Coverage with 
the complete vaccine course for the routine cohort in the UK has exceeded 80%. 
Since the programme was introduced evidence has emerged that HPV immunisation is 
likely to provide protection against a wider range of HPV-related diseases, including anal, 
penile and oropharyngeal cancers. Questions have subsequently been raised on whether the 
immunisation programme should now include boys and/or MSM and at the June 2012 JCVI 
meeting, the committee asked the Health Protection Agency (HPA) to consider modelling 
work to assess the impact and cost-effectiveness of HPV immunisation of MSM. It was 
acknowledged that this would take some time to complete due to a lack of data on the 
incidence of HPV in MSM, the prevalence of HPV infections in MSM by age and prevalence in 
the settings where vaccination could be offered to MSM. 
1 JCVI statement on human papillomavirus vaccines to protect against cervical cancer 
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10. At the June 2012 JCVI meeting, the committee also agreed that a call for evidence 
be issued to ask for information relating to: 
a two dose HPV vaccination schedule; 
the impact of the current HPV programme; 
HPV immunisation of MSM; 
the impact of HPV immunisation on a wider range of HPV-related diseases; and 
the potential impact of higher valency vaccines. 
In October 2013 the committee agreed that consideration of options for vaccinating MSM 
should be prioritised and agreed that modelling would be required to assess the cost-
effectiveness of a targeted programme to vaccinate MSM. The committee also agreed that a 
HPV sub-committee should be formed to look at all the issues around HPV vaccination under 
consideration, including vaccination of MSM when attending sexual health services and to 
report its findings and recommendations back to the JCVI. 2 
At the January 2014 HPV Subcommittee meeting the Subcommittee was informed that modelling 
to inform a decision about vaccinating MSM on attendance at sexual health services was 
underway and would be completed by the autumn of 20143, and so the Subcommittee met 
again in September 2014 to consider the results of the modelling and cost-effectiveness 
analyses on vaccinating MSM when attending sexual health services (GUM and HIV clinics)4. 
JCVI considered the findings and advice of the HPV Subcommittee at its October 2014 
meeting and advised that an interim statement should be issued and that stakeholders should 
be invited to comment on the validity of the modelling and cost-effectiveness analyses and 
the interim advice of the Committee. The Committee also advised, for assurance purposes, that 
the modelling and cost-effectiveness work undergo additional peer review in parallel to the 
stakeholder consultation.5 
Impact and Cost-effectiveness analysis 
JCVI’s consideration of a vaccination programme for MSM when attending sexual health services 
was primarily based on its assessment of a modelling and cost-effectiveness study conducted 
and coordinated by Public Health England in collaboration with University College London 
(UCL) and the London School of Hygiene and Tropical 
Medicine6. 
2 Minute of the JCVI meeting held on 2 October 2013  
3 Minute of the HPV sub-committee held on 20 January 2014  
4 Minute of the HPV sub-committee September 2014 
5 Minute of the JCVI meeting held on 1 October 2014 
6 Jit et al (unpublished). The impact and cost-effectiveness of selective HPV vaccination of men who have sex 
with men via genitourinary medicine clinics: a rapid assessment. 
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Methodology 
The modelling and cost-effectiveness study considered vaccination of four groups of MSM 
attending GUM and HIV clinics: HIV positive MSM aged 16-25 years, HIV positive MSM aged 16-40 
years, MSM aged 16-25 years and MSM aged 16-40 years. In all scenarios both the 
quadrivalent and bivalent vaccines were considered and MSM were assumed to be vaccinated 
with a three dose schedule. 
Dynamic SIRS models (Susceptible, Immune, Recovered, Susceptible) were used for the study 
and the modelling considered the impact of vaccination on anal, penile and oropharyngeal 
cancers, and anogenital warts (AGW). Impact on cancers of the oral cavity and larynx, for 
which there is not yet strong evidence for a causal link with HPV 16 was not included and noted as 
a potential (unestimated) additional benefit. 
Costs and benefits were discounted at 3.5% and JCVI criteria were used for assessing cost-
effectiveness. The administrative cost per dose used in the base case was the same as that for 
the girls’ programme which is delivered in schools. In the sensitivity analysis a much higher fee 
was also explored, based on the national non-mandatory tariff for consultations at GUM clinics. 
Additionally, in the base case scenario the list prices of the vaccines were used in the model and a 
threshold price at which the vaccines would be cost-effective was also calculated. 
Data Sources 
Data from a number of published and unpublished sources were evaluated in determining the 
most plausible parameters for the analysis undertaken. The analysis accounted for data on: 
vaccine efficacy; 
the proportion of men who are MSM; 
MSM partner change rates; 
the proportion of MSM attending GUM clinics; 
rates of MSM attendance at GUM clinics; 
HIV prevalence in MSM including estimates of undiagnosed infection; 
disease progression rates from HPV infection to anal cancer; 
anal cancer incidence in MSM; 
the age distribution of all male anal cancers; 
anal cancer incidence adjusted according to HIV status; 
age specific incidence of penile and oropharyngeal cancers associated with HPV 
infection; 
HPV-related risk for penile and oropharyngeal cancer in MSM, adjusted according to 
HIV status; 
the proportion of cancers attributable to HPV 16 and 18 infections; 
anal cancer survival rates calculated using data for rectal cancer as a proxy; 
oropharyngeal cancer survival rates adjusted to reflect the better survival rates for 
HPV-related oropharyngeal cancers; 
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costs updated to 2012/13 GBP values; 
treatment costs per episode of AGW in men; 
estimates of quality of life loss/disutility; 
estimates for duration of each episode of care, treatment and recovery time, adjusted for 
MSM; 
estimates for treatment costs for anal and penile cancers; 
treatment costs for oropharyngeal cancers were calculated relative to the cost of cervical 
cancer; 
treatment costs for oral cavity and laryngeal cancers based on the costs for treatment of 
oropharyngeal cancers; 
administration costs based on the cost for the (school-based) HPV immunisation 
programme for young girls, with a sensitivity analysis assuming higher administration costs 
based on the proposed national non-mandatory tariff for consultations at GUM clinics. 
JCVI and the sub-committee agreed that the parameters values used in the analysis were 
the most plausible based on the available evidence. These values will however be 
independently peer reviewed according to the standard process for independent review for 
JCVI. The results of the peer review process will be provided to the HPV sub-committee for 
consideration, who will in turn report back to JCVI prior to finalisation of the Committee’s 
position. 
Considerations of the Committee 
During its deliberations JCVI noted that where evidence was limited or unavailable 
that a number of assumptions had been made in parameterising the model. In 
particular the Committee noted assumptions in the base case scenario that: 
100% acceptance, uptake and completion of a 3-dose schedule would be achieved in 
MSM attending GUM clinics; 
lifelong protection against vaccine strains (protection for 20 years in sensitivity analyses); 
duration of protection was the same regardless of HIV status; 
cross-protection against high-risk non-vaccine HPV types had not been considered for 
either vaccine (due to the limited evidence available regarding the presence and longevity 
of cross-protection, and because HPV 16 and 18 accounted for a higher proportion of 
HPV associated non-cervical cancers, than cervical cancers); 
the bivalent vaccine did not provide cross-protection against AGW (given the 
limited evidence regarding the impact and longevity of cross-protection); 
vaccination would provide protection against future infection in seropositive individuals who 
had cleared their infection (as demonstrated in vaccination trials in females) 
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anal cancer incidence was taken to be higher among GUM attendees compared to non-
GUM attendees (MSM) with the risk of HPV related cancer adjusted according to HIV 
status (anal and other cancers); 
the age and time-dependent reduction in anal cancers due to vaccination had been 
applied to non-anal cancers (due to limited evidence of the natural history of the non-
anal cancers); 
HIV positive individuals would attend GUM clinics more frequently than HIV negative 
MSM, regardless of whether or not their HIV had been diagnosed, with 17.8% of HIV 
infected individuals assumed to be undiagnosed. 
20. The Committee noted that these assumptions could lead to an over or underestimation of 
the impact of vaccination, however the HPV sub-committee and JCVI considered that the 
assumed parameters would, on balance, provide a 
reasonable indication of the impact of HPV vaccination in MSM vaccinated in GUM 
clinics. 
Uncertainty  
The Committee identified a number of uncertainties regarding the behaviours of HIV positive 
MSM, and the impact of vaccination in this group. The data were generally poorer for this 
group as the numbers were smaller, meaning it was difficult to estimate the risk difference 
between HIV positive and HIV negative MSM in terms of cancer. The Committee considered 
that for HIV positive MSM there was a greater uncertainty on duration of protection from HPV 
vaccination as there was no evidence available. 
A number of assumptions regarding the clinical course of disease and the sexual mixing of sub-
groups of MSM had also been made. However the committee agreed that further 
parameterisation within the model, and inclusion of additional data of limited quality would only 
have a small impact on the overall outcomes of the model, and would lead to an increased level of 
uncertainty with regards to the findings. Lower uptake, within reasonable limits, would have a very 
limited impact on the cost-effectiveness of the programme. A lower completion rate could, 
however, have an impact on the cost-effectiveness of the programme, as three doses were 
likely required to achieve long term protection. This had not been examined in the modelling 
work undertaken, although the Committee noted that the impact of lower uptake might possibly 
be balanced out by any increased attendance due to the availability of HPV vaccination. 
There was little evidence on the levels of uptake which could be expected and there were no 
data for MSM on the levels of immunity achieved from only two doses of vaccine. However, 
some studies had shown a high level of willingness to be vaccinated and a small pilot study in 
north London indicated an 80% uptake of the offer to vaccinate. 
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Results  
The Committee noted that the impact on AGW was smaller than the impact on the HPV 
associated cancers, as the model assumed many MSM had AGW at their first visit to a GUM 
clinic. However, despite the larger impact on cancer, the benefits of preventing AGW were of 
importance in the model as they occurred much earlier after vaccination and thus were less 
impacted by discounting. Because of this much of the net-benefits of a targeted programme were 
due to the prevention of AGW and the cost-effectiveness of HPV vaccination in MSM was 
therefore driven to a large extent by the prevention of AGW. 
At the list price the quadrivalent vaccine was the more cost-effective vaccine in all scenarios and the 
bivalent vaccine was significantly less cost-effective, because much of the total net health 
benefits were due to the prevention of AGW. However, if the current standard non-mandatory 
tariff price for GUM clinics was used as the administration cost (as opposed to an opportunity 
cost), then no option was cost-effective. 
Under the criteria used by JCVI, vaccinating HIV positive MSM aged 16 to 25 years was cost-
effective at the list price of the vaccine. Vaccinating HIV positive MSM aged 16 to 40 years was 
also incrementally cost-effective under the base case assumptions. Extending vaccination to all 
MSM aged 16 to 40 years was not incrementally cost-effective when using the list price of the 
vaccines. However, vaccination of all MSM aged 16 to 40 years was cost-effective under the 
criteria used by JCVI at a threshold vaccine price below the list price. 
JCVI noted that vaccination of older MSM was cost-effective because of on-going HPV 
acquisition and disease risk in older MSM, the late age at which HIV is acquired among MSM 
(more become HIV positive after the age of 25) and the fact that HIV positive MSM account for 
over 50% of the cancers in the absence of vaccination and also have a significant burden of 
AGW. 
Operational issues  
Whilst the analyses reviewed indicated that a programme could be cost-effective, the Committee 
agreed that key operational and delivery issues would need to be addressed, should such a 
programme be considered. 
As sexual health in England is commissioned by Local Authorities (LAs) vaccination 
programmes undertaken in this setting, primarily Hepatitis B vaccination, were not 
commissioned or procured centrally. The Committee considered that obtaining the vaccine at a 
price which was cost-effective for MSM vaccination in GUM and HIV clinics was highly likely to 
depend on the vaccine being centrally procured. 
The Committee advised that it would be very important to closely monitor vaccine coverage and 
completion and the impact of the programme if it is implemented as the outcome would also 
influence the consideration of a programme for adolescent boys. 
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Conclusion and advice 
JCVI chose GUM clinics as the setting to be considered when assessing the 
impact and cost-effectiveness of a programme for the vaccination of MSM as this 
was the most accessed sexual health service by MSM for which sufficient 
quantitative sexual health data could be obtained to inform the modelling and cost-
effective analyses. Whilst there were a number of uncertainties associated with 
assumptions made in the analyses reviewed, the Committee agreed that a 
programme to vaccinate MSM aged 16-40 years should be considered, provided that 
the programme could be undertaken at a price where administration and vaccine 
costs combined were cost-effective. Vaccinating all MSM aged 16-40 years 
attending GUM or HIV clinics was the programme of choice in part because of the 
greater uncertainty around implementation of a strategy of vaccinating only HIV 
positive MSM. 
A targeted programme of vaccinating MSM in GUM and HIV clinics was 
considered highly likely to prevent HPV associated cancers in MSM. The analysis 
however indicated that substantial benefit would also be realised from the 
prevention of AGW, and that cost-effectiveness of a targeted programme was 
reliant on the prevention of AGW infections in MSM. The Committee therefore 
considered that any vaccine used for a programme targeting MSM should also 
provide protection against HPV types 6 and 11 responsible for the majority of 
cases of AGW in the UK. 
The Committee has therefore concluded that a programme for the vaccination of 
MSM aged 16 to 40 years should be implemented in GUM and HIV clinics in the 
UK using the quadrivalent HPV vaccine, subject to the programme being 
commissioned and implemented at a cost-effective price. 
Additional considerations  
JCVI has recognised that the mechanisms and arrangements by which a targeted 
programme of vaccinating MSM in GUM and HIV clinics could be undertaken are 
complex and would require appropriate commissioning and procurement 
arrangements to be in place. JCVI therefore further advised that DH should 
consider options for implementation, in collaboration with Public Health England, 
NHS England and Local Authorities. 
Invitation to stakeholders 
The consultation concerns JCVIs consideration of the scientific evidence for a 
programme to vaccinate MSM assessing sexual health services. However, JCVI 
has also identified potential issues around commissioning and implementation that 
are still to be resolved concerning arrangements to deliver a cost-effective 
programme via GUM and HIV clinics. Of note are some unresolved issues around the 
administrative cost of delivering vaccination via sexual health services and the 
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arrangements for procurement and delivery. Usually the Committee has a clear 
estimate of the administrative cost for delivering vaccination for a programme 
under consideration but because of this unprecedented situation JCVI has 
identified a cost-effective threshold that combines the cost of vaccination and 
administration. 
The advice of JCVI is made with reference to the UK immunisation programme and 
may not 
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36. Assessment of the potential impact and cost-effectiveness of targeted 
vaccination of MSM was a priority among the issues in HPV vaccination under 
consideration by JCVI. The Committee has acknowledged stakeholder concerns that 
MSM are a group at high risk of H PV infection and subsequent disease as they 
receive little 
indirect protection from the highly successful HPV vaccination programme in 
adolescent girls. JCVI has noted a number of assumptions in the modelling 
and cost-effectiveness study, including a 100% uptake and completion of a 3-
dose course of vaccination and lifelong protection against vaccine strains, as 
well as various areas of uncertainty owing to scarcity of data around the clinical 
course of disease and the impact of vaccination in HIV positive MSM. Despite 
these reservations JCVI has been able to come to an informed decision based 
on the findings of the modelling and cost-effective work and provide advice on 
vaccinating MSM in GUM settings. JCVI would now like to invite and consult 
stakeholders to comment on the validity of the assumptions and findings of the 
modelling and cost-effectiveness study and the interim advice of the Committee. 
Comments to JCVI should be sent to JCVI-consultation@phe.gov.uk by no 
later than January 7 2015. 
The Joint Committee on Vaccination and 
Immunisation November 2014 
Notes 
The Joint Committee on Vaccination and Immunisation (JCVI) is an independent Departmental Expert Committee and a 
statutory body constituted for the purpose of advising the Secretary of State on “The provision of vaccination and 
immunisation services being facilities for the prevention of illness”. 
The JCVI’s terms of reference as agreed by the UK health departments are - “To advise UK health departments on 
immunisations for the prevention of infections and/or disease following due consideration of the evidence on the 
burden of disease, on vaccine safety and efficacy and on the impact and cost-effectiveness of immunisation strategies. 
To consider and identify factors for the successful and effective implementation of immunisation strategies. To identify 
important knowledge gaps relating to immunisations or immunisation programmes where further research and/or 
surveillance should be considered.” 
